Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS
Document Type and Number:
WIPO Patent Application WO/2004/052847
Kind Code:
A2
Abstract:
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula (I): or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula (I), including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula (I).

Inventors:
Coghlan, Michael Joseph (7467 River Highlands Drive, Fishers, IN, 46038, US)
Green, Jonathan Edward (7464 Glendale Drive, Avon, IN, 46123, US)
Grese, Timothy Alan (7516 Pine Royal Drive, Indianapolis, IN, 46256, US)
Jadhav, Prabhakar Kondaji (7422 Fox Hollow Ridge, Zionsville, IN, 46077, US)
Matthews, Donald Paul (7736 Wawasee Drive, Indianapolis, IN, 46250, US)
Steinberg, Mitchell Irvin (1516 Cedar, South Bend, IN, 46617, US)
Fales, Kevin Robert (6384 Grannysmith Lane, Avon, IN, 46123, US)
Bell, Michael Gregory (9170 Powderhorn Lane, Indianapolis, IN, 46256, US)
Application Number:
PCT/US2003/016213
Publication Date:
June 24, 2004
Filing Date:
June 13, 2003
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ELI LILLY AND COMPANY (Lilly Corporate Center, Indianapolis, IN, 46285, US)
Coghlan, Michael Joseph (7467 River Highlands Drive, Fishers, IN, 46038, US)
Green, Jonathan Edward (7464 Glendale Drive, Avon, IN, 46123, US)
Grese, Timothy Alan (7516 Pine Royal Drive, Indianapolis, IN, 46256, US)
Jadhav, Prabhakar Kondaji (7422 Fox Hollow Ridge, Zionsville, IN, 46077, US)
Matthews, Donald Paul (7736 Wawasee Drive, Indianapolis, IN, 46250, US)
Steinberg, Mitchell Irvin (1516 Cedar, South Bend, IN, 46617, US)
Fales, Kevin Robert (6384 Grannysmith Lane, Avon, IN, 46123, US)
Bell, Michael Gregory (9170 Powderhorn Lane, Indianapolis, IN, 46256, US)
International Classes:
C07D295/08; A61K31/015; A61K31/03; A61K31/04; A61K31/045; A61K31/055; A61K31/09; A61K31/10; A61K31/335; A61K31/381; A61K31/404; A61K31/415; A61K31/4164; A61K31/4184; A61K31/423; A61K31/428; A61K31/435; A61K31/4402; A61K31/4406; A61K31/4436; A61K31/4453; A61K31/4965; A61K31/5377; A61K31/55; A61P1/04; A61P1/16; A61P3/04; A61P3/08; A61P3/10; A61P3/12; A61P3/14; A61P5/26; A61P5/38; A61P5/46; A61P7/04; A61P7/10; A61P9/00; A61P9/02; A61P9/10; A61P9/12; A61P11/00; A61P11/06; A61P13/12; A61P17/00; A61P17/06; A61P17/10; A61P19/02; A61P19/10; A61P25/02; A61P25/18; A61P25/22; A61P25/24; A61P25/28; A61P29/00; A61P35/00; A61P35/02; A61P37/02; A61P37/06; A61P37/08; A61P43/00; C07C22/04; C07C22/08; C07C25/22; C07C25/24; C07C33/38; C07C39/17; C07C39/23; C07C39/42; C07C43/215; C07C43/225; C07C43/23; C07C47/548; C07C47/57; C07C49/835; C07C205/06; C07C205/35; C07C211/32; C07C211/45; C07C215/76; C07C217/84; C07C233/07; C07C233/65; C07C233/84; C07C235/16; C07C251/40; C07C251/48; C07C255/50; C07C261/04; C07C271/14; C07C275/28; C07C307/10; C07C311/03; C07C311/08; C07C311/09; C07C311/16; C07C311/20; C07C311/21; C07C311/29; C07C317/14; C07C317/32; C07C321/28; C07C323/49; C07D209/08; C07D209/34; C07D211/18; C07D213/127; C07D213/16; C07D213/65; C07D213/73; C07D213/76; C07D213/81; C07D221/16; C07D223/20; C07D231/12; C07D231/18; C07D233/26; C07D233/64; C07D233/84; C07D235/26; C07D241/12; C07D241/20; C07D241/26; C07D261/08; C07D263/52; C07D263/56; C07D263/58; C07D277/60; C07D295/092; C07D295/22; C07D295/26; C07D313/14; C07D333/80; C07D337/12; C07D337/14; C07D401/06; C07D403/06; C07D405/04; C07D405/06; C07D409/04; C07D471/04; C07D487/04; C07D491/044; (IPC1-7): C07C311/00
Domestic Patent References:
WO2000006137A22000-02-10
Foreign References:
US3351588A1967-11-07
US3519621A1970-07-07
GB1501321A1978-02-15
GB1001822A1965-08-18
GB1242096A1971-08-11
GB1043158A1966-09-21
Other References:
L.H. WERNER, ET AL.: "Imidazoline derivatives with antiarrhytmic activity" JOURNAL OF MEDICINAL CHEMISTRY, vol. 10, no. 4, July 1967 (1967-07), pages 575-582, XP002283810 AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US ISSN: 0022-2623
F. GADIENT, ET AL.: "Über neuartige tricyclische Thiazepin- und Thiepin-Derivate" HELVETICA CHIMICA ACTA, vol. 45, no. 6, 20 October 1962 (1962-10-20), pages 1860-1870, XP002283811 VERLAG HELVETICA CHIMICA ACTA, BASEL, CH
F.J. VILLANI, ET AL.: "Derviatives of 12,11-dihydro-5H-dibenzo[a,d]cycloheptene and related compounds. II" JOURNAL OF MEDICINAL CHEMISTRY, vol. 7, no. 4, July 1964 (1964-07), pages 457-460, XP002283812 AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US ISSN: 0022-2623
T. BILLE-SAME, ET AL.: "Fulvènes et éthylènes thermochromes. LXXII. (1) Observations dans la série du dibenzo[a,d]cyclohepta[1,4]diène" BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE, no. 11, November 1972 (1972-11), pages 4212-4214, XP002283813 SOCIETE FRANCAISE DE CHIMIE, PARIS, FR ISSN: 0037-8968
A.A. CORDI, ET AL.: "Synthesis and structure-activity of 4(5)-(2,2-diphenylethyl)imidazoles as new alpha2-adrenorecptor agonists" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 25, no. 7, 1990, pages 557-568, XP002283814 EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR ISSN: 0223-5234
X.-M. CHENG, ET AL.: "Synthesis and structure-activity relationships of 9-substitiuted acridines as endothelin-A receptor antagonists" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 24, 17 December 1996 (1996-12-17), pages 2999-3002, XP002283815 ELSEVIER SCIENCE PUBLISHERS, OXFORD, GB
J.-M. BASTIAN, ET AL: "4H-Benzo[4,5]cyclohepta[1,2-b]thiophene" HELVETICA CHIMICA ACTA, vol. 49, 22 January 1966 (1966-01-22), pages 214-234, XP002263672 VERLAG HELVETICA CHIMICA ACTA, BASEL, CH ISSN: 0018-019X
A. DAICH, ET AL.: "On the synthesis and reactivity of 4,10-dihydrobenzo[b]thieno- [2,3-e]thiepin-10-acetic acid and 5,10-dihydrobenzo[e]thieno[2,3-b]thiepin- 10-acetic acid" JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 29, no. 7, 1992, pages 1789-1795, XP002283816 HETEROCORPORATION, PROVO, US
H. POLMAN, ET AL.: "Photoaddition of aromatic ketones to some arylacetylenes; formation of alpha,beta-unsaturated ketones and aldehydes" RECUEIL DES TRAVAUX CHIMIQUES DES PAYS-BAS, vol. 92, 1973, pages 845-854, XP008031504 ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL ISSN: 0165-0513
G. WITTIG, ET AL.: "Über Ringerweiterung und Ringverengerung auf der Basis von Ylidisomerisationen" JUSTUS LIEBIGS ANNALEN DER CHEMIE, vol. 594, 1955, pages 89-118, XP008031512 VERLAG CHEMIE, WEINHEIM, DE ISSN: 0075-4617
M.A. DAVIS, ET AL.: "New psychotropic agents. VIII. Analogues of amitriptyline containing the normeperidine group" JOURNAL OF MEDICINAL CHEMISTRY, vol. 10, no. 4, July 1967 (1967-07), pages 627-635, XP002284192 AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US
Attorney, Agent or Firm:
Wilson, Alexander (ELI LILLY AND COMPANY, P. O. Box 6288 Indianapolis, IN, 46206-6288, US)
Kingsbury, Oliver W. (Eli Lilly and Company, P.O. Box 6288 Indianapolis, IN, 46206-6288, US)
Download PDF:
Claims:
We claim:
1. A method of treating a pathological disorder susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: Formula I wherein, A, B, and C each independently represent an aryl, heterocycle, or benzofused heterocyclic ring; X and Y together representCH2CH2, CH=CH, CH2O, OCH2, CH2S, SCH2, CH2SO, SOCH2, CH2SO2, SO2CH2, CH2NR10, NR10CH2, NR10CO, CONR10, or a group of the formula wherein W and Z each independently represent hydrogen, fluoro, or chloro; W'and Z' each independently represent hydrogen, fluoro, chloro, or methyl; and Q represents NH, O, S, or CH2 ; represents asingle or double bond; RI represents hydrogen, halo, hydroxy, cyano, nitro, amino, oxo, (C1C6) alkyl, (ClC6) alkoxy, hydroxy (ClC6) alkyl, hydroxy (CiC6) alkoxy, (C2C6) alkenyl, (C2 C6) alkynyl, CH2NH2, halo (CIC6) alkyl, halo (C1C6) alkoxy, C (CF3) 20H, S02NH2, S02NR9R1O, SO2RI 1, NHS02R11, N (CH3) SO2CH3, NR9R10, CH2NH (OH), CH2NH (SO2R11), NHCOR12, COR12, CHNR13, OR14, SR14, (C3C7)cycloalkyl, aryl, substituted aryl, (C1C4) alkylaryl, (C1C4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (ClC¢) alkylheterocycle, or (CiC4) alkylsubstituted heterocycle ; provided that where"C"represents an aryl group, Rl is other than oxo, (C2 C6) alkenyl, or (C2C6) alkynyl ; R2 through R8 each independently represent hydrogen, halo, hydroxy, cyano, nitro, amino, (C1C6)alkyl, (C1C6)alkoxy, hydroxy(C1C6)alkyl, hydroxy(C1C6)alkoxy, (C2C6) alkenyl, (C2C6) alkynyl, CH2NH2, halo (CiC6) alkyl, halo (CIC6) alkoxy, C (CF3) 20H, SO2NH2, SO2NR9R10, S02R1 1, NHS02R11, NR9R10, CH2NH (OH), CH2NH (SO2R11), NHCOR12, COR12, CHNR13, OR14, SR14, (C3C7) cycloalkyl, aryl, substituted aryl, (CC4) alkyl (CIC6) alkoxy, (C1C4) alkylaryl, (C1C4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (ClC4) alkylheterocycle, or (C1C4) alkyl substituted heterocycle; provided that where"A","B", or"C"represents an aryl group, each of R2 through R7 is other than (C2C6) alkenyl or (C2C6) alkynyl ; R9 represents independently at each occurrence cyano, (C1C6) alkyl, (Ci C6) alkoxy, (C1C4) alkyl(C1C6) alkoxy, halo (CiC6) alkyl, hydroxy (CIC6) alkyl, (C3 C7) cycloalkyl, NH(C1C6) alkylamine, N, N (CiC6) dialkylamine, aryl, substituted aryl, (C1C4) alkylaryl, (ClC4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (C1 C4) alkylheterocycle, or (ClC4) alkylsubstituted heterocycle ; @ R10 represents independently at each occurrence hydrogen or (ClC6) alkyl or R9 and R10 together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocycle group; , Rl 1 represents independently at each occurrence amino, (C1C6)alkyl, (C1 C6) alkoxy, halo (CIC6) alkyl, (C3C7) cycloalkyl, aryl, substituted aryl, (C1C4) alkylaryl, (C1C4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (C1C4) alkyl heterocycle, or (ClC4) alkylsubstituted heterocycle; R12 represents independently at each occurrence hydrogen, amino, (CiC6) alkyl, hydroxy (C1C6) alkyl, halo (CIC6) alkyl, (ClC6) alkoxy, (CIC6) alkyl (CIC6) alkoxy, (C3 C7) cycloalkyl, NH(C1C6)alkylamine, N,N(C1C6)dialkylamine, aryl, substituted aryl, (C1C4) alkylaryl, (CtC4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (Cl C4) alkylheterocycle, or (C1C4) alkylsubstituted heterocycle ; R13 represents independently at each occurrence OH, (CiC6) alkyl, (C3 C7) cycloalkyl, aryl, heterocycle, or a substituted aryl or heterocycle ; R14 represents independently at each occurrence (C3C7) cycloalkyl, aryl, substituted aryl, acyl, (C1C4) alkylaryl, (CC4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (ClC4) alkylheterocycle, (CtC4) alkylsubstituted heterocycle, or (C,C4) alkyl (C3C7) cycloalkyl ; or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 wherein said disorder is susceptible to mineralocorticoid receptor or glucocorticoid receptor modulation.
3. The method according to claim 2 wherein said disorder is selected from the group consisting Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic congestive heart failure (CHF), psychoses, cognitive disorders, memory disturbances, depression, bipolar disorder, anxiety disorders, personality disorders, breast cancer, peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varicies, Addison's Disease, muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Thl/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hypergylcemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus, , erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, and cutaneous Tcell lymphoma, emphysema, Alzheimer's Disease, or multiple sclerosis.
4. The method according to claim 3 wherein said disorder is diastolic or systolic congestive heart failure, inflammation, rheumatoid arthritis, autoimmune disorder, asthma, or chronic obstructive pulmonary disease.
5. A method according to any one of claims 14 wherein the compound of Formula I is one wherein, "A"represents an aryl or heterocycle ring selected from the group consisting of "B"represents an aryl or heterocyclic ring selected from the group consisting of "C"represents an aryl, heterocyclic, or benzofused heterocycle ring selected from the group consisting of.
6. The method according to claim 5 wherein"A"represents "B"represents and"C"represents.
7. A method according to any one of Claims 16 wherein XY represents CH2CH2, CH2O, OCH2, CH2S, SCH2, NR10CO , CONR10, CH2NR10, NR10CH2, orCH=CH.
8. The method according to Claim 7 wherein XY representsCH2CH2, CH2O, OCH2, CH2S, SCH2, NR10CO, CO NR10, CH2NR10, NR10CH2, or CH=CH, wherein R10 represents hydrogen or methyl.
9. The method according to Claim 8 wherein XY represents CH2CH2, CH2O, or OCH2.
10. A method according to any one of Claims 19 wherein" " represents a double bond.
11. A method according to any one of Claims 110 wherein R1 represents hydrogen, halo, hydroxy, cyano, nitro, amino, oxo, (ClC6) alkyl, (C1C6) alkoxy, hydroxy (CiC6) alkyl, CH2NH2, halo (CIC6) alkyl, halo (CIC6) alkoxy, S02NH2, SO2NR9RlO, SO2R11, NH SO2Rl l, NR9R1O, NHCORl2, COR12, CHNR13, OR14, SR14, heterocycle, (ClC4) alkylheterocycle, or substituted heterocycle, provided that where"C"represents an aryl group then RI is other than oxo.
12. The method according to Claim 11 wherein Rl represents halo, amino, oxo, (CiC6) alkyl, (ClC6) alkoxy, hydroxymethyl, difluromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, SO2NR9R10, NH SO2R11, NHCOR12, COR12, OR14, or (CIC4) alkylheterocycle, provided that where"C"represents an aryl group then Rl is other than oxo.
13. The method according to Claim 12 wherein when RI represents SO2NR9RlO, R9 represents (C1C6) alkyl, (C1C4) alkyl(C1C6)alkoxy, halo(C1C6) alkyl, (C3C7) cycloalkyl, aryl, (ClC4) alkylaryl, heterocycle and RIO represents hydrogen or methyl, or R9 and RIO together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycle.
14. The method according to Claim 12 wherein when Rl represents NH SO2R1 I, R11 represents amino, (ClC6) alkyl, halo (ClC6) alkyl, (CiC6) alkoxy, (C3 C7) cycloalkyl, aryl, substituted aryl, heterocycle ; or substituted heterocycle.
15. The method according to Claim 14 wherein RI I represents methyl, ethyl, propyl, isopropyl, butyl, or 2methyl propyl.
16. The method according to Claim 12 wherein when Rl represents NHCOR12, R12 represents H, amino, {ClC6) alkyl, (ClC6) alkoxy, hydroxy (C1 C6) alkyl, (CtC) alkyl (CIC6) alkoxy, halo (ClC6) alkyl, NHmethylamine, NH dimethylamine, NHethylamine, or heterocycle.
17. The method according to Claim 12 wherein when Rl represents COR12, R12 represents H, amino, (ClC6) alkyl, (C1C6) alkoxy, or hydroxy(C1C6)alkyl.
18. The method according to Claim 12 wherein when RI represents OR14, R14 represents (C1C) alkylheterocycle.
19. The method according to Claim 12 wherein (ClC) alkylheterocycle represents a group of the formula.
20. A method according to any one of Claims 119 wherein R2 represents hydrogen, halo, hydroxy, (CiC6) alkyl, (CiC6) alkoxy, halo (CIC6) alkyl, (C3 C7) cycloalkyl, or (ClC4) alkylheterocycle.
21. The method according to Claim 20 wherein R2 represents hydrogen or (ClC4) alkylheterocycle.
22. The method according to Claim 21 wherein R2 represents hydrogen.
23. A method according to any one of Claims 122 wherein R3 represents hydrogen, halo, or (CiC6) alkyl.
24. The method according to Claim 23 wherein R3 represents hydrogen.
25. A method according to any one of Claims 124 wherein R4R7 each independently represent hydrogen, halo, hydroxy, cyano, amino, (CC6) alkyl, (C1 C6) alkoxy, halo (CIC6) alkyl, halo(C1C6) alkoxy, SO2NH2, S02CH3, NH SO2R11, NR9R10, NHCOR12, COR12, OR14, SR14, or aryl.
26. The method according to Claim 25 wherein R4R7 each independently represent hydrogen, halo, hydroxy, cyano, amino, (C1C6) alkyl, (C1C6)alkoxy, CHF2, CF3, OCHF2, OCF3, NH SOzRl 1, NR9R10, NHCOR12, COR12, OR14, or aryl.
27. The method according to Claim 26 wherein R4R7 each independently represent hydrogen, halo, hydroxy, cyano, amino, (C1C6) alkyl, (ClC6) alkoxy, CHF2, CF3, OCHF2, OCF3, NH S02CH3, dimethylamino, NHCOCH3, COR12 wherein R12 represents hydrogen, amino, or methoxy ; OR14 wherein Rl4 represents (CIC4) alkyl aryl, (CiC4) alkylsubstituted aryl, (C1C4) alkylheterocycle, or (CiC4) alkyl (C3 C7) cycloalkyl ; or aryl.
28. The method according to Claim 27 wherein R4R7 each independently represent hydrogen, hydroxy, halo, (C1C6) alkyl, (CIC6) alkoxy, or OR14 wherein R14 represents (C1C4) alkylaryl, (C1C4) alkylsubstituted aryl, (C1C4) alkylheterocycle, or (C1C4)alkyl(C3C7)cycloalkyl.
29. The method according to Claim 28 wherein R4 and R6 each independently represent hydrogen, halo, (C1C6) alkyl, (ClC6) alkoxy, or ORt4 wherein R14 represents (CIC4) alkylaryl, (C1C4) alkylsubstituted aryl, (ClC4) alkylheterocycle, or (Cl C4) alkyl (C3C7) cycloalkyl.
30. The method according to Claim 28 wherein R5 and R7 each independently represent hydrogen, hydroxy, halo, (CiC6) alkyl, or (CIC6) alkoxy.
31. A method according to any one of Claims 130 wherein R8 represents hydrogen, halo, (C1C6) alkyl, hydroxy (CC6) alkyl, (C1C4)alkyl(C1C6)alkoxy, COR12, (C3C7) cycloalkyl, aryl, or substituted aryl.
32. The method according to Claim 31 wherein R8 represents hydrogen, halo, (CiC6) alkyl, hydroxymethyl, (C1C4)alkyl(C1C6) alkoxy, COR12 wherein R12 represents (ClC6) alkoxy ; (C3C7) cycloalkyl, phenyl, or substituted aryl.
33. The method according to Claim 32 wherein R8 represents hydrogen, halo, (ClC6) alkyl, (CiCa) alkyl (CIC6) alkoxy, or (C3C7) cycloalkyl.
34. The method according to Claim 33 wherein R8 represents halo, (Cl C6) alkyl, or (ClC4) alkyl (CIC6) alkoxy.
35. The method according to Claim 33 wherein R8 represents hydrogen.
36. The method according to Claim 1 wherein "A"and"B"each independently represent phenyl or heterocycle ; X and Y together represent CH2CH2, CH=CH, CH2O, OCH2, CH2S, SCH2, CH2SO, SOCH2, CH2SO2, SO2CH2, CH2NR10, NR10CH2, NR10CO, CONR10, or a group of the formula wherein W and Z each independently represent hydrogen, fluoro, or chloro ; represents a single or double bond; RI represents hydrogen, halo, hydroxy, cyano, nitro, amino, oxo, (C1C6) alkyl, (C1C6) alkoxy, hydroxy (CIC6) alkyl, CH2NH2, halo (C1C6) alkyl, halo (CIC6) alkoxy, S02NH2, SO2NR9R10 wherein R9 represents (C1C6) alkyl, halo (CIC6) alkyl, (C1 C4) alkyl(C1C6)alkoxy, aryl, (C1C4) alkylaryl, (C3C7) cycloalkyl and RIO represents hydrogen or (C1C6) alkyl or R9 and R10 together represent a substituted or unsubstituted heterocycle ; SO2R11 wherein R11 represents (ClC6) alkyl; NH S02R11 wherein RI 1 represents (C1C6) alkyl, halo (C1C6) alkyl, (C3C7) cycloalkyl, aryl, substituted aryl, heterocycle, or substituted heterocycle; NR9R10 wherein R9 represents (ClC6) alkyl or cyano and RIO represents hydrogen or methyl; NHCOR12 wherein R12 represents H, amino, (ClC6) alkyl, (C1C6) alkoxy, hydroxy (CIC6) alkyl, (C1C) alkyl (CIC6) alkoxy, halo (CIC6) alkyl, NHmethylamine,NHethylamine, or heterocycle; COR12 wherein R12 represents H, amino, (C1C6) alkyl, (C1C6)alkoxy, hydroxy (CIC6) alkyl; OR14 wherein R14 represents (C1C4) alkylheterocycle or acetyl; SR14 wherein R14 represents (C1 C6) alkyl; heterocycle, (C1C4)alkylheterocycle, or substituted heterocycle, provided that where"C"represents an aryl group then RI is other than oxo; R2 represents hydrogen, halo, hydroxy, (C1C6) alkyl, (C1C6) alkoxy, halo (C1 C6) alkyl, (C3C7) cycloalkyl, or (C1C4) alkylheterocycle ; R3 represents wherein hydrogen, halo, or (C1C6) alkyl; R4 and R6 each independently represent hydrogen, halo, hydroxy, cyano, amino, (C1C6) alkyl, (C1C6) alkoxy, halo (CIC6) alkyl, hydroxymethyl, SO2CH3, NH S02R11 wherein Rl 1 represents (CiC6) alkyl; NR9R10 wherein R9 and RIO each represent (C1 C6)alkyl, NHCOR12 wherein R12 represents (C1C6) alkyl ; COR12 wherein R12 represents hydrogen, amino, or (ClC6) alkoxy; OR14 wherein R14 represents (Cl C4) alkyl(C3C7)cycloalkyl, (C1C4) alkylaryl, (C1C4) alkylsubstituted aryl, or (C1 C4) alkylheterocycle ; SR14 wherein R14 represents (C1C6) alkyl; or aryl; R5 and R7 each independently represent hydrogen, hydroxy, halo, (C1C6) alkyl, or (CiC6) alkoxy; and RS represents hydrogen, halo, (C1C6) alkyl, hydroxy (ClC6) alkyl, (ClC4) alkyl (ClC6) alkoxy, COR12 wherein R12 represents methoxy, ethoxy, hydroxymethyl, or methoxymethyl; (C3C7) cycloalkyl, aryl or substituted aryl.
37. A novel compound of Formula I : Formula I wherein, A, B, and C each independently represent an aryl, heterocycle, or benzofused heterocyclic ring; X and Y together represent CH2CH2, CH2=CH, CH2O, OCH2, CH2S, SCH2, CH2SO, SOCH2, CH2SO2, SO2CH2, CH2 NUI , NR10CH2, NR10CO, CONR10, or a group of the formula wherein W and Z each independently represent hydrogen, fluoro, or chloro; W'and Z' each independently represent hydrogen, fluoro, chloro, or methyl; and Q represents NH, O, S, or CH2 ; represents a single or double bond; Rl represents hydrogen, halo, hydroxy, cyano, nitro, amino, oxo, (CiC6) alkyl, (C1C6) alkoxy, hydroxy (CIC6) alkyl, hydroxy (CC6) alkoxy, (C2C6) alkenyl, (C2 C6) alkynyl, CH2NH2, halo (CIC6) alkyl, halo (C1C6) alkoxy, C (CF3) 20H, S02NH2, SO2NR9R10, SO2R11, NHSO2R11, N (CH3) S02CH3, NR9R10, CH2NH (OH), CH2NH (SO2R11), NHCOR12, COR12, CE13, OR14, SR14, (C3C7)cycloalkyl, aryl, substituted aryl, (CIC4) alkylaryl, (C1C4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (CiC4) alkylheterocycle, or (C1C4) alkylsubstituted heterocycle; provided that where"C"represents an aryl group, R1 is other than oxo, (C2 C6) alkenyl, or (C2C6) alkynyl, further provided that where"C"represents a benzofused heterocycle then R1 may also represent hydrogen; R2 through R8 each independently represent hydrogen, halo, hydroxy, cyano, nitro, amino, (CC6) alkyl, (C1C6) alkoxy, hydroxy (CIC6) alkyl, hydroxy (CiC6) alkoxy, (C2C6) alkenyl, (C2C6) alkynyl, CH2NH2, halo (C1C6) alkyl, halo (ClC6) alkoxy, C (CF3) 20H, SO2NH2, SO2NR9R10, SO2R11, NHSO2R11, NR9R10, CH2NH (OH), CH2NH (SO2RI 1), NHCOR12, COR12, CHNR13, OR14, SR14, (C3C7)cycloalkyl, aryl, substituted aryl, (ClC4) alkyl(C1C6) alkoxy, (ClC4) alkylaryl, (C1C4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (C1C4) alkylheterocycle, or (C1C4) alkyl substituted heterocycle ; provided that where"A","B", or"C"represents an aryl group, each of R2 through R7 is other than (C2C6) alkenyl or (C2C6) alkynyl; further provided that where C represents a phenyl ring and RI represents halo then at least one of R2 and R3 is other than hydrogen, (ClC6) alkyl, aryl, substituted aryl, (C1 C4) alkylaryl, (ClC4) alkylsubstituted aryl, CHF2, or CF3 ; further provided that where C represents a sixmembered ring and RI represents cyano, amino, NR9R10, or NHCOCH3 and R2 and R3 are each hydrogen, then RI is not bound at the 4position of said sixmembered ring; further provided that where C represents a sixmembered ring and RI represents nitro, and R2 and R3 are each hydrogen, then R1 is not bound at the 2,4, or 6position of said sixmembered'ring ; R9 represents independently at each occurrence cyano, (C1C6) alkyl, (Cl C6) alkoxy, (CiCa) alkyl (CIC6) alkoxy, halo (CIC6) alkyl, hydroxy (CIC6) alkyl, (C3 C7) cycloalkyl, NH(C1C6)alkylamine, N,N(C1C6)dialkylamine, aryl, substituted aryl, (C1C4)alkylaryl, (C1C4)alkylsubstituted aryl, heterocycle, substituted heterocycle, (Cl C4) alkylheterocycle, or (ClC4) alkylsubstituted heterocycle; R10 represents independently at each occurrence hydrogen or (C1C6) alkyl or R9 and RIO together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocycle group ; RI 1 represents independently at each occurrence amino, (C1C6)alkyl, (C1 C6) alkoxy, halo (CIC6) alkyl, (C3C7) cycloalkyl, aryl, substituted aryl, (C1C4)alkylaryl, (C1C4)alkylsubstituted aryl, heterocycle, substituted heterocycle, (C1C4)alkyl heterocycle, or (C1C4) alkylsubstituted heterocycle; R12 represents independently at each occurrence hydrogen, amino, (C1C6) alkyl, hydroxy (ClC6) alkyl, halo (CIC6) alkyl, (ClC6) alkoxy, (CiC6) alkyl (CIC6) alkoxy, (C3 C7) cycloalkyl, NH(CIC6) alkylamine, N, N(CwC6) dialkylamine, aryl, substituted aryl, (ClC4) alkylaryl, (CIC4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (Cl C4) alkylheterocycle, or (ClC4) alkylsubstituted heterocycle; R13 represents independently at each occurrence OH, (C1C6) alkyl, (C3 C7) cycloalkyl, aryl, heterocycle, or a substituted aryl or heterocycle; R14 represents independently at each occurrence (C3C7) cycloalkyl, aryl, substituted aryl, acyl, (CC4) alkylaryl, (C1C4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (C1C4) alkylheterocycle, (C1C4) alkylsubstituted heterocycle, or (C1C4) alkyl (C3C7) cycloalkyl ; or a pharmaceutically acceptable salt thereof.
38. The compound according to Claim 37 wherein the compound of Formula I is one wherein, "A"represents an aryl or heterocycle ring selected from the group consisting "B"represents an aryl or heterocyclic ring selected from the group consisting of "C"represents an aryl, heterocyclic, or benzofused heterocycle ring selected from the group consisting of or a pharmaceutically acceptable salt thereof.
39. The compound according to claim 38 wherein"A"represents "B"represents and"C"represents or a pharmaceutically acceptable salt thereof.
40. A compound according to any one of claims 3739 wherein XY represents CH2CH2, CH2O, OCH2, CH2S, SCH2, NR10CO, CONR10, CH2NR10, NR10CH2, or CH=CH.
41. The compound according to Claim 40 wherein XY representsCH2 CH2,CH2 O,0CH2,CHa S,SCH2,NR10CO, CONR10, CH2NR10, NR10CH2, orCH=CH, wherein RIO represents hydrogen or methyl.
42. The compound according to Claim 41 wherein XY representsCH2 CH2, CH2O, or OCH2,.
43. A compound according to any one of Claims 3742 wherein represents a double bond.
44. A compound according to any one of Claims 3743 wherein Rl represents hydrogen, halo, hydroxy, cyano, nitro, amino, oxo (ClC6) alkyl, (CIC6) alkoxy, hydroxy (CIC6) alkyl, CH2NH2, halo (C1C6) alkyl, halo (CIC6) alkoxy, S02NH2, S02NR9R1O, SO2R11, NH S02Rl1, NR9R1O, NHCOR12, COR12, CHNR13, OR14, SR14, heterocycle, (C1C4) alkylheterocycle, or substituted heterocycle, provided that where"C"represents an aryl group then R1 is other than oxo.
45. The compound according to Claims 44 wherein Rl represents halo, amino, oxo, (CIC6) alkyl, (C1C6) alkoxy, hydroxymethyl, difluromethyl, trifluoromethyl, difluoromethoxy, trifluoromethoxy, SO2NR9R10, NH SO2R11, NHCOR12, COR12, OR14, or (CC4) alkylheterocycle, provided that where"C"represents an aryl group then RI is other than oxo.
46. The compound according to Claim 45 wherein when RI represents SO2NR9R10, R9 represents (ClC6) alkyl, (CIC4) alkyl (CIC6) alkoxy, halo (ClC6) alkyl, (C3C7) cycloalkyl, aryl, (C1C4) alkylaryl, heterocycle and RIO represents hydrogen or methyl, or R9 and RI 0 together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycle ;.
47. The compound according to Claim 45 wherein when R1 represents NH SO2R11, R11 represents amino, (ClC6) alkyl, halo (CIC6) alkyl, (ClC6) alkoxy, (C3 C7) cycloalkyl, aryl, substituted aryl, heterocycle, or substituted heterocycle.
48. The compound according to Claim 47 wherein RI I represents methyl, ethyl, propyl, isopropyl, butyl, or 2methyl propyl.
49. The compound according to Claim 45 wherein when RI represents NHCOR12, R12 represents H, amino, (C1C6) alkyl, (C1C6) alkoxy, hydroxy (CI C6) alkyl, (C1C) alkyl(C1C6) alkoxy, halo (ClC6) alkyl, NHmethylamine, NH dimethylamine, NHethylamine, or heterocycle.
50. The compound according to Claim 45 wherein when Rl represents COR12 , R12 represents H, amino, (C1C6) alkyl, (C1C6) alkoxy, or hydroxy (CC6) alkyl.
51. The compound according to Claim 45 wherein when RI represents OR14, R14 represents (ClC) alkylheterocycle.
52. The compound according to Claim 45 wherein (CIC) alkylheterocycle represents a group of the formula.
53. A compound according to any one of Claims 3752 wherein R2 represents hydrogen, halo, hydroxy, (CiC6) alkyl, (CiC6) alkoxy, halo (CC6) alkyl, (C3 C7) cycloalkyl, or (C1C4) alkylheterocycle.
54. The compound according to Claim 53 wherein R2 represents hydrogen or (ClC4) alkylheterocycle.
55. The compound according to Claim 54 wherein R2 represents hydrogen.
56. A compound according to any one of Claims 3755 wherein R3 represents hydrogen, halo, or (CIC6) alkyl.
57. The compound according to Claim 56 wherein R3 represents hydrogen.
58. A compound according to any one of Claims 3757 wherein R4R7 each independently represent hydrogen, halo, hydroxy, cyano, amino, (CiC6) alkyl, (Cl C6) alkoxy, halo (CC6) aLkyl, halo (CC6) alkoxy, SO2NH2, SO2CH3, NH SO2R11, NR9R10, NHCOR12, COR12, OR14, SR14, or aryl.
59. The compound according to Claim 58 wherein R4R7 each independently represent hydrogen, halo, hydroxy, cyano, amino, (C1C6) alkyl, (C1C6) alkoxy, CHF2, CF3, OCHF2, OCF3, NH SO2R11, NR9R10, NHCOR12, COR12, OR14, or aryl.
60. The compound according to Claim 59 wherein R4R7 each independently represent hydrogen, halo, hydroxy, cyano, amino, (C1C6) alkyl, (C1C6) alkoxy, CHF2, CF3, OCHF2, OCF3, NH SO2CH3, dimethylamine, NHCOCH3, COR12 wherein R12 represents hydrogen, amino, or methoxy ; OR14 wherein R14 represents (ClC4) alkyl aryl, (C1C4) alkylsubstituted aryl, (C1C4) alkylheterocycle, or (ClC4) alkyl (C3 C7) cycloalkyl; or aryl.
61. The compound according to Claim 60 wherein R4R7 each independently represent hydrogen, hydroxy, halo, (CIC6) alkyl, (CiC6) alkoxy, or OR14 wherein R14 represents (CIC4) alkylaryl, (CiC4) alkylsubstituted aryl, (ClCa) alkylheterocycle, or (ClC4) alkyl(C3C7) cycloalkyl.
62. The compound according to Claim 61 wherein R4 and R6 each independently represent hydrogen, halo, (C1C6) alkyl, (C1C6) alkoxy, or OR14 wherein R14 represents (ClC4) alkylaryl, (C1C4) alkylsubstituted aryl, (C1C4) alkylheterocycle, or (ClC4) alkyl(C3C7) cycloalkyl.
63. The compound according to Claim 61 wherein R5 and R7 each independently represent hydrogen, hydroxy, halo, (C1C6) alkyl, or (ClC6) alkoxy.
64. A compound according to any one of Claims 3763 wherein R8 represents hydrogen, halo, (CiC6) alkyl, hydroxy (CiC6) alkyl, (C1C4) alkyl (CiC6) alkoxy, COR12, (C3C7) cycloalkyl, aryl, or substituted aryl.
65. The compound according to Claim 64 wherein R8 represents hydrogen, halo, (CiC6) alkyl, hydroxymethyl, (C1C4) alkyl (C1C6) alkoxy, COR12 wherein R12 represents (ClC6) alkoxy; (C3C7) cycloalkyl, phenyl, or substituted aryl.
66. The compound according to Claim 65 wherein R8 represents hydrogen, halo, (C1C6) alkyl, (C1C4) alkyl (CIC6) alkoxy, or (C3C7) cycloalkyl.
67. The compound according to Claim 66 wherein R8 represents halo (Cl C6) alkyl, (C1C4) alkyl (C1C6)alkoxy.
68. The compound according to Claim 66 wherein R8 represents hydrogen.
69. The compound according to Claim 37 wherein "A"and"B"each independently represent phenyl or heterocycle; X and Y together represent CH2CH2, CH=CH, CH2O, OCH2, CH2S, SCH2, CH2SO, SOCH2, CH2SO2, SO2CH2, CH2NR10, NR10CH2, NR10CO, CONR10, or a group of the formula wherein W and Z each independently represent hydrogen, fluoro, or chloro ; represents a single or double bond; Rl represents halo, hydroxy, cyano, nitro, amino, oxo, (C1C6) alkyl, (Cl C6) alkoxy, hydroxy (CIC6) alkyl, CH2NH2, halo (CiC6) alkyl, halo (CIC6) alkoxy, SO2NH2 , SO2NR9R10 wherein R9 represents (C1C6) alkyl, halo (ClC6) alkyl, (CiC4) alkyl (Cl C6) alkoxy, aryl, (CiC4) alkylaryl, (C3C7) cycloalkyl and RIO represents hydrogen or (Cl C6) alkyl or R9 and R10 together represent a substituted or unsubstituted heterocycle; SO2R11 wherein R11 represents (ClC6) alkyl ; NH SO2R1 1 wherein R11 represents (C1 C6) alkyl, halo (CIC6) alkyl, (C3C7) cycloalkyl, aryl, substituted aryl, heterocycle, or substituted heterocycle; NR9R10 wherein R9 represents (CIC6) alkyl or cyano and RIO represents hydrogen or methyl; NHCOR12 wherein R12 represents H, amino, (Cl C6) alkyl, (C1C6) alkoxy, hydroxy (CIC6) alkyl, (C1C) alkyl (CIC6) alkoxy, halo (C1 C6) alkyl, NHmethylamine,NHethylamine, or heterocycle; COR12 wherein R12 represents H, amino, (ClC6) alkyl, (C1C6) alkoxy, hydroxy (CIC6) alkyl ; OR14 wherein R14 represents (CiC4) alkylheterocycle or acetyl; SR14 wherein R14 represents (Cl C6) alkyl; heterocycle, (ClC4) alkylheterocycle, or substituted heterocycle, provided that where"C"represents an aryl group then RI is other than oxo ; further provided that where"C"represents a benzofused heterocycle then RI may also represent hydrogen; R2 represents hydrogen, halo, hydroxy, (C1C6) alkyl, (C1C6) alkoxy, halo (C1 C6) alkyl, (C3C7) cycloalkyl, or (C1C4) alkylheterocycle ; R3 represents wherein hydrogen, halo, or (ClC6) alkyl; provided that where C represents a phenyl ring and R1 represents halo then at least one of R2 and R3 is other than hydrogen, (CIC6) alkyl, aryl, substituted aryl, (Cl C4) alkylaryl, (C1C4) alkylsubstituted aryl, CHF2, or CF3; further provided that where C represents a sixmembered ring and R1 represents cyano, amino, NR9R10, or NHCOCH3 and R2 and R3 are each hydrogen, then RI is not bound at the 4position of said sixmembered ring; further provided that where C represents a sixmembered ring and Rl represents nitro, and R2 and R3 are each hydrogen, then RI is not bound at the 2,4, or 6position of said sixmembered ring; R4 and R6 each independently represent hydrogen, halo, hydroxy, cyano, amino, (C1C6) alkyl, (C1C6) alkoxy, halo (C1C6) alkyl, hydroxymethyl, S02CH3, NH SO2R11 wherein Rl 1 represents (CC6) alkyl ; NR9R10 wherein R9 and R1O each represent (Cl C6) alkyl, NHCOR12 wherein R12 represents (ClC6) alkyl; COR12 wherein R12 represents hydrogen, amino, or (ClC6) alkoxy; orl4 wherein R14 represents (C1 C4) alkyl(C3C7)cycloalkyl, (C1C4)alkylaryl, (C1C4) alkylsubstituted aryl, or (C1 C4) alkylheterocycle; SR14 wherein R14 represents (ClC6) alkyl; or aryl; R5 and R7 each independently represent hydrogen, hydroxy, halo, (C1C6) alkyl, or (ClC6) alkoxy; and R8 represents hydrogen,. halo, (C1C6) alkyl, hydroxy (CiC6) alkyl, (CiC4) alkyl (C1C6) alkoxy, COR12 wherein R12 represents methoxy, ethoxy, hydroxymethyl, or methoxymethyl ; (C3C7) cycloalkyl, aryl or substituted aryl.
70. A compound of the formula or a pharmaceutically acceptable salt thereof.
71. A compound of the formula or a pharmaceutically acceptable salt thereof.
72. A compound of the formula or a pharmaceutically acceptable salt thereof.
73. A compound of the formula or a pharmaceutically acceptable salt thereof.
74. A compound of the formula or a pharmaceutically acceptable salt thereof.
75. A compound of the formula or a pharmaceutically acceptable salt thereof.
76. A compound of the formula or a pharmaceutically acceptable salt thereof.
77. A compound of the formula or a pharmaceutically acceptable salt thereof.
78. A compound of the formula or a pharmaceutically acceptable salt thereof.
79. A compound of the formula or a pharmaceutically acceptable salt thereof.
80. A compound of the formula or a pharmaceutically acceptable salt thereof.
81. A compound of the formula or a pharmaceutically acceptable salt thereof.
82. A compound of the formula or a pharmaceutically acceptable salt thereof.
83. A compound of the formula or a pharmaceutically acceptable salt thereof.
84. A compound of the formula or a pharmaceutically acceptable salt thereof.
85. A compound of the formula or a pharmaceutically acceptable, salt thereof.
86. A compound of the formula or a pharmaceutically acceptable salt thereof.
87. A compound of the formula or a pharmaceutically acceptable salt thereof.
88. A compound of the formula or a pharmaceutically acceptable salt thereof.
89. A compound of the formula or a pharmaceutically acceptable salt thereof.
90. A compound of the formula or a pharmaceutically acceptable salt thereof.
91. A compound of the formula or a pharmaceutically acceptable salt thereof.
92. A compound of the formula or a pharmaceutically acceptable salt thereof.
93. A compound of the formula or a bpharmaceutically acceptable salt thereof.
94. A compound of the formula or a pharmaceutically acceptable salt thereof.
95. A compound of the formula or a pharmaceutically acceptable salt thereof.
96. A compound of the formula or a pharmaceutically acceptable salt thereof.
97. A compound of the formula or a pharmaceutically acceptable salt thereof.
98. A compound of the formula or a pharmaceutically acceptable salt thereof.
99. A compound of the formula or a pharmaceutically acceptable salt thereof.
100. A compound of the formula or a pharmaceutically acceptable salt thereof.
101. A compound of the formula or a pharmaceutically acceptable salt thereof.
102. A compound of the formula or a pharmaceutically acceptable salt thereof.
103. A compound of the formula or a pharmaceutically acceptable salt thereof.
104. A compound of the formula or a pharmaceutically acceptable salt thereof.
105. A compound of the formula or a pharmaceutically acceptable salt thereof.
106. A compound of the formula or a pharmaceutically acceptable salt thereof.
107. A compound of the formula or a pharmaceutically acceptable salt thereof.
108. A compound of the formula or a pharmaceutically acceptable salt thereof.
109. A compound of the formula or a pharmaceutically acceptable salt thereof.
110. A compound of the formula or a pharmaceutically acceptable salt thereof.
111. A compound of the formula or a pharmaceutically acceptable salt thereof.
112. A compound of the formula f or a pharmaceutically acceptable salt thereof.
113. A method of treating a physiological disorder susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof effective amount of a novel compound of Formula I according to claim 37.
114. The method according to claim 113 wherein said disorder is susceptible to mineralocorticoid or glucocorticoid receptor modulation.
115. The method according to Claim 114 wherein said disorder is selected from the group consisting of Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic. congestive heart failure (CHF), psychoses, cognitive disorders, memory disturbances, depression, bipolar disorder, anxiety disorders, personality disorders, breast cancer, peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varicies, Addison's Disease, muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa,granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Thl/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hypergylcemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus, , erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous Tcell lymphoma, emphysema, Alzheimer's Disease, and multiple sclerosis.
116. The method according to claim 115, wherein said disorder is diastolic or systolic congestive heart failure, inflammation, rheumatoid arthritis, an autoimmune disorder, asthma, or chronic obstructive pulmonary disease.
117. The method according to claim 116, wherein said disorder is diastolic or systolic congestive heart failure or rheumatoid arthritis.
118. A method of modulating a steroid hormone nuclear receptor comprising administering to a patient in need thereof an effective amount of a compound of Formula I according to Claim 37.
119. The method of Claim 118 wherein said steroid nuclear receptor is the mineralocorticoid receptor or the glucocorticoid receptor.
120. A pharmaceutical composition comprising an effective amount of a compound of Formula I according to Claim 37 in combination with a pharmaceutically acceptable carrier.
121. The use of a compound of Formula I : Formula I wherein, A, B, and C each independently represent an aryl, heterocycle, or benzofused heterocyclic ring; X and Y together representCHzCH2,CH=CH,CHa 0,OCH2, CH2S, SCH2, CH2SO, SOCH2, CH2SO2, SO2CH2, CH2 NR10, NR10CH2, NR10CO, CONR10, or a group of the formula wherein W and Z each independently represent hydrogen, fluoro, or chloro ; W'and Z' each independently represent hydrogen, fluoro, chloro, or methyl; and Q represents NH, O, S, or CH2 ; represents a single or double bond; RI represents hydrogen, halo, hydroxy, cyano, nitro, amino, oxo, (C1C6) alkyl, (C1C6) alkoxy, hydroxy (CIC6) alkyl, hydroxy (CiC6) alkoxy, (C2C6) alkenyl, (C2 C6) alkynyl, CH2NH2, halo (CIC6) alkyl, halo (CiC6) alkoxy, C (CF3) 20H, S02NH2, SO2NR9R10, SO2R11, NHSO2R11, N (CH3) SO2CH3, NR9R10, CH2NH (OH), CH2NH (SO2R11), NHCOR12, COR12, CHNR13, OR14, SR14, (C3C7) cycloalkyl, aryl, substituted aryl, (C1C4) alkylaryl, (C1C4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (ClC4) alkylheterocycle, or (CiC4) alkylsubstituted heterocycle; provided that where"C"represents an aryl group, RI is other than oxo, (C2 C6) alkenyl, or (C2C6) alkynyl ; R2 through R8 each independently represent hydrogen, halo, hydroxy, cyano, nitro, amino, (CIC6) alkyl, (C1C6) alkoxy, hydroxy (C1C6) alkyl, hydroxy (C1C6)alkoxy, (C2C6) alkenyl, (C2C6) alkynyl, CH2NH2, halo (CIC6) alkyl, halo (CIC6) alkoxy, C (CF3) 20H, SO2NH2, SO2NR9R10, S02RI 1, NHS02Rl 1, NR9RI 0, CH2NH (OH), CH2NH (SO2R11), NHCOR12, COR12, CHNR13, OR14, SR14, (C3C7) cycloalkyl, aryl, substituted aryl, (CiC4) alkyl(C1C6)alkoxy, (C1C4)alkylaryl, (C1C4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (CIC4) alkylheterocycle, or (ClC4) alkyl substituted heterocycle; provided that where"A","B", or"C"represents an aryl group, each of R2 through R7 is other than (C2C6) alkenyl or (C2C6) alkynyl; R9 represents independently at each occurrence cyano, (ClC6) alkyl, (Cl C6) alkoxy, (C1C4) alkyl (CIC6) alkoxy, halo (ClC6) alkyl, hydroxy (CiC6) alkyl, (C3 C7) cycloalkyl, NH(C1C6)alkylamine, N,N(C1C6) dialkylamine, aryl, substituted aryl, (C1C4) alkylaryl, (C1C4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (Cl C4) alkylheterocycle, or (ClC4) alkylsubstituted heterocycle; R10 represents independently at each occurrence hydrogen or (C1C6) alkyl or R9 and RIO together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocycle group; R11 represents independently at each occurrence amino, (ClC6) alkyl, (Cl C6) alkoxy, halo (C1C6) alkyl, (C3C7) cycloalkyl, aryl, substituted aryl, (C1C4) alkylaryl, (C1C4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (C1C4)alkyl heterocycle, or (CIC4) alkylsubstituted heterocycle; R12 represents independently at each occurrence hydrogen, amino, (ClC6) alkyl, hydroxy (C1C6) alkyl, halo (C1C6) alkyl, (CiC6) alkoxy, (C1C6) alkyl(C1C6)alkoxy, (C3 C7) cycloalkyl, NH (CiC6) alkylamine, N,N(C1C6)dialkylamine, aryl, substituted aryl, (C1C4) alkylaryl, (CiC4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (Cl C4) alkylheterocycle, or (CsC4) alkylsubstituted heterocycle; R13 represents independently at each occurrence OH, (C1C6) alkyl, (C3 C7) cycloalkyl, aryl, heterocycle, or a substituted aryl or heterocycle; R14 represents independently at each occurrence (C3C7) cycloalkyl, aryl, substituted aryl, acyl, (C1C4) alkylaryl, (CiC4) alkylsubstituted aryl, heterocycle, substituted heterocycle, (ClC4) alkylheterocycle, (C1C4) alkylsubstituted heterocycle, or (ClC4) alkyl(C3C7) cycloalkyl ; or a novel compound of Formula I according to Claim 37, or pharmaceutically acceptable salts thereof, for the manufacture of a medicament for the treatment of diastolic or systolic congestive heart failure or rheumatoid arthritis.
Description:
TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS BACKGROUND OF THE INVENTION Nuclear hormone receptors are an evolutionarily conserved class of intracellular receptor proteins which have been termed"ligand dependent transcription factors". Evans et al. SCIENCE, 240: 889 (1988). The nuclear hormone receptor gene superfamily encodes structurally-related receptor proteins for glucocorticoids (e. g. cortisol, corticosterone, cortisone), androgens, mineralocorticoids (e. g. aldosterone), progestins, estrogen, and thyroid hormone. Also included within this superfamily of nuclear receptors are receptor proteins for vitamin D, retinoic acid, 9-cis retinoic acid, as well as those receptors for which no cognate ligands have been identified ("orphan receptors") Ribeiro et al., Annual Rev. Med. , 46: 443-453 (1995). Steroid hormone receptors represent a subset of the nuclear hormone receptor superfamily. So named according to the cognate ligand which complexes with the receptor in its native state, the steroid hormone nuclear receptors include the glucocorticoid receptor (GR), the androgen receptor (AR), the mineralocorticoid receptor (MR), the estrogen receptor (ER), and the progesterone receptor (PR). Tenbaum et al., Int. J. Biochem. Cell. Bio. , 29 (12): 1325- 1341 (1997).

In contrast to membrane bound receptors, nuclear hormone receptors encounter their respective ligands following entry of the ligand into the cell. Once ligand binding occurs, the ligand-receptor complex modulates transcription of target genes within the cell nucleus. For example, most ligand-free nuclear receptors are bound in a complex with heat shock proteins (hsps) in the cytoplasm. Following entry of circulating hormone into the cell, binding elicits a conformational change in the receptor, dissociating the receptor from the hsp. The ligand bound receptors translocate to the nucleus, where they act as monomers as well as hetero-and homodimers in binding to particular hormone response elements (HREs) in the promoter regions of target genes. The HRE-receptor complex then, in turn, regulates transcription of proximally-located genes. (see Ribeiro et al., supra. ). On the other hand, thyroid hormone receptors (TRs) and other non-steroid receptors such as vitamin D receptor (VDR) and retinoic acid receptors (RAR) are bound to their respective HRE in the absence of hsps and/or cognate ligand. Hormones released

from the circulation enter the cell, binding in the nucleus to these receptors which, in turn, hetero-dimerize to other nuclear receptors such as 9-cis retinoic acid (RXR). As with the steroid hormone nuclear receptors, following ligand binding, the ligand-bound receptor complex again regulates transcription of neighboring genes.

Mineralocorticoids and glucocorticoids exert profound influences on a multitude of physiological functions by virtue of their diverse roles in growth, development, and maintenance of homeostasis. The actions are mediated by the MR and GR which share approximately 94% homology in their respective DNA binding regions, and approximately 57% homology in their respective ligand-binding domains. Kino et al., J. of Endocrinology, 169,437-445 (2001). In visceral tissues, such as the kidney and the gut, MR regulates sodium retention, potassium excretion, and water balance in response to aldosterone. In addition, MR expression in the brain appears to play a role in the control of neuronal excitability, in the negative feedback regulation of the hypothalamic- pituitary-adrenal axis, and in the cognitive aspects of behavioral performance. Castren et al., J. of Neuroendocrinology, 3, 461-466 (1993). GR, which is ubiquitously expressed in almost all tissues and organ systems, is crucial for the integrity of central nervous system function and the maintenance of cardiovascular, metabolic, and immune homeostasis.

Kino et al., J. of Endocrinology, 169,437-445 (2001).

Elevations in aldosterone levels, or excess stimulation of mineralocorticoid receptors, are linked to several pathological disorders or pathologic disease states including, Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, and disorders associated with excess catecholamine levels. Hadley, M. E., ENDOCRINOLOGY, 2nd Ed. , pp. 366-381, (1988) ; and Brilla et al., Journal of Molecular and Cellular Cardiology, 25 (5), pp. 563-575 (1993). Additionally, elevated aldosterone levels have been increasingly implicated with congestive heart failure (CHF). In CHF, the failing heart triggers hormonal mechanisms in other organs in response to the attending reductions in blood flow and blood pressure seen with CHF. In particular, the kidney activates the renin-angiotensin-aldosterone system (RAAS) causing an increase in aldosterone production by the adrenals which, in turn, promotes water and sodium

retention, potassium loss, and further edema. Although historically it was believed that aldosterone participated in the etiology of CHF only as a result of its salt retaining effects, several recent studies have implicated elevated aldosterone levels with events in extra- adrenal tissues and organs, such as myocardial and vascular fibrosis, direct vascular damage, and baroreceptor dysfunction. Pitt et al., New Eng. J. Med., 341 : 709-717 (1999).

These findings are particularly significant since angiotensin converting enzyme (ACE) inhibitors, which were once thought to completely abolish aldosterone production, are now believed to only transiently suppress aldosterone production which has been shown to occur in extra-adrenal tissues including the heart and vasculature. Weber, New Eng. J.

Med. , 341: 753-755 (1999); Fardella and Miller, Annu. Rev. Nutr. , 16: 443-470 (1996).

The involvement of aldosterone acting via MR in CHF was confirmed in the recently completed RALES (Randomized Aldactone Evaluation Study) study. Pitt et al., New Eng. J. Med. , 341: 709-717 (1999). The RALES study demonstrated that the use of Aldactone (spironolactone), a well-known competitive MR antagonist, in combination with standard CHF therapy, reduced cardiac related mortality by 30% and frequency of hospitalization by 35% in patients suffering from advanced CHF. However, spironolactone therapy has also been associated with attending side effects such as gastric bleeding, diarrhea, azotemia, hyperchloremic metabolic acidosis an type-4 renal tubule acidosis, nausea, gynecomastia, erectile dysfunction, hyperkalemia, and irregular menses.

Thus, the mineralocorticoid receptor represents a viable target for CHF therapy either alone or in combination with conventional CHF therapies such as vasodilators (ACE inhibitors), inotropics (digoxin), diuretics, or beta blockers. Molecules, preferably non- steroids, which bind to the mineralocorticoid receptor and modulate receptor activity without the attending side effects of current therapies would be particularly desirable.

Finally, published international PCT application WO 02/17895 discloses that aldosterone antagonists are useful in the treatment of subjects suffering from one or more cognitive dysfunctions including, but not limited to psychoses, cognitive disorders (such as memory disturbances), mood disorders (such as depression and bipolar disorder), anxiety disorders, and personality disorders. In particular, Smythe et al., Pharm. Biochem and Behav., (1997); 56 (3); 507-513 and Young et al, Arch. Gen. Psychiatry, (2003); 60; 24-28, respectively, report that mineralocorticoid receptors, and modulation of MR activity, are involved in anxiety and major depression. In addition, Sasano et al.,

Anticancer Research, 17; 2001-2007 (1997) reports that expression of MR may be related to differentiation of breast carcinomas. Thus MR modulators may also have utility in treating cancer, particularly of the breast.

Glucocorticoids (e. g. cortisol, corticosterone, and cortisone), and the glucocorticoid receptor, have also been implicated in the etiology of a variety of pathological disorders or pathologic disease states. For example, cortisol hyposecretion is implicated in the pathogenesis of Addison's Disease and may result in muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, and hypoglycemia.

On the other hand, excessive or prolonged secretion of glucocorticoids has been correlated to Cushing's Syndrome and may also result in obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, and polydipsia.

Hadley, M. E., ENDOCRlNOLOGY, 2nd Ed., pp. 366-381, (1988). Further, Coghlan et al., United States Patent No. 6,166, 013, issued December 26,2000, discloses that GR selective agents could modulate GR activity and, thus, be useful in the treatment of inflammation, tissue rejection, auto-immunity, malignancies such as leukemias and lymphomas, Cushing's syndrome, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Thl/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hypergylcemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome. Coghlan et al. also discloses that GR modulators are especially useful in disease states involving systemic inflammation such as inflammatory bowel disease, systemic lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, organ transplantation, hepatitis, and cirrhosis; and that GR modulating compounds have been used as immunostimulants, repressors, and as wound healing and tissue repair agents.

In addition, Coghlan et al. discloses that GR modulators have also found use in a variety of topical diseases such as inflammatory scalp alopecia, panniculitis, psoriasis,

discoid lupus erythematosus, inflamed cysts, atopic dermatitis, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, systemic lupus erythematosus, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, contact dermatitis, atopic dermatitis, lichen planus, exfoliative dermatitis, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, and cutaneous T-cell lymphoma.

Finally, GR Modulators may also have utility in treating respiratory disorders, such as emphysema, and neuroinflammatory disorders, such as multiple sclerosis and Alzheimer's Disease.

Thus, it is clear that a ligand which has affinity for steroid hormone nuclear receptors, and particularly for MR and/or GR, could be used to modulate (i. e. repress, antagonize, agonize, partially antagonize, partially agonize) receptor activity and target gene expression, thereby influencing a multitude of physiological functions related to alterations in steroid hormone levels and/or steroid hormone receptor activity. In this regard, such ligands could be useful to treat a wide range of pathological disorders susceptible to steroid hormone nuclear receptor modulation.

Several art references disclose tricyclic derivative molecules useful as, inter alia, photographic coupling and developing agents, thromboxane A2 modulators, and as histamine H2 antagonists. Further, tricyclic-derivative compounds have also been disclosed as having pharmacological utility as, inter alia, antidepressants and anti- inflammatory agents. Surprisingly, however, and in accordance with the present invention, applicants have discovered a series of tricyclic compounds, particularly dibenzosuberane, dibenzoxapine, dibenzazapine, and dibenzthiepine derivatives, with affinity for steroid hormone nuclear receptors, and particularly for MR and GR. Such compounds could modulate receptor activity and, thus, have utility in treating pathological disorders related to alterations in steroid hormone level and/or to alterations in steroid hormone nuclear receptor activity. As a further embodiment, the present invention also provides a novel series of novel non-steroidal tricyclic compounds that exhibit steroid hormone nuclear receptor affinity and modulating activity. Such methods and compounds could address a long felt and continuing need for safe and effective pharmaceutical interventions without the attending side effects of steroidal-type agents.

The treatment of steroid hormone related disorders is hereby furthered.

The following references describe examples of the state of the art as it relates to the present invention.

U. S. Patent No. 4,282, 233 discloses tricyclic molecules (i. e. Loratadine (ClaritinT) as H2 antagonists.

U. S. Patent No. 4,999, 363 (and family members) discloses tricyclic molecules as thromboxane A2 antagonists.

U. S. Patent Nos. 5, 378,701 and 5,478, 840 and 5,607, 955 disclose tricyclic molecules as angiotensin II antagonists.

U. S. Patent No. 6,362, 188 B1 discloses tricyclic molecules as farnesyl protein transferase inhibitors.

Published International PCT Application WO 99/33786 discloses tricyclic propanamide derivative molecules as anti-inflammatory agents.

Published International PCT Application WO 96/19458 and U. S. Patent Nos.

5,696, 130 ; 5,994, 544; 6,017, 924, and 6, 121, 450 disclose quinoline derivative analogs as steroid hormone receptor modulators.

Published International PCT Application WO 00/06137 and U. S. Patent No.

6,166, 013 disclose triphenylmethane compounds as glucocorticoid receptor modulators.

U. S. Patent No. 6,147, 066 discloses anti-mineralocorticoid receptor compounds for use in treating drug withdrawal syndrome.

U. S. Patents Nos. 6,008, 210 and 6,093, 708 disclose spirolactone compounds, such as spironolactone and epoxymexrenone, with affinity for the mineralocorticoid receptor for use in the treatment of myocardial fibrosis.

U. S. Patent No. 5,024, 912 discloses 5H Dibenzo (A, D) cycloheptenylidene and 5H Dibenzo (A, D) cycloheptanylidene derivatives as electrophotographic photosensitive agents.

U. S. Patents Nos. 4,741, 976,4, 539,507, 5,093, 210, and 5,166, 022 disclose the use of tricyclic molecules in electroluminescent devices.

SUMMARY OF THE INVENTION The present invention is directed to the discovery that the tricyclic compounds of the present invention, as defined below, are modulators of steroid hormone nuclear

receptors. Accordingly, the present invention provides a method of treating a pathological disorder susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula:

Formula I wherein, A, B, and C each independently represent an aryl, heterocycle, or benzofused- heterocyclic ring; X and Y together represent -CH2-CH2-, -CH=CH-, -CH2-O-, -O-CH2-, - S-,-S-CH2-,-CH2-SO-,-SO-CH2-,-CHZ---SO2-,-SOz-CH2-, -CH2-NR10-, -NR10-CH2-, -NR10-CO-, -CO-NR10-, or a group of the formula wherein W and Z each independently represent hydrogen, fluoro, or chloro; W'and Z' each independently represent hydrogen, fluoro, chloro, or methyl; and Q represents NH, O, S, or CH2 ; represents a single or double bond; R1 represents hydrogen, halo, hydroxy, cyano, nitro, amino, oxo, (Cl-C6) alkyl, (C-C6) alkoxy, hydroxy (Cl-C6) alkyl, hydroxy (Cl-C6) alkoxy, (C2-C6) alkenyl, (C2- C6) alkynyl, CH2NH2, halo(C1-C6)alkyl, halo(C1-C6) alkoxy, C (CF3) 20H, S02NH2, SONR9R10, SO2R11, NHSO2R11, N(CH3)SO2CH3, NR9R10, CH2NH(OH),

CH2NH (SO2R11), NHCOR12, COR12, CHNR13, OR14, SR14, (C3-C7)cycloalkyl, aryl, substituted aryl, (C1-C4) alkyl-aryl, (C1-C4) alkyl-substituted aryl, heterocycle, substituted heterocycle, (Cl-C4) alkyl-heterocycle, or (C1-C4) alkyl-substituted heterocycle; provided that where"C"represents an aryl group, Rl is other than oxo, (C2- C6) alkenyl, or (C2-C6) alkynyl; R2 through R8 each independently represent hydrogen, halo, hydroxy, cyano, nitro, amino, (Ci-C6) alkyl, (Ci-C6) alkoxy, hydroxy (C1-C6) alkyl, hydroxy (Ci-C6) alkoxy, (C2-C6) alkenyl, (C2-C6) alkynyl, CH2NH2, halo (C1-C6) alkyl, halo (Cl-C6) alkoxy, C (CF3) 20H, S02NH2, SO2NR9R10, SO2R11, NHSO2R11, NR9R10, CH2NH (OH), CH2NH (S02Rll), NHCOR12, COR12, CHNR13, OR14, SR14, (C3-C7) cycloalkyl, aryl, substituted aryl, (Ci-C4) alkyl- (Cl-C6) alkoxy, (Ci-C4) alkyl-aryl, (Ci-C4) alkyl-substituted aryl, heterocycle, substituted heterocycle, (C1-C4) alkyl-heterocycle, or (C1-C4) alkyl- substituted heterocycle; provided that where"A", "B", or"C"represents an aryl group, each of R2 through R7 is other than (C2-C6) alkenyl or (C2-C6) alkynyl ; R9 represents independently at each occurrence cyano, (C1-C6) alkyl, (Cl- C6) alkoxy, (C1-C4) alkyl-(C1-C6)alkoxy, halo (Ci-C6) alkyl, hydroxy (Cl-C6) alkyl, (C3- C7) cycloalkyl, NH-(C1-C6) alkylamine, N, N- (CI-C6) dialkylamine, aryl, substituted aryl, (C1-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, heterocycle, substituted heterocycle, (C1- C4) alkyl-heterocycle, or (C1-C4) alkyl-substituted heterocycle; RIO represents independently at each occurrence hydrogen or (Cl-C6) alkyl or R9 and R10 together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocycle group; Rl l represents independently at each occurrence amino, (CI-C6) alkyl, (Cl- C6) alkoxy, halo (C1-C6) alkyl, (C3-C7) cycloalkyl, aryl, substituted aryl, (Ci-C4) alkyl-aryl, (C1-C4) alkyl-substituted aryl, heterocycle, substituted heterocycle, (Cl-C4) alkyl- heterocycle, or (C1-C4) alkyl-substituted heterocycle; R12 represents independently at each occurrence hydrogen, amino, (Cl-C6) alkyl, hydroxy (CI-C6) alkyl, halo (Cl-C6) alkyl, (Ci-C6) alkoxy, (Ci-C6) alkyl- (Ci-C6) alkoxy, (-C3- C7) cycloalkyl, NH- (CI-C6) alkylamine, N, N- (CI-C6) dialkylamine, aryl, substituted aryl, (Ci-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, heterocycle, substituted heterocycle, (Cl- C4) alkyl-heterocycle, or (C1-C4) alkyl-substituted heterocycle;

R13 represents independently at each occurrence OH, (Cl-C6) alkyl, (C3- C7) cycloalkyl, aryl, heterocycle, or a substituted aryl or heterocycle; R14 represents independently at each occurrence (C3-C7) cycloalkyl, aryl, substituted aryl, acyl, (Cl-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, heterocycle, substituted heterocycle, (Cl-C4) alkyl-heterocycle, (Cl-C4) alkyl-substituted heterocycle, or (C -C4) alkyl- (C3-C7) cycloalkyl ; or a pharmaceutically acceptable salt thereof.

Examples of such disorders include Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic congestive heart failure (CHF), peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varicies, Addison's Disease, muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Thl/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hypergylcemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis,

cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus, , erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous T-cell lymphoma, emphysema, Alzheimer's Disease, and multiple sclerosis.

As a particular aspect, the present invention provides a method of treating a pathological disorder susceptible to mineralocorticoid or glucocorticoid receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of Formula I, as described more fully herein and above. As a more particular aspect, the present invention provides a method of treating a pathological disorder susceptible to mineralocorticoid or glucocorticoid receptor antagonism comprising administering to a patient in need thereof an effective amount of a compound of Formula I, as described herein and above. As an even more particular aspect, the present invention provides a method of treating systolic and/or diastolic congestive heart failure or inflammation or rheumatoid arthritis comprising administering to a patient in need thereof an effective amount of a compound of Formula I, as described herein and above.

Certain of the tricyclic compounds corresponding to Formula I are believed to be novel and, thus, to constitute another embodiment of the present invention. As such, the present invention also provides a novel compound of Formula I : Formula I wherein,

A, B, and C each independently represent an aryl, heterocycle, or benzofused heterocyclic ring ; X and Y together represent -CH2-CH2-, -CH=CH-, -CH2-O-, -O-CH2-, - CH2-S-, -S-CH2-, -CH2-SO-, -SO-CH2-, -CH2-SO2-, -SO2-CH2-, -CH2-NR10-, -NR10-CH2-, -NR10-CO-, -CO-NR10-, or a group of the formula wherein W and Z each independently represent hydrogen, fluoro, or chloro; W'and Z' each independently represent hydrogen, fluoro, chloro, or methyl; and Q represents NH, O, S, or CH2 ; represents a single or double bond; RI represents halo, hydroxy, cyano, nitro, amino, oxo, (Ci-C6) alkyl, (Cl- C6) alkoxy, hydroxy (Ci-C6) alkyl, hydroxy (Ci-C6) alkoxy, (C2-C6) alkenyl, (C2-C6) alkynyl, CH2NH2, halo (Ci-C6) alkyl, halo (Cl-C6) alkoxy, C (CF3) 20H, S02NH2, SO2NR9R10, SO2R11, NHSO2R11, N(CH3)SO2CH3,NR9R10, CH2NH (OH), CH2NH (SO2R11), NHCOR12, COR12, CHNR13, OR14, SR14, (C3-C7) cycloalkyl, aryl, substituted aryl, (Cl-C4) alkyl-aryl, (C1-C4) alkyl-substituted aryl, heterocycle, substituted heterocycle, (Cl- C4) alkyl-heterocycle, or (Cl-C4) alkyl-substituted heterocycle; provided that where"C"represents an aryl group, RI is other than oxo, (C2- C6) alkenyl, or (C2-C6) alkynyl ; further provided that where"C"represents a benzofused-heterocycle then RI may also represent hydrogen; R2 through R8 each independently represent hydrogen halo, hydroxy, cyano, nitro, amino, (Ci-C6) alkyl, (Cl-C6) alkoxy, hydroxy (CI-C6) alkyl, hydroxy (CI-C6) alkoxy, (C2- C6) alkenyl, (C2-C6) alkynyl, CH2NH2, halo (Cl-C6) alkyl, halo (Ci-C6) alkoxy, C (CF3) 20H, SO2NH2, SO2NR9R10, SO2R11, NHSO2Rll, NR9R10, CH2NH (OH), CH2NH (SO2R11), NHCOR12, COR12, CHNR13, OR14, SR14, (C3-C7)cycloalkyl, aryl, substituted aryl, (Ci-C4) alkyl-aryl, (Cl-C4) alkyl-(C1-C6)alkoxy, (C1-C4) alkyl-substituted aryl, heterocycle, substituted heterocycle, (C1-C4) alkyl-heterocycle, or (Cl-C4) alkyl-substituted heterocycle;

provided that where"A","B", or"C"represents an aryl group, each of R2 through R7 is other than (C2-C6) alkenyl or (C2-C6) alkynyl ; further provided that where"C"represents a phenyl ring and RI represents halo then at least one of R2 and R3 is other than hydrogen, (Cl-C6) alkyl, aryl, substituted aryl, (Cl-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, CHF2, or CF3 ; further provided that where"C"represents a six-membered ring and Rl represents cyano, amino, NR9R10, or NHCOCH3 and R2 and R3 are each hydrogen, then RI is not bound at the 4-position of said six-membered ring; further provided that where"C"represents a six-membered ring and R1 represents nitro, and R2 and R3 are each hydrogen, then Rl is not bound at the 2,4, or 6-position of said six-membered ring; R9 represents independently at each occurrence cyano, (C1-C6)alkyl, (C1- C6) alkoxy, (Cl-C4) alkyl- (Cl-C6) alkoxy, halo (CI-C6) alkyl, hydroxy (CI-C6) alkyl, (C3- C7) cycloalkyl, NH- (CI-C6) alkylamine, N, N- (CI-C6) dialkylamine, aryl, substituted aryl, (Ci-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, heterocycle, substituted heterocycle, (C1- C4) alkyl-heterocycle, or (C I-C4) alkyl-substituted heterocycle ; R10 represents independently at each occurrence hydrogen or (Cl-C6) alkyl or R9 and R10 together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocycle group; Rl l represents independently at each occurrence amino, (Cl-C6) alkyl, (Cl- C6) alkoxy, halo (Cl-C6) alkyl, (C3-C7) cycloalkyl, aryl, substituted aryl, (C1-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, heterocycle, substituted heterocycle, (Cl-C4) alkyl- heterocycle, or (Cl-C4) alkyl-substituted heterocycle; R12 represents independently at each occurrence hydrogen, amino, (Cl-C6) alkyl, hydroxy (C1-C6) alkyl, halo (CI-C6) alkyl, (Cl-C6) alkoxy, (Cl-C6) alkyl-(C1-C6)alkoxy, (C3- C7) cycloalkyl, NH- (Ci-C6) alkylamine, N,N-(C1-C6) dialkylamine, aryl, substituted aryl, (Ci-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, heterocycle, substituted heterocycle, (C1- C4) alkyl-heterocycle, or (C1-C4) alkyl-substituted heterocycle; R13 represents independently at each occurrence OH, (Cl-C6) alkyl, (C3- C7) cycloalkyl, aryl, heterocycle, or a substituted aryl or heterocycle; R14 represents independently at each occurrence (C3-C7) cycloalkyl, aryl, substituted aryl, acyl, (Cl-C4) alkyl-aryl, (C1-C4) alkyl-substituted aryl, heterocycle,

substituted heterocycle, (Cl-C4) alkyl-heterocycle, (CI-C4) alkyl-substituted heterocycle, or (Ci-C4) alkyl-(C3-C7) cycloalkyl ; or a pharmaceutically acceptable salt thereof.

In another embodiment, the present invention provides a method of treating a pathological disorder susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a novel compound of Formula I, or a pharmaceutically acceptable salt thereof, as described more fully herein and above. Examples of such disorders include Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic congestive heart failure (CHF), peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varicies, Addison's Disease, muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, ) hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Thl/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hypergylcemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma

gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus, , erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, and cutaneous T-cell lymphoma.

As a particular aspect, the present invention provides a method of treating a pathological disorder susceptible to mineralocorticoid or glucocorticoid receptor modulation comprising administering to a patient in need thereof an effective amount of a novel compound of Formula I, as described herein and above. More particularly, the present invention provides a method of treating a pathological disorder susceptible to mineralocorticoid or glucocorticoid receptor antagonism comprising administering to a patient in need thereof an effective amount of a novel compound of Formula I, as described herein and above. As an even more particular aspect, the present invention provides a method of treating systolic and/or diastolic congestive heart failure or inflammation comprising administering to a patient in need thereof an effective amount of a novel compound of Formula I, as described herein and above.

In addition, the present invention also provides a method of modulating a steroid hormone nuclear receptor comprising administering to a patient in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. More particularly, the present invention provides a method of modulating MR or GR comprising administering to a patient in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, as described herein and above. As an even more particular aspect, the present invention provides a method of modulating MR or GR comprising administering to a patient in need thereof an effective amount of a novel compound of Formula I, as described herein and above. More particular still, the present invention provides a method of antagonizing MR or GR comprising administering to a patient in need thereof an effective amount of a compound of Formula I, or a novel compound of Formula I, all as described herein and above.

In addition, the present invention provides pharmaceutical compositions of compounds of Formula I, including any pharmaceutically acceptable salts and hydrates thereof, comprising a compound of Formula I in combination with a pharmaceutically acceptable carrier, diluent or excipient. More particularly, the present invention provides

pharmaceutical compositions comprising a novel compound of Formula I in combination with a pharmaceutically acceptable carrier, diluent or excipient. This invention also encompasses novel intermediates, and processes for the synthesis of the compounds of Formula I.

The present invention also provides the use of a compound of Formula I, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a pathological disorder susceptible to steroid hormone nuclear receptor modulation. More particularly, the present invention provides the use of a novel compound of Formula I, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating a pathological disorder susceptible to steroid hormone nuclear receptor modulation. As an even more particular aspect, the present invention provides the use of a novel compound of Formula I for the manufacture of a medicament for treating congestive heart failure or inflammation.

DETAILED DESCRIPTION OF THE INVENTION The present invention provides compounds with affinity for steroid hormone nuclear receptors, particularly MR and/or GR, which could be used to modulate (i. e. repress, antagonize, agonize, partially antagonize, partially agonize) receptor activity and gene expression, thereby influencing physiological functions related to steroid hormone levels and/or steroid hormone receptor activity. In this regard, such ligands are believed to be useful in treating or preventing a multitude of pathological disorders susceptible to steroid hormone nuclear receptor modulation. Thus, methods for the treatment or prevention of pathological disorders susceptible to steroid hormone nuclear receptor modulation constitute an important embodiment of the present invention. As a particular aspect, the present invention provides compounds useful as mineralocorticoid or glucocorticoid receptor modulators. As a more particular aspect, the present invention provides compounds useful as mineralocorticoid or glucocorticoid receptor antagonists.

In addition, certain of the compounds of Formula I are believed to be novel which constitute yet another important embodiment of the present invention.

As will be understood by the skilled artisan, some of the compounds useful for the methods of the present invention may be available for prodrug formulation. As used herein, the term"prodrug"refers to a compound of Formula I which has been structurally

modified such that in vivo the prodrug is converted, for example, by hydrolytic, oxidative, reductive, or enzymatic cleavage, into the parent molecule ("drug") as given by Formula I.

Such prodrugs may be, for example, metabolically labile ester derivatives of the parent compound where said parent molecule bears a carboxylic acid group. Conventional procedures for the selection and preparation of suitable prodrugs are well known to one of ordinary skill in the art. Conversely, some compounds of Formula I may be suitable as antedrugs. "Antedrugs"are themselves pharmacologically active agents, containing metabolically labile functional groups, that upon administration are subsequently deactivated in vivo. Lee et al., Arch. Pharm. Res., 25 (2); 111-136 (2002) provides a discussion of such antedrugs and their utility.

It is also understood that many of the steroid hormone nuclear receptor modulators of the present invention may exist as pharmaceutically acceptable salts and, as such, pharmaceutically acceptable salts are therefore included within the scope of the present invention. The term"pharmaceutically acceptable salt"as used herein, refers to salts of the compounds of Formula I, which are substantially non-toxic to living organisms.

Typical pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a pharmaceutically acceptable mineral or organic acid or an organic or inorganic base. Such salts are known as acid addition and base addition salts. It is further understood by the skilled reader that salt forms of pharmaceutical compounds are commonly used because they are often more readily crystallized, or more readily purified, than are the free bases. In all cases, the use of the pharmaceutical compounds of the present invention as salts is contemplated in the description herein. Hence, it is understood that where compounds of Formula I are capable of forming salts, the pharmaceutically acceptable salts and isoforms thereof are encompassed in the names provided herein.

Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like. Examples of such pharmaceutically acceptable salts are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, bromide, iodide, hydroiodide,

dihydroiodide, acetate, propionate, decanoate, caprylate, acrylate, formate, hydrochloride, dihydrochloride, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleat, butyne-1, 4-dioate, hexyne-1, 6-dioate, benzoate, chlorobenzoate, methylbenzoate, hydroxybenzoate, methoxybenzoate, phthalate, xylenesulfonate, phenyl acetate, phenyl propionate, phenyl butyrate, citrate, lactate, a-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, napththalene-2-sulfonate, mandelate and the like. Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like.

As used herein, the term"stereoisomer"refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures which are not interchangeable. The three-dimensional structures are called configurations. As used herein, the term"enantiomer"refers to one of two stereoisomers whose molecules are nonsuperimposable mirror images of one another. The term"chiral center"refers to a carbon atom to which four different groups are attached. As used herein, the term "diastereomers"refers to stereoisomers which are not enantiomers. In addition, two diastereomers which have a different configuration at only one chiral center are referred to herein as"epimers". The terms"racemate", "racemic mixture"or"racemic modification" refer to a mixture of equal parts of enantiomers.

The compounds of the present invention may have one or more chiral centers and may, therefore, exist in a variety of stereoisomeric configurations. As a consequence of these chiral centers the compounds of the present invention may occur as racemates, mixtures of enantiomers, and as individual enantiomers as well as diastereomers and mixtures of diastereomers. All such racemates, enantiomers, and diastereomers are within the scope of the present invention. Enantiomers of the compounds provided by the present invention can be resolved, for example, by one of ordinary skill in the art using standard techniques such as those described by J. Jacques, et al.,"Enantiomers, Racemates, and Resolutions", John Wiley and Sons, Inc., 1981.

The terms"R"and"S"are used herein as commonly used in organic chemistry to denote specific configuration of a chiral center. The term"R" (rectus) refers to that configuration of a chiral center with a clockwise relationship of group priorities (highest to second lowest) when viewed along the bond from the chiral carbon toward the lowest priority group. The term"S" (sinister) refers to that configuration of a chiral center with a counterclockwise relationship of group priorities (highest to second lowest) when viewed along the bond from the chiral carbon toward the lowest priority group. The priority of groups is based upon their atomic number (in order of decreasing atomic number). A partial list of priorities and a discussion of stereochemistry is contained in"Nomenclature of Organic Compounds : Principles and Practice", (J. H. Fletcher, et al., eds. , 1974) at pages 103-120.

The specific stereoisomers and enantiomers of compounds of Formula I can be prepared by one of ordinary skill in the art utilizing well known techniques and processes, such as those disclosed by Eliel and Wilen, "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., 1994, Chapter 7 ; Separation of Stereoisomers, Resolution, Racemization; and by Collet and Wilen, "Enantiomers, Racemates, and Resolutions", John Wiley & Sons, Inc., 1981. For example, specific stereoisomers and enantiomers can be prepared by stereospecific syntheses using enantiomerically and geometrically pure, or enantiomerically or geometrically enriched starting materials. In addition, the specific stereoisomers and enantiomers can be resolved and recovered by techniques such as chromatography on chiral stationary phases, enzymatic resolution or fractional recrystallization of addition salts formed by reagents used for that purpose.

As will be appreciated by one of ordinary skill in the art, molecules containing a carbon-carbon double bond may exist as geometric isomers. Two methods are commonly used to designate the specific isomers, the"cis-trans"method and the"E and Z"method depending on whether the groups attached to each of the ethylene carbons are the same or different. A discussion of geometric isomerism and the naming of specific isomers is found in March, "Advanced Organic Chemistry", John Wiley & Sons, 1992, Chapter 4.

All such geometric isomers, as well as mixtures of individual isomers, are contemplated and provided by the present invention.

Where used herein, the term"Pg"refers to a suitable oxygen or nitrogen protecting group. Suitable oxygen or nitrogen protecting groups, as used herein, refers to those

groups intended to protect or block the oxygen or nitrogen group against undesirable reactions during synthetic procedures. Whether the term"Pg", as used herein, represents an oxygen protecting group or a nitrogen protecting group will be readily apparent to the ordinarily skilled artisan. The suitability of the oxygen or nitrogen protecting group used will depend upon the conditions that will be employed in subsequent reaction steps wherein protection is required, and is well within the knowledge of one of ordinary skill in the art.

Commonly used nitrogen protecting groups are disclosed in Greene,"Protective Groups In Organic Synthesis, 3rd Edition" (John Wiley & Sons, New York (1999)).

Suitable nitrogen protecting groups comprise acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl,. alpha. -chlorobutyryl, benzoyl, 4- chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and the like; sulfonyl groups such as benzenesulfonyl, p-toluenesulfonyl and the like ; carbamate forming groups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p- nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4- dimethoxybenzyloxycarbonyl, 3, 5-dimethoxybenzyloxycarbonyl, 2,4- dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5- dimethoxybenzyloxycarbonyl, 3,4, 5-trimethoxybenzyloxycarbonyl, 1- (p-biphenylyl)-l- methylethoxycarbonyl,. alpha.,. alpha. -dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2, 2, - trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9- methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, phenylthiocarbonyl and the like ; alkyl groups such as benzyl, triphenylmethyl, benzyloxymethyl and the like ; and silyl groups such as trimethylsilyl and the like. Commonly used oxygen protecting groups are also disclosed in Greene (supra).

Suitable oxygen protecting groups comprise alkyl groups such as methyl, ethyl, and the like; silyl groups such as t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, and the like, with t-butyldimethylsilyl being preferred. Other commonly used oxygen protecting groups include benzyl, 4-nitrophenyl methyl, benzoyl, and the like.

As used herein the term" (Cl-C4) alkyl" refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms and includes, but is not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and the like.

As used herein the term" (C1-C6) alkyl" refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 6 carbon atoms and includes, but is not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, n-hexyl, and the like. It is understood that the term" (Cl-C4) alkyl" is included within the definition of" (Cl-C6) alkyl".

As used herein the term" (Cl-Cio) alkyl" refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 10 carbon atoms and includes, but is not limited to methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tertiary butyl, pentyl, isopentyl, hexyl, 2,3-dimethyl-2-butyl, heptyl, 2,2-dimethyl-3-pentyl, 2-methyl-2-hexyl, octyl, 4-methyl-3-heptyl and the like. It is understood that the terms" (Cl-C4) alkyl" and " (Ci-C6) alkyl" are included within the definition of" (C1-Cio) alkyl".

As used herein, the terms"Me","Et","Pr","i-Pr","Bu"and"t-Bu"refer to methyl, ethyl, propyl, isopropyl, butyl and tert-butyl respectively.

As used herein, the term" (Cl-C4) alkoxy" refers to an oxygen atom bearing a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms and includes, but is not limited to methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, and the like. As used herein the term" (Cl-C6) alkoxy" refers to an oxygen atom bearing a straight or branched, monovalent, saturated aliphatic chain of 1 to 6 carbon atoms and includes, but is not limited to methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, n-pentoxy, n- hexoxy, and the like. It is understood that the term" (Cl-C4) alkoxy" is included within the definition of" (Ci-C6) alkoxy".

As used herein, the term"hydroxy (Cl-C4) alkyl" refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms bearing a hydroxyl group attached to one of the carbon atoms. As used herein, the term"hydroxy (Cl-C6) alkyl" refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 6 carbon atoms bearing a hydroxyl group attached to one of the carbon atoms. It is understood that the term"hydroxy (CI-C4) alkyl" is included within the definition of"hydroxy (Cl- C6) alkyl". As used herein, the term"hydroxy (Cl-C4) alkoxy" refers to an oxygen atom bearing a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon

atoms, further bearing a hydroxyl group attached to one of the carbon atoms. As used herein, the term"hydroxy (Cl-C6) alkoxy" refers to an oxygen atom bearing a straight or branched, monovalent, saturated aliphatic chain of 1 to 6 carbon atoms, further bearing a hydroxyl group attached to one of the carbon atoms. It is understood that the term "hydroxy (Cl-C4) alkoxy" is included within the definition of"hydroxy (Cl-C6) alkoxy".

As used herein, the term" (CI-C6) alkyl- (CI-C6) alkoxy" refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 6 carbon atoms which has a (Cl- C6) alkoxy group attached to the aliphatic chain. The term "(C1-C4)alkyl-(C1-C6)alkoxy" refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms which has a (Cl-C6) alkoxy group attached to the aliphatic chain. It is understood that the term" (CI-C4) alkyl- (CI-C6) alkoxy" is included within the definition of "(Cl-C6) alkyl-(Cl-C6) aLkoxy"."(Cl-C6) alkoxymethylene"refers to a methylene group bearing a (Cl-C6) alkoxy group." (C1-C6) alkoxy (Cl-C6) alkoxy-methylene refers to a methylene group bearing a (Cl-C6) alkoxy group which, in turn, bears an additional (Cl- C6) alkoxy group attached to the aliphatic chain.

As used herein, the terms"halo","halide"or"hal"of"Hal"refer to a chlorine, bromine, iodine or fluorine atom, unless otherwise specified herein.

As used herein, the term"halo (CI-C4) alkyl" refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms bearing one or more halo groups attached to one or more of the carbon atoms. As used herein, the term"halo (Cl- C6) alkyl" refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 6 carbon atoms bearing one or more halo groups attached to one or more of the carbon atoms. It is understood that the term"halo (CI-C4) alkyl''is included within the definition of"halo (CI-C6) alkyl". Typical examples of"halo (Ci-C6) alkyl" include CF3, CHF2, CH2F, and the like. As used herein, the term"halo (Cl-C4) alkoxy" refers to an oxygen atom bearing a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms, further bearing one or more halo groups attached to one or more of the carbon atoms. As used herein, the term"halo (Cl-C6) alkoxy" refers to an oxygen atom bearing a straight or branched, monovalent, saturated aliphatic chain of 1 to 6 carbon atoms, further bearing one or more halo groups attached to one or more of the carbon atoms. It is understood that the term"halo (Cl-C4) alkoxy" is included within the

definition of''halo (Cl-C6) alkoxy". Typical examples of''halo (Cl-C6) alkoxy" include OCF3, OCHF2, OCH2F, and the like.

As used herein the term "(C2-C6)alkenyl" refers to a straight or branched, monovalent, unsaturated aliphatic chain having from two to six carbon atoms and having a double bond. Typical (C2-C6) alkenyl groups include ethenyl (also known as vinyl), 1- methylethenyl, 1-methyl-l-propenyl, 1-butenyl, 1-hexenyl, 2-methyl-2-propenyl, 1- propenyl, 2-propenyl, 2-butenyl, 2-pentenyl, and the like.

As used herein the term" (C2-C6) alkynyl" refers to a straight or branched, monovalent, unsaturated aliphatic chain having from two to six carbon atoms and having a triple bond.

As used herein, the term"acyl"refers to a hydrogen or a (Cl-C6) alkyl group attached to a carbonyl group. Typical acyl groups include formyl, acetyl, propionyl, butyryl, valeryl, and caproyl.

As used herein, the term"aryl"refers to a monovalent carbocyclic group containing one or more fused or non-fused phenyl rings and includes, for example, phenyl, 1-or 2-naphthyl, 1,2-dihydronaphthyl, 1,2, 3,4-tetrahydronaphthyl, and the like.

The term"substituted aryl"refers to an aryl group substituted with one to three moieties, preferably one or two, chosen from the group consisting of acyl, halogen, hydroxy, cyano, nitro, amino, (Cl-C6) alkyl, (C1-C4)alkylsulfonyl, halo (CI-C6) alkyl, (Cl-C6) alkoxy, halo (Cl-C6) alkoxy, (Cl-C6) alkylthio, (C3-C7)cycloalkyl, (C1-C4)alkyl-(C3-C7)cycloalkyl, aryl, (CI-C4) alkyl-aryl, heterocycle, (C1-C4) alkyl-heterocycle, (Cl-C4) alkoxy-heterocycle, (Cl-C6) alkoxycarbonyl, , N, N (Cl-C6) dialkylamine, NH (Cl-C6) alkylamine, NHS02 (Cl- C4) alkyl, (C1-C4) alkyl-N, N-(C1-C6) dialkylamine, (Cl-C4) alkoxy-N, N-(CI-C6) dialkylamine difluoromethyl, difluoromethoxy, trifluoromethyl, trifluoromethoxy, CF2CF3, benzoyl, phenoxy, or an aryl or heterocycle group further substituted with one to two moieties selected from the group consisting of : (C1-C4) alkyl, (C3-C7) cycloalkyl, halo, hydroxy, (C1-C4) alkoxy, CF3,

OCF3, CHF2, OCHF2, CF2CF3, cyano, nitro, amino, NH (Cl-C4) alkylamine, and N, N- (CI-C4) dialkylamine; As used herein, the term" (CI-C6) alkYl-arYl" refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 6 carbon atoms which has an aryl group attached to the aliphatic chain." (Cl-C4) alkyl-aryl" refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms which has an aryl group attached to the aliphatic chain. It is understood that the term" (CI-C4) alkyl-aryl" is included within the definition of" (Cl-C6) alkyl-aryl. Examples of" (Cl-C6) alkyl-aryl" include the following: and the like.

As used herein, the term" (CI-C4) alkyl-substituted aryl"refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms which has a substituted aryl group, as described above, attached to the aliphatic chain. Examples of " (Cl-C4) alkyl-substituted aryl"include methylbenzyl, phenylbenzyl, nitrobenzyl, methoxybenzyl, chlorobenzyl, bromobenzyl, dimethlybenzyl, aminobenzyl, dichlorobenzyl, and the like.

As used herein, the term"aryl (Cl-C6) alkoxy" refers to an oxygen atom bearing a straight or branched, monovalent, saturated aliphatic chain of 1 to 6 carbon atoms wherein said aliphatic chain, in turn, bears an aryl group.

As used herein the term" (C3-Clo) cycloalkyl" refers to a saturated hydrocarbon ring structure composed of one or more fused or unfused rings containing from three to ten carbon atoms. Typical (C3-Clo) cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantanyl, and the like. "(C3- C7) cycloalkyl" refers to a saturated hydrocarbon ring structure composed of one or more fused or unfused rings containing from three to seven carbon atoms. It is understood that the definition of" (C3-C7) cycloalkyl" is included within the definition of "(C3- Clo) cycloalkyl". The term"substituted (C3-C7) cycloalkyl"refers to a"(C3-C7) cycloalkyl group substituted with one or two moieties chosen from the group consisting of halogen, hydroxy, cyano, nitro, amino, (Cl-C6) alkyl, (Cl-C6) alkoxy, (Cl-C4) alkyl- (C3- Cio) cycloalkyl, (Cl-C4) alkyl-aryl, (Cl-C6) alkoxycarbonyl, N, N (Cl-C6) dialkylamine, NH (Cl-C6) alkylamine, (Cl-C4) alkyl-N, N-Cl-C6dialkylamine, difluoromethyl, difluoromethoxy, trifluoromethyl, and trifluoromethoxy.

As used herein, the term" (Ci-C4) alkyl- (C3-C7) cycloalkyl" refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms which has a (C3- C7) cycloalkyl attached to the aliphatic chain. Included within the term" (Cl-C4) alkyl- (C3- C7) cycloalkyl" are the following: and the like. As used herein, the term" (Cl-C4) alkyl-substituted (C3-C7) cycloalkyl"refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms bearing a substituted (C3-C7) cycloalkyl group attached to the aliphatic chain.

As used herein the term" (C3-C7) cycloalkoxy" refers to an oxygen atom bearing a saturated hydrocarbon ring structure composed of one or more fused or unfused rings containing from three to seven carbon atoms.

As used herein, the term" (Ci-C6) alkoxycarbonyl"refers to a carbonyl group having a (Cl-C6) alkyl group attached to the carbonyl carbon through an oxygen atom.

Examples of this group include t-butoxycarbonyl, methoxycarbonyl, ethoxycarbonyl and the like. It is understood that the term" (CI-C4) alkoxycarbonyl"is included within the definition of" (Cl-C6) alkoxycarbonyl".

As used herein the term"heterocycle"refers to a saturated or unsaturated, five-or six-membered ring, which contains one to four heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen. It is understood that the remaining atoms are carbon and that the heterocycle may be attached at any point which provides for a stable structure. Examples of heterocycle groups include thiophenyl, furyl, tetrahydrofuryl, pyrrolyl, imidazolyl, pyrrazolyl, thiazolyl, thiazolidinyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, pyridyl, pyridinyl, pyrimidyl, pyrazinyl, pyridiazinyl, triazinyl, imidazolyl, dihydropyrimidyl, tetrahydropyrimdyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrazolidinyl, pyrimidinyl, imidazolidimyl, morpholinyl, pyranyl, thiomorpholinyl, and the like. As used herein, the term"benzofused heterocyclic ring"or "benzofused heterocycle"refers to a saturated or unsaturated, five-or six-membered ring, which contains one to four heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, and which is fused to a phenyl group. Representative"benzofused heterocyclic rings"include benzooxazole, benzoimidazole, benzimidazole, benzofuran, benzothiophene, benzothiazole, azaindole, and indole.

The term"substituted heterocycle"represents a heterocycle group substituted with one or two moieties chosen from the group consisting of acyl, halogen, hydroxy, cyano, nitro, amino, (Cl-C6) alkyl, (Cl-C4) alkylsulfonyl, halo (Cl-C6) alkyl, (Cl-C6) alkoxy, halo (Cl-C6) alkoxy, (Cl-C6) alkylthio, (C3-C7) cycloalkyl, (Cl-C4) alkyl- (C3-C7) cycloalkyl, aryl, (Cl-C4) alkyl-aryl, heterocycle, (Cl-C4) alkyl-heterocycle, (Cl-C4) alkoxy-heterocycle, (Cl-C6) alkoxycarbonyl, , N, N (Cl-C6) dialkylamine, NHCOCH3, NH (Cl-C6) alkylamine, NHS02 (Cl-C4) alkyl, (Cl-C4) alkyl-N, N-Cl-C6dialkylamine, (Cl-C4) alkoxy-N, N-Cl- C6dialkylamine, difluoromethyl, difluoromethoxy, trifluoromethyl, trifluoromethoxy,

CF2CF3, or an aryl or heterocycle group further substituted with one to two moieties selected from the group consisting of : (Cl-C4) alkyl, (C3-C7) cycloalkyl, halo, hydroxy, (Cl-C4) alkoxy, CF3, OCF3, CHF2, OCHF2, CF2CF3, cyano, nitro, amino, NH (Cl-C4) alkylamine, and N, N- ( Cl-C4) dialkylamine ; Examples of substituted heterocycle include methylisoxazole, dimethylisoxazole, methylimidazole, trifluoromethyl imidazole, pyridinyl thiophene, and the like. The term "substituted benzofused heterocycle"represents a benzofused heterocycle group substituted with one or two moieties chosen from the group consisting of acyl, halogen, hydroxy, cyano, nitro, amino, (Cl-C6) alkyl, halo (Cl-C6) alkyl, or (Cl-C6) alkoxy.

As used herein, the term" (Cl-C4) alkyl-heterocycle" refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms which has a heterocycle group attached to the aliphatic chain. Examples of" (Cl-C4) alkyl-heterocycle" include:

and the like.

The term" (Cl-C4) alkyl-substituted heterocycle"refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms bearing a substituted heterocycle group attached to the aliphatic chain.

As used herein, the term" (Cl-C4) alkoxy-heterocycle" refers to an oxygen atom bearing a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms which has a heterocycle group attached to the aliphatic chain. Examples of" (C1- C4) alkoxy-heterocycle" include :

and the like.

The term" (Cl-C4) alkoxy-substituted heterocycle"refers to a straight or branched, monovalent, saturated aliphatic chain of 1 to 4 carbon atoms bearing a substituted heterocycle group attached to the aliphatic chain.

As used herein the term"NH (C3-C7) cycloalkyl"refers to an amino group substituted with a saturated hydrocarbon ring structure composed of one or more fused or unfused rings containing from three to seven carbon atoms.

As used herein the term''N, N- (Ci-C6) dialkylamine" refers to a nitrogen atom substituted with two straight or branched, monovalent, saturated aliphatic chains of 1 to 6 carbon atoms. Included within the term"NN- (Cl-C6) dialkylamine" are-N (CH3) 2, - N (CH2CH3) 2,-N (CH2CH2CH3) 2,-N (CH2CH2CH2CH3) 2, and the like."NH- (Cl-C6) alkylamine"refers to a nitrogen atom substituted with a straight or branched, monovalent, saturated aliphatic chains of 1 to 6 carbon atoms.

As used herein the term" (Cl-C6) alkyl-NN-Cl-C6dialkylamine" refers to straight or branched, monovalent, saturated aliphatic chain of 1 to 6 carbon atoms which has an N, N- (Ci-C6) dialkylamine attached to the aliphatic chain. Included within the term" (Cl- C6) alkyl-N, N- (Ci-C6) dialkylamine" are the following:

and the like.

As used herein the term" (Cl-C6) alkoxy-N, N- (CI-C6) dialkylamine" refers to an oxygen atom bearing a straight or branched, monovalent, saturated aliphatic chain of 1 to 6 carbon atoms which has an N, N-Cl-C6 dialkylamine attached to the aliphatic chain.

Included within the term"Cl-C6 alkoxy-N, N- (Ci-C6) dialkylamine" are the following:

and the like.

The compounds of the present invention have an aryl, heterocycle, or benzofused- heterocycle ring (ring"C"of Formula I) attached to the tricyclic core. Each of these ring structures, in turn, may be singularly or multiply substituted as denoted in Formula I. As a consequence, a uniform method of numbering is needed to denote the positions on the rings where substitution occurs or may occur. As such, where ring"C"is a five- membered ring, the following numbering pattern is used to denote the positions on the ring where substitution occurs, or may occur

Where ring"C"is a six-membered ring, the following numbering pattern is used to denote the positions on the ring where substitution occurs, or may occur

As stated, the compounds of the present invention may have a benzofused- heterocycle ring (ring"C"of Formula 0 attached to the tricyclic core. Each of these ring

structures, in turn, may be singularly or multiply substituted as denoted in Formula I.

More particularly, where ring"C"is a benzofuzed-heterocycle, ring"C"attaches to the tricyclic core of Formula I through the phenyl portion of the bicyclic system and the substituents R1-R3 attach to ring"C"through the heteroatom containing portion of the bicyclic ring system. This particular configuration of ring"C", when"C"represents a benzofuzed heterocycle, in relation to the tricyclic core of Formula I and the substituents Rl-R3 is given by the following: Representative examples where ring"C"is a benzofused-heterocycle include benzoimidazole, benzothiazole, benzooxazole, benzothiadiazole, indazole, indole, oxindole, and benzimidazole.

Representative examples where ring"C"is a benzofused-heterocycle and at least one of Rl-R3 is other than hydrogen, include benzoimidazolone, benzothiazolone, benzooxazolone, indoline, N-methylbenzoimidazolone, N-ethylbenzoimidazolone, N- propylbenzoimidazolone, N-isopropylbenzoimidazolone, N-isobutylbenzoimidazolone, N-trifluoroethylbenzoimidazolone, N-phenylbenzoimidazolone, N- pyridinylbenzoimidazolone, N-imidazolylbenzoimidazolone, N- thiazolylbenzoimidazolone, N-oxazolylbenzoimidazolone, N- morpholinoethylbenzoimidazolone, N-morpholinopropylbenzoimidazolone, N- methylpiperazinylethylbenzoimidazolone, N- (l-piperdinyl) ethylbenzoimidazolone, N- (l- pyrrolidinyl) ethylbenzoimidazolone, N- (l-piperdin-4-yl) ethylbenzoimidazolone, N- (l- methylpiperdin-4-yl) benzoimidazolone, N- (l-pyrrolidin-3-yl) benzoimidazolone, and N- (1-methylpyrrolidin-3-yl) benzoimidazolone, and the like.

The designation refers to a bond that protrudes forward out of the plane of the page.

The designation refers to a bond that protrudes backward out of the plane of the page.

As used herein, the term"steroid hormone nuclear receptor modulator"refers to those nuclear hormone receptor ligands which bind to any one of GR, MR, AR, ER, or PR, of the larger class of nuclear hormone receptors, and either agonize, antagonize, partially agonize, partially antagonize, or repress the receptor's activity.

As used herein the term"mineralocorticoid receptor"or"MR"refers to the mineralocorticoid receptor subtype, of the larger class of nuclear hormone receptors, which binds the mineralocorticoid hormone aldosterone, as its cognate ligand.

The term"mineralocorticoid receptor modulator"or"mineralocorticoid modulator"or "MR modulator"as used herein, refers to those nuclear hormone receptor ligands which bind to the mineralocorticoid receptor subtype and modulate (i. e. agonize, antagonize, partially agonize, partially antagonize, or repress) the receptor activity. As a particular embodiment, the present invention provides antagonists of MR activity.

As used herein the term"glucocorticoid receptor"or"GR"refers to the glucocorticoid receptor subtype, of the larger class of nuclear hormone receptors, which binds the glucocorticoid hormones cortisol, corticosterone, or cortisone as its cognate ligand. The term"glucocorticoid receptor modulator"or"glucocorticoid modulator"or "GR modulator", as used herein, refers to those nuclear hormone receptor ligands which bind to the glucocorticoid receptor subtype and modulate (i. e. agonize, antagonize, partially agonize, partially antagonize, or repress) the receptor activity.

As used herein, the term"disorder susceptible to steroid hormone nuclear receptor modulation"refers to any pathological disorder, of any origin, known or believed to be responsive to administration of a modulator (i. e. agonist, antagonist, partial agonist, or partial antagonist) of a steroid hormone nuclear receptor. Such pathological disorders include Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and systolic congestive heart failure (CHF), peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varicies, Addison's Disease, muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis,

polyuria, polydipsia, inflammation, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Thl/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hypergylcemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus, , erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema multiform, cutaneous T-cell lymphoma, emphysema, Alzheimer's Disease, and multiple sclerosis.

As used herein the term"congestive heart failure" (CHF) or"congestive heart disease"refers to a disease state of the cardiovascular system whereby the heart is unable to efficiently pump an adequate volume of blood to meet the requirements of the body's tissues and organ systems. Typically, CHF is characterized by left ventricular failure (systolic dysfunction) and fluid accumulation in the lungs, with the underlying cause being attributed to one or more heart or cardiovascular disease states including coronary artery disease, myocardial infarction, hypertension, diabetes, valvular heart disease, and cardiomyopathy. The term"diastolic congestive heart failure"refers to a state of CHF characterized by impairment in the ability of the heart to properly relax and fill with blood. Conversely, the term"systolic congestive heart failure"refers to a state of CHF

characterized by impairment in the ability of the heart to properly contract and eject blood.

As appreciated by one of skill in the art, pathological disorders may present as a "chronic"condition, or an"acute"episode. The term"chronic", as used herein, means a condition of slow progress and long continuance. As such, a chronic condition is treated when it is diagnosed and treatment continued throughout the course of the disease.

Conversely, the term"acute"means an exacerbated event or attack, of short course, followed by a period of remission. Thus, the treatment of pathological disorders contemplates both acute events and chronic conditions. In an acute event, compound is administered at the onset of symptoms and discontinued when the symptoms disappear.

As described above, a chronic condition is treated throughout the course of the disease.

As used herein the term"patient"refers to a mammal, such a mouse, gerbil, guinea pig, rat, dog or human. It is understood, however, that the preferred patient is a human.

As used herein, the terms"treating","treatment", or"to treat"each mean to alleviate symptoms, eliminate the causation of resultant symptoms either on a temporary or permanent basis, and to prevent, slow the appearance, or reverse the progression or severity of resultant symptoms of the named disorder. As such, the methods of this invention encompass both therapeutic and prophylactic administration.

As used herein the term"effective amount"refers to the amount or dose of the compound, upon single or multiple dose administration to the patient, which provides the desired effect in the patient under diagnosis or treatment. An effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances. In determining the effective amount or dose of compound administered, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of mammal ; its size, age, and general health; the degree of involvement or the severity of the disease involved; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.

A typical daily dose will contain from about 0. 01 mg/kg to about 100 mg/kg of each compound used in the present method of treatment. Preferably, daily doses will be

about 0.05 mg/kg to about 50 mg/kg, more preferably from about 0.1 mg/kg to about 25 mg/kg.

Oral administration is a preferred route of administering the compounds employed in the present invention whether administered alone, or as a combination of compounds capable of acting as a mineralocorticoid receptor modulator. Oral administration, however, is not the only route, nor even the only preferred route. Other preferred routes of administration include transdermal, percutaneous, pulmonary, intravenous, intramuscular, intranasal, buccal, sublingual, or intrarectal routes. Where the steroid hormone nuclear receptor modulator is administered as a combination of compounds, one of the compounds may be administered by one route, such as oral, and the other may be administered by the transdermal, percutaneous, pulmonary, intravenous, intramuscular, intranasal, buccal, sublingual, or intrarectal route, as particular circumstances require.

The route of administration may be varied in any way, limited by the physical properties of the compounds and the convenience of the patient and the caregiver.

The compounds employed in the present invention may be administered as pharmaceutical compositions and, therefore, pharmaceutical compositions incorporating compounds of Formula I, and more particularly the novel compounds of Formula I, are important embodiments of the present invention. Such compositions may take any physical form that is pharmaceutically acceptable, but orally administered pharmaceutical compositions are particularly preferred. Such pharmaceutical compositions contain, as an active ingredient, an effective amount of a compound of Formula I, including the pharmaceutically acceptable salts and hydrates thereof, which effective amount is related to the daily dose of the compound to be administered. Each dosage unit may contain the daily dose of a given compound, or may contain a fraction of the daily dose, such as one- half or one-third of the dose. The amount of each compound to be contained in each dosage unit depends on the identity of the particular compound chosen for the therapy, and other factors such as the indication for which it is given. The pharmaceutical compositions of the present invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing well known procedures.

The following discussion provides typical procedures for preparing pharmaceutical compositions incorporating the compounds of the present invention.

However, the following is in no way intended to limit the scope of the pharmaceutical compositions provided by the present invention.

Compositions are preferably formulated in a unit dosage form, each dosage containing from about 1 to about 500 mg of each compound individually or in a single unit dosage form, more preferably about 5 to about 300 mg (for example 25 mg). The term"unit dosage form"refers to a physically discrete unit suitable as unitary dosages for a patient, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier, diluent, or excipient.

The inert ingredients and manner of formulation of the pharmaceutical compositions are conventional. The usual methods of formulation used in pharmaceutical science may be used here. All of the usual types of compositions may be used, including tablets, chewable tablets, capsules, solutions, parenteral solutions, intranasal sprays or powders, troches, suppositories, transdermal patches and suspensions. In general, compositions contain from about 0.5% to about 50% of the compounds in total, depending on the desired doses and the type of composition to be used. The amount of the compound, however, is best defined as the"effective amount", that is, the amount of each compound which provides the desired dose to the patient in need of such treatment.

The activity of the compounds employed in the present invention do not depend on the nature of the composition, hence, the compositions are chosen and formulated solely for convenience and economy.

Capsules are prepared by mixing the compound with a suitable diluent and filling the proper amount of the mixture in capsules. The usual diluents include inert powdered substances such as starches, powdered cellulose especially crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, grain flours, and similar edible powders.

Tablets are prepared by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars such as

lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidine and the like.

Polyethylene glycol, ethylcellulose and waxes can also serve as binders.

Tablets are often coated with sugar as a flavor and sealant. The compounds may also be formulated as chewable tablets, by using large amounts of pleasant-tasting substances such as mannitol in the formulation, as is now well-established practice.

Instantly dissolving tablet-like formulations are also now frequently used to assure that the patient consumes the dosage form, and to avoid the difficulty in swallowing solid objects that bothers some patients.

A lubricant is often necessary in a tablet formulation to prevent the tablet and punches from sticking in the die. The lubricant is chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils.

Tablet disintegrators are substances which swell when wetted to break up the tablet and release the compound. They include starches, clays, celluloses, algins and gums. More particularly, corn and potato starches, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponge, cation-exchange resins, alginic acid, guar gum, citrus pulp and carboxymethylcellulose, for example, may be used, as well as sodium lauryl sulfate.

Enteric formulations are often used to protect an active ingredient from the strongly acid contents of the stomach. Such formulations are created by coating a solid dosage form with a film of a polymer which is insoluble in acid environments, and soluble in basic environments. Exemplary films are cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate.

When it is desired to administer the compound as a suppository, the usual bases may be used. Cocoa butter is a traditional suppository base, which may be modified by addition of waxes to raise its melting point slightly. Water-miscible suppository bases comprising, particularly, polyethylene glycols of various molecular weights are in wide use, also.

Transdermal patches have become popular recently. Typically they comprise a resinous composition in which the drugs will dissolve, or partially dissolve, which is held in contact with the skin by a film which protects the composition. Many patents have

appeared in the field recently. Other, more complicated patch compositions are also in use, particularly those having a membrane pierced with innumerable pores through which the drugs are pumped by osmotic action.

It is understood by one of ordinary skill in the art that the procedures as described above can also be readily applied to a method of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation, and particularly congestive heart failure.

Particular Aspects of the Methods and Uses of the Invention The following list sets out several groupings of particular substituents and particular variables for compounds of Formula I. It will be understood that certain methods and uses as described herein, employing compounds of Formula I having such particular substituents or variables, represent particular aspects of the methods and uses of the present invention. It will be further understood that each of these groupings of particular substituents and particular variables may be combined with other provided groupings, to create still additional particular aspects of the methods and uses of the present invention.

Thus, a particular aspect of the methods and uses of the present invention is one wherein the compound to be administered is a compound of Formula I, wherein: (a)"A"represents phenyl, pyridine, pyrimidine, pyrazine, thiophene, oxazole, imidazole, or thiazole; (b)"A"represents a ring selected from the following (c) "A"represents the following (d)"A"represents

(e) "B"represents phenyl, pyridine, pyrimidine, pyrazine, thiophene, oxazole, imidazole, or thiazole; (f) "B"represents an aryl or heterocyclic ring selected from the following

(g) "B"represents the following

(h)"B"represents

(i) C represents an aryl, heterocycle, or benzofused heterocycle selected from the following (j) C represents the following (k)"C"represents a benzofused heterocycle having a non-hydrogen substituent at at least one of Rl-R3, wherein said benzofused heterocycle having a non- hydrogen substituent is given by the following:

(1) "C"represents a benzofused heterocycle having a non-hydrogen substituent at at least one of Rl-R3, wherein said benzofused heterocycle having a non-hydrogen substituent is given by the following : (m. ) X-Y represents-CH2-CH2-,-CHz-O-,-O-CH2-,-CHZ-S-, -S-CH2-, -NR10-CO-, -CO-NR10-, -CH2-NR10-, -NR10CH2-,-CH=CH-, or a group of the formula wherein W and Z each represent hydrogen, fluoro, or chloro; and W'and Z'each represent hydrogen, fluoro, chloro, or methyl, and Q represents NH, O, S, or CH2 ; (n) X-Y represents-CHa-CH2-,-CH2-O-,-CH=CH-, or a group of the formula wherein W and Z each represent hydrogen, fluoro, or chloro; and W'and Z'each represent fluoro, chloro, or methyl, and Q represents NH, O, S, or CH2 ; (o) X-Y represents -O-CH2-, -CH2-S-, -S-CH2-, -NR10-CO- -CO-NR10-,-CHNRIO-, or-NR10-CH2- ; (p) X-Y represents-CH2-CH2- ;

(q) X-Y represents-CHx-0- ; (r) X-Y represents -O-CH2-; (s) X-Y represents -CH2-S-; (t) X-Y represents -S-CH2-; (u) X-Yrepresents-NR10CO-; (v) X-Y represents -NR10-CO- wherein R10 represents hydrogen or methyl; (w) X-Y represents-CO-NR10- ; (x) X-Y represents -CO-NR10- wherein R10 represents hydrogen or methyl; (y) X-Y represents-CHz-NR10- ; (z) X-Y represents-CH2-NR10-wherein R10 represents hydrogen or methyl ; (aa) X-Y represents-NR10-CH2- ; (bb) X-Y represents -NR10-CH2- wherein R10 represents hydrogen or methyl; (cc) X-Y represents-CH=CH- ; represents a double bond.

Additional particular aspects of the methods and uses of the present invention are those wherein the compound to be administered is a compound of Formula I, wherein Rl is as follows: (a) Rl represents hydrogen, halo, hydroxy, cyano, nitro, amino, oxo, (Cl- C6) alkyl, (Ci-C6) alkoxy, hydroxy (Ci-C6) alkyl, hydroxy (Ci-C6) alkoxy, (C2- C6) alkenyl, (C2-C6) alkynyl, CH2NH2, halo (CI-C6) alkyl, halo (Ci-C6) alkoxy, S02NH2, SO2NR9R10, SO2R11, NH SO2Rll, N (CH3) SO2CH3, CH2NH (SO2R11), NR9R10, NHCOR12, COR12, CHNR13, OR14, SR14, C3-C7) cycloalkyl, heterocycle, (Cl-C4) alkyl-heterocycle, or substituted heterocycle, provided that where"C"represents an aryl group then RI is other than oxo, (C2-C6) alkenyl, or (C2-C6) alkynyl ;

(b) Rl represents SO2R11, N (CH3) S02CH3, OR14, SR14, (C3-C7) cycloalkyl, (Cl-C4) alkyl-heterocycle or oxo provided"C"does not represent an aryl group when Rl is oxo; (c) RI represents hydrogen, halo, hydroxy, cyano, nitro, amino, (Cl-C6) alkyl, (Cl- C6) alkoxy, hydroxy (Ci-C6) alkyl, hydroxy (CI-C6) alkoxy, (C2-C6) alkenyl, (C2- C6) alkynyl, CH2NH2, halo (C1-C6) alkyl, halo (Ci-C6) alkoxy, S02NH2, SO2NR9R10, NHSO2R11, CH2NH(SO2R11), NR9R10, NHCOR12, COR12, CHNR13, heterocycle, substituted heterocycle, provided that where"C" represents an aryl group then Rl is other than (C2-C6) alkenyl or (C2- C6) alkynyl ; (d) Rl represents halo, hydroxy, cyano, amino, (Cl-C6) alkyl, (Cl-C6) alkoxy, hydroxymethyl, CH2NH2, CHF2, CF3, OCHF2, OCF3, S02NH2, SO2NR9R10, NH SO2R11, CH2NH (SO2Rl l), NR9R10, NHCOR12, COR127 CHN (OH), heterocycle, substituted heterocycle; Further particular aspects are those methods and uses wherein the compound to be administered is a compound of Formula I wherein Rl is as follows : (a) RI represents halo ; (b) Rl represents bromo, chloro, or fluoro; (c) RI represents hydroxy attached at the 3,4, or 5 position of ring"C"when"C" represents a six-membered ring; (d) RI represents cyano; (e) Rl represents amino; (f) Rl represents oxo provided"C"does not represent an aryl group ; (g) Rl represents methyl, ethyl, propyl, or isopropyl ; (h) Rl represents methyl; (i) Rl represents methoxy or ethoxy; (j) Rl represents methoxy; (k) RI represents hydroxymethyl ; (1) Rl represents aminomethyl; (m) Rl represents difluoromethyl, trifluoromethyl, difluoromethoxy, or trifluoromethoxy;

(n) RI represents difluoromethyl, trifluoromethyl, or difluoromethoxy; (o) Rl represents sulfonamido ; (p) R1 represents SO2NR9R10 ; (q) Rl represents SO2NR9R10, wherein R9 represents (Cl-C6) alkyl, (Cl- C6) alkoxy, (C1-C4) alkyl-(C1-C6) alkoxy, halo (CI-C6) alkyl, (C3-C7) cycloalkyl, aryl, substituted aryl, (C1-C4) alkyl-aryl, (C1-C4) alkyl-substituted aryl, heterocycle, substituted heterocycle, (C1-C4) alkyl-heterocycle, or (Cl-C4) alkyl- substituted heterocycle and R10 represents hydrogen or methyl, or R9 and R10 together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycle; (r) Rl represents S02NR9R1O, wherein R9 represents (Cl-C6) alkyl, (C1-C4) alkyl- (Cl-C6) alkoxy, halo (Ci-C6) alkyl, (C3-C7) cycloalkyl, aryl, (Ci-Ca) alkyl-aryl, heterocycle and R10 represents hydrogen or methyl, or R9 and RIO together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycle; (s) Rl represents N-(methyl)-sulfonamido, N-(ethyl)-sulfonamido, N,N- (dimethyl) sulfonamido, N- (propyl) sulfonamido, N- (benzyl)-sulfonamido, N- (2-methoxy ethyl) sulfonamido, morpholino-sulfonyl, N- (phenyl)- sulfonamido, N- (cyclopropyl)-sulfonamido, 4- (4-trifluoromethyl-phenyl)- piperidinyl sulfonamido, or N- (2, 2, 2-trifluoro-ethyl)-sulfonamido ; (t) Rl represents SO2Rl l wherein Rl l represents amino, (Cl-C6) alkyl, or morpholino; (u) Rl represents SO2R1 l wherein Rl l represents methyl; (v) Rl represents NH S02R11 ; (w) Rl represents NH SO2Rl l wherein Rl l represents amino, (C1-C6) alkyl, halo (Ci-C6) alkyl, (C1-C6) alkoxy, (C3-C7) cycloalkyl, aryl, substituted aryl, heterocycle, or substituted heterocycle ; (x) Rl represents NH SO2R1 1 wherein R11 represents amino, (C1-C6) alkyl, (Cl- C6) alkoxy, (C3-C7) cycloalkyl, aryl, substituted aryl, heterocycle, or substituted heterocycle;

(y) R1 represents NH S02R11 wherein Rl l represents (Cl-C6) aLkyl, (Cl- C6) alkoxy, (C3-C7) cycloalkyl, NH-(C1-C6) alkylamine, aryl, substituted aryl, heterocycle, or substituted heterocycle; (z) Rl represents NH S02Rl 1 wherein Rl l represents methyl, ethyl, propyl, isopropyl, butyl, or 2-methyl propyl ; (aa) Rl represents NH S02Rl 1 wherein Rl I represents methyl; (bb) Rl represents NH SO2R11 wherein R11 represents methyl and wherein said NH SO2Rl l group is attached at the 3,4, or 5 position of ring"C"when "C"represents a six-membered ring.

(cc) RI represents NH SO2R1 1 wherein RI 1 represents methyl and wherein said NH SO2R11 group is attached at the 3 or 5 position of ring"C"when"C" represents a six-membered ring.

(dd) Rl represents NH SO2R11 wherein Rl l represents trifluoromethyl or difluoromethyl; (ee) RI represents NH SO2Rl 1 wherein RI 1 represents cyclopropyl ; (ff) Rl represents NH SO2R11 wherein Rl 1 represents phenyl ; (gg) RI represents NH SO2Rl 1 wherein RI I represents phenyl substituted one to two times with a substituent individually selected from the group consisting methyl, methoxy, chloro, fluoro, and trifluoromethyl; (hh) RI represents NH S02Rl 1 wherein Rl 1 represents 4-methylphenyl, 4- fluorophenyl, 4-chlorophenyl, 4-methoxyphenyl, 3,4-dichlorophenyl, or 3- trifluoromethylphenyl, ; (ii) Rl represents NH SO2Rl I wherein Rl 1 represents heterocycle; (jj) Rl represents NH SO2R11 wherein R11 represents thiophene or imidazole; (kk) RI represents NH SO2R11 wherein R11 represents substituted heterocycle; (11) Rl represents NH SO2R1 1 wherein Rl 1 represents substituted imidazole, isoxazole, thiazole, or thiophene; (mm) Rl represents NH SO2R11 wherein R11 represents substituted imidazole, isoxazole, or thiophene; (nn) Rl represents NH S02Rll wherein R11 represents 1, 2-dimethyl-lH imidazole, 3,5-dimethylisoxazole, 1-methyl-lH imidazole, or 5-pyridin-2-yl- thiophene, or a group of the formula:

(oo) R1 represents NH SO2R11 wherein R11 represents 1, 2-dimethyl-lH imidazole, 3,5-dimethylisoxazole, 1-methyl-lH imidazole, or 5-pyridin-2-yl- thiophene; (pp) Rl represents N (CH3) S02CH3 ; (qq) Rl represents CH2NHS02CH3 (rr) Rl represents NR9R10 ; (ss) Rl represents NR9R10, wherein R9 represents (Cl-C6) alkyl or cyano and R10 represents hydrogen or methyl; (tt) Rl represents NR9RlO, wherein R9 represents (Cl-C6) alkyl and R10 represents hydrogen or methyl; (uu) RI represents methylamine or dimethylamine; (w) Rl represents NHCOR12 ; (ww) Rl represents NHCOR12 wherein R12 represents H, amino, (Cl-C6) alkyl, (Cl-C6) alkoxy, hydroxy (Cl-C6) alkyl, (Cl-C) alkyl- (Cl-C6) alkoxy, halo (C1- C6) alkyl, NH-methylamine, NH-ethylamine, or heterocycle; (xx) Rl represents NHCOR12 wherein R12 represents H, amino, (Cl-C6) alkyl, or heterocycle; (yy) Rl represents NHCOR12 wherein R12 represents H, amino, methyl, trifluoromethyl, hydroxymethyl, methoxymethyl, (zz) Rl represents NHCOR12 wherein R12 represents NH-methylamine, NH- ethylamine, or N, N-dimethylamine ; (aaa) Rl represents acetamido, isonicotinamido, or NHCONH2; (bbb) Rl represents COR12 ; (ccc) Rl represents COR12 wherein R12 represents H, amino, (Cl-C6) alkyl, (Cl- C6) alkoxy, hydroxy (Cl-C6) alkyl; (ddd) RI represents COR12 wherein R12 represents H, amino, (Cl-C6) alkyl, or heterocycle ;

(eee) Rl represents COR12 wherein R12 represents (Cl-C6) alkoxy or hydroxy (CI-C6) alkyl ; (fff) Rl represents CHO, CONH2 ; (ggg) Rl represents COOCH3 ; (hhh) Rl represents COCH20H ; (iii) Rl represents CONH (CH3) or CONH (CH2CH3) ; (jjj) Rl represents OR14 wherein R14 represents (C1-C)alkyl-heterocycle or acetyl; (kkk) Rl represents OR14 wherein R14 represents acetyl; (lll) Rl represents OR14 wherein R14 represents a group of the formula (mmm) Rl represents OR14 wherein R14 represents a group of the formula

(nnn) Rl represents SR14 wherein R14 represents methyl; (ooo) Rl represents cyclopropyl ; (ppp) Rl represents heterocycle; (qqq) Rl represents pyrazine, pyridine, pyrazole, imidazole, or isoxazole; (rrr) Rl represents pyrazin-2-yl, pyridin-2-yl, 1H pyrazol-5yl, or pyridin-3-yl; (sss) RI represents substituted heterocycle; (ttt) Rl represents substituted pyrazine, substituted pyridine, substituted pyrazole, substituted imidazole, or substituted isoxazole; or (uuu) Rl represents 4-trifluoromethyl-lH imidazolyl, 3,5-dimethyl isoxazolyl.

(aaaa) Rl represents (Cl-C4) alkyl-heterocycle; (bbbb) Rl represents a group of the formula

Additional particular aspects of the methods and uses of the present invention are those wherein the compound to be administered is a compound of Formula I, wherein R2 is as follows: (a) R2 represents hydrogen, halo, hydroxy, cyano, amino, (C1-C6) alkyl, (Cl- C6) alkoxy, hydroxymethyl, CH2NH2, halo (Ci-C6) alkyl, halo (Cl-C6) alkoxy, SO2NH2, S02NR9R1°, NH S02R11, CH2NH (SO2R11), NR9R10, NHCOR12, COR12, CHN (OH), (C3-C7) cycloalkyl, heterocycle, (Ci-C4) alkyl- heterocycle, or substituted heterocycle; (b) R2 represents hydrogen, (C3-C7) cycloalkyl, or (Cl-C4) alkyl-heterocycle ; (c) R2 represents hydrogen, halo, hydroxy, cyano, amino, (Cl-C6) alkyl, (Cl- C6) alkoxy, hydroxymethyl, CH2NH2, halo (CI-C6) alkyl, halo (Ci-C6) alkoxy, S02NH2, SO2NR9R10, NH S02Rl 1, CH2NH (SO2R11), NR9R10, NHCOR12, COR12, CHN (OH), heterocycle, or substituted heterocycle; (d) R2 represents hydrogen, halo, hydroxy, (Cl-C6) alkyl, (Cl-C6) alkoxy, CHF2, CF3, OCHF2, or OCF3 ; Further particular aspects are those methods and uses wherein the compound to be administered is a compound of Formula I wherein R2 is as follows: (a) R2 represents halo; (b) R2 represents cyclopropyl, or a group of the formula (c) R2 represents cyclopropyl ; (d) R2 represents a group of the formula (e) R2 represents a group of the formula (f) R2 represents bromo, chloro, or fluoro; (g) R2 represents hydroxy;

(h) R2 represents (Cl-C6) alkyl; (i) R2 represents methyl, isopropyl, or 2-methylpropyl; (j) R2 represents methyl ; (k) R2 represents (Cl-C6) alkoxy ; (1) R2 represents methoxy; (m) R2 represents CHF2, CF3, OCHF2, or OCF3 ; or (n) R2 represents hydrogen.

Additional particular aspects of the methods and uses of the present invention are those wherein the compound to be administered is a compound of Formula I, wherein R3 is as follows: (a) R3 represents hydrogen, halo, hydroxy, cyano, amino, (Cl-C6) alkyl, (Cl- C6) alkoxy, hydroxymethyl, CH2NH2, halo (Cl-C6) alkyl, halo (Cl-C6) alkoxy, S02NH2, SO2NR9R10, NH SO2R11, CH2NH(SO2R11), NR9R10, NHCOR12, COR12, CHN (OH), heterocycle, or substituted heterocycle; (b) R3 represents hydrogen, halo, or (Cl-C6) alkyl; (c) R3 represents halo; (d) R3 represents bromo, chloro, of fluoro ; (e) R3 represents (Cl-C6) alkyl; (f) R3 represents methyl; or (g) R3 represents hydrogen.

Additional particular aspects of the methods and uses of the present invention are those wherein the compound to be administered is a compound of Formula I, wherein R4 through R7 are as follows: (a) R4 through R7 each independently represent hydrogen, halo, hydroxy, cyano, amino, (Cl-C6) alkyl, (Cl-C6) alkoxy, hydroxymethyl, CH2NH2, CHF2, CF3, OCHF2, OCF3, SO2NH2, S02CH3, SO2NR9R10, NH SO2R11, CH2NH (SO2R11), NR9R10, NHCOR12, COR12, CHN (OH), OR14, SR14, aryl, heterocycle, or substituted heterocycle; (b) R4 through R7 each independently represent hydrogen, SO2NH2, S02CH3, OR14, SRl4, or aryl ;

(c) R4 through R7 each independently represent hydrogen, halo, hydroxy, cyano, amino, (C1-C6) alkyl, (Cl-C6) alkoxy, hydroxymethyl, CH2NH2, CHF2, CF3, OCHF2, OCF3, S02NH2, SONR9R10, NH SO2R11, CH2NH 9SO2R11), NR9R10, NHCOR12, COR12, CHN (OH), heterocycle, or substituted heterocycle; (d) R4 through R7 each independently represent hydrogen, halo, hydroxy, (Cl- C6) alkyl, (C1-C6) alkoxy, or OR14_ Further particular aspects are those methods and uses wherein the compound to be administered is a compound of Formula I wherein R4 through R7 are as follows: (a) R4 through R7 each independently represent halo; (b) R4 through R7 each independently represent bromo, chloro, or fluoro; (c) R4 through R7 each independently represent hydroxy; (d) R4 through R7 each independently represent (Cl-C6) alkyl,; (e) R4 through R7 each independently represent methyl, ethyl, isopropyl, or 2- methylpropyl (f) R4 through R7 each independently represent methyl; (g) R4 through R7 each independently represent (Cl-C6) alkoxy ; (h) R4 through R7 each independently represent methoxy, methylethoxy, ethoxy, or propyloxy; (i) R4 through R7 each independently represent methoxy ; (j) R4 through R7 each independently represent OR14 ; (k) R4 through R7 each independently represent OR14 wherein R14 represents (Cl-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, (Cl-C4) alkyl-heterocycle, or (Cl-C4) alkyl- (C3-C7) cycloalkyl; (1) R4 through R7 each independently represent OR14 wherein R14 cyclopropylmethyl, benzyl, phenylethyl, methoxyphenyl ethyl or a group of the formula (m) R4 through R7 each independently represent a group of the formula

(n) R4 through R7 each independently represent cyclopropylmethoxy ; (o) R4 through R7 each independently represent trifluoromethyl, difluoromethyl, trifluoromethoxy, or difluoromethoxy; (p) R4 through R7 each independently represent cyano, or amino; (q) R4 through R7 each independently represent hydroxymethyl or aminomethyl ; (r) R4 through R7 each independently represent SO2NH2, SO2CH3, or SCH3 ; (s) R4 through R7 each independently represent NHCOR12 or COR12 ; (t) R4 through R7 each independently represent NHCOR12 or COR12 wherein R12 represents independently at each occurrence hydrogen, amino, methyl, or methoxy; (u) R4 through R7 each independently represent phenyl; (v) R4 through R7 each independently represent NH SO2R11 ; (w) R4 through R7 each independently represent NH S02Rl 1 wherein R11 represents (Cl-C6) alkyl ; (x) R4 through R7 each independently represent NH SO2CH3 ; (y) R4 through R7 each independently represent NR9R10 ; (z) R4 through R7 each independently represent NR9R10 wherein R9 represents methyl and R10 represent methyl; (aa) R4 through R7 each independently represent hydrogen.

Still additional particular aspects of the methods and uses of the present invention are those wherein the compound to be administered is a compound of Formula I, wherein R4 and R6 are as follows: (a) R4 and R6 each independently represent hydrogen, halo, hydroxy, cyano, amino, (Cl-C6) alkyl, (Cl-C6) alkoxy, halo (Cl-C6) alkyl, hydroxymethyl, CH2NH2, SO2NH2 S02CH3, NH SO2R11, NR9R10, NHCOR12, COR12, OR14, SR14, or aryl ;

(b) R4 and R6 each independently represent hydrogen, halo, hydroxy, cyano, amino, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propyloxy, methylethoxy, difluromethyl, trifluoromethyl, hydroxymethyl, SO2CH3, NH SO2Rl l wherein Rll represents (Cl-C6) alkyl, NR9R10 wherein R9 and R10 represents (Cl-C6) alkyl, NHCOR12 wherein R12 represents (Cl-C6) alkyl; COR12 wherein R12 represents hydrogen, amino, or (Cl-C6) alkoxy; OR14 wherein R14 represents (Cl-C4) alkyl-(C3-C7) cycloalkyl, (Cl-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, or (Cl-C4) alkyl-heterocycle; SR14 wherein R14 represents (Cl-C6) alkyl; or aryl ; (c) R4 and R6 each independently represent chloro, bromo, or fluoro ; (d) R4 and R6 each independently represent hydroxy; (e) R4 and R6 each independently represent cyano, or amino ; (f) R4 and R6 each independently represent methyl, ethyl, propyl, or isopropyl ; (g) R4 and R6 each independently represent methoxy, ethoxy, propyloxy, or methylethoxy; (h) R4 and R6 each independently represent difluromethyl, trifluoromethyl, or hydroxymethyl ; (i) R4 and R6 each independently represent S02CH3 ; (j) R4 and R6 each independently represent NH SO2CH3 ; (k) R4 and R6 each independently represent dimethylamine ; (1) R4 and R6 each independently represent CHO, CONH2, or COOCH3 ; (m) R4 and R6 each independently represent OR14 wherein R14 represents (Cl- C4) alkyl- (C3-C7) cycloalkyl, (Cl-C4) alkyl-aryl, (Ci-C4) alkyl-substituted aryl, or (Cl-C4) alkyl-heterocycle; (n) R4 and R6 each independently represent OR14 wherein R14 represents cyclopropylmethyl, phenylethyl, methoxyphenyl ethyl, or a group of the formula (o) R4 and R6 each independently represent cyclopropylmethoxy ; (p) R4 and R6 each independently represent a group of the formula

(q) R4 and R6 each independently represent SCH3 ; (r) R4 and R6 each independently represent phenyl; or (s) R4 and R6 each independently represent hydrogen.

Still additional particular aspects of the methods and uses of the present invention are those wherein the compound to be administered is a compound of Formula I, wherein R5 and R7 are as follows: (a) R5 and R7 each independently represent hydrogen, hydroxxy, halo, (Cl- C6) alkyl, or (Cl-C6) alkoxy ; (b) R5 and R7 each independently represent hydroxy; (c) R5 and R7 each independently represent chloro, bromo, or fluoro : (d) R5 and R7 each independently represent methyl, or methoxy; or (e) R5 and R7 each independently represent hydrogen.

Yet additional particular aspects of the methods and uses of the present invention are those wherein the compound to be administered is a compound of Formula I, wherein R8 is as follows: (a) R8 represents hydrogen, halo, (C1-C6) alkyl, hydroxy (Cl-C6) alkyl, (Cl- C4) alkyl -(C1-C6) alkoxy, COR12, (C3-C7) cycloalkyl, aryl or substituted aryl; (b) R8 represents bromo, chloro, or fluoro; (c) R8 represents methyl, ethyl, propyl, isopropyl, or 2-methylpropyl; (d) R8 represents hydroxymethyl ; (e) R8 represents (C1-C4) alkyl- (Cl-C6) alkoxy ; (f) R8 represents methoxymethyl; (g) R8 represents COR12 wherein R12 represents methoxy, ethoxy, hydroxyamethyl, or methoxymethyl; (h) R8 represents (C3-C7) cycloalkyl; (i) R8 represents phenyl, methoxyphenyl, methylphenyl, or phenyl-phenyl; or (j) R8 represents hydrogen.

In addition, it will be understood that a most particular aspect of the methods and uses of the present invention are those wherein the compound to be administered is any compound of Formula I exemplified herein.

Particular Aspects of the Novel Compounds of the Invention As discussed previously, certain compounds of Formula I are believed to be novel and, thus, to represent another embodiment of the present invention. The following list sets out several groupings of particular substituents and particular variables of the novel compounds of Formula 1. It will be understood that novel compounds of Formula I having such particular substituents and variables represent particular aspects of the present invention. It will be further understood that each of these groupings may be combined with other provided groupings, to create still additional particular aspects of the present invention.

Thus, a particular aspect of the novel compounds of Formula I is one wherein: (a)"A"represents phenyl, pyridine, pyrimidine, pyrazine, thiophene, oxazole, imidazole, or thiazole; (b)"A"represents a ring selected from the following (c)"A"represents the following (d)"A"represents

(f) "B"represents phenyl, pyridine, pyrimidine, pyrazine, thiophene, oxazole, imidazole, or thiazole; (g) "B"represents an aryl or heterocyclic ring selected from the following

(h) "B"represents the following (i)"B"represents (j)"C"represents an aryl, heterocycle, or benzofused heterocycle selected from the following

(j)"C"represents the following

(k)"C"represents a benzofused heterocycle having a non-hydrogen substituent at at least one of Rl-R3, wherein said benzofused heterocycle having a non-hydrogen substituent is given by the following: (p) "C"represents a benzofused heterocycle having a non-hydrogen substituent at at least one of Rl-R3, wherein said benzofused heterocycle having a non- hydrogen substituent is given by the following:

(m) X-Y represents -CH2-CH2-, -CH2-O-, -O-CH2-, -CH2-S-, -S-CH2-, -NR10-CO-, -CO-NR10-, -CH2-NR10-, -NR10-CH2-, -CH=CH-, or a group of the formula wherein W and Z each represent hydrogen, fluoro, or chloro; and W'and Z'each represent hydrogen, fluoro, chloro, or methyl, and Q represents NH, O, S, or CH2; (n) X-Y represents-CH2-CH2-,-CHz-O-,-CH=CH-, or a group of the formula wherein W and Z each represent hydrogen, fluoro, or chloro; and W'and Z'each represent fluoro, chloro, or methyl, and Q represents NH, 0, S, or CH2 ; (o) X-Y represents-0-CH2-,-CH-S-,-S-CH2-,-NR10-CO- , -CO-NR10-, -CH2-NR10-, or -NR10-CH2-; (p) X-Y represents -CH2-CH2-; (q) X-Y represents-C H2-°-; (r) X-Y represents -O-CH2-;

(s) X-Y represents -CH2-S-; (t) X-Y represents-S-CH2- ; (u) X-Y represents -NR10-CO-; (v) X-Y represents -NR10-CO- wherein R10 represents hydrogen or methyl; (w) X-Y represents -CO-NR10-; (x) X-Y represents-CONR10-wherein R10 represents hydrogen or methyl; (y) X-Yrepresents-CHz--NR10- ; (z) X-Y represents-CH2NR10-wherein R10 represents hydrogen or methyl; (aa) X-Y represents-NR10-CH2- ; (bb) X-Y represents -NR10-CH2- wherein R10 represents hydrogen or methyl; (cc) X-Y represents-CH=CH- ; represents a double bond.

Additonal particular aspects of the novel compounds of the present invention are those wherein the novel compound is a compound of Formula I, wherein Rl is as follows: (a) Rl represents halo, hydroxy, cyano, nitro, amino, oxo, (Cl-C6) alkyl, (Cl- C6) alkoxy, hydroxy (Cl-C6) alkyl, hydroxy (Ci-C6) alkoxy, (C2-C6) alkenyl, (C2- C6) alkynyl, CH2NH2, halo (C1-C6) alkyl, halo (Ci-C6) alkoxy, S02NH2, SO2NR9R10, SO2R11, NHSO2R11, N (CH3) S02CH3, CH2NH (SO2Rl l), NR9R10, NHCOR12, COR12, CHNR13, OR14, SR14, (C3-C7) cycloalkyl, heterocycle, (Cl-C4) alkyl-heterocycle, or substituted heterocycle, provided that where"C"represents an aryl group then Rl is other than oxo, (C2- C6) alkenyl or (C2-C6) alkynyl ; further provided that where"C"represents a phenyl ring and Rl represents halo then at least one of R2 and R3 is other than hydrogen, (Cl-C6) alkyl, aryl, substituted aryl, (Cl-C4) alkyl-aryl, (Cl-C4) alkyl-

substituted aryl, CHF2, or CF3 ; further provided that where"C"represents a benzo-fused heterocycle then Rl may also represent hydrogen further provided that where"C"represents a six-membered ring and Rl represents cyano, amino, NR9R10, or NHCOCH3 and R2 and R3 are each hydrogen, then Rl is not bound at the 4-position of said six-membered ring; further provided that where"C"represents a six-membered ring and Rl represents nitro, and R2 and R3 are each hydrogen, then Rl is not bound at the 2,4, or 6-position of said six-membered ring; (b) Rl represents S02R1 l, N (CH3) S02CH3, ORl4, SR14, (C3-C7) cycloalkyl, (Cl-C4) alkyl-heterocycle or oxo provided"C"does not represent an aryl group when Rl is oxo; (c) Rl represents halo, hydroxy, cyano, nitro, amino, (Cl-C6) alkyl, (Cl- C6) alkoxy, hydroxy (Cl-C6) alkyl, hydroxy (Ci-C6) alkoxy, (C2-C6) alkenyl, (C2- C6) alkynyl, CH2NH2, halo (CI-C6) alkyl, halo (Ci-C6) alkoxy, SO2NH2, S02NR9RlO, NHS02Rll, CH2NH (SO2R11), NR9R10, NHCOR12, COR12 , CHNR13, heterocycle, or substituted heterocycle, provided that where"C" represents an aryl group then Rl is other than (C2-C6) alkenyl or (C2- C6) alkynyl; further provided that where"C"represents a phenyl ring and RI represents halo then at least one of R2 and R3 is other than hydrogen, (Cl- C6) alkyl, aryl, substituted aryl, (Cl-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, CHF2, or CF3 ; further provided that where"C"represents a benzo-fused heterocycle then Rl may also represent hydrogen further provided that where"C"represents a six-membered ring and Rl represents cyano, amino, NR9R10, or NHCOCH3 and R2 and R3 are each hydrogen, then Rl is not bound at the 4-position of said six-membered ring; further provided that where"C"represents a six-membered ring and R1 represents nitro, and R2 and R3 are each hydrogen, then Rl is not bound at the 2,4, or 6-position of said six-membered ring; (d) RI represents halo, hydroxy, cyano, amino, (Cl-C6) alkyl, (Cl-C6) alkoxy, hydroxymethyl, CH2NH2, CHF2, CF3, OCHF2 ,OCF3, SO2NH2, SO2NR9R10, NH S02R11, CH2NH (SO2Rl 1), NR9R10, NHCOR12, COR12 , CHN (OH), heterocycle, substituted heterocycle, provided that where"C"

represents a phenyl ring and Rl represents halo then at least one of R2 and R3 is other than hydrogen, (Cl-C6) alkyl, aryl, substituted aryl, (Cl-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, CHF2, or CF3 ; further provided that where"C" represents a benzo-fused heterocycle then Rl may also represent hydrogen; further provided that where"C"represents a six-membered ring and Ri represents cyano, amino, NR9RlO, or NHCOCH3 and R2 and R3 are each hydrogen, then RI is not bound at the 4-position of said six-membered ring; Further particular aspects are those methods and uses wherein the compound to be administered is a compound of Formula I wherein Rl is as follows: (a) R1 represents halo provided that where"C"represents a phenyl ring then at least one of R2 and R3 is other than hydrogen, (Cl-C6) alkyl, aryl, substituted aryl, (Ci-C4) alkyl-aryl, (Ci-C4) alkyl-substituted aryl, CHF2, or CF3 ; (b) Rl represents bromo, chloro, or fluoro provided that where"C"represents a phenyl ring then at least one of R2 and R3 is other than hydrogen, (Cl- C6) alkyl, aryl, substituted aryl, (Cl-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, CHF2, or CF3 ; (c) Rl represents hydroxy attached at the 3,4, or 5 position of ring"C"when"C" represents a six-membered ring; (d) RI represents cyano provided that where"C"represents a six-membered ring and R2 and R3 are each hydrogen, then Rl is not bound at the 4-position of said six-membered ring; (e) RI represents amino provided that where"C"represents a six-membered ring and R2 and R3 are each hydrogen, then Rl is not bound at the 4-position of said six-membered ring; (f) Rl represents oxo provided"C"does not represent an aryl group; (g) Rl represents methyl, ethyl, propyl, or isopropyl ; (h) Rl represents methyl; (i) Rl represents methoxy or ethoxy ; (j) Rl represents methoxy; (k) RI represents hydroxymethyl ; (1) RI represents aminomethyl;

(m) Rl represents difluoromethyl, trifluoromethyl, difluoromethoxy, or trifluoromethoxy; (n) RI represents difluoromethyl, trifluoromethyl, or difluoromethoxy; (o) Rl represents sulfonamido ; (p) Rl represents S02NR9R10 ; (q) Rl represents SO2NR9R10, wherein R9 represents (Cl-C6) alkyl, (Cl- C6) alkoxy, (C1-C40 alkyl-(C1-C6) alkoxy, halo (Ci-C6) alkyl, (C3-C7) cycloalkyl, aryl, substituted aryl, (Cl-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, heterocycle, substituted heterocycle, (Cl-C4) alkyl-heterocycle, or (Cl-C4) alkyl- substituted heterocycle and R10 represents hydrogen or methyl, or R9 and R10 together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycle; (r) Rl represents SO2NR9R10, wherein R9 represents (Cl-C6) alkyl, (C1-C4) alkyl- (Ci-Ce) alkoxy, halo (Cl-C6) alkyl, (C3-C7) cycloalkyl, aryl, (Ci-C4) alkyl-aryl, heterocycle and R10 represents hydrogen or methyl, or R9 and R10 together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycle; (s) Rl represents N-(methyl)-sulfonamido, N-(ethyl)-sulfonamido, N, N- (dimethyl) sulfonamido, N-(propyl) sulfonamindo, N-(benzyl)-sulfonamido, N- (2-methoxy ethyl) sulfonamido, morpholino-sulfonyl, N- (phenyl)- sulfonamido, N- (cyclopropyl)-sulfonamido, 4- (4-trifluoromethyl-phenyl)- piperidinyl sulfonamido, or N- (2, 2, 2-trifluoro-ethyl)-sulfonamido ; (t) RI represents SO2R11 wherein Rl 1 represents amino, (Cl-C6) alkyl, or morpholino; (u) R1 represents SO2Rl 1 wherein R11 represents methyl; (v) RI represents NH S02Rl 1 ; (w) Rl represents NH SO2R11 wherein R11 represents amino, halo (CI-C6) alkyl, (C1-C6) alkyl, (C1-C6) alkoxy, (C3-C7) cycloalkyl, aryl, substituted aryl, heterocycle, or substituted heterocycle; (x) R1 represents NH SO2Rl 1 wherein Rl 1 represents amino, (C1-C6) alkyl, (Cl- C6) alkoxy, (C3-C7) cycloalkyl, aryl, substituted aryl, heterocycle, or substituted heterocycle;

(y) Rl represents NH SO2R11 wherein Rl 1 represents (C1-C6) alkyl, (C1- C6) alkoxy, (C3-C7) cycloalkyl, aryl, substituted aryl, heterocycle, or substituted heterocycle; (z) Rl represents NH SO2R1 l wherein Rl 1 represents methyl, ethyl, propyl, isopropyl, butyl, or 2-methyl propyl ; (aa) Rl represents NH S02Rl 1 wherein Rl 1 represents methyl; (bb) Rl represents NH S02Rl 1 wherein Rl 1 represents methyl and wherein said NH SO2R1 l group is attached at the 3,4, or 5 position of ring"C"when "C"represents a six-membered ring.

(cc) Rl represents NH SO2R11 wherein R11 represents methyl and wherein said NH S02Rl 1 group is attached at the 3 or 5 position of ring"C"when"C" represents a six-membered ring.

(dd) Rl represents NH S02Rl 1 wherein Rl 1 represents trifluoromethyl or difluoromethyl; (ee) Rl represents NH S02Rl 1 wherein RI l represents cyclopropyl ; (ff) Rl represents NH SO2R11 wherein R11 represents phenyl; (gg) Rl represents NH S02Rl 1 wherein Rl 1 represents phenyl substituted one to two times with a substituent individually selected from the group consisting of methyl, methoxy, chloro, fluoro, and trifluoromethyl; (hh) Rl represents NH SO2R11 wherein R11 represents 4-methylphenyl, 4- fluorophenyl, 4-chlorophenyl, 4-methoxyphenyl, 3,4-dichlorophenyl, or 3- trifluoromethylphenyl; (ii) Rl represents NH S02Rl 1 wherein Rl 1 represents heterocycle; (jj) Rl represents NH SO2Rl l wherein Rl 1 represents thiophene or imidazole; (kk) Rl represents NH S02Rl 1 wherein Rl 1 represents substituted heterocycle; (11) Rl represents NH S02Rl 1 wherein Rl 1 represents substituted imidazole, isoxazole, thiazole or thiophene; (mm) Rl represents NH SO2R11 wherein R11 represents substituted imidazole, isoxazole, or thiophene; (nn) Rl represents NH SO2R11 wherein R11 represents 1, 2-dimethyl-lH imidazole, 3,5-dimethylisoxazole, 1-methyl-lH imidazole, or 5-pyridin-2-yl- thiophene, or a group of the formula:

(oo) R1 represents NH S02Rll wherein Rll represents 1, 2-dimethyl-lH imidazole, 3,5-dimethylisoxazole, 1-methyl-lH imidazole, or 5-pyridin-2- yl-thiophene; (pp) Rl represents N (CH3) SO2CH3 ; (qq) Rl represents CH2NHS02CH3 (rr) Rl represents NR9R10 provided that where"C"represents a six-membered ring and R2 and R3 are each hydrogen, then Rl is not bound at the 4- position of said six-membered ring; (ss) Rl represents NR9R10, wherein R9 represents (Cl-C6) alkyl or cyano and R10 represents hydrogen or methyl provided that where"C"represents a six-membered ring and R2 and R3 are each hydrogen, then RI is not bound at the 4-position of said six-membered ring; ; (tt) RI represents NR9R10, wherein R9 represents (Cl-C6) alkyl and R10 represents hydrogen or methyl provided that where"C"represents a six- membered ring and R2 and R3 are each hydrogen, then Rl is not bound at the 4-position of said six-membered ring; ; (uu) Rl represents NR9R10, wherein R9 represents (Cl-C6) aLkyl and R10 represents hydrogen or methyl provided that where"C"represents a six- membered ring and R2 and R3 are each hydrogen, then Rl is not bound at the 4-position of said six-membered ring; (w) Rl represents methylamine or dimethylamine, provided that where"C" represents a six-membered ring and R2 and R3 are each hydrogen, then R1 is not bound at the 4-position of said six-membered ring; (ww) RI represents NHCOR12 provided that where"C"represents a six- membered ring and R2 and R3 are each hydrogen, then RI is not bound at the 4-position of said six-membered ring when Rl represents NHCOCH3 ;

(xx) Rl represents NHCOR12 wherein R12 represents H, amino, (Cl-C6) alkyl, (Cl-C6) alkoxy, hydroxy (Ci-C6) alkyl, (Ci-C) alkyl- (Ci-C6) alkoxy, halo (C1- C6) alkyl, NH-methylamine, NH-ethylamine, or heterocycle, provided that where"C"represents a six-membered ring and R2 and R3 are each hydrogen, then Rl is not bound at the 4-position of said six-membered ring when Rl represents NHCOCH3; ; (yy) Rl represents NHCOR12 wherein R12 represents H, amino, (Cl-C6) alkyl, or heterocycle provided that where"C"represents a six-membered ring and R2 and R3 are each hydrogen, then Rl is not bound at the 4-position of said six-membered ring when Rl represents NHCOCH3 ; (zz) Rl represents NHCOR12 wherein R12 represents H, amino, methyl, trifluoromethyl, hydroxymethyl, methoxymethyl, provided that where"C" represents a six-membered ring and R2 and R3 are each hydrogen, then Rl is not bound at the 4-position of said six-membered ring when Rl represents NHCOCH3 ; (aaa) Rl represents NHCOR12 wherein R12 represents NH-methylamine, NH- ethylamine, or N, N-dimethylamine ; (bbb) Rl represents NHCOCH3, isonicotinamido, or NHCONH2 provided that where"C"represents a six-membered ring and R2 and R3 are each hydrogen, then R1 is not bound at the 4-position of said six-membered ring when R1 represents NHCOCH3; (ccc) R1 represents COR12 ; (ddd) R1 represents COR12 wherein R12 represents H, amino, (Cl-C6) alkyl, (Cl- C6) alkoxy, hydroxy (Cl-C6) alkyl ; (eee) Rl represents COR12 wherein R12 represents H, amino, (Cl-C6) alkyl, or heterocycle; (fff) Rl represents COR12 wherein R12 represents (Cl-C6) alkoxy or hydroxy (Ci-C6) alkyl ; (ggg) RI represents CHO, CONH2 ; (hhh) Rl represents COOCH3 ; (iii) Rl represents COCH2OH ; (jjj) Rl represents CONH (CH3) or CONH (CH2CH3) ;

(kkk) Rl represents OR14 wherein R14 represents (Cl-C) alkyl-heterocycle or acetyl; (111) Rl represents OR14 wherein R14 represents acetyl; (mmm) Rl represents OR14 wherein R14 represents a group of the formula (nnn) Rl represents OR14 wherein R14 represents a group of the formula

(ooo) RI represents SR14 wherein R14 represents methyl; (ppp) R1 represents cyclopropyl ; (qqq) Rl represents heterocycle; (rrr) Rl represents pyrazine, pyridine, pyrazole, imidazole, or isoxazole; (sss) RI represents pyrazin-2-yl, pyridin-2-yl, 1H pyrazol-5yl, or pyridin-3-yl; (ttt) Rl represents substituted heterocycle; (uuu) Rl represents substituted pyrazine, substituted pyridine, substituted pyrazole, substituted imidazole, or substituted isoxazole; or (vvv) Rl represents 4-trifluoromethyl-lH imidazolyl, 3, 5-dimethyl isoxazolyl.

(www) Rl represents (C1-C4) alkyl-heterocycle ; (xxx) Rl represents a group of the formula

Additional particular aspects of the novel compounds of the present invention are those wherein the compound of Formula I is one wherein R2 is as follows: (a) R2 represents hydrogen, halo, hydroxy, cyano, amino, (Cl-C6) alkyl, (Cl- C6) alkoxy, hydroxymethyl, CH2NH2, halo (Ci-C6) alkyl, halo (Cl-C6) alkoxy, S02NH2, SONR9RlO, NH SO2Rl l, CH2NH (SO2R11), NR9R10, NHCOR12, COR12, CHN (OH), (C3-C7) cycloalkyl, heterocycle, (Cl-C4) alkyl- heterocycle, or substituted heterocycle;

(b) R2 represents hydrogen, (C3-C7) cycloalkyl, or (Cl-C4) alkyl-heterocycle ; (c) R2 represents hydrogen, halo, hydroxy, cyano, amino, (C1-C6) alkyl, (Cl- C6) alkoxy, hydroxymethyl, CH2NH2, halo (C1-C6) alkyl, halo (C1-C6) alkoxy, SO2NH2, SO2NR9R10, NH SO2R11, CH2NH(SO2R11), NR9R10, NHCOR12, COR12, CHN (OH), heterocycle, or substituted heterocycle; (d) R2 represents hydrogen, halo, hydroxy, (Ci-C6) alkyl, (C1-C6) alkoxy, CHF2, CF3, OCHF2, or OCF3 ; Further particular aspects are those novel compounds wherein the compound of Formula I is one wherein R2 is as follows: (a) R2 represents halo; (b) R2 represents cyclopropyl, or a group of the formula

(c) R2 represents cyclopropyl ; (d) R2 represents a group of the formula (e) R2 represents a group of the formula

(f) R2 represents bromo, chloro, or fluoro; (g) R2 represents hydroxy; (h) R2 represents (Cl-C6) alkyl; (i) R2 represents methyl, isopropyl, or 2-methylpropyl; (j) R2 represents methyl; (k) R2 represents (Cl-C6) alkoxy;

(1) R2 represents methoxy; (m) R2 represents CHF2, CF3, OCHF2, or OCF3 ; or (n) R2 represents hydrogen.

Additional particular aspects of the novel compounds of the present invention are those wherein the compound of Formula I is one wherein R3 is as follows: (a) R3 represents hydrogen, halo, hydroxy, cyano, amino, (Cl-C6) alkyl, (Cl- C6) alkoxy, hydroxymethyl, CH2NH2, halo (CI-C6) alkyl, halo (Cl-C6) alkoxy, SO2NH2, SO2NR9R10, NH SO2R11, CH2NH (SO2R11), NR9R10, NHCOR12, COR12, CHN (OH), heterocycle, or substituted heterocycle; (b) R3 represents hydrogen, halo, or (Cl-C6) alkyl; (c) R3 represents halo; (d) R3 represents bromo, chloro, of fluoro ; (e) R3 represents (Cl-C6) alkyl ; (f) R3 represents methyl; or (g) R3 represents hydrogen.

Additional particular aspects of the novel compounds of the present invention are those wherein the compound of Formula I is one wherein R4 through R7 are as follows: (a) R4 through R7 each independently represent hydrogen, halo, hydroxy, cyano, amino, (Cl-C6) alkyl, (C1-C6) alkoxy, hydroxymethyl, CH2NH2, CHF2, CF3, OCHF2, 0CF3, SO2NH2, SO2CH3, SO2NR9R10, NH SO2Rl 1, CH2NH (SO2R11), NR9R10, NHCOR12, COR12, CHN (OH), OR14, SR14, aryl, heterocycle, or substituted heterocycle; (b) R4 through R7 each independently represent hydrogen, SO2NH2, S02CH3, OR14, SR14, or aryl; (c) R4 through R7 each independently represent hydrogen, halo, hydroxy, cyano, amino, (C1-C6) alkyl, (C1-C6) alkoxy, hydroxymethyl, CH2NH2, CHF2, CF3, OCHF2, 0CF3, S02NH2, SO2NR9R10, NH S02R11, CH2NH (SO2R11), NR9R10, NHCOR12, COR12, CHN (OH), heterocycle, or substituted heterocycle;

(c) R4 through R7 each independently represent hydrogen, halo, hydroxy, (Cl- C6) alkyl, (Cl-C6) alkoxy, or OR14 ; Further particular aspects are those compounds of Formula I wherein R4 through R7 are as follows: (a) R4 through R7 each independently represent halo; (b) R4 through R7 each independently represent bromo, chloro, or fluoro; (c) R4 through R7 each independently represent hydroxy; (d) R4 through R7 each independently represent (Cl-C6) alkyl; (e) R4 through R7 each independently represent methyl, ethyl, isopropyl, or 2- methylpropyl ; (f) R4 through R7 each independently represent methyl; (g) R4 through R7 each independently represent (Cl-C6) alkoxy ; (h) R4 through R7 each independently represent methoxy, methylethoxy, ethoxy, or propyloxy; (i) R4 through R7 each independently represent methoxy; (j) R4 through R7 each independently represent OR14 ; (k) R4 through R7 each independently represent OR14 wherein R14 represents (Cl-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, (Cl-C4) alkyl-heterocycle, or (C1-C4) alkyl-(C3-C7) cycloalkyl ; (1) R4 through R7 each independently represent OR14 wherein R14 cyclopropylmethyl, benzyl, phenylethyl, methoxyphenyl ethyl or a group of the formula (m) R4 through R7 each independently represent a group of the formula (n) R4 through R7 each independently represent cyclopropyhnethoxy ; (o) R4 through R7 each independently represent trifluoromethyl, difluoromethyl, trifluoromethoxy, or difluoromethoxy;

(p) R4 through R7 each independently represent cyano, or amino; (q) R4 through R7 each independently represent hydroxymethyl, or aminomethyl; (r) R4 through R7 each independently represent SO2NH2, SO2CH3, or SCH3 ; (s) R4 through R7 each independently represent NHCOR12 or COR12; (t) R4 through R7 each independently represent NHCOR12 or COR12 wherein R12 represents independently at each occurrence amino, methyl, or methoxy; (u) R4 through R7 each independently represent phenyl; (v) R4 through R7 each independently represent NH S02R1 l ; (w) R4 through R7 each independently represent NH SO2R1 1 wherein Rl represents (Cl-C6) alkyl; (x) R4 through R7 each independently represent NH SO2CH3 ; (y) R4 through R7 each independently represent NR9R10; (z) R4 through R7 each independently represent NR9R10 wherein R9 represents methyl and R10 represent methyl; (aa) R4 through R7 each independently represent hydrogen.

Still additional particular aspects of the novel compounds of the present invention are those wherein the compound is a compound of Formula I, wherein R4 and R6 are as follows: (a) R4 and R6 each independently represent hydrogen, halo, hydroxy, cyano, amino, (Cl-C6) alkyl, (Cl-C6) alkoxy, halo (Cl-C6) alkyl, hydroxymethyl, CH2NH2, SO2NH2, S02CH3, NH SO2R11, NR9R10, NHCOR12, COR12, OR14, SR14, or aryl; (b) R4 and R6 each independently represent hydrogen, halo, hydroxy, cyano, amino, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propyloxy, methylethoxy, difluromethyl, trifluoromethyl, hydroxymethyl, S02CH3, NH S02Rl 1 wherein Rl 1 represents (Cl-C6) alkyl, NR9R10 wherein R9 and R10 represents (Cl-C6) alkyl, NHCOR12 wherein R12 represents (Cl-C6) alkyl; COR12 wherein R12 represents hydrogen, amino, or (Cl-C6) alkoxy ; OR14 wherein R14 represents (Cl-C4) alkyl-(C3-C7) cycloalkyl, (Cl-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, or (Cl-C4) alkyl-heterocycle; SR14 wherein R14 represents (Cl-C6) alkyl ; or aryl;

(c) R4 and R6 each independently represent chloro, bromo, or fluoro; (d) R4 and R6 each independently represent hydroxy; (e) R4 and R6 each independently represent cyano, or amino ; (f) R4 and R6 each independently represent methyl, ethyl, propyl, or isopropyl ; (g) R4 and R6 each independently represent methoxy, ethoxy, propyloxy, or methylethoxy; (h) R4 and R6 each independently represent difluromethyl, trifluoromethyl, or hydroxymethyl; (i) R4 and R6 each independently represent SO2CH3 ; (j) R4 and R6 each independently represent NH S02CH3 ; (k) R4 and R6 each independently represent dimethylamine ; (1) R4 and R6 each independently represent CHO, CONH2, or COOCH3 ; (m) R4 and R6 each independently represent OR14 wherein R14 represents (Cl- C4) alkyl- (C3-C7) cycloalkyl, (Cl-C4) alkyl-aryl, (Cl-C4) alkyl-substituted aryl, or (Cl-C4) alkyl-heterocycle; (n) R4 and R6 each independently represent OR14 wherein R14 represents cyclopropylmethyl, phenylethyl, methoxyphenyl ethyl, or a group of the formula

(o) R4 and R6 each independently represent cyclopropylmethoxy ; (p) R4 and R6 each independently represent a group of the formula

(q) R4 and R6 each independently represent SCH3; and (r) R4 and R6 each independently represent phenyl; (s) R4 and R6 each independently represent hydrogen;

Still additional particular aspects of the novel compounds of the present invention are those wherein the compound is a compound of Formula I, wherein R5 and R7 are as follows: (a) R5 and R7 each independently represent hydrogen, hydroxxy, halo, (C1- C6) alkyl, or (C1-C6) alkoxy ; (b) R5 and R7 each independently represent hydroxy; (c) R5 and R7 each independently represent chloro, bromo, or fluoro; (d) R5 and R7 each independently represent methyl, or methoxy; (e) R5 and R7 each independently represent hydrogen; Yet additional particular aspects of the novel compounds of the present invention are those wherein the compound of Formula I is one wherein R8 is as follows: (a) R8 represents hydrogen, halo, (C1-C6) alkyl, hydroxy (Cl-C6) alkyl, (C1- C4) alkyl- (CI-C6) alkoxy, COR12, (C3-C7) cycloalkyl, aryl or substituted aryl; (b) R8 represents bromo, chloro, or fluoro ; (c) R8 represents methyl, ethyl, propyl, isopropyl, or 2-methylpropyl; (d) R8 represents hydroxymethyl; (e) R8 represents (C1-C4) alkyl- (Cl-C6) alkoxy; (f) R8 represents methoxymethyl ; (g) R8 represents COR12 wherein R12 represents methoxy, ethoxy, hydroxyamethyl, or methoxymethyl ; (h) R8 represents (C3-C7) cycloalkyl; (i) R8 represents phenyl, methoxyphenyl, methylphenyl, or phenyl-phenyl; (j) R8 represents hydrogen.

In addition, it will be understood that a most particular aspect of the novel compounds of the present invention are those wherein the compound is any novel compound of Formula I exemplified herein.

Compounds of the present invention, including novel compounds, can be further divided into sections as represented by Formulas I (a) through I (g) below. As such, methods and uses employing compounds of Formula I (a) -I (g), as well as novel compounds of Formula I (a) -I (g), represent more particular aspects of the present

invention. Section 1, as given by Formula I (a), contains derivatives of Formula I having substitution on the"C"ring but not on the"A"or"B"rings. Section 2, as given by Formula I (b), contains derivatives of Formula I having substitution on the"C"ring and further on the"A"and/or"B"rings. Section 3, as given by Formula I (c), contains derivatives of Formula I wherein the"C"ring further represents a heterocyclic or benzofused heterocyclic. Section 4, as given by Formula I (d), contains derivatives of Formula I wherein the"A"and/or"B"ring further represents a heterocyclic ring.

Section 5, as given by Formula I (e), contains derivatives of Formula I wherein the bridge depicted by-X-Y-represents a fused cyclopropyl structure. Section 6, as given by Formula I (f), contains derivatives of Formula I wherein the bridge depicted by-X-Y- contains a heteroatom or heteroatom containing group at either the X or Y position.

Finally, Section 7, as given by Formula I (g), contains derivatives of Formula I wherein R8 is other than hydrogen and the bridge depicted by-X-Y-contains either a heteroatom or heteroatom containing group at either the X or Y position or both X and Y are CH2.

Formula I (a) wherein represents a double bond; Rl represents hydrogen, halo, hydroxy, cyano, nitro, amino, (Cl-C6) alkyl, (Cl- C6) alkoxy, halo (Cl-C6) alkyl, hydroxy (Cl-C6) alkyl, halo (Ci-C6) alkoxy, S02NR9RlO, SO2Rll, NHSO2Rll, CH2NHSO2Rll, N (CH3) SO2Rl-l, NR9R10, NHCOR12, COR12, CH2NH2, SR14, heterocycle, or substituted heterocycle; R2 represents hydrogen, halo, hydroxy, (Cl-C6) alkyl, (Cl-C6) alkoxy, or halo (Cl- C6) alkyl ;

R3 represents hydrogen or halo; R9 represents independently at each occurrence cyano, (Cl-C6) alkyl, (Cl-C4) alkyl- (Cl-C6) alkoxy, halo (Cl-C6) alkyl, (C3-C7) cycloalkyl, aryl, or (Cl-C4) alkyl-aryl; R10 represents independently at each occurrence hydrogen or (CI-C6) alkyl, or R9 and R10 together with the nitrogen to which they are attached form a substituted or unsubstituted heterocycle RI l represents independently at each occurrence amino, (Ci-C6) alkyl, halo (Cl- C6) alkyl, NH- (Ci-C6) alkylamine, N,N-(C1-C6) dialkylamine, aryl, substituted aryl, heterocycle, or substituted heterocycle; R12 represents independently at each occurrence H, amino, (C1-C6) alkyl, or heterocycle; and R14 represents (Cl-C6) alkyl.

Formula I (b) wherein represents a double bond ; Rl represents hydrogen, halo, hydroxy, cyano, amino, (Cl-C6) alkyl, (C1- C6) alkoxy, halo (Cl-C6) alkyl, halo (Cl-C6) alkoxy, NHSO2R11, NR9R10, CH2NH (SO2Rll), NHCOR12, COR12, OR14 ; R2 represents hydrogen or halo; R3 represents hydrogen; R4 and R6 each independently represent hydrogen, halo, hydroxy, cyano, amino, (Cl-C6) alkyl, (Ci-C6) alkoxy, halo (Cl-C6) alkyl, NHSO2R11, NR9R10, NHCOR12, COR12, OR14, SO2R11, SR14, aryl, or heterocycle ;

R5 and R7 each independently represent hydrogen, halo, hydroxy, or (C1- C6) alkoxy ; R9 represents independently at each occurrence cyano or (Cl-C6) alkyl; R10 represents independently at each occurrence hydrogen or (Cl-C6) alkyl ; Rl 1 represents independently at each occurrence amino, (Cl-C6) alkyl, halo (C1- C6) alkyl, NH-(C1-C6) alkylamine, N, N- (Cl-C6) dialkylamine, aryl, substituted aryl, heterocycle, or substituted heterocycle; R12 represents independently at each occurrence H, amino, (Cl-C6) alkyl, (C1- C6) alkoxy, hydroxy (C1-C6) alkyl, (Ci-C) alkyl- (CI-C6) alkoxy, halo (Cl-C6) alkyl, NH- methylamine, NH-dimethylamine, NH-ethylamine, or heterocycle; and R14 represents independently at each occurrence (Cl-C6) alkyl, (Cl-C4) alkyl-aryl, (C1-C4) alkyl-substituted aryl, (C1-C4) alkyl-heterocycle, or (Cl-C4) alkyl-(C3-C7)cycloalkyl.

Formula I (c) wherein represents a double bond "C"represents a heterocycle or benzofused heterocycle ring; Rl represents hydrogen, halo, hydroxy, amino, oxo, (Cl-C6) alkyl, (Cl-C6) alkoxy, NHSO2R11, or (Cl-C4) alkyl-heterocycle; R2 represents hydrogen, halo, (Ci-C6) alkyl, (C3-C7) cycloalkyl, heterocycle, or (Cl- C4) alkyl-heterocycle; R3 represents hydrogen; R4 and R6 each independently represent hydrogen, halo, hydroxy, cyano, amino, (C1-C6) alkyl, (C1-C6) alkoxy, or halo (Cl-C6) alkyl ;

R5 and R7 each independently represent hydrogen, halo, hydroxy, (Cl-C6) alkyl, or (Cl-C6) alkoxy; and R11 represents (Cl-C6) alkyl.

Formula I (d) wherein "A"and"B", each independently represent phenyl or a heterocycle, provided at least one of"A"and"B"is a heterocycle; "C"is as previously defined; represents a double bond Rl represents hydrogen, halo, hydroxy, amino, oxo, (Cl-C6) alkyl, (Cl-C6) alkoxy, halo (Cl-C6) alkyl, NHSO2R11, NHCOR12, COR12, (C3-C7) cycloalkyl, heterocycle, or (Cl-C4) alkyl-heterocycle, provided that when"C"represents aryl then Rl is other than oxo; R2 represents hydrogen, halo, hydroxy, (C1-6) alkyl, or (C3-C7) cycloalkyl ; R3 represents hydrogen; R4 and R6 each independently represent hydrogen, halo, hydroxy, cyano, amino, (Cl-C6) alkyl, (Cl-C6) alkoxy, halo (Ci-C6) alkyl, or NHCOR12 ; R5 and R7 each independently represent hydrogen or halo; Rl 1 represents (Cl-C6) alkyl or aryl; and R12 represents independently at each occurrence (Cl-C6) alkyl or (Cl-C6) alkoxy.

Formula I (e)

Wherein W and Z each independently represent hydrogen, fluoro, or chloro represents a double bond "C"represents phenyl or benzofused heterocycle; Rl represents hydrogen, hydroxy, amino, oxo, or NHS02Rl l, provided that when "C"represents aryl then Rl is other than oxo; R2 and R3 each represent hydrogen; and Rll represents (Cl-C6) alkyl.

Formula I (f)

wherein represents a double bond; "A"and"B"represent phenyl or heterocycle and"C"is as previously defined; X and Y together represent -CH2-O-, -O-CH2-, -CH2-S-, -S-CH2-, <BR> <BR> - CH2-,-CH, NR10-,-NR10 CH2-,-NR10-CO-, or-CO-NR10-, wherein R10 is as previously defined ;

Rl represents hydrogen, halo, hydroxy, amino, oxo, (Cl-C6) alkyl, (Ci-C6) alkoxy, halo (Cl-C6) alkyl, hydroxy (Cl-C6) alkyl, NHSO2R11, CH2NH(SO2R11), NHCOR12, COR12, oR14, (C3-C7) cycloalkyl, or (Cl-C4) alkyl-heterocycle, provided that when"C" represents aryl then Rl is other than oxo; R2 represents hydrogen, halo, (C1-C6) alkyl, (C3-C7) cycloalkyl, heterocycle, or (C1- C4) alkyl-heterocycle; R3 represents hydrogen, or (Cl-C6) alkyl ; R4 and R6 each independently represent hydrogen, halo, (C1-C6) alkyl, (Cl- C6) alkoxy, halo (Cl-C6) alkyl, or COR12 ; and R5 and R7 each independently represent hydrogen, halo, (C1-C6) alkyl, or (C1- C6) alkoxy.

R10 represents independently at each occurrence hydrogen (Cl-C6) alkyl ; RI 1 represents independently at each occurrence (Cl-C6) alkyl, halo (C x aryl, substituted aryl, or (C3-C7) cycloalkyl ; R12 represents independently at each occurrence (Cl-C6) alkyl, (C1-C6) alkoxy, NH-methylamine, NH-dimethylamine, or NH-ethylamine; and R14 represents acetyl.

Formula I (g) wherein represents a double bond; "A"and"B"represent phenyl or heterocycle and"C"is as defined previously;

X and Y together represent-CHz-O-,-O-CH2-,-CH2-S-,-S-CH2-, - CH2-SO-, -SO-CH2-, -CH2-SO2-, -SO2-CH2-, -CH2-NR10-, -NR10- CH2-,-NR'O-CO-, or-CO-NR10--, Rl represents hydrogen, halo, hydroxy, amino, oxo, and NHSO2Rl l, provided that when"C"represents aryl then Rl is other than oxo; R2 and R3 each individually represent hydrogen or halo ; R4 and R6 each independently represent hydrogen, halo, (Cl-C6) alkyl, (Cl- C6) alkoxy, or OR14 ; R5 and R7 each independently represent hydrogen or halo; R8 represents halo, (Cl-C6) alkyl, (Cl-C6) alkoxy, hydroxy (Cl-C6) alkyl, (Cl- C4) alkyl- (Cl-C6) alkoxy, COR12, aryl, or substituted aryl; RIO represents hydrogen or (Cl-C6) alkyl; Rl 1 represents (Cl-C6) alkyl ; R12 represents (Cl-C6) alkoxy; and R14 represents (C1-C4)alkyl-(C3-C7)cycloalkyl.

Further particular aspects of the methods and uses employing compounds of Formula I (a)-I (g) are provided by the groupings of particular substituents and particular variables, as set forth above, for the methods and uses employing compounds of Formula I, generally. Further particular aspects of the novel compounds of Formula I (a) -I (g) are provided by the groupings of particular substituents and particular variables, as set forth above, for the novel compounds of Formula I, generally.

All of the compounds of Formula I, including the novel compounds of Formula I, can be can be chemically prepared, for example, by following the synthetic routes set forth in the Schemes below. However, the following discussion is not intended to be limiting to the scope of the present invention in any way. For example, the specific synthetic steps for the routes described for the synthesis of compounds of a particular section herein, may be combined in different ways, or in conjunction with steps from different schemes, to prepare additional compounds of Formula I or compounds of a different section. For example, the conditions described in Scheme VII, Step C may be employed to synthesize the final products of many of the compounds of Formula I

including, for example, derivatives wherein the bridge depicted by-X-Y-contains a heteroatom or heteroatom containing group at either the X or Y position.

All substituents, unless otherwise indicated, are as previously defined. The reagents and starting materials are readily available to one of ordinary skill in the art. For example, certain reagents or starting materials can be prepared by one of ordinary skill in the art following procedures disclosed in J. Prakt. Chem. 333 (4) (1991); J. Marsh, Advanced Organic Chemistry (4th edition) ; J. Med. Chem. (1990); J. S. Buck and W. S. Ide, Organic Synthesis Coll. Vol. II, 622-623, (1943) J. P. Wolfe and S. L. Buchwald, Organic Synthesis, (78) 23-31 (2000); Tetrahedron Letters, 39 (51) 9365-9368 (1998); F. Kurzer, Organic Synthesis, Coll. Vol. (IV) 49 (1963); and Synthetic Communications, 1129-1135 (1991). Additional reagents, starting materials, or useful procedures may be found in M Kurokawa, F Sato, Y Masuda, T Yoshida and Y Ochi, Chem. Phare. Bull., 39; 10; (1991) 2564-5273, Y Ohishi, H Yoshitaka, M Mitsuo, T Mukai, K Kimura, M Nagahara, Chem.

Pharm. Bull., 38; 4; (1990) 1066-1068, Inman, Raiford, JACS ; 56 (1934) 1586-1587, Clark, Pessolano, JACS ; 80 (1958) 1662, P. Bollinger, P. Cooper.; H. U. Gubler, A.

Leutwiler, T. PayneHelv. Chim. Acta ; 73; (1990); 1197, G. Vassilikogiannakis, M.

Hatzimarinaki, M. Orfanapoulos J. Org Chem., 65,8180 ; Y. Girard, J. G. Atkinson, P. C.

Belanger, J. J. Fuentes, J. Rokach, C. S. Rooney, D. C. Remy, C. A. Hunt J Org.

Chem., 48; (1983); 3220, D. S. Matteson, D. Majumder Organometallics, 2; (1983); 230; Journal of Heterocyclic Chemistry, 73; (1971) Journal of Medicinal Chemistry, 33; (1990); 3095, Journal of Organic Chemistry, 60; (1995); 7508, Bergmann, E. D., Solomonovici, A., Synthesis, (1970); 183-189, Poirier et al. , Org Letters, 3; 23; (2001); 3795-3798, Spanish Patent ES2092957 Al (1996); Brown, C. , et al. , J. Chem. Soc. , Perkin Trans. 1, 3007 (1982); Deck, L. M. , et al. , Org. Prep. Proceed. Int. , 22 (4); 495-500, (1990); Lee, J. C. , et al. , Synth. Comm. , 25 (9), 1367-1370 (1995); Ho, Z. C. , et al., Tetrahedron, 52 (41), 13189-13200 (1996); M Murata, T Takashi, S Watanabe and Y Yusuru, J. Org.

Chem. ; 65 (1) 164-168 (2000); and T. Ishiyama, M. Murata, N. Miyaura, J. Org. Chem., 60 (23), 7508-7510 (1995). Other necessary reagents and starting material may be made by procedures which are selected from standard techniques of organic and heterocyclic chemistry, techniques which are analogous to the syntheses of known structurally similar compounds, and the procedures described in the Examples below, including any novel procedures.

Scheme I provides procedures for the synthesis of compounds of Formula I wherein the bond represented by"-----"attached to the tricyclic core is a double bond and at least one of Rl through R3 is, for example, an N-substituted-or unsubstituted- sulfonamido group.

Scheme I R4 R6 4, TR Step, AStep B R5 R7 S02CI o SO3Et 6 o R4 R6 w i (1) (2) R5 R7 HO3S (3) (4) Step C SOC) r I SO2CI R4 \ R6 R4 R6 R5 R7 Step D R5 R7 R"R'N02s CIO2 s (5}

In Scheme I, Step A, a substituted or unsubstituted toluenesulfonyl chloride derivative of formula (1) is reacted with an excess of ethanol in an inert solvent such as dioxane at about 0 to 50°C for about 10 to 48 hours, according to a procedure similar to that in J. Prakt. Chem. 333 (4) (1991). The HC1 produced is neutralized in situ with a base, such as triethylamine or pyridine, with the progress of the reaction being followed by tlc. After work-up, the crude product can be purified using silica gel to give sulfate ester of formula (2).

In Scheme I, Step B, the anion of the methyl sulfate ester of formula (2) is first generated using an appropriate base, such as n-butyl-Li, sec-butyl-Li, or t-butyl-Li at about-78 to 25°C, in an inert solvent such as THF. For a general discussion of anion formation see J. Marsh, Advanced Organic Chemistry (4th edition) 606-610. After generation of the anion is complete, a tricyclic, for example substituted or unsubstituted dibenzosuberane (formula (3) ), is added. During acidic work-up, the carbinol dehydrates to the olefin and the sulfate ester hydrolyzes to the corresponding sulfonic acid to provide the compound of formula (4).

In Scheme I, Step C, using thionyl chloride and following methods well known to one of ordinary skill in the art, the sulfonic acid is converted to the corresponding sulfonyl chloride of formula (5). Inert solvents, such as methylene chloride, may be used and a catalytic amount of N, N-dimethylformamide increases the reaction rate. (J. Marsh, Advanced Organic Chemistry (4th ed. ); 499) provides a detailed description and additional literature references.

In Scheme I, Step D, the sulfonyl chloride is reacted with an excess of a substituted or unsubstituted amine, at about 10 to 60°C for 2 to 24 hours, in an inert solvent such as THF, dioxane or methylene chloride (which may contain an acid scavenger such as pyridine or triethylamine) to provide the compound of Formula I, wherein at least one of Rl through R3 is, for example, an N-substituted-or unsubstituted- sulfonamido group. The product can then be purified using standard techniques such silica gel chromatography, eluting with suitable eluent such as ethyl acetate and hexane.

Scheme II provides procedures for the synthesis of compounds of Formula I wherein the bond represented by attached to the tricyclic core is a double bond and at least one of Rlthrough R3 is, for example, halo or (Cl-C4) alkoxy.

Scheme II R4 R6 R4 R6 _ i Step A R5 R7 (3) H z z ho liz z (3)"ifL z (6) (7) (Z is for example halo or C1-C4 alkoxy) Step B R4 R6 i R5 R7 Formula I (at least one of R1 R3 is Z ; Z is halo or C1-C4 alkoxy) z

In Scheme It, Step A, the lithium anion of dibenzosuberane is first generated using an appropriate base such as n-butyl-Li, sec-butyl-Li, or t-butyl-Li at about-78 to 25°C in an inert solvent such as THF, diethyl ether, or diglyme, for about 0.5-5 hours. After anion generation is complete, the solution is cooled to about-25 to 10°C and a solution of an unsubstituted or substituted benzaldehyde derivative of formula (6) is added and the corresponding carbinol of formula (7) is isolated.

In Scheme II, Step B, the carbinol is dehydrated to the corresponding olefin derivative using 1-25% concentrated H2SO4 in glacial acetic acid at a temperature of about 25 to 100°C, for about 1 to 24 hours. The product of Formula I, wherein at least one of Rl through R3 is ; for example, halo or (Cl-C4) alkoxy, can then be purified using standard techniques such silica gel chromatography, eluting with suitable eluent such as ethyl acetate and hexane.

Scheme ni provides procedures for the synthesis of compounds of Formula I wherein the bond represented by attached to the tricyclic core is a double bond and at least one of Rl through R3 is, for example, hydroxy, difluoromethoxy, trifluoromethoxy, and the like R4 R6 R4 R6 R4 R6 w i w i I Step A3 R5I R7 Step B RS<R7 MeO HO RO Ho ru RO Formula I Formula I Formula I (at least one of R1 R3 is OMe) (at least one of R1 R3 is OH) (at least one of R1 R3 is OR ; R is for example CHF2 or CF3)

Scheme m In Scheme III, Step A, a compound of Formula I, wherein at least one of Rl through R3 is methoxy, is readily converted to a phenol derivative by treatment with either pyridine hydrochloride or boron tribromide. For a more detailed discussion of the formation of phenols from methyl ethers see J. Marsh, Advanced Organic Chemistry (4th edition) 433-434.

In Scheme m, Step B, the phenol derivative of Formula I may be converted, for example, to a fluoromethoxy derivative using standard procedures as detailed in J. Med.

Chem. 1230-1241 (1990). The products of Formula I can all be purified using standard techniques known in the art, such as silica gel chromatography with a suitable eluent such as ethyl acetate and hexane.

Schemes IV (a) -IV (d) provide yet additional procedures for the synthesis of compounds of Formula I wherein the bond represented by attached to the tricyclic core is a double bond. For example, Scheme IV (a) provides procedures for synthesizing compounds of Formula I wherein at least one of Rl through R3 is a heterocyclic group.

Scheme IV (a) R4 R6 R4 R6 i _ i_ J C Step A 0/n\N OH>ZB i Formula I (8) Step B I R4 R6 R5 R7 R5 R7 Het Formula I

In Scheme IV (a), Step A, the lithium anion of the aryl halide derivative of Formula I (at least one of Rl through R3 is halo) is first generated by dissolving the aryl halide derivative in a suitable solvent such as THF, diethyl ether, or dioxane, cooling to a temperature of about-78 to-25°C, followed by addition of an appropriate base such as n- butyl-Li, sec-butyl-Li, or t-butyl-Li. The reaction is stirred for about 10 to 45 minutes to generate the anion. The boronic acid derivatives of formula (8) are prepared by quenching the anion of Formula I with triisopropyl borate followed by acidic hydrolysis.

In Scheme IV (a), Step B, following procedures well known in the art, the compound of formula (8) is treated under standard conditions with a compound of the general formula Het-Hal, (wherein Het is a heterocyclic moiety and Hal is bromo, chloro, or iodo) to provide the compound of Formula I wherein at least one of RI through R3 is a heterocyclic moiety.

Scheme IV (b) R4 R6 R4 R6 R5 R7 R5 R7 Step C N halo CIZOS Formula I (g) Step D r R4 R6 R5 R7 R"R'N02S Formula I

In Scheme IV (a), Step C, the lithium anion of the aryl bromide derivative of Formula I (at least one of Rl through R3 is halo) is first generated by dissolving the aryl halide derivative in a suitable solvent such as THF, diethyl ether, or dioxane, cooling to a temperature of about-78 to-25°C, followed by addition of an appropriate base such as n- butyl-Li, sec-butyl-Li, or t-butyl-Li. The reaction is stirred for about 10 to 45 minutes to generate the anion. Using standard techniques, the aryl sulfonyl chloride of formula (9) is prepared by quenching the aryl halide anion with sulfuryl chloride.

In Scheme IV (b), Step D, the aryl sulfonyl chloride derivative of formula (9) is treated with N-substituted-or unsubstituted-amines, as previously described in Scheme I above, to provide the compound of Formula I, wherein at least one of Rl through R3 is, for example, an N-substituted-or unsubstituted sulfonamide. The product can then be purified using standard techniques such silica gel chromatography, eluting with suitable eluent such as ethyl acetate and hexane.

Scheme IV (c) R4 Step R4 R6 w i w R5 I R7 Ste E R5/I R7 halo NC Formula I Formula I StepF (b)/ Step F (b) Step F (a) R4 Step R4 R6 R5 R7 R5 R7 R5 R7 R5 R7 NH2C H2 Formula I Formula I (at least one of R1 R3 is CH2NH2) (at least one of R1 R3 is CONH2)

In Scheme IV (c), Step E, the aryl halide derivative is dissolved in a suitable solvent, such as N-methylpyrrolidinone (NMP), and sparged with nitrogen for 5-15 minutes. Solid CuCN and CuI are added and the reaction is heated to-a temperature ranging from about 100 to 150°C for 1 to 24 hour. The reaction is then cooled and shaken with aqueous ferric chloride and ethyl acetate, to provide the benzonitrile derivative of

Formula I. The product can then be purified using standard techniques such silica gel chromatography, eluting with suitable eluent such as ethyl acetate and hexane.

In Scheme IV (c), Step F (a), the benzonitrile is first dissolved in a suitable solvent, such as DMSO, then solid K2CO3 is added, followed by about 30% H202. The reaction is stirred for about 3 hours followed by quenching with water. The product of Formula I, wherein at least one of Rl through R3 is, for example COR12 is then collected and dried under vacuum. Alternatively, in Step F (b), the benzonitrile may be reduced to the corresponding aminomethyl. For example, the corresponding nitrile is first dissolved in diethyl ether. Lithium aluminum hydride is then added and the reaction is stirred at room temperature for 1-24 h. The reaction is quenched by using procedures known in the art and as described in Fieser and Fieser, Reagents for Organic Synthesis, Vol. 1 pp 581-595.

The inorganic solids are then filtered and washed with ether. After drying (MgS04) and concentration, the crude compound is obtained wherein at least one of RI through R3 is aminomethyl. Further purification can be accomplished using column chromatography with the appropriate solvents.

Scheme IV (d) provides procedures for the synthesis of compounds of Formula I wherein at least one of Rl through R3 is, for example, a fluoromethyl, hydroxy, or an oxime.

Scheme IV (d) R3 R5 R3 R5 R3 R5 R4 < R6 R4 R4 R6 R4 R6 R4 R6 R4 R6 Step G Step H x OHC F2HC Formula I Formula I Formula I or R2 is X ; X is halo) (R1 or R2 is CHO) (Ri or R2 is CHF2) Step I Step J R3 R5 R3 R5 R4 i w i R4 R6 R4 R6 HOH2C w HONHC v Formula I Formula I or R2 is CHOH) (R is CHNR12 or R2 is CHNR

In Scheme IV (d), Step G, the lithium anion of the aryl halide derivative of Formula I is first generated by dissolving the aryl bromide derivative in a suitable solvent such as THF, diethyl ether, or dioxane, cooling to a temperature of about-78 to-25°C, followed by addition of an appropriate base such as n-butyl-Li, sec-butyl-Li, or t-butyl-Li.

The reaction is stirred for about 10 to 45 minutes to generate the anion. Using standard techniques, the aldehyde derivative of Formula I (at least one of Rl through R3 is CHO) is then generated by reacting the anion with N, N-dimethylformamide.

In Scheme IV (d), Step H, the aldehyde derivative is converted into a fluoromethyl derivative by dissolving in dichloromethane and treating with 1 to 5 equivalents of a fluorinating agent such as diethylamino sulfur trifluoride (DAST) and stirring at about 10 to 50°C for 5 to 48 hours.

In Scheme IV (d), Step I, using standard procedures, the aldehyde derivatives of Formula I (at least one of Rl through R3 is CHO) are reduced to the corresponding alcohol derivatives by reaction with sodium borohydride in ethanol.

In Scheme IV (d), Step J, using methods as described in J. S. Buck and W. S. Ide, Organic Synthesis Coll. Vol. II, 622-623, (1943) the aldehyde derivative of Formula I is converted to the corresponding oxime derivative of Formula I under standard conditions.

The Formula I products of Steps G, H, I and J, may all be purified using standard techniques such silica gel chromatography, eluting with a suitable eluent such as ethyl acetate and hexane.

Schemes V (a) -V (b) provide procedures for the synthesis of various N- substituted-and unsubstituted-amine derivatives of Formula I (at least one of Rl through R3 is, for example, amino, N-substituted amino, or N, N-disubstituted amino) wherein the bond represented by attached to the tricyclic core is a double bond. R4 R6 R4 R6 R4 R6 R5 Step A < Step s wR7 halo ho ha (o HzN Formula I Formula I H I Formula I oSO2 R Step C R4 R6 R5 R7 /\ alkyl I/SO2 , SOZ R Formula I

Scheme V (a) In Scheme V (a), Step A, the halo derivative of Formula I, prepared as described previously in Scheme II, is converted to an arylamine derivative using procedures as described in J. P. Wolfe and S. L. Buchwald, Organic Synthesis, Vol 78 23-31 (2000).

After work-up, the crude imine is hydrolyzed to the amine using aqueous hydrochloric acid in tetrahydrofuran. The amines are purified by trituration with toluene/hexane or using silica gel chromatography, eluting with ethyl acetate and hexane.

In Scheme V (a), Step B, the amine derivative of Formula I is converted to a substituted-amine derivative by reaction with a sulfonyl chloride in pyridine at a temperature of about 10 to 50°C for about 5 to 48 hours. The crude product of Formula I wherein at least one of Rl through R3 is, for example an N- [sulfonyl]-amino moiety can then be purified using silica gel chromatograph, eluting with a mixture of ethyl acetate and hexane.

In Scheme V (a), Step C, the N- [sulfonyl]-amines may be converted to disubstituted-amine derivatives according to procedures as detailed in Tetrahedron Letters, 39 (51) 9365-9368 (1998). The anion is generated using sodium hydride in N, N- dimethylformamide at temperatures ranging from about 0 to 30°C for about 0.25 to 2 hours. After addition of excess iodomethane, the reaction is stirred at room temperature for about 1 to 24 hours and then the crude product of Formula I, wherein at least one of Rl through R3 is, for example, a disubstituted N, N- [alkyl, sulfonyl]-amine can then be purified using silica gel chromatograph, eluting with a mixture of ethyl acetate and hexane.

Scheme V (b) R4 R6 R5 R7 H2N HN Formula I Step D Step E R4 R6 R4 R6 w i w i R5 R7 R5 R7 /\/\ H2N/) ND han Formula I HN Formu) a) Formula I (R1 or R2 is N, N-(C1-C4) dialkylamine)

In Scheme V (b), Step D, the amine derivative of Formula I prepared as described in Scheme V (a), above, is converted to the corresponding urea using procedures as described by F. Kurzer, Organic Synthesis, Coll. Vol. (IV) 49 (1963). For example, a compound of Formula I, wherein at least one of R1 is NH2 is combined with HOAc and water. A solution of sodium cyanate in water is then added to the mixture of the amine derivative. The reaction is stirred at room temperature for about 2 hours and then poured into water. The compound of Formula I, wherein at least one of R1 through R3 is, for example NRCONH2 is then extracted with EtOAc, dry (MgS04) and concentrated to provide crude product. The crude product may then be purified by standard techniques such as silica gel chromatography, eluting with a mixture of ethyl acetate and hexane.

(Alternatively in Step D, the amine derivative of Formula I is converted into an amide derivative of Formula L by reacting with an acid halide in pyridine at about 10 to 50°C for about 5 to 48 hours. The crude product of can then be purified using silica gel chromatography, eluting with a mixture of ethyl acetate and hexane).

In Scheme V (b), Step E, the amine derivative of Formula I is mono-or di- alkylated using standard procedures well known to those of ordinary skill in the art. For a detailed descriptions of such methods, see Synthetic Communications, 1129-1135 (1991).

The crude products of Formula I, wherein at least one of RI through R3 is, for example NH- (C1-C4) alkylamine or N, N- (Cl-C4) dialkylamine, can then be purified using silica gel chromatography, eluting with a mixture of ethyl acetate and hexane.

To provide compounds of Formula I wherein the bond represented by"-----" attached to the dibenzosuberane core is a single bond, the olefin moiety of the compounds of Formula I, prepared according to Schemes I-V above, can be readily reduced using a catalyst such as palladium on carbon (5 to 10%) in a solvent such as ethanol or methanol.

The pressure of hydrogen used may vary from atmospheric to 60 psi. The reaction is performed at temperatures ranging from about 20 to 50°C for 1 to 20 hours. For more details on hydrogenation of olefins, see H. O. House, Modern Synthetic Reactions, 2nd edition, pp. 1-34 (1972).

Schemes VI provides yet additional procedures for the synthesis of compounds of Formula I. Scheme VI is particularly useful where at least one of Rl through R3 is, for example, nitro or amino; wherein X and Y represent-CH=CH- ; and wherein the bond represented by attached to the tricyclic core is a double bond.

Scheme VI (11) "-0 E POEt Rq. R6 R5 w R7 R5 wR7 O ¢Y O OZN i (10) Formula I (at least one of R1-R3 is nitro) In Scheme VI, the phosphonate of structure (11) is first dissolved in a suitable solvent, such as DMF, DMSO or acetonitrile at room temperature under an inert atmosphere. An appropriate base, such as sodium hydride, is then added. After stirring

from 0.5 to 6 hours, the dibenzosuberone-or dibenzosuberenone-derivative of structure (10), dissolved in a suitable solvent such as DMF, is then added. The reaction is stirred for about 6 to 24 hours and then quenched with aqueous HC1. The product, wherein at least one of Rl through R3 is, for example nitro, is then extracted into EtOAc, dried (MgS04) and concentrated. The product is purified using column chromatography, eluted with EtOAc/hexanes. (For a more detailed discussion of this Horner-Emmons procedure, see J. Marsh, Advanced Organic Chemistry (4th edition) pp 959-960 and references cited therein).

Scheme VII provides procedures for the synthesis of compounds of Formula I employing Suzuki coupling conditions. In particular, the procedures of Scheme VII are useful for synthesizing compounds of Formula I wherein a heterocyclic or substituted heterocyclic ring is attached to the tricyclic core of Formula I; and wherein the bond represented by attached to the tricyclic core is a double bond.

Scheme VII R4 R4 R4 R6 _Step A 'St/'R7 /\ R7 R5 u - R5 \ R7 1 MeM Br R5 DMAP-HBr3 Br I 2) HCI (10) (12) (13) Step C B (OH) 2 Rl-Step D R 2R 3Z R2 R R4 R6 R4 R6 R5 R7 R5 R7 R5/I \ R7 R5/I \ R7 X (HO) 2B Y z (14) Formula I Step E Hetero-CI R4 R5 < R7 R5 u Hetero Formula I

In Scheme VII, Step A, the dibenzosuberone derivative (10) is dissolved in an appropriate solvent such as diethyl ether, dioxane or tetrahydrofuran and 1 to 5 equivalents of methylmagnesium bromide is added. After 2-24 hours, the intermediate carbinol derivative is converted to the exomethylene derivative by cooling to 0°C and adding HC1. After stirring for about 1-18 hours, the reaction is shaken with EtOAc and water. The organic solutions dried (MgS04) and concentrated. The crude product of structure (12) is purified by short path column chromatography (silica gel, hexane containing EtOAc).

In Step B, the compound of structure (12) is dissolved in a solvent such as methylene chloride, chloroform, carbon tetrachloride or 1,2-dichloroethane and treated with a slight excess of dimethylaminopyridine tribromide. The reaction is stirred at room temperature for about 1-24 hours. The excess brominating reagent is quenched with Na2SO3 and the reaction is partitioned between water and organic solvent. The solvent is dried (Na2SO4) and concentrated under reduced pressure to yield the crude product of structure (13). The crude compound of structure (13) is purified by short path column chromatography (silica gel, hexane containing EtOAc).

In Step D, derivatives of structure (14) are prepared by adding t-BuLi portionwise (exotherm) to a solution of the vinyl bromide (13) in dry THF at-78°C under N2. The reaction is stirred at-78°C for 45min and trimethyl borate is then added. The reaction is warmed to room temperature and stirred for about an additional 30min. The mixture is then concentrate using standard procedures, ethylene glycol and toluene are added, and the reaction refluxed overnight. The reaction is then cooled to room temperature, the layers separated and the ethylene glycol layer extracted with toluene. the toluene layers are then combined and concentrated to provide the compound of structure (14). The crude product (14) can then be purified by silica gel chromatography eluting with ethyl acetate: hexanes : triethylamine.

In Step C, the vinyl bromide of structure (13) and aryl boronic acid are mixed in dioxane. 2. 0M aqueous Na2CO3 is then added and the reaction sparged with N2 for 5min.

Pd (PPh3) 4 is added and the reaction vial immediately sealed. The reaction is heated to about t 70-100°C for about 8-24 h. The reaction is then quenched with H20 and the product of Formula I extracted into CH2C12. After drying (Na2SO4) and concentration, the crude product is purified using chromatography on silica gel, eluting with ethyl acetate/hexanes to obtain the purified product of Formula I.

In Step E, a mixture of the vinyl borate of structure (14), a substituted or unsubstituted chloroheterocycle, cesium fluoride and [1, l'-bis (diphenylphosphino) - ferrocene] dichloropalladium (IT) (1: 1 complex with CH2C12) in dioxane is heated at about 50-100°C for about 12-72 h. The solvent is removed using a stream of nitrogen and the resulting residue is shaken with H20 and CHUCK and loaded onto a Varian ChemElut CE1005 solid-phase extraction cartridge. Elute with CH2C12, and concentrate using standard procedure to obtain the crude product of Formula I, wherein a heterocycle or

substituted heterocycle is attached to the tricyclic core. The crude product can then be purified by mass-guided reverse-phase HPLC to obtain the purified product of Formula I.

Alternatively, in Step E, a mixture of vinyl borate (14), a substituted or unsubstituted chloroheterocycle, K2C03 and ethanol is sparged with N2 for 10min. Pd (PPh3) 4 is then added and the reaction sealed immediately. The reaction is heated at about 70-100°C for about 12-72 h. The mixture is then concentrated under N2, then H20 (lmL) and ethyl acetate (1mL) are added. The residue is load onto a Varian ChemElut CE1005 solid- phase extraction cartridge. Elute with ethyl acetate, collect, and concentrate the crude reaction. The crude product can then be purified on silica gel, eluting with ethyl acetate/hexanes to obtain the pure product of Formula I wherein a substituted or unsubstituted heterocycle is attached to the tricyclic core.

Scheme VIII provides yet additional procedures for the synthesis of compounds of Formula I, particularly those wherein rings A and/or B are heterocyclic rings.

Scheme VIII R4 R6 R4 R6 R7 R5 R7 : Q . R2 R3 R1 t RA 3 R2 R3 Formula I In Scheme VIII, a solution of the appropriate substituted or unsubstituted benzyl magnesium bromide in THF is added to a solution of (10) in THF under Ar. The resulting solution is stirred for about 1-24 h at about 25 °C before quenching with saturated, aqueous ammonium chloride. The mixture is filtered and the magnesium salts washed with diethyl ether. The filtrate is then with water and brine, dried (Na2SO4), and concentrated under reduced pressure. The resulting tertiary alcohol can then be purified by column chromatography (hexanes/ethyl acetate).

The crude carbinol is dissolved in CHC13 and concentrated hydrochloric acid is then added. The resulting dark solution is stirred for 2 h at about 25 °C. Water and CHC13 are added, the layers separated, and the organic layer washed successively with

saturated, aqueous sodium bicarbonate and brine. The crude product of Formula I is then dried (MgSO4) and concentrated via rotary evaporation. The crude material may then be purified by flash chromatograpy (hexanes/ethyl acetate) to provide the purified final product of Formula I (wherein A and/or B are, for example, heterocyclic rings).

Additional Schemes for the synthesis of compounds of the invention: Scheme IX provides procedures useful for the synthesis of compounds of Formula I wherein the"C"ring represents an N-substituted benzimidazole derivative.

Scheme IX Br Br Br Step A ¢>NO2 Step Bp NH2 N J rN /NO N 2/NH2 -q--- zon N (15) OJ (16) Br OBO Step C I Step D I zon N (N \\O N rN N 0 ou (17) (18)

In Scheme IX, Step A, 5-bromo-2-fluoro-nitrobenzene is mixed with about 2 equivalents of a substituted amine, for example 4- (2-aminoethyl) morpholine, in THF. The reaction is stirred at room temperature for about 18h. The THF is removed under reduced pressure and the residue partitioned between water and ethyl acetate. The organic layer is dried (MgS04) and concentrated to provide compound of structure (15).

In Scheme IX, Step B, the compound of structure (15) is dissolved in ethyl acetate or THF and 5% Pt/C (sulfide) is added. The slurry is placed under 60psi hydrogen gas at room temperature for about 8h. The reaction is then filtered and concentrated to provide, for example, the compound of structure (16) as a dark red oil. Compound (16) may then be purified, for example by using a short plug of silica gel and 10% 2N NH3 in MeOH/dichloromethane.

In Scheme IX, Step C, the compound of structure (16) is mixed with NaHC03, water, and methanol. Slowly, phenyl chloroformate (about 1.5 equivalents) is added and the reaction is stirred for about lh at room temperature. 5N NaOH (about 1.5 equivalents) is then added and the reaction is stirred overnight at room temperature. The solid of structure (17) is collected by vacuum filtration and washed with methanol.

In Scheme IX, Step D, under a blanket of nitrogen, a solution of compound (17) in THF is cooled to about 5°C and 3N ethylmagnesium bromide is added. After about 1/2h, the reaction is cooled to about-72°C and slowly 1.7M t-BuLi is added. The reaction is allowed to warm to about-55°C, then trimethyl borate is added and the reaction is allowed to stir at room temperature overnight. 5N HC1 is then added and the reaction stirred for about 4h. The pH is adjusted to about 6-7 and the crude boronic acid is extracted into ethyl acetate, dried and concentrated to give the crude acid which is then slurred with toluene and pinacol is added. The reaction is heated briefly and stirred overnight. Ethyl acetate and aqueous NaHC03 are added, the organics extracted with water and the dried (MgS04) organic layer is evaporated to give the purified product of compound (18).

Schemes X-XDI provide procedures useful for the synthesis of compounds of Formula I wherein the"A"and/or"B"ring represents a heterocyclic ring, which may be substituted or unsubstituted. Also, Scheme X demonstrates an alternative procedure to that described in Scheme VII, Step A for converting the ketone moiety to a methylene by use of the Tebbe reagent.

Scheme X Step A Step B, C p R3 R3 (19) R2 R1 R2 R1 Formula I

In Scheme X, Step A, to a solution of, for example, 9, 10-dihydro-1-thia- benzo [f] azulene-4-one (see P. Bollinger, P. Cooper.; H. U. Gubler, A. Leutwiler, T. Payne Helv. Chim. Acta 1990, 73,1197) at about-40°C is added about 3 equiv of a 0.5 M solution of Tebbe reagent in toluene and about 3 equiv of pyridine in THF (0.1 M) under Ar. The resulting mixture is stirred for about 2 h then allowed to warm to 0 °C over ca.

30 min period before diluting with diethyl ether. 5 N sodium hydroxide is then added carefully until bubbling ceases, then solid Na2SO4, and the reaction stirred for about 1 h.

The mixture is then filered through Celite@, then the filtrate by rotary evaporation. The crude residue of compound (19) may then be purified by standard techniques such as column chromatography (hexanes) to give the purified product of structure (19).

In Scheme X, Steps B and C, the compound of structure (19) may be treated according to the procedures as described in Scheme VII, Steps B and C to provide the compound of Formula I.

Scheme XI x s x s x s u CI Sep A CI St Iw Iw Iw i i NH2 NH2 NHSO2Me Formula I (i) Formula I (ii) Formula ! (iii) (X=HorO) (X=HorO) (X=HorCf) In Scheme XI, procedures for the synthesis of compounds of Formula I wherein "A"or"B"represents a chlorothiophene are provided. In Scheme XI, Step A, about 2 equiv of n-BuLi-hexanes is added dropwise to a solution of a compound of Formula I (i), for example 3-(9, 10-Dihydro-l-thia-benzo [fazulen-4-ylidenemethyl)-phenylamine, in

THF at about 0 °C under Ar. The resultant dark solution is stirred for about 1 h before adding about 2.5 equiv of hexachloroethane in THF. The reaction is stirred for about 2 h, quenched with excess water, and acidified to neutral pH. The aqueous layer is extracted with diethyl ether (3 X) and then dried (MgS04), and the combined organic layers are concentrated under reduced pressure. The crude product (Formula I (ii) ) may then be purifed using standard techniques, such as by column chromatography to give the 2- chlorothiophene derivative compound.

In Scheme XI, Step B, the amino group of Ring"C"may be treated according to procedures as described in Scheme V (a), Step B to provide further methanesulfonamide derivatives of Formula I (iii).

Scheme XII N Step A N s 31-s-Me i (20) (21) Step B, C u N N 1 ' _Me Me-\S, lez I I NHSO2Me NHSO2Me Formula I

Scheme XII provides procedures for the synthesis of derivatives of Formula I wherein Ring"A"and or"B"represents a methylated heterocycle, particularly a methylated thiazole. In Scheme XII, Step A, add about 1.2 equiv of n-BuLi-hexanes dropwise to a solution of compound (20) (4-methylene-9, 10-dihydro-4H-3-thia-1-aza-

benzo [f] azulene) in THF at about- under Ar. The resultant dark green solution is stirred for about 5 min before adding about 1.2 equiv of iodomethane in THF. The reaction is allowed to warm and stirred at room temperature for about 18 h before quenching with excess water. The layers are separated and the aqueous layer extracted with, for example, diethyl ether (3 X) and then dried (MgS04. The combined organic layers may then be concentrated under reduced pressure and the product (Structure (21) ) used in the next step without further purification.

In Scheme XII, Steps B and C, the compound of structure (21) is treated according to procedures as described Scheme VII, Steps B and C to provide the compound of Formula I wherein Ring"A"and or"B"represents a methylated heterocycle.

Scheme XIII OMe C1 O J Step A Step, B 0 N Step C I,-I/_ o Iw s z (22) (23) (23) OMe 0 N Step D Step E nez /S /O (24) (25) (26) \ N + N // NHSO2Me NHSO2Me Formula I

Scheme XHI provides additional procedures for the synthesis of compounds of Formula I wherein Ring"A"and or"B"represents a thiazole. In Scheme XIII, Step A, a flask is charged with equimolar methyl dichloroacetate and 3-phenyl-prionaldehyde in diethyl ether. The solution is cooled to about 0 °C and about 1 equiv of sodium methoxide in methanol is added over a 1 h period. The mixture is vigourously stirred for

about 2 h at about 0 C and then allow to warm to room temperature before adding brine.

The layers are separated, dried (MgS04) and the organic concentrated to give the crude residue of compound (22).

In Scheme XIII, Step B, reflux the compound of structure (22) and thiourea in MeOH for about 4 h, then basify with ammonia-MeOH and add brine. The reaction is then extract with, for example ethyl acetate, then the combined organic layers are washed with brine, dried (MgS04), and concentrated under reduced pressure to give the compound of structure (23).

In Scheme XIII, Step C, about one equiv of the compound of structure (23) and about 3 equiv of isoamyl nitrite in THF are refluxed for about 3 h. Evaporate The volatile components are evaporated to provide the compound of structure (24).

In Scheme XIII, Step D, a thick slurry of the compound of structure (24) and polyphosphoric acid (PPA) is rapidly stirred and heated to about 140 °C for about 24 h and then about 150 °C for about 5 h. Carefully the hot mixture is added to ice-cold aqueous sodium hydroxide. The reaction is then extracted, for example with EtOAc, and the combined organic layers washed with brine, dried (MgS04), and concentrated under reduced pressure. The crude residue of structure (25) may then be purified by standard techniques, such as by column chromatography (10% to 50% EtOAc: hexanes) to provide the purified compound of structure (25).

In Scheme XIII, Step E, the compound of structure (25) is treated according to procedures as described in Scheme VII, Step A to provide compound of structure (26).

In Scheme XIII, Steps F and G, the compound of structure (26) is treated according to procedures as described Scheme VII, Steps B and C to provide the compound of Formula I wherein Ring"A"and or"B"represents a thiazole ring.

Alternatively, the desired starting thiazole ketone can be prepared as as shown in Scheme XE (b), below. In step A, 2-chloro-3-oxo-butyric acid ethyl ester in THF is treated with first NaH (1 equivalent) then n-BuLi (1 equivalent) while the temperature is held at about-60 to-10°C and then the appropriately substituted benzyl bromide added.

In Step B, the intermediate 2-chloro-3-oxo-5-phenyl-pentanoic acid ethyl ester derivative is reacted with thiourea in refluxing ethanol for 1-24 hours. This ester can be cyclized using PPA and heating at from 160-250°C for 1-15 hours. As described in Scheme

Xin (a), Step C, the amino moiety can be converted to-H. This intermediate ketone can be converted to final products as in Scheme Xin (a), Steps E, F and G.

Scheme XIII (b) R4 o o Br O O R5t O O R5 Et0 EtO - ci Step A Step B N R6 R6 \\ EtOZC/SN R4 R5 R4 R4 ry r \\ f / EtZC SN O SN G JR6

Scheme XIV provides additional procedures for the synthesis of compounds of Formula I wherein ring"A"and or"B"is substituted.

Scheme XIV R6 R4 1 R7 R6 R5 R4 R7 Step A R5 w i Step B/ R5 R7 Buzz (27) (28) Formula I

In Scheme XIV, Step A, a mixture of 2-3 equiv of bromomethyltriphenylphosphonium bromide (see G. Vassilikogiannakis, M.

Hatzimarinaki, M. Orfanapoulos J Org. Chem., 65,8180) in THF (0.5 M) is cooled to about-78 °C and about 2-3 equiv of LiHMDS-THF is added dropwise to give a bright

yellow mixture. The reaction is stirred for about 1 h at about-78 °C and then for about 10 min at 0 °C. The mixture is re-cooled to about-78 °C and the compound of structure (27) is added. The dark mixture to is allowed to warm to room temperature and stirred for about 3.5 h before adding saturated, aqueous saturated ammonium chloride and diluting with pentane. The mixture is filtered through celite, the filtrate concentrated under reduced pressure, and purifed by standard techniques such as column chromatography (1% to 2% to 3% to 5% EtOAc: hexanes) to give the compound of structure (28) as a 1: 1 mixture of geometric isomers.

In Scheme XIV, Step B, the compound of structure (28) is treated according to procedures as described in Scheme VII, Step C to provide the compound of Formula I.

Scheme XV provides additional procedures for the synthesis of compounds of Formula I wherein ring"A"and or"B"represents a heterocyclic ring and additionally shows methodology to prepare useful intermediate vinyl borate ester derivatives.

Scheme XV N N O-B O-B O O O )/ (30) (30) E isomer Z isomer Step B 3 I\ I\ i i NHSO2Me NHSO2Me Formula I Formula I E isomer Z isomer

In Scheme XV, Step A, about one equiv of, for example, 5,6-dihydro- benzo [d] pyrrolo [1, 2-a] azepin-11-one (structure (29)) (see Y. Girard, J. G. Atkinson, P. C.

Belanger, J. J. Fuentes, J. Rokach, C. S. Rooney, D. C. Remy, C. A. Hunt J. Org Chem.

1983, 48, 3220) in THF is added to a solution of about 2.5 equiv of pinicol lithio (trimethylsilyl) methaneboronate (see D. S. Matteson, D. Majumder Organometallicsl983, 2,230), about 1 equiv TMEDA, about 2.5 equiv of tetramethylpiperidine (TMP), and THF at about-78 °C. The solution is allowed to warm to room temperature and stirred for about 3.5 h before quenching with excess water. The reaction is extracted with Et2O (4 X), dried (MgS04) and concentrated under reduced pressure. The crude residue may then be purified by standard techniques such as column chromatography (5% to 10% EtOAc: hexanes) to give the pure E-isomer and Z-isomer of structure (30).

In Scheme XV, Step B, the compound of structure (30) is treated according to procedures as described in Scheme VII, Step C to provide the E and Z isomer of the compound of Formula I.

Scheme XVI provides yet additional procedures for synthesizing compounds of Formula I wherein ring"A"and or"B"represents a heterocyclic ring.

Scheme XVI 0 Br ber \ j \OH + ( F StepA % 1 OH I \ F OH F CN : o (31) Step B F Step CN F i i CON) (32) (33) Step D N, I \ F F _ Br Br (34) (34) Step E N N F F N u R3 R3 R2 Rl R2 Rl R2 p R2 Formula I

In Scheme XVI, Step A, diisopropylamine is dissolved in dry tetrahydrofuran and the resulting mixture cooled to about-78 °C. Butyllithium is then added and the reaction mixture is warmed to about 0 °C then a fine slurry of 2-methyl-nicotinic acid in THF (25 mL) is added portionwise during about 10 min. The resulting slurry is stirred for about lh, then 3-fluorobenzyl bromide is added and the mixture is stirred for about 5 min. The reaction is quenched with water and extracted with diethyl ether. The pH of the aqueous layer is adjusted to about 3.1 with concentrated aqueous hydrochloric acid solution. The resulting slurry is treated with ethyl acetate and stirred to dissolve all solids. The layers are separated and the aqueous layer extracted with ethyl acetate. Concentrate the

combined extracts are then concentrated to dryness to provide the compound of structure (31).

In Scheme XVI, Step B, the compound of Structure (31) is combined with polyphosphoric acid (about 100 g) and heated to about 160 °C for about 6 h. The reaction mixture is allowed to slowly cool over 12h, then reheated to about 160 °C and poured into ice. The transfer is completed using water and the pH of the aqueous mixture adjusted to about 8.0 with 50% aqueous sodium hydroxide solution. The product of structure (32) is extracted with methylene chloride. The combined organic extracts are dried with magnesium sulfate, filtered and concentrated. The compound of structure (32) may then be purified using standard techniques such as flash chromatography (25% ethyl acetate/hexanes to 50% ethyl acetate/hexanes) to provide the purified product of the compound of structure (32). (See Journal of Heterocyclic Chemistry 1971,73).

In Scheme XVI, Step C, a mixture of compound (32) and dry THF is chilled to about 0 °C. This mixture is treated with methyl magnesium bromide, the cooling removed, and the mixture is stirred at room temperature for about 15 min. The reaction is quenched, while cooling with an ice-water bath, by adding saturated aqueous ammonium chloride solution (50 mL). The layers are separated and the aqueous layer extracted with methylene chloride (2x50 mL). The combined organic layers are dried with magnesium sulfate, filtered, and concentrated to provide the intermediate product of structure (33) as a thick crude oil. Without further purification, this residue is dissolved in a solution of sulfuric acid in acetic acid (3% by volume, 50 mL) and the mixture stirred at room temperature for about 12-18 h. The reaction mixture is concentrated to remove excess solvent and the resulting orange residue dissolved in 1N aqueous sodium hydroxide solution (25 mL) and ethyl acetate (50 mL). the pH of the resulting mixture is adjusted to about 8 with 5N aqueous sodium hydroxide solution. The layers are separted, and the aqueous extracted with ethyl acetate (2x50 mL). The combined organic layers are dried with magnesium sulfate, filtered, and concentrated to provide the compound of structure (33).

In Scheme XVI, Step D, the compound of structure (33) is treated according to procedures as described in Scheme VII, Step B, to provide E and Z isomer of compound (34).

In Scheme XVI, Step E, the compound of structure (34) is treated according to procedures as described in Scheme VII, Step C to provide the E and Z isomer of the compound of Formula I.

Scheme XVII provides yet additional procedures for synthesizing compounds of Formula I wherein ring"A"and or"B"represents a heterocyclic ring and wherein the bridge depicted by-X-Y-contains a heteroatom or heteroatom containing group at either the X or Y position.

Scheme XVII 0 0 0 \ F Step A N, I \ F - iii O (35) (36) stem C Step 13NFF N Br Br (37) (37) Step C 0 0 1 I \ F + F I I Neu I R3 R3 R1 R1 Formula I

In Scheme XVII, Step A, the compound of structure (35), for example, (8-fluoro- 11H-10-oxa-1-aza-dibenzo [a, d] cyclohepten-5-one) (see Journal ofMedicinal Chemistry 1990,33, 3095) and anhydrous tetrahydrofuran (25 mL) are combined and the solution

cooled to about 0 °C. Tebbe reagent (0. 5M/L solution in toluene) is then added, cooling is removed, and the mixture stirred for about 10 min. The reaction is quenched by adding saturated aqueous Rochelle's salt solution and the biphasic mixture stirred rapidly for about 10 min. the layers are then separated and the aqueous layer extracted with ethyl acetate. The combined organic layers are dried with magnesium sulfate, filtered and concentrated. The crude product of compound (36) may then be purified using standard techniques such as flash chromatography (25% ethyl acetate/hexanes) to provide the purified product of structure (36).

In Scheme XVII, Step B, the compound of structure (36) is treated according to procedures as described in Scheme VII, Step B, to provide E and Z isomer of compound (37).

In Scheme XVII, Step C, the compound of structure (37) is treated according to procedures as described in Scheme VII, Step C to provide the E and Z isomer of the compound of Formula I.

Scheme XVm provides general procedures for the synthesis of compounds of Formula I wherein ring"A"and or"B"is contains an ether moeity Scheme XVIII OH OH OR Step A Step B Br J wOR (i) (ii) (iii) Step C r /1/\ °R Formula I NHSO2Me

In Scheme XVIII, Step A, the compound of structure (i) (5-methylene-10, 11- dihydro-5H-dibenzo [a, d] cyclohepten-2-ol), prepared from commercially available 2- hydroxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-one using procedures as described Scheme VII, Step A, is treated under conditions as described in SchemeVII, Step B to provide the compound of structure (ii) (5-bromomethylene-10, 11-dihydro-5H- dibenzo [a, d] cyclohepten-2-ol) In Scheme XVIII, Step B, 2.5 equivalents of PS-TBD Resin (commercially available: Argonaut Technologies) is added to a fritted vessel. The bottom of the vessel is capped and about 1.0 equivalent of 5-bromomethylene-10, 11-dihydro-5H- dibenzo [a, d] cyclohepten-2-ol in acetonitrile is added. About 0.8 equivalents of the appropriate alkyl halide in acetonitrile is then added and the top of the vessel is capped and the vessel rotated for about 48-96 hours. The vessel is then uncapped and the filtrate collected into a screw-cap vial. The resin is washed with acetonitrile followed by dichloromethane. The filtrate is combined with the washings and concentrate under vacuum.

In Scheme XVEII, Step C, into the screw capped vial containing the bromomethylene ether, about 1.2 equivalents of potassium carbonate and about 1.1

equivalents of, for example, N- [3- (4, 4,5, 5-tetramethyl- [1, 3,2]-dioxaboronan-2-yl)- phenyl]-methanesulfonamide, is added. The solution is purged with nitrogen for about 5 min. then about 0.1 equivalents of palladium tetrakis (triphenylphosphine) is added into the vial. The vial is capped and heated to about 90-100 °C for about 16 hours with continuous stirring. The reaction is then loaded onto Chem-Elute column (Varian Sample Prep) primed with water and the column is eluted with ethyl acetate. The filtrate is then concentrated under vacuum and may be purified by standard techniques such as silica gel chromatography.

Determination of Biological Activity To demonstrate that compounds of the present invention have affinity for steroid hormone nuclear receptors, and thus have the capacity to modulate steroid hormone nuclear receptors, soluble MR and GR binding assays are performed. All ligands, radioligands, solvents, and reagents employed in the binding assays are readily available from commercial sources, or can be readily synthesized by the ordinarily skilled artisan.

Mineralocorticoid Receptor Binding Assay : The full length human MR gene is cloned from a human kidney or human brain cDNA library. Briefly, using synthetic oligonucleotide primers (Eli Lilly and Company, Indianapolis) directed to nucleotides 20-54 and 3700-3666 of the human MR, polymerase chain reaction (PCR) is performed under standard conditions using a human cDNA library. The PCR reaction is performed in a final volume of 50111 containing about lgl of a 50X stock solution of polymerase; about 1 p1 of a 50X stock solution of dNTP ; about 5, u1 of an appropriate PCR buffer; about ljj, l of each primer; about 5 l of a H. kidney or H. brain cDNA library; and about 36p1 of water. The reaction is allowed to denature for about 30 seconds at 95 degrees Celsius, anneal for about 30 seconds at 55 degrees Celsius, and extend for about 5 minutes at 72 degrees Celsius, the sequence being repeated for a total of about 35 cycles. The desired PCR product (3.68 Kb) is confirmed by gel electrophoresis and subsequently cut from the gel and stored at about-20 degrees Celsius until extraction. To extract the cDNA product from the agarose gel, the QIAEX II Gel Extraction protocol (QIAGEN, Inc. ) is employed according to the manufacturer's instructions. Following extraction, the MR cDNA is cloned into an appropriate cloning

vector (Zero Blunt TOPO PCR Cloning Kit (Invitrogen, Inc. ) and a pAcHLT-baculovirus transfer vector (B. D./Pharminogen), then expressed in SF9 insect cells, essentially according to manufacturer's instructions. Sf9 cells are grown at a scale where gram quantity cell pellets are obtained for subsequent use in the MR binding assay. Harvested cell pellets are lysed by repeated freeze-thaw cycles (about 4) in a suitable lysis buffer then centrifuged at about 1 X 103G (with the supernatant being saved for future assays).

MR binding assays are performed in a final total volume of about 250, l containing about 20-25pg of protein and 0. 5nM of [3H]-aldosterone plus varying concentrations of test compound or vehicle. The assay binding buffer consists of 30mM sodium molybdate, 30mM of TRIS-HCI, 5mM sodium phosphate, 5mM sodium pyrophosphate, and about 10% glycerol, pH=7.5.

Briefly, assays are prepared at RT in 96-well Falcon 3072 plates, each well containing 210, u1 of binding buffer, log, of [3 H]-aldosterone, lOgI of test compound/vehicle, and 20p1 of the resuspended receptor protein extract. Incubations are carried out at 4 degrees Celsius with shaking for about 16 hours. 200ut aliquots of each incubation are filtered onto Millipore HA 0.45micron 96-well filter plates, pre-moistened with cold 30mM TRIS-HC1. The filter plates are suctioned dry with vacuum and immediately washed 3X with cold 30mM TRIS-HC1. The plates are then punched out and the amount of receptor-ligand complex is determined by liquid scintillation counting using 4ml of Ready Protein Plus liquid scintillation cocktail.

IC50 values (defined as the concentration of test compound required to decrease [3H]-aldosterone binding by 50%) are then determined. Ki values for each respective test compound can then be calculated by application of the Cheng-Prusoff equation as described in Cheng et al., Relationship Between The Inhibition Constant (Ki) and The Concentration of Inhibitor Which Causes 50% Inhibition (IC50) of an Enzymatic Reaction, Biochem. Pharmacol., 22: 3099-31088 ; (1973).

Glucocorticoid Receptor Binding Assay : To demonstrate the GR modulating potency of compounds of the present invention the following source of glucocorticoid receptor is employed. A549 human lung epithelial cells (ATCC) are grown at a scale where gram quantity cell pellets are obtained.

Harvested cell pellets are washed twice in cold phosphate buffered saline, centrifuged,

and resuspended in cold assay binding buffer. The assay binding buffer consists of 10% glycerol, 50mM Tris-HCl (pH7.2), 75mM sodium chloride, 1. 5mM magnesium chloride, 1. 5mM EDTA, and lOmM sodium molybdate. Cell suspensions were lysed via sonication, centrifuged, and the"extract"supernatant is snap frozen and stored at-80C until needed.

GR binding assays are performed in a final volume of 140ul containing 50-200ug of A549 cell extract and 1. 86nM [3H]-dexamethasone (Amersham) plus varying concentrations of test compound or vehicle. Briefly, assays are prepared at RT in 96-well Fisher 3356 plates, each well containing 100ul of A549 cell extract, 20ul of [3H]-dexamethasone, and 20ul of test compound/vehicle. Incubations are carried out at 4 degrees Celsius for 16 hours. After incubation, 70ul of 3X dextran-coated charcoal solution is added to each reaction, mixed, and incubated for 8 minutes at RT.

3X-dextran-coated charcoal solution consists of 250ml assay binding buffer, 3.75g Norit A charcoal (Sigma), and 1.25g dextran T-70 (Amersham). Charcoal/unbound radioligand complexes are removed by centrifugation of the plate and 140ul of supernatant from each well is transferred to another 96 well Optiplate (Packard Instruments). 200ul of Microscint-20 scinillant (Packard Instruments) is added to each well and amount of receptor bound radioligand is determined using Packard Instruments TopCount instrument.

IC50 values, defined as the concentration of test compound required to decrease [3H]-dexamethasone binding by 50%, are then determined. Ki values for each respective test compound can then be calculated by application of the Cheng-Prusoff equation as described in Cheng et al., Relationship Between The Inhibition Constant (Ki) and The Concentration of Inhibitor Which Causes 50% Inhibition (IC50) of an Enzymatic Reaction, Biochem. Pharmacol., 22: 3099-31088; (1973).

Binding assay protocols for PR, AR, and ER, similar to those described above for MR and GR, can be readily designed by the ordinarily skilled artisan. United States Patent No. 6,166, 013 provides examples of such protocols. Representative compounds of the present invention have a Ki in the MR or GR binding assay of < 50pM. Table I (see infra. ) provides MR and GR binding data for a representative sample of the exemplified compounds of the present invention.

To demonstrate the ability of compounds of the present invention to modulate the activity of a steroid hormone receptor (i. e. either agonize, antagonize, partially agonize, or partially antagonize), bioassays are performed which detect modulation of target gene expression in cells transiently transfected with a nuclear receptor protein and a hormone response element-reporter gene construct. The solvents, reagents, and ligands employed in the functional assay are readily available from commercial sources, or can be synthesized by one of ordinary skill in the art.

Functional Assay of Mineralocorticoid Receptor Modulation: For the MR transient transfection assay, COS-7 cells are transfected with full length human MR and a 2XGRE-luciferase gene construct. Following transfection, the ability of test compounds to modulate expression of the luciferase reporter gene product is monitored. Briefly, on day one, COS cells are harvested from cell culture plates using standard procedures such as treatment with Trypsin-EDTA (GIBCO BRL). Culture medium is then added to the cells and the cell-medium mixture is plated in 96-well plates coated with poly- (d)-lysine (approximately 3 X 104 cells/well). Cells are grown for about 4 hours then transfected with Fugene-6 reagent with plasmids containing human MR, previously cloned into pc. DNA 3.1 expression vector, and 2XGRE-reporter gene construct (GRE-luciferase), previously cloned into pTAL-luc vector. Transfection is carried out in DMEM with 5% fetal calf serum, charcoal treated. 24 hours later cells are exposed to various concentrations of aldosterone in the presence and absence of test compound and incubated for an additional 24 hours. The reaction is terminated by the addition of lysis buffer followed by luciferin (luciferase substrate). Luciferase expression, as an indicator of ligand induced MR transactivation, is monitored by chemiluminescence measured using a microtiter plate luminometer (MLX). The kinetic inhibition constant (Kb or Kp) can then be determined by analysis of dose-response curves for aldosterone, in the presence and absence of test compound, using standard techniques.

Table I Mineralocorticoid and Glucocorticoid Receptor Binding Assay Values Example MR Ki GR Ki No. (nM) (nM 206 (a) +++ +++ 262 +++ +++ 197 (a) +++ +++ 125 +++ +++ 267 +++ +++ 199 (a) +++ +++ 199 (b) +++ +++ 207 +++ +++ 274 +++ +++ 141 +++ +++ 182 +++ +++ 184 (a) +++ +++ 181 (a) +++ +++ 268 +++ +++ 208 (b) +++ +++ 50 +++ +++ 208 (a) +++ +++ 162 +++ +++ 183 +++ +++ 105(b) +++ +++ 187 +++ +++ 206 (b) +++ +++ 184 (b) +++ +++ 188 (a) +++ +++ 214 +++ +++ 205 (a) +++ +++ 211 (a) +++ +++ 222 (a) +++ +++ 178 +++ +++ 163 +++ +++ 200 (a) +++ ++ 91 +++ +++ 200 (b) +++ +++ 185 (b) +++ ++ 191 +++ +++ 258 +++ +++ 201 +++ +++ 161 +++ +++ 189 +++ +++ 161 (b) +++ +++ 90 +++ +++ 48 +++ +++ 253 +++ +++ 75 +++ +++ 208 (c) +++ +++ 92 +++ +++ 57 +++ +++ 49 +++ +++ 186 +++ +++ 192 +++ +++ 198 (a) +++ +++ 215 +++ +++ 223 +++ 149 +++ +++ 112 +++ +++ 221 (a) +++ +++ 1-55 ++ 216 +++ +++ 263 +++ ++ 188 (b) +++ +++ 86 +++ +++ 202 +++ ++ 171 +++ +++ 185(a) +++ +++ 205 (c) +++ 261 +++ +++ 167 +++ +++ 173 (a) +++ +++ 126 181 (b) +++ +++ 254 +++ +++ 81 +++ + 1 +++ +++ 65 +++ + 251 +++ +++ 153 +++ ++ 45 +++ ++ 177 +++ ++ 71 +++ +++ 151 +++ ++ 157 +++ ++ 193 +++ +++ 74 +++ +++ 231 +++ +++ 121 +++ + 175 +++ + 105 +++ +++ 272 +++ + 54 +++ +++ 211 (b) +++ ++ 271 +++ +++ 133 +++ ++ 5 +++ +++ 135 +++ + 229 +++ ++ 132 +++ ++ 4 +++ ++ 198 (b) +++ ++ 129 +++ +++ 62 +++ + 221 (b) +++ +++ 72 +++ + 104 +++ +++ 259 +++ + 128 +++ ++ 108 +++ +++ 110 +++ +++ 145 +++ +++ 245 +++ + 130 +++ + 2 +++ +++ 95 +++ ++ 93 +++ +++ 70 +++ ++ 253 +++ + 106 +++ +++ 228 +++ ++ 114 +++ +++ 116 +++ +++ 220 +++ + 170(b) +++ +++ 118 +++ +++ 85 +++ +++ 224 +++ +++ 47 +++ ++ 80 +++ +++ 94 +++ +++ 210 ++ 78 +++ ++ 69 +++ 194 +++ +++ 107 +++ NT 236 +++ +++ 87 +++ +++ 31 +++ + 35 +++ +++ 27 +++ ++ 64 +++ +++ 117+++ +++ 148 +++ ++ 120 +++ + 60 +++ + 259 +++ + 249 +++ +++ 113 +++ +++ 212 +++ ++ 225 +++ + 152 +++ + 219 +++ ++ 154 +++ ++ 42 +++ + 6 +++ 256 +++ ++ 180 +++ ++ 84 +++ + 225 +++ NT 143 +++ + 217 +++ + 96 +++ + 68 +++ +++ 169 +++ +++ 255 +++ +++ 173 (b) +++ + 196 +++ +++ 137 +++ ++ 168 +++ ++ 99 +++ ++ 82 +++ ++ 218 +++ ++ 131 +++ + 166 +++ + 52 +++ + 77 +++ +++ 32 +++ ++ 79 +++ +++ 109 +++ +++ 170 (a) +++ ++ 174 +++ ++ 195 (a) +++ ++ 233 +++ + 227 +++ ++ 88 +++ ++ 244 +++ + 237 +++ + 73 +++ ++ 76 ++ 3 ++ ++ 230 ++ + 264 ++ + 41 ++ + Table I (Continued) Mineralocorticoid and Glucocorticoid Receptor Binding Assay Values Example MR Ki GR Ki No. (nM) (nM) 699 +++ +++ 700 +++ 701 +++ 702 +++ + 521 +++ +++ 522 +++ +++ 363 +++ +++ 364 +++ +++ 498 +++ ++ 499 +++ +++ 703 +++ +++ 287 +++ +++ 365 +++ +++ 366 +++ +++ 367 +++ + 368 +++ + 369 +++ + 447 +++ +++ 448 +++ + 449 +++ + 500 +++ +++ 501 +++ +++ 502 +++ 370 ++ 371 +++ +++ 372 +++ ++ 465 +++ ++ 466 +++ ++ 373 +++ + 374 +++ +++ 375 +++ +++ 722 +++ +++ 723 +++ +++ 376 +++ +++ 377 +++ + 301 +++ +++ 302 +++ +++ 450..... 451 +++ + 334 +++ +++ 335 +++ +++ 452 +++ ++ 378 +++ ++ 379 +++ + 524 +++ +++ 503 +++ +++ 303 +++ +++ 380 +++ ++ 453 +++ ++ 336 +++ + 504 +++ +++ 337 ++ 338 ++ 339 +++ +++ 454 +++ +++ 481 +++ +++ 407 +++ +++ 408 +++ +++ 409 +++ +++ 410 +++ +++ 304 +++ +++ 340 +++ +++ 341 +++ +++ 558 +++ 342 +++ +++ 488 +++ +++ 525 +++ +++ 526 +++ + 527 +++ + 528 +++ ++ 529 +++ + 530 +++ +++ 531 +++ +++ 532 +++ ++ 533 +++ ++ 534 +++ + 535 ++ + 305 +++ ++ 306 +++ 278 +++ 381 +++ +++ -128- 286 382 +++ +++ 559 +++ +++ 307 +++ +_+ 455 +++ + 456 +++ + 411 +++ +++ 412 +++ ++ 347 +++ +++ 348 +++ +++ 308 +++ + 309 +++ ++ 427 +++ + 578 +++ + 579 +++ +++ 739 +++ +++ 580 +++ + 581 +++ + 740 +++ +++ 582 +++ + 330 583 +++ + 584 ++ + 585 +++ + 586 +++ + 587 +++ + 589 +++ + 383 560 +++ ++ 536 +++ +++ 588 +++ +++ 589 +++ +++ 310 +++ ++ 483 (a) +++ +++ 483 (b0 +++ +++ 280 +++ ++ 457 +++ +++ 349 +++ +++ 537 +++ + 458 +++ +++ 311 +++ +++ 312 +++ +++ 313 +++ 314 +++ +++ 413 +++ +++ 414 +++ +++ 467 +++ +++ 538 +++ +++ 331 +++ 332 +++ 627 +++ ++ 628 +++ +++ 468 469 +++ +++ 470 +++ + 471 +++ +++ 290 +++ ++ 291 +++ +++ 659 ++ + 629 +++ +++ 630 +++ +++ 315 +++ + 350 +++ +++ 316 +++ +++ 351 +++ +++ 317 +++ + 318 741 +++ +++ 539 +++ +++ 540 +++ +++ 541 +++ ++ 542 +++ + 543 +++ + 544 +++ ++ 292 +++ +++ 459 +++ ++ 293 +++ +++ 631 +++ ++ 611 294 +++ + 660 604 +++ ++ 783 +++ +++ 384 +++ +++ 632 +++ +++ 633 +++ +++ 385 +++ ++ 561 +++ ++ 352 +++ +++ 295 +++ +++ 296 +++ + 545 +++ + 661 +++ +++ 662 +++ +++ 634 +++ +++ 635 +++ ++ 281 +++ + 297 +++ + 386 +++ +++ 387 +++ +++ 636 +++ +++ 637 +++ +++ 663 +++ +++ 664 +++ +++ 665 +++ +++ 666 +++ +++ 415 +++ +++ 416 +++ +++ 417 +++ +++ 418 +++ ++ 460 +++ ++ 461 +++ +++ 462 +++ ++ 605 +++ +++ 606 +++ +++ 562 +++ +++ 667 ++ + 668 +++ ++ 669 +++ +++ 343 ++ +++ 484 (a) ++ +++ 590 +++ ++ 840 +++ +++ 793 +++ +++ 794 +++ +++ 795 +++ +++ 796 +++ +++ 388 +++ +++ 389 +++ +++ 753 +++ +++ 344 +++ +++ 463 +++ + 464 +++ + 638 +++ ++ 612 +++ + 742 +++ +++ 743 +++ +++ 744 +++ +++ 745 +++ +++ 390 +++ +++ 391 +++ +++ 472 +++ + 473 +++ + 797 +++ +++ 798 +++ +++ 639 +++ + 319 +++ +++ 704 +++ +++ 705 +++ +++ 799 +++ +++ 800 +++ +++ 724 +++ +++ 725 +++ +++ 801 +++ +++ 802 +++ +++ 670 +++ +++ 671 +++ +++ 672 +++ +++ 673 +++ +++ 674 +++ +++ 675 +++ +++ 676 +++ +++ 677 +++ +++ 678 +++ 679 +++ +++ 680 +++ ++ 681 +++ +++ 682 +++ ++ 754 726 +++ +++ 727 +++ +++ 728 +++ +++ 729 +++ +++ 392 +++ +++ 393 +++ +++ 320 +++ +++ 321 +++ +++ 353 +++ +++ 640 +++ +++ 549 +++ + 484 (b) +++ +++ 482 +++ +++ 546 +++ +++ 547 +++ +++ 746 +++ +++ 747 +++ +++ 748 +++ 755 +++ +++ 322 +++ +++ 323 +++ +++ 324 ++ 563 +++ +++ 564 +++ +++ 838 +++ +++ 839 +++ +++ 706 +++ +++ 707 +++ +++ 708 +++ +++ 709 +++ +++ 565 +++ + 683 +++ +++ 684 +++ +++ 550 +++ +++ 551 +++ +++ 771 +++ +++ 772 +++ +++ 325 +++ +++ 641 +++ ++ 642 +++ ++ 643 +++ + 730 +++ +++ 731 +++ +++ 732 +++ +++ 733 +++ +++ 609 +++ ++ 710 +++ +++ 591 +++ + 592 +++ + 711 +++ ++ 712 +++ +++ 607 +++ ++ 713 +++ +++ 326 +++ 327 +++ +++ 773 +++ +++ 774 +++ +++ 841 +++ +++ 842 +++ +++ 566 +++ + 593 +++ + 749 +++ +++ 750 +++ +++ 751 +++ +++ 623 +++ +++ 624 +++ +++ 734 +++ +++ 735 +++ +++ 714-+++ + 715 +++ ++ 775 +++ +++ 776 +++ +++ 803 +++ +++ 804 716 +++ ++ 717 +++ 594 +++ +++ 595 +++ +++ 817 +++ +++ 818 +++ +++ 298 +++ + 299 +++ ++ 644 645 +++ 805 +++ +++ 806 +++ +++ 718 +++ + 300 +++ ++ 807 +++ +++ 808 +++ +++ 596 +++ + 836 +++ +++ 837 +++ +++ 809 +++ 810 +++ +++ 419 +++ +++ 420 +++ +++ 421 +++ +++ 597 +++ +++ 598 +++ +++ 613 +++ +++ 552 +++ +++ 553 +++ +++ 777 +++ +++ 778 +++ +++ 345 +++ + 346 +++ + 827 +++ +++ 828 +++ +++ 829 +++ +++ 830 +++ +++ 831 +++ +++ 832 +++ +++ 422 +++ 811 +++ +++ 812 +++ +++ 423 +++ +++ 424 +++ +++ 736 +++ +++ 737 +++ +++ 738 +++ +++ 779 +++ +++ 625 +++ 618 +++ 646 +++ ++ 784 +++ +++ 785 +++ +++ 786 +++ +++ 608 +++ + 614 +++ ++ 554 +++ ++ 780 +++ +++ 813 +++ +++ 814 +++ 617 +++ +++ 647 +++ ++ 819 11 1 +++ 820 +++ +++ 821 +++ 822 +++ +++ 752 +++ +++ 436 +++ +++ 787 +++ +++ 788 +++ +++ 789 +++ +++ 790 +++ +++ 833 +++ +++ 823 +++ +++ 824 +++ +++ 833 +++ 823 +++ 824 +++ 719 +++ 843 815 +++ 816 +++ 791 +++ 792 +++ 756 +++ 425 +++ 426 +++ 781 +++ 782 +++ 720 +++ 825 +++ 826 +++ 485 (a) 328 329 +++ 439 +++ +++ 440 +++ + 489 +++ + 490 ++ + 621 +++ 622 +++ + 602 +++ +++ 603 +++ +++ 282 +++ +++ 283 +++ + 284 +++ 285 +++ 288 +++ 505 +++ ++ 506 +++ +++ 507 ++ +++ 508 +++ + 441 +++ +++ 491 +++ + 354 +++ 355 +++ +++ 356 +++ +++ 357 +++ +++ 509 +++ +++ 394 +++ +++ 395 +++ + 289 +++ ++ 358 359 +++ +++ 759 +++ ++ 133 +++ +++ 760 +++ + 761 +++ +++ 762 +++ +++ 763 +++ +++ 764 +++ +++ 76+5 +++ +++ 475 +++ + 476 +++ +++ 442 +++ +++ 443 +++ + 649 ++++ 510 +++ + 511 +++ +++ 486 +++ 512 +++ +++ 619 +++ +++ 620 +++ +++ 555 +++ +++ 556 +++ +++ 396 +++ +++ 650 +++ +++ 397 +++ + 548 +++ + 444 +++ +++ 651 +++ ++ 652 +++ + 653 +++ ++ 398 +++ +++ 399 +++ + 654 +++ +++ 567 +++ + 568 +++ +++ 569 +++ + 557 +++ +++ 721 +++ +++ 655 +++ +++ 570 +++ ++ 571 +++ +++ 572 +++ +++ 573 +++ +++ 656 +++ +++ 400 +++ +++ 657 +++ +++ 513 ++ 514 ++ +++ 515 +++ + 516 +++ +++ 445 +++ + 492 +++ + 493.. 494.... 685 +++ +++ 686 +++ 517 +++ ++ 574 +++ +++ 575 +++ +++ 576 +++ + 577 +++ +++ 687 +++ +++ 518 +++ +++ 487 +++ ++ 766 +++ + 767 +++ +++ 360 +++ ++ 361 +++ +++ 688 +++ +++ 401 +++ +++ 495 +++ +++ 437 +++ ++ 474 +++ ++ 626 +++ + 402 +++ + 519 +++ +++ 520 +++ +++ 446 +++ +++ 768 +++ + 769 +++ +++ 770 403 +++ +++ 404 +++ +++ 689 +++ 690 ++ 691 ++ i i i 692 +++ +++ 693 +++ +++ 694 +++ +++ 695 +++ +++ 696 +++ +++ 405 +++ +++ 406 +++ +++ 362 +++ ++ 496 +++ +++ 497 +++ +++ 697 +++ 698 ++ + + 477 +++ + 478 +++ +

Legend: "+"represents a value of dz 10, 000nM "++"represents a value of # 1,000nM "+++"represents a value of 500nM "--"indicates the value was not determined The following preparations and examples further illustrate the invention and represent typical synthesis of the compounds of Formula I, including any novel compounds, as described generally above. The reagents and starting materials are readily available to, or may be readily synthesized by, one of ordinary skill in the art. As used herein, the following terms have the meanings indicated:"i. v." refers to intravenously; "p. o." refers to orally;"i. p." refers to intraperitoneally;"eq"or"equiv."refers to equivalents ;"g"refers to grams;"mg"refers to milligrams ;"refers to liters ;"mL"

refers to milliliters ;"p, L" refers to microliters;"mol"refers to moles;"mmol"refers to millimoles;"psi"refers to pounds per square inch ;"mm Hg"refers to millimeters of mercury;"min"refers to minutes;"h"or"hr"refers to hours ;"°C"refers to degrees Celsius;"TLC"refers to thin layer chromatography ;"HPLC"refers to high performance liquid chromatography ;"Rf"refers to retention factor;"Rt"refers to retention time ;"8" refers to part per million down-field from tetramethylsilane ;"THF"refers to tetrahydrofuran ;"DMF"refers to N, N-dimethylformamide ; "DMSO"refers to dimethyl sulfoxide ; "aq"refers to aqueous;"EtOAc"refers to ethyl acetate;"iPrOAc"refers to isopropyl acetate ;"MeOH"refers to methanol;"MTBE"refers to tert-butyl methyl ether; "PPh3"refers to triphenylphosphine;"DEAD"refers to diethyl azodicarboxylate;"RT" refers to room temperature;"Pd-C"refers to palladium over carbon; NaBH (OAc) 3 refers to sodium triacetoxyborohydride;"Bn"refers to benzyl ;"BnNH2"refers to benzyl amine ; H2 refers to hydrogen ;"Ki"refers to the dissociation constant of an enzyme-antagonist complex and serves as an index of ligand binding; and"Is0"and"ID 100"refer to doses of an administered therapeutic agent which produce, respectively, a 50 % and 100% reduction in a physiological response.

Instrumental Analysis Unless otherwise indicated, lH NMR spectra are recorded on a either a 300 MHz or 400 MHz Varian spectrometer at ambient temperature. Data are reported as follows: chemical shift in ppm from internal standard tetramethylsilane on the 8 scale, multiplicity (b = broad, s = singlet, d = doublet, t = triplet, q = quartet, qn = quintet and m = multiplet), integration, coupling constant (Hz) and assignment. Positive and negative electrospray mass spectral data are obtained on a Micromass Platform LCZ equipped with an autosampler. Analytical thin layer chromatography is performed on EM Reagent 0.25- mm silica gel 60-F plates. Visualization is accomplished with UV light. HPLC analysis is performed on an Agilent 1100 Series HPLC using an acetonitrile/0.03M phosphate buffer (80/20) as the mobile phase using an Agilent Eclipse XDB-C8 analytical 4. 6xl50mm 5- micron column. Melting points are determined on a Mettler Toledo FP62 melting point apparatus. GC-MS data are obtained on an Agilent HP6890 GC using a HP-5MS (30m, 0.25mm i. d. , 0. 25um film) column.

Section 1 (derivatives of Formula I having substitution on the"C"ring but not on the"A" or"B"rings.) Preparation 1 2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzenesulfonyl chloride A. Preparation of 2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- benzenesulfonic acid (LY622781, ERO-A01318-26B) 1. Treat a mixture of o-toluenesulfonyl chloride (22g, 115mmol) in dioxane (200mL) with triethylamine (28mL, 200mmol) and cool to 10°C. Add ethanol (50mL) and allow the reaction to warm to room temperature. After 18 h, acidify the reaction and remove most of the solvent under reduced pressure. Partition the residue between water/EtOAc.

Dry the organic layer with MgS04 and concentrate to give 22.6g colorless oil. Purify using flash chromatography (10% EtOAc/hexane) to give 7.4g of pure ester. 1H NMR (CDC13) al. 50 (t, 3H), 2.64 (s, 3H), 4.08 (q, 2H), 7.34 (m, 2H), 7.50 (t, 1H), 7.96 (d, 2H).

(Literature ref : J. Prakt. Chem. 333 (4) 625-635 (1991).

2. Under a blanket of nitrogen, cool (6.4g, 32mmol) toluene-2-sulfonic acid ethyl ester in THF (140mL) to-70°C. Add n-butyllithium (1.6M, 22. 5mL, 36mmol) slowly. An orange solid forms. After 20 minutes, add a solution of dibenzosuberone (6.32g, 30mmol) in THF (15mL). Allow warming to room temperature and stir for 2 h. Concentrate to

remove most of the THF and dissolve the residue in EtOAc and shake vigorously with 5N HC1 for 5 minutes. Dry the organic layer (MgS04) and concentrate to give 10.8g crude product as a dark red oil. Purify the crude product by flash chromatography (300g silica gel, 5% HOAc/EtOAc) to give crude sulfonic acid. Remove residual HOAc by repeatedly azeotroping with toluene to yield 910mg orange solid.'H NMR (DMSO-d6) 2. 80-3.44 (br m, 4H), 6.54 (d, 1H), 6.78-7. 76 (m, 12H) ; MS (ES) 361 (M-1).

B. Preparation of 2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- benzenesulfonyl chloride (ERO-A01318-30) Treat a mixture of 2- (10, 11-dihydro dibenzo [a, d] cyclohepten-5-ylidenemethyl)- benzenesulfonic acid (710mg, 2mmol) in thionyl chloride (lOmL) with 5 drops DMF and reflux for 40 minutes. TLC (10% EtOAc/hexane) shows a new higher Rf material and no starting material. The material is then concentrated to give 760mg crude sulfonyl chloride, which is used without further purification. (Note: To confirm the structure, a small aliquot is reacted with methylamine. The MS (ES) of the corresponding sulfonamide is readily detected).

Following the procedures essentially as described in Preparation 1 above, and using the appropriately substituted arylsulfonyl chloride, the following sulfonyl chlorides were prepared: Preparation 2 2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-5-methyl-benzenesulfonyl chloride To confirm the structure, a small aliquot is reacted with methylamine. The MS (ES) of the corresponding sulfonamide is readily detected Preparation 3 4-Chloro-2- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-5-methyl- benzenesulfonyl chloride

To confirm the structure, a small aliquot is reacted with methylamine. The MS (ES) of the corresponding sulfonamide is readily detected Preparation 4 3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzenesulfonyl chloride

To confirm the structure, a small aliquot is reacted with methylamine. The MS (ES) of the corresponding sulfonamide is readily detected Example 1 3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-N-methyl- benzenesulfonamide

Treat a solution of 3- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- benzenesulfonyl chloride (95mg, 0. 25mmol) in THF (2mL) with methylamine (300dol 40% aqueous solution, 3. 5mmol) at room temperature. Stir reaction overnight at room temperature, then concentrate under a stream of N2. Take residue up in 2mL CH2Cl2 and shake with 2mL 1N HC1. Load the biphasic solution onto a Varian ChemElut 1005 solid- phase extraction column and elute with 10-15mL CH2Ck. Collect organics and concentrate under N2 stream. Purify via silica gel chromatography (1: 3 ethyl acetate: hexanes) to afford 45mg (48%) of yellow solid, mp 153. 9°C. lH NMR (CDC13) 6 2.48 (s, 3H), 2.79-3. 61 (br m, 4H), 4.19 (br s, 1H), 6.78-7. 63 (m, 13H); MS (ES) 376 (M+H). HPLC shows 94% purity.

Following the procedures essentially as described in Example 1 above, reaction of the appropriate sulfonyl chloride from Preparations 1-4 and the appropriate amine gives the following compounds: Example 2 2-(10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-5, N-dimethyl- benzenesulfonamide Prepared in 49% from the sulfonyl chloride (500mg, 1. 27mmol) and methanesulfonyl chloride to give white needles (EtOH), mp 174. 9°C. 1H NMR 8 2.36 (s, 3H), 2.77 (d, 3H), 3.29 (br s, 4H), 4.51 (q, 1H), 6.73-7. 29 M, 10H), 7.58 (m, 1H), 7.82 (s, 1H); MS (ES) 390 (M+1). HPLC shows 99.6% purity.

Example 3 2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzenesulfonamide

Prepared in 18% yield as a white solid,'H NMR (CDC13) 8 3.29 (br s, 4H), 4. 97 (br s, 2H), 6.76-7. 65 (m, 13H); MS (ES) 361 (M-1).

Example 4 2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-N-methyl- benzenesulfonamide Prepared in 16% yield as a white solid, mp 149°C, MS (ES) 376 (M+1), 374 (M-1).

Example 5 2-(10,11-Dihydro-dibenzo[a,d] cyclohepten-5-ylidenemethyl) -N, N-dimethyl- benzenesulfonamide Prepared in 28% yield as a white solid, 1H NMR (CDCl3) # 2.90 (s, 6H), 3. 18 (br s, 4H), 6.79-7. 95 (m, 13H); MS (ES) 390 (M+1).

Example 6 2-(10,11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-N-propyl- benzenesulfonamide

Prepared in 23% yield as a white solid, mp 155. 6°C, lH NMR (CDC13) 8 0. 98 (t, 3H), 1.61 (q, 2H), 3.05 (q, 2H), 3.30 (br s, 4H), 4.57 (br t, 1H), 6.78-7. 42 (m, 13H); MS (ES) 404 (M+1), 402 (M-1).

Example 7 2- (10, 11-Dihydro-dibenzo [a, d]cyclohepten-5-ylidenemethyl)-N-(2-methoxy-ethyl)- benzenesulfonamide

Prepared in 10% yield to give a white solid.'H NMR (CDC13) 8 2.85-3. 70 (m, 11H), 5.13 (br t, 1H), 6.84-8. 01 (m, 13H); MS (ES) 420 (M+H), 418 (M-H).

Example 8 4-[2-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidenemethyl) -benzenesulfonyl]- morpholine

Prepared in 29% yield as a white solid, mp 139. 3°C. lH NMR (CDC13) 8 2.76-3. 89 (m, 12H), 6.57-7. 93 (m, 13H). MS (ES) 432 (M+H).

Example 9 4-Chloro-2-(10,11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-5-methyl- benzenesulfonamide MS (ES) 408 (M-H). HPLC shows 81% purity.

Example 10 4-Chloro-2- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-5, N, N-trimethyl- benzenesulfonamide White solid, mp 199. 9°C. 1H NMR (CDCl3) 8 2.36 (s, 3H), 2.95 (s, 6H), 2.98-3. 66 (br m, 4H), 6.79-7. 80 (m, 11H) ; MS (ES) 438 (M+H), 436 (M-H.; HPLC shows 98% purity.

Example 11 4-Chloro-2- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-5-methyl-N- propyl-benzenesulfonamide

White solid. MS (ES) 452 (M+H), 450 (M-H). HPLC shows 97% purity.

Example 12 4- [4-Chloro-2- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-5-methyl- benzenesulfonyl]-morpholine

White solid, mp 194. 7°C. IH NMR (CDC13) 5 2.20 (s, 3H), 2.65-3. 67 (m, 12H), 6.63- 7.60 (m, 11H) ; MS (ES) 480 (M+H). HPLC shows 98% purity.

Example 13 2- [2- (2-Ethyl-phenyl)-penta-1, 4-dienyl]-5-methyl-N-phenyl-benzenesulfonamide ; compound with propene

White solid, mp 220. 4°C. lH NMR (CDCl3) 8 2.31 (s, 3H), 2.85-3. 60 (br m, 4H), 4.54 (br t, 1H), 6.10-7. 84 (m, 17H); MS (ES) 452 (M+H), 450 (M-H). HPLC shows 93% purity.

Example 14 N-Cyclopropyl-2- (10, ll-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-5-methyl- benzenesulfonamide White solid, mp 160. 8°C. MS (ES) 416 (M+H), 414 (M-H). HPLC shows 86% purity.

Example 15 N-Benzyl-2- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-5-methyl- benzenesulfonamide Colorless oil, slowly crystallized, mp 138. 3°C. lH NMR (CDC13) 8 2. 34 (s, 3H), 2.87- 3.69 (br s, 4H), 4.28 (d, 2H), 4.82 (br t, 1H), 6.70-7. 85 (m, 17H); MS (ES) 464 (M-H).

HPLC shows 96% purity.

Example 16 1- [2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-5-methyl- benzenesulfonyl]-4- (4-trif luoromethyl-phenyl)-piperidine

White foam. MS (ES) 588 (M+H). HPLC shows 96% purity.

Example 17 2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-N-ethyl-5-methyl- benzenesulfonamide White foam, mp 172. 4°C. MS (ES) 402 (M-H). HPLC shows 95% purity.

Example 18 2-(10,11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-5-methyl- benzenesulfonamide 'H NMR (CDC13) b2. 38 (s, 3H), 2.80-3. 80 (br m, 4H), 6.77-7. 92 (m, 12H); MS (ES) 375 (M-H. HPLC shows 78% purity.

Example 19 2-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidenemethyl)-5, N, N-trimethyl- benzenesulfonamide

White solid, mp 186. 6°C. MS (ES) 404 (M+H).

Example 20 2-(10,11-Dihydro-dibenzo[a,d] cyclohepten-5-ylidenemethyl) -5-methyl-N-propyl- benzenesulfonamide

White solid, mp 149. 8°C. MS (ES) 418 (M+H), 416 (M-H). HPLC shows 96% purity.

Example 21 2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-N- (2-methoxy-ethyl)-5- methyl-benzenesulfonamide lH NMR (CDC13) 6 2.33 (s, 3H), 2.85-3. 20 (m, 11H), 5.12 (br t, 1H), 6.61-7. 33 (m, 12H); MS (ES) 434 (M+H), 432 (M-H). HPLC shows 98% purity.

Example 22 4- [2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-5-methyl- benzenesulfonyl]-morpholine

White solid, mp 157. 2°C. lH NMR (CDC13) 8 2.35 (s, 3H), 2.85-4. 00 (m, 12H), 6.72- 7.75 (m, 12H); MS (ES) 446 (M+H). HPLC shows 95% purity.

Example 23 2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-5-methyl-N- (2, 2,2-trifluoro- ethyl)-benzenesulfonamide

White needles, mp 100. 7°C. tH NMR (CDC13) 8 2.35 (s, 3H), 3.0-3. 6 (br s, 4H), 3.76 (m, 2H), 5.05 (br t, 1H), 6.75-7. 62 (m, 11H), 7.78 (s, 1H); MS (ES) 457 (M+H), 456 (M-H).

HPLC shows 99% purity.

Example 24 3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzenesulfonamide

White crystalline solid, mp 204. 0°C. lH NMR (DMSO-d6) 8 2.77-3. 45 (br m, 4H), 6.81- 7.68 (br m, 15H); MS (ES) 384 (M+Na). HPLC shows 98% purity.

Example 25 3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-N, N-dimethyl- benzenesulfonamide

White crystalline solid, mp 167. 3°C. 1H NMR (CDCl3) # 2.54 (s, 6H), 2.80-3. 64 (br m, 4H), 6.86 (s, 1H), 6.91-7. 56 (m, 12H) ; MS (ES) 390 (M+H). HPLC shows 96% purity.

Example 26 4- [3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzenesulfonyl]- morpholine

Off-white crystalline solid. 1H NMR (CDC13) 8 2.73 (m, 4H), 2.82-3. 63 (br m, 4H), 3.70 (m, 4H), 6.86 (s, 1H), 6.92-7. 51 (m, 12H); MS (ES) 432 (M+H). HPLC shows 96% purity.

Example 27 4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-N-methyl- benzenesulfonamide White solid, mp 189. 7°C. lH NMR (CDC13) 8 2.65 (d, 3H), 2.81-3. 65 (br m, 4H), 4.23 (br m, 1H), 6.85 (s, 1H), 6.94-7. 67 (m, 12H); MS (ES) 376 (M+H), 374 (M-H). HPLC shows 98% purity.

Preparation 5 (3-Bromo-phenyl)- (10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-5-yl)-methanol Under nitrogen, cool a THF (300mL) solution of dibenzosuberane (23.9g, 123mmol) to 0°C and add n-BuLi (1.6M, 90mL, 144mmol). Remove the cooling bath and the reaction stir at ambient temperature for 1 h. Cool the orange solution to 5°C and add a solution of 3-bromobenzaldehyde (22. 8g, 123mmol) in THF (lOOmL). After 30 min., quench the reaction with saturated NH4C1 (200mL) and remove most of the THF under reduced pressure. Shake the residue with brine/EtOAc. Dry the organic layer (MgS04) and concentrate to give 49.2g colorless oil. HPLC shows 86% purity. The compound is sufficiently pure to carry on to the next reaction. Purify a small portion on silica gel using

EtOAc/hexane to give a colorless oil that rapidly crystallized, mp 93. 9°C, 1H NMR (CDC13) 53. 00 (m, 2H), 3.57 (m, 2H), 3.94 (d, lH), 5.30 (d, lH), 6. 38 (d, lH), 6.76-7. 34 (m, 12H) ; MS (EI) 360 (M-H20).

Using the procedures essentially as described in Preparation 5, and the appropriately substituted benzaldehyde, the following crude alcohol intermediates are made. Unless otherwise stated, these intermediate carbinols are not isolated or characterized, buth rather, used in the synthesis of compounds of Formula I without purther purification.

Preparation 6 (2-Bromo-phenyl)-(10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-5-yl)-methanol Light yellow solid, mpl46. 9°C. MS (FD) 361 (M-H20).

Preparation 7 (4-Bromo-phenyl)- (10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-5-yl)-methanol Viscous yellow oil, MS (EI) 360 (M-H20). HPLC (IS080-lOM) t=1.86min.

Preparation 8 (2-Methoxy-phenyl)-(10, 1 1-dihydro-5H-dibenzo [a, d] cyclohepten-5-yl)-methanol

Pale yellow solid, mp 113.1°C.

Preparation 9 (3-Methoxy-phenyl)-(10,11-dihydro-5H-dibenzo [a, d] cyclohepten-5-yl)-methanol Pale yellow solid, mpl32. 1°C.

Preparation 10 (4-Methoxy-phenyl)- (10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-5-yl)-methanol Pale yellow solid, mpl03. 1°C.

Preparation 11 (3-Bromo-4-methoxy-phenyl)- (10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-5-yl)- methanol

HPLC (IS080-10M) t=1.75min.

Preparation 12 (2, 3-Dimethoxy-phenyl)- (10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-5-yl)-methanol Used without further characterization or purification.

Preparation 13 (3, 4-Dimethoxy-phenyl)-(10,11-dihydro-5H-dibenzo [a, d] cyclohepten-5-yl)-methanol HPLC (IS080-10M) t=1. 43min.

Preparation 14 (3-bromo-5-methoxy-phenyl)-(10, 1 1-dihydro-5H-dibenzo [a, d] cyclohepten-5-yl)-methanol

Used without further characterization or purification.

Example 28 5- (3-Bromo-benzylidene)-10, 11-dihydro-5H-dibenzo- [a, d] cycloheptene Add the crude product from Preparation 5 above (48.85g, 129mmol) to a premixed solution of HOAc (300mL) and concentrated H2S04 (6mL). Reflux the solution for 2.5 h and then cool to ambient temperature. Shake the reaction with EtOAc (lL)/water (1L).

Wash the organic layer again with water and then 1N NaOH (2x). Dry the organic layer (MgS04) and concentrate to give 54g crude product. Recrystallize from hexane to afford 26.6g (57%) light tan crystals, mp 104. 7°C, lH NMR (CDC13) 6 2.97 (br d, 2H), 3.43 (br d, 2H), 6.50 (s, 1H), 6.86-7. 47 (m, 12H) ; MS (FAB+) 360. HPLC shows 98.3% purity.

Anal: Calcd. for C22Hl7Br : C, 73.14 ; H, 4.74. Found: C, 73. 22 ; H, 4.84.

Following the procedures essentially as described in Example 28 above, reaction of the appropriate crude alcohol intermediate from Preparations 6-14 above, gives the following compounds: Example 29 5-(2-Bromo-benzylidene)-10,11-dihydro-5H-dibenzo-[1,d] cycloheptene

Recrystallize from hexane, mp 122. 7°C, 1H NMR (CDC13) 5 2.80-3. 64 (br s, 4H), 6.60- 7.20 (m, 11H), 7.45-7. 57 (m, 2H) ; MS (EI) 360.

Example 30 5-(4-Bromo-benzylidene)-10,11-dihydro-5H-dibenzo-[a, d] cycloheptene Viscous oil, 1H NMR (CDC13) 8 2. 80-3. 64 (br m, 4H), 6.74-7. 55 (m, 13H); MS (EI) 360.

HPLC shows 96.4% purity.

Example 31 5- (2-Methoxy-benzylidene)-10, 11-dihydro-SH-dibenzo- [a, d] cycloheptene Recrystallize from hexane, mp 129. 3°C, IH NMR (CDC13) 8 2.80-3. 64 (br m, 4H), 3.86 (s, 3H), 6.59-7. 58 (m, 13H). HPLC shows 100% purity.

Example 32 5- (3-Methoxy-benzylidene)-10, 11-dihydro-SH-dibenzo- [a, d] cycloheptene

Triturate with hexane, mp 83. 0°C ; 1H NMR (CDC13) S 2.80-3. 60 (m, 4H), 3.55 (s, 3H), 6.48-7. 50 (m, 13H). HPLC shows 98.8% purity.

Example 33 5- (4-Methoxy-benzylidene)-10, 11-dihydro-5H-dibenzo- [a, d] cycloheptene Purify on silica gel using CH2C12. Recrystallize from hexane/CH2Cl2, mp 116. 8°C. lH NMR (CDC13) 8 2.94 (br d, 2H), 3.46 (br d, 2H), 3.77 (s, 3H), 6.65-7. 48 (m, 13H).

Example 34 5-(3-Bromo-4-methox-benzylidene)-10,11-dihydro-5H-dibenzo [a, d] cycloheptene Recrystallize from hexane/toluene, mp 140. 7°C. 1H NMR (CDC13) â2. 94 (br d, 2H), 3.45 (br d, 2H), 3.83 (s, 3H), 6.64-7. 48 (m, 12H). HPLC shows 95% purity.

Example 35 5- (2, 3-Dimethoxy-benzylidene) -10, 11-dihydro-5H-dibenzo [a, d] cycloheptene

Purify on silica gel using EtOAc/hexane. Light yellow solid, mp 130. 6°C.'H NMR (CDC13) 8 2.94 (br d, 2H), 3.45 (br d, 2H), 3. 82 (s, 3H), 3.95 (s, 3H), 6.27 (dd, 1H), 6.65- 7.27 (m, 9H), 7.57, m, 1H) ; MS (ES) 343 (M+H). HPLC shows 91% purity.

Example 36 5- (3, 4-Dimethoxy-benzylidene) -10, 11-dihydro-SH-dibenzo [a, d] cycloheptene Purify on silica gel using EtOAc/hexane to give a white solid, mp 102. 8°C. IH NMR (CDC13) 8 2.80-3. 60 (br dd, 4H), 3.42 (s, 3H), 3.83 (s, 3H), 6.42 (s, 1H), 6.72 (m, 3H), 7.06-7. 47 (m, 8H). HPLC shows 97% purity.

Example 40 5- (5-Bromo-2-methoxy-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene Following the procedures essentially as described for Preparation 5 and Example 28 above, using dibenzosuberane (15. 0g, 77.2mmol) and 5-bromo-o-anisaldehyde (16.6g, 77. 2mmol), recrystallization from boiling toluene/hexanes affords 19.78g (65%) of the

title compound as a tan solid. 1H-NMR (CDC13) 8 2.76-3. 70 (br m, 4H), 3.81 (s, 3H), 6.69 (d, 1H), 6.76 (d, 1H), 6.88-7. 29 (m, 9H), 7.53 (m, 1H); HPLC shows 100% purity.

Example 41 3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-4-methoxy-phenylamine Following the procedures essentially as described in Example 86 below, and using 5- (5- bromo-2-methoxy-benzylidene)-10,11-dihydro-5H-dibenzo[a,d] cycloheptene (10. Og, 25. 56mmol), affords 6.52g (78%) of the title compound as a solid. MS (ES) 328 (M+H) ; HPLC shows 99% purity.

Example 42 N- [3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -4-methoxy-phenyl]- methanesulfonamide Following the procedures essentially as described in Example 90 below, and using 3- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -4-methoxy-phenylamine (500mg, 1. 53mmol), affords 398mg (64%) of the title compound as a white foam. MS (ES) 423 (M+H), 404 (M-H); HPLC shows 100% purity.

Example 45 N- [5- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -2-methyl-phenyl]- methanesulfonamide

Following the procedure essentially as described for Example 219, below, and using 5- bromomethylene-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (300mg, 1. 05mmol) and (3-amino-4-methylphenyl) boronic acid hydrochloride (217mg, 1. 16mmol), yields 245mg (75%) 5- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-2-methyl- phenylamine as a brown oil. Then, following procedures essentially as described in Example 90, below, and using 5- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidenemethyl)-2-methyl-phenylamine (100mg, 0. 321mmol), affords 35mg (28%) of the title compound as a colorless oil. MS (ES) 407 (M+NH4), 388 (M-H) ; HPLC shows 98% purity.

Example 46 N- (3-Bromo-4-methyl-phenyl)-methanesulfonamide Following the procedures essentially as described for Example 90, below, and using 3- bromo-4-methylaniline (5. 00g, 26. 9mmol), recrystallization from boiling toluene/hexanes affords 6. 08g (86%) of the title compound as a tan crystalline solid. MS (ES) 263 (M-H), HPLC shows 100% purity.

Preparation 15 N- [4-Methyl-3- (4, 4,5, 5-tetramethyl- [1, 3, 2] dioxaborolan-2-yl) -phenyl]- methanesulfonamide

Mix N-(3-bromo-4-methyl-phenyl)-methanesulfonamide (500mg, 1.89mmol), bis (pinacolato) diboron (576mgj 2. 27mmol), and potassium acetate (557mg, 5. 67mmol) in DMSO (6mL). Sparge solution with N2 for 10min, then add Pd (dppf) Cl2 (1: 1 complex with CH2C12, 154mg, 0. 189mmol) and heat to 85°C overnight. Cool reaction mixture to room temperature, dilute with ethyl acetate (lOOmL), and wash organics four times with H20. Dry (MgS04) and concentrate organics to a brown oil. Chromatograph on silica gel (40g), eluting with 20% to 40% ethyl acetate/hexanes affords 415mg (71 %) of the title compound as a colorless oil. MS (ES) 329 (M+NH4), 310 (M-H); HPLC shows 96% purity.

Example 47 N- [3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-4-methyl-phenyl]-<BR> methanesulfonamide Following the procedures essentially as described in Example 219, below, and using N- [4-methyl-3- (4, 4,5, 5-tetramethyl-[1, 3,2] dioxaborolan-2-yl)-phenyl]-methanesulfonamide (120mg, 0. 386mmol) and 5-bromomethylene-10, 1 1-dihydro-5H- dibenzo [a, d] cycloheptene (100mg, 0. 351mmol) affords 83mg (61%) of the title compound as a yellow solid. MS (ES) 407 (M+NH4), 388 (M-H) ; HPLC shows 91% purity.

Preparation 16 N- (3-Bromo-2-methyl-phenyl)-methanesulfonamide

Following procedures essentially as described in Example 90, below, and using 2-methyl- 3-bromoaniline (5. 00g, 26. 87mmol), recrystallization from boiling toluene/hexanes affords 6.77g (95%) of the title compound as a light green solid. MS (ES) 263 (M-H); HPLC shows 100% purity.

Preparation 17 N- [2-Methyl-3- (4, 4,5, 5-tetramethyl-[1, 3,2] dioxaborolan-2-yl) -phenyl]- methanesulfonamide Mix N- (3-bromo-2-methyl-phenyl)-methanesulfonamide (500mg, 1. 89mmol), bis (pinacolato) diboron (576mg, 2.27mmol), and potassium acetate (557mg, 5. 67mmol) in DMSO (6mL). Sparge solution with N2 for 5min, then add Pd (dppf) Cl2 (1: 1 complex with CH2C12, 154mg, 0. 189mmol) and heat to 85°C overnight. Cool reaction mixture to room temperature, dilute with ethyl acetate (lOOmL), and wash organics three times with H20. Dry (MgS04) and concentrate organics to a brown oil. Chromatograph on silica gel (40g), eluting with 20% to 40% ethyl acetate/hexanes affords 458mg (78%) of the title compound as a colorless oil. MS (ES) 310 (M-H) ; HPLC shows 76% purity.

Example 48 N- [3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-2-methyl-phenyl]- methanesulfonamide

Following the procedures essentially as described in Example 219, below, and using N- [2-methyl-3- (4, 4,5, 5-tetramethyl- [1, 3, 2} dioxaborolan-2-yl)-phenyl]-methanesulfonamide (120mg, 0. 386mmol) and 5-bromomethylene-10, 11-dihydro-5H- dibenzo [a, d] cycloheptene (100mg, 0. 351mmol), purification by UV-guided semi- preparatory reverse-phase HPLC affords 18mg (13%) of the title compound as a yellow oil. MS (ES) 407 (M+NH4), 388 (M-H); HPLC shows 96% purity.

Preparation 18 5-Bromo-2-fluoro-phenylamine Dissolve 4-bromo-1-fluoro-2-nitrobenzene (5. 00g, 22. 73mmol) and SnCl2 (dihydrate, 25.46g, 113. 6mmol) in ethanol (100mL) and heat to reflux overnight. Cool to room temperature and concentrate in-vacuo. Dissolve residue in ethyl acetate and basify with saturated aqueous NaHCO3. Filter through a pad of Celite and extract filtrate with ethyl acetate. Dry (MgS04) and concentrate organics to a brown oil. Chromatograph on 90g silica gel, eluting with 5% to 10% ethyl acetate/hexanes affords 2.85g (66%) of the title compound as a tan oil. MS (ES) 191 (M+H) ; HPLC shows 99% purity.

Preparation 19 N- (5-Bromo-2-fluoro-phenyl)-methanesulfonamide

Dissolve 5-bromo-2-fluoro-phenylamine (1.40g, 7. 37mmol), N, N-dimethylamino-4- pyridine (90mg, 0.737mmol), and methanesulfonyl chloride (1.69g, 14. 74mmol) in CH2C12 (lOmL) and pyridine (lOmL). Stir under N2 for 4h and concentrate in-vacuo.

Dilute residue with 1. OON aqueous HC1 (20mL) and extract into ethyl acetate. Dry (MgS04) and concentrate organics to a yellow solid. Dissolve in THF (20mL) and add 1. OM tetrabutylammonium fluoride/TBF (4. 83mL, 4. 83mmol). Heat to reflux for 3h, then add H2O and brine. Extract into ethyl acetate, then dry (MgS04) and concentrate organics to a white solid. Recrystallization from boiling toluene/hexanes affords 768mg (39%) of the title compound as a white solid. MS (ES) 267 (M-H); HPLC shows 100% purity.

Example 49 N- [5- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -2-fluoro-phenyl]- methanesulfonamide Following the procedures essentially as described in Example 219 (below) and using (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidene) -boronic acid (0.197M in dioxane, 3.35mL, 0. 660mmol) and N- (5-bromo-2-fluoro-phenyl)-methanesulfonamide (147mg, 0. 550mmol) affords 141mg (65%) of the title compound as a purple foam. MS (ES) 411 (M+NH4), 392 (M-H) ; HPLC shows 91% purity.

Preparation 20 N- (3-Fluoro-5-iodo-phenyl)-methanesulfonamide

Dissolve 3-fluoro-5-iodoaniline (600mg, 2. 53mmol) (prepared as described in published PCT International Application W096/23783 A1, published August 8,1996), methanesulfonyl chloride (896mg, 7. 83mmol), triethylamine (1. 91g, 18.9mmol), and N, N-dimethylamino-4-pyridine (31mg, 0. 253mmol) in CH2Ck (lOmL) and stir at room temperature overnight. Dilute with l. OON aqueous HC1 (20mL) and extract into ethyl acetate. Dry (MgS04) and concentrate organics to a yellow solid. Dissolve solid in THF (50mL) and add l. OM tetrabutylammonium fluoride (2.8mL). Heat to reflux for 3. 5h.

Cool to room temperature, dilute with H20, and extract into ethyl acetate. Dry (MgS04) and concentrate organics. Chromatograph on silica gel (40g), eluting with 20% to 35% ethyl acetate/hexanes affords 618mg (78%) of the title compound as a white solid. MS (ES) 314 (M-H) ; HPLC shows 100% purity.

Example 50 N- [3- ( 10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -5-fluoro-phenyl]- methanesulfonamide Following procedures essentially as described in Example 219, below, and using 10,11- dihydro-dibenzo [a, d] cyclohepten-5-ylidene) -boronic acid (0. 198M in dioxane, 5. 1mL, 1. 02mmol) and N- (3-fluoro-5-iodo-phenyl)-methanesulfonamide (268mg, 0. 850mmol), purification by W-guided reverse-phase semi-preparatory HPLC affords 108mg (32%) of the title compound as a colorless oil. MS (ES) 394 (M+H), 392 (M-H); HPLC shows 99% purity.

Example 51 5- (3, 5-Dimethoxy-benzylidene) -10, 11-dihydro-SH-dibenzo [a, d] cycloheptene

Following procedures essentially as described in Preparation 5 and Example 28, above, and using dibenzosuberone (2. 00g, 10. 29mmol) and 3,5-dimethoxybenzaldehyde (1.71g, 10.29mmol), affords 1.43g (41%) of the title compound as a yellow foam. IH-NMR (CDC13) 8 2.79-3. 64 (br m, 4H) ; 3.55 (s, 6H), 6.20 (d, 2H), 6.25 (t, 1H), 6.72 (s, 1H), 7.06-7. 30 (m, 7H), 7.48 (m, 1H) ; HPLC shows 99% purity.

Example 52 5- (2, 5-Dimethoxy-benzylidene) -10, 11-dihydro-5H-dibenzo [a, d] cycloheptene Following procedures essentially as described in Preparation 5 and Example 28, above, and using dibenzosuberone (2. 00g, 10. 29mmol) and 2, 5-dimethoxybenzaldehyde (1.71g, 10. 29mmol) affords 1.27g (36%) of the title compound as a yellow solid. 1H-NMR (CDC13) 8 2.74-3. 67 (br m, 4H), 3.34 (s, 3H), 3.83 (s, 3H), 6.27 (d, 1H), 6.65 (dd, 1H), 6.77 (d, 1H), 6.98-7. 28 (m, 8H), 7.56 (dd, 1H); HPLC shows 99% purity.

Example 53 5- (2, 4-Dimethoxy-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene

Following procedures essentially as described in Preparation 5 and Example 28, above, and using dibenzosuberone (2. 00g, 10. 29mmol) and 2,4-dimethoxybenzaldehyde (1.71g, 10. 29mmol) affords 231mg (7%) of the title compound as a white foam. 1H-NMR (CDC13) b 2.70-3. 67 (br m, 4H), 3.73 (s, 3H), 3.84 (s, 3H), 6.15 (dd, 1H), 6.41 (d, 1H), 6.61 (d, 1H), 6.9-7. 27 (m, 8H), 7.56 (dd, 1H); HPLC shows 98% purity.

Example 54 5- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzene-1, 3-diol

Following procedures essentially as described in Example 57, below, and using 5- (3, 5- dimethoxy-benzylidene)-l 0, 11-dihydro-5H-dibenzo [a, d] cycloheptene (664mg, 1.94mmol), affords 608mg (99%) of the title compound as a colorless oil. IH-NMR (CDC13) 6 2.73-3. 62 (br m, 4H), 4.89 (br s, 2H), 6.07 (d, 2H), 6.14 (t, 1H), 6.64 (s, 1H), 7.04-7. 28 (7H), 7.44 (m, 1H) ; HPLC shows 98% purity.

Example 57 3-(10,11-Dihydro-dibenzoi[a,d] cyclohepten-5-ylidenemethyl) -phenol

Stir a molten mixture of 5- (3-methoxy-benzylidene)-10, 11-dihydro-SH- dibenzo [a, d] cycloheptene (1. 1 lg, 3. 55mmol) and pyridine hydrochloride (lOg, 87mmol) at 215°C for 40 min. Cool the reaction mixture to 100°C, dilute with 1N HC1, and extract with ethyl acetate. Dry organics (MgS04), filter, and concentrate to a brown oil containing the title compound. Purification via silica gel chromatography (1: 6 ethyl acetate: hexanes) affords 940mg (89%) of a tan oil. 1H NMR (CDC13) 8 2.76-3. 63 (br m, 4H), 4.59 (s, 1H), 6.45 (s, 1H), 6.64 (m, 2H), 6.75 (s, 1H), 6.99-7. 52 (m, 9H); MS (ES) 299 (M+H), 297 (M-H). HPLC shows 97% purity.

Example 60 4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol Following procedures essentially as described in Example 57, above, and using 5- (4- methoxy-benzylidene) -10, 11-dihydro-SH-dibenzo [a, d] cycloheptene gives the title compound in 60% yield as a white crystalline solid, mp 56. 9°C. IH NMR (CDC13) 8 2.77-3. 60 (br m, 4H), 4.71 (s, 1H), 6.62 (d, 2H), 6.73 (s, 1H), 6.92 (d, 2H), 7.02-7. 50 (m, 8H) ; MS (ES) 297 (M-H). HPLC shows 97% purity.

Example 62 4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzene-1, 2-diol Following procedures essentially as described in Example 57, above, and using 5- (3, 4- dimethoxy-benzylidene) -10, 11-dihydro-5H-dibenzo [a, d] cycloheptene gives the title compound in 79% yield as a brown foam, mp 138. 0°C. IH NMR (CDC13) 8 2.76-3. 62 (br

m, 4H), 4. 84 (s, 1H), 5.07 (s, 1H), 6.47 (s, 1H), 6.55 (m, 11H) ; MS (ES) 313 (M-H).

HPLC shows 95% purity.

Example 63 2-Amino-4- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol Following procedures essentially as described in Example 57, above, and using 5- (10, 11- dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -2-methoxy-phenylamine gives the title compound in 75% yield as a brown foam, mp 158. 8°C. IH NMR (CDC13) 8 2.72-4. 45 (br m, 6H), 6.31-7. 54 (br m, 13H). MS (ES) 314 (M+H), 312 (M-H). HPLC shows 98% purity.

Example 64 N- [5- (10, 1 I-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -2-hydroxy-phenyl]- methanesulfonamide Cool a solution of N-[5-(10,11-dihydro-dibenzo[a,d]cyclohepten-5-ylidenemethyl) -2- methoxy-phenyl]-methanesulfonamide (100mg, 0. 247mmol) in CHUCK (5mL) to 0°C.

Add 23. 3#L (62mg, 0.247mmol) BBr3 and warm up to room temperature. Stir for 20min, then add 30. ODL (79. 5mg, 0. 317mmol) more BBr3. Stir at room temperature for 1 h, then dilute reaction with 90mL saturated aqueous NaHC03. Stir overnight. Separate the layers, and extract the aqueous layer with CH2C12. Combine and dry organics

(MgS04), filter, and concentrate to afford 94mg (97%) of a white foam, mp 122. 6°C. IH NMR (CDC13) 8 2.70 (s, 3H), 2.79-3. 59 (br m, 4H), 5.94 (s, 1H), 6.39 (s, 1H), 6.70-7. 98 (m, 12H); MS (ES) 414 (M+Na), 390 (M-H). HPLC shows 99% purity.

Example 65 5- (3-Difluoromethoxy-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene Add pellets of KOH (376mg, 6.7mmol) to a solution of 3- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenol (200mg, 0. 67mmol) in isopropanol (lOmL). Bubble chlorodifluoromethane (Freon 22) slowly into the reaction mixture for 2 h. Concentrate the reaction mixture, and take the residue up in 1N HC1. Extract into ethyl acetate, dry organics (MgS04), filter, and concentrate to a milky tan oil containing the title compound. Purify via silica gel chromatography (1: 20 ethyl acetate: hexanes) to afford 108mg (20%) of a white solid, mp 91. 3°C. 1H NMR (CDC13) 8 2.66-3. 56 (br m, 4H), 6.12 (t, 1H, J=80Hz), 6.55-7. 43 (m, 13H); MS (El) 348. HPLC shows 97% purity.

Example 66 5-(2-Difluoromethoxy-benzylidene)-10, 1 1-dihydro-5H-dibenzo [a, d} cycloheptene Following the procedures essentially as described in Example 65 above, 5- (2- difluoromethoxy-benzylidene) -10, 11-dihydro-5H-dibenzo [ad] cycloheptene gives the title

compound in 20% yield as a white solid, mp 81. 1°C. 1H NMR (CDC13) 8 2. 76-3. 72 (br m, 4H), 6.57 (t, 1H, J=72Hz), 6.75-7. 57 (m, 13H); MS (EI) 348. HPLC shows 95% purity.

Example 67 5- (4-Difluoromethoxy-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene Following the procedures essentially as described in Example 65 above, 5- (4- difluoromethoxy-benzylidene) -10, 11-dihydro-5H-dibenzo [a, d] cycloheptene gives the title compound in 46% yield as a white solid, mp 65. 8°C. 1H NMR (CDC13) 8 2.76-3. 64 (br m, 4H), 6.44 (t, 1H, J=76Hz), 6.76 (s, 1H), 6.84-7. 50 (m, 12H); MS (EI) 348. HPLC shows 100% purity.

Preparation 21 3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzenesulfonyl chloride Under a blanket of nitrogen, cool 5-(3-bromo-benzylidene)-10,11-dihydro-5H-dibenzo- [a, d] cycloheptene (2.8g, 7.75mmol) in THF (40mL) to-78°C and add n-BuLi (1.6M, 5.8mL, 9. 3mmol) via syringe. After 20 min, add sulfuryl chloride (800p1, lOmmol). The color lightened immediately. Quench the reaction with saturated NH4Cl and mix the reaction with water/EtOAc. Dry (MgS04) and concentrate to give 2.7g pale yellow oil.

Purify on silica gel using a gradient of 100% hexane to 30% EtOAc/hexane to give 380mg (13%) sulfonyl chloride. Stir a small aliquot with dimethylamine for several hours. MS (ES) gives the correct mass for the dimethylsulfonamide derivative.

Preparation 22 4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten. 5-ylidenemethyl)-benzenesulfonyl chloride

Prepared using Procedure E to give 142mg (8%) sulfonyl chloride as a pale yellow oil.

Example 68 4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzaldehyde Under nitrogen, cool 5-(4-bromo-benzylidene)-10,11-dihydro-5H-dibenzo- [a, d] cycloheptene (2.2g, 6. lmmol) in THF (40mL) to-65°C and add n-BuLi (1.6M, 5mL, 8mmol) via syringe. After 15 minutes, add DMF (lmL, 14mmol). After 1 h, the quench the reaction with saturated NH4C1 and partition between water/EtOAc. Dry (MgS04) and concentrate to yield 1. 8g crude aldehyde. Purify on silica gel using hexane/EtOAc to give 940mg colorless oil that slowly crystallized to give a white solid, mp 106. 4°C ; 1H NMR (CDC13) 8 2.80-3. 60 (br dd, 4H), 6.84 (s, 1H), 6.92-7. 63 (m, 12H), 9.90 (s, 1H) ; MS (EI) 310. HPLC shows 96% purity.

Example 69 2-(10,11-Dihydro-dibenzo[a,d] cyclohepten-5-ylidenemethyl) -benzaldehyde

Following procedures essentially as described in Example 68, the title compound was prepared from the corresponding bromide derivative to give white crystals (hexane/EtOAc, 42%), mp 198. 9°C.'H NMR (CDC13) 8 2.80-3. 60 (br s, 4H), 6.67-7. 86 (m, 13H), 10.42 (s, lH); MS (El) 310. HPLC shows 97% purity.

Example 70 3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzaldehyde Following procedures essentially as described in Example 68 the title compound was isolated as a white solid (38%), mp 86. 7°C. IH NMR (CDC13) 2. 80-3.60 (br dd, 4H), 6.84 (s, 1H), 6.93-7. 65 (m, 12H), 9.81 (s, 1H); MS (En 310. HPLC shows 97% purity.

Example 71 5- (2-Difluoromethyl-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene Dissolve 2- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzaldehyde (100mg, 0. 32mmol) in CH2C12 (3mL) and add (diethylamino) sulfur trifluoride (DAST) (21001, 1. 6mmol). Stir the reaction overnight at ambient temperature. Shake the crude reaction with saturated NaHC03/CH2Cl2. Dry (MgS04) and concentrate to give 110mg

crude product. Purify on silica gel using hexane/CH2Cl2 to give 50mg (47%) title compound as a white solid, mp. 13. 3°C. IH NMR (CDC13) 8 2.80-3. 60 (br s, 4H), 6.72- 7.58 (m, 14H); MS (EI) 332. HPLC shows 98% purity.

Example 72 5-(3-Difluoromethyl-benzylidene)-10,11-dihydro-5H-dibenzo[a, d] cycloheptene Following procedures essentially as described in Example 71, the title compound was prepared as a light yellow solid (39%), mp 92. 5°C.'H NMR (CDC13) 8 2.96 (br d, 2H), 3.44 (br d, 2H), 6.45 (t, 1H, J=70Hz), 6.80 (s, 1H), 6.94-7. 33 (m, 11H), 7.48 (m, 1H) ; MS (EI) 332. HPLC shows 94% purity.

Example 73 5- (4-Difluoromethyl-benzylidene)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene Following procedures essentially as described in Example 71, the title compound was prepared as a colorless oil (39%) ; IH NMR (CDC13) 8 2.80-3. 60 (br dd, 4H), 6.47 (t, 1H, J=55Hz), 6.72 (s, 1H), 6. 87-7. 24 (m, 11H), 7.42 (m, 1H); MS (EI) 332. HPLC shows 100% purity.

Example 74 [2-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidenemethyl)-p henyl]-methanol

Treat a solution of 2- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- benzaldehyde (125mg, 0. 4mmol) in EtOH (4mL) with NaBH4 (30mg, 0. 8mmol). After 4 h at room temperature, quench the reaction with 1N HCl and concentrate. Shake the residue en with water/EtOAc. Dry the organic layer (MgS04) and concentrate to give 130mg crude product. Purify on silica gel (EtOAc/hexane) to give 90mg (72%) colorless oil which slowly crystallized, mp 121. 8°C.'H NMR (CDC13) 8 3.28 (br s, 4H), 4.85 (s, 2H), 6.77-7. 60 (m, 13H; MS (EI) 312. HPLC shows 98% purity.

Example 75 [3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenyl]-methanol

Following procedures essentially as described in Example 74, the title compound was obtained as a colorless oil which slowly crystallized. 1H NMR (CDC13) 8 3.03 (br d, 2H), 3.47 (br d, 2H), 4.55 (s, 2H), 6. 84 (s, 1H), 6.93-7. 31 (m, 11H), 7.52 (m, 1H); MS (EI) 312. HPLC shows 93% purity.

Example 76 [4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-methanol

Following procedures essentially as described in Example 74, the title compound was obtained as a colorless oil (65%) ; IH NMR (CDC13) #3. 03 (br d, 2H), 3.47 (br d, 2H), 4.62 (s, 2H), 6. 78 (s, 1H), 7.02-7. 34 (m, 11H), 7.520 (m, 1H) ; MS (El) 312.

Example 77 2-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidenemethyl)-be nzaldehyde oxime

Dissolve 2- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzaldehyde (1 lOmg, 0. 35mmol) in EtOH (4mL). In a separate flask, dissolve hydroxylamine hydrochloride (35mg, 0. 5mmol) in water (lmL). Add this solution the aldehyde solution and stir at room temperature for 18h. Pour the reaction into water (300mL) and extract the product into EtOAc. Dry (MgS04) and concentrate to give 140mg crude product.

Purity on silica gel using EtOAc/hexane to give 82mg (72%) title compound as a white solid. 1H NMR (CDC13) 8 3.31 (br s, 4H), 6.73-7. 33 (m, 11H), 7.55 (m, 1H), 7.70 (dd, 1H), 8.58 (s, 1H); MS (ES) 326 (M+1), 324 (M-1). HPLC shows 98% purity.

Example 78 3-(10,11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzaldehyde oxime

Following procedures essentially as described in Example 77, the title compound was prepared in 55% yield from 3- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- benzaldehyde (50mg, 0. 161mmol).'HNMR (CDC13) # 2. 92 (br d, 2H), 3.36 (br d, 2H), 6.72 (s, 1H), 6.87-7. 43 (m, 12H), 7.87 (s, 1H) ; MS (ES) 326 (M+1).

Example 79 4-(10, 1 1-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzaldehyde oxime

Following procedures essentially as described in Example 77, the title compound was prepared in 55% yield from 4- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- benzaldehyde (117mg, 0. 38mmol). 1H NMR (CDC13) # 2.77 (br d, 2H), 3.21 (br d, 2H), 6.57 (s, 1H), 6.61-7. 64 (m, 12H), 7.82 (s, 1H) ; MS (ES) 326 (M+1). HPLC shows 97% purity.

Example 80 2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzonitrile

Sparge a mixture of 5-methylene-10, 1 1-dihydro-5H-dibenzo [a, d] cycloheptene (2. 0g, 9. 7mmol) (prepared as described in Journal of Organic Chemistry, 53 (8) 1768-1774 (1988) ), 2-bromobenzonitrile ( (1. 77g, 9.7mmol), NaOAc (lg, 12 mmol) and dimethylacetamide (lOOmL) with nitrogen for 15 minutes. Add Hermann catalyst (320mg, 0.46mmol) (Chem. Eur. J. 1357-1364 (1997) ) and heat at 150°C for 6 days. Cool the reaction and partition between water (1L) and EtOAc (500mL). Wash the organic layer with water (3 x 1L). Dry (MgS04) and concentrate under reduced pressure to give 3.3g brown oil. Purify on silica gel using EtOAc/hexane 500mg nitrile that is 81% pure by glc. Recrystallize (EtOH) to give 213mg (7%) pale yellow plates, mp 185. 4°C. IH NMR (CDC13) 5 3.04 (br d, 2H), 3.47 (br s, 2H), 6.82-7. 34 (m, 11H), 7.62 (m, 2H); MS (ES) 308 (M+1). HPLC shows 98% purity.

Example 81 3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzonitrile Purge a solution of 5- (3-bromo-benzylidene)-10, 11-dihydro-5H-dibenzo- [a, d] cycloheptene (4.2g, 11.6mmol) in N-methylpyrrolidinone (80mL) with nitrogen for 10 minutes. Add CuI (6.7g, 35mmol) and CuCN (3.1g, 35mmol) and heat to 130°C.

After 1 hour, cool the reaction to ambient temperature and shake with aqueous FeCl3 (200mL) and EtOAc (200mL). Wash the organic layer with water, dry with MgS04 and concentrate to obtain 6.4g crude product. Purify on silica gel using EtOAc/hexane to obtain 2. 55g (71%) title compound as a white solid, mp 115. 7°C. IH NMR (CDC13) 6 3.02 (br d, 2H), 3.40 (br d, 2H), 6.77 (s, 1H), 6.93 (dd, 1H), 7.02-7. 49 (m, l 1H) ; MS (EI) 307. HPLC shows 98% purity.

Example 82 4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzonitrile

Following procedures essentially as described in Example 8 land using 5- (4-bromo- benzylidene) -10, 11-dihydro-5H-dibenzo- [a, d] cycloheptene (4.2g, 11. 6mmol) gives 2.02g (57%) as tan viscous oil. 1H NMR (CDC13) 8 3.06 (br d, 2H), 3.48 (br d, 2H), 6.85 (s, 1H), 6.98 (dd, 1H), 7.06-7. 57 (m, 11H ; MS (EI) 307. HPLC shows 97% purity.

Example 83 2-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidenemethyl)-be nzamide

Dissolve 2- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzonitrile (lOOmg, 0. 32mmol) in DMSO (3mL) and add solid K2C03 (50mg) followed by 30% H202 (10001). Stir the reaction for 3 h. and quench by pouring into water. Collect the white solid and dry in a vacuum oven to yield 84mg (81%). 1H NMR (DMSO-d6) 52. 95 (br s, 2H), 3.38 (br s, 2H), 6.67-7. 56 (m, 12H), 7.90 (s, 1H); MS (ES) 326 (M+1), 324 (M-1). HPLC shows 95% purity.

Example 84 3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzamide

Following procedures essentially as described in Example 83 and starting with 3- (10, 11- dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -benzonitrile (480mg, 1.56mmol) gives 445mg (88%) as an off white solid. 1H NMR (DMSO-d6) 8 2.95 (br s, 2H), 3.40 (br s, 2H), 6.85-7. 54 (m, 10H), 7.61 (d, 1H), 7.72 (s, 1H), 7.84 (s, 1H) ; MS (ES) 326 (M+1), 324 (M-1). HPLC shows 94% purity.

Example 85 4-(10,11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzamide Following procedures essentially as described in Example 83 and starting with 4- (10, 11- dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -benzonitrile (230mg, 0. 75mmol) gives 226mg (93%) white powder. 1H NMR (DMSO-d6) 8 2.95 (br s, 2H), 3.38 (br s, 2H), 6.82-7. 54 (m, 11H), 7.67 (d, 1H), 7.87 (s, 1H) ; MS (ES) 326 (M+1). HPLC shows 96% purity.

Example 86 3-(10, 1 1-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine

Dissolve 5- (3-bromo-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (3. OOg, 8. 30mmol) in toluene (75mL) and add the following reagents: tris (dibenzylidine acetone) dipalladium (O) (380mg, 0.415mmol), racemic BINAP (517mg, 0. 830mmol), sodium t-butoxide (1.12g, 11. 6mmol), and benzophenone imine (3. 48mL, 3.76g, 20. 76mmol). Heat the mixture to reflux overnight. Cool to room temperature and dilute with H20. Extract into ethyl acetate and dry organics (MgS04). Concentrate organics and take the residue up in a 1: 1 mixture of THF and 1N HC1. After 2 h, extract into ethyl acetate and dry organics (MgS04). Concentrate to a brown solid containing the title compound. Boil the solid in a 5: 1: 0.1 mixture of toluene : ethyl acetate: THF. Cool the suspension to-26°C and filter, collect 1.98g (80%) of a white solid, mp 204. 3°C.'H NMR (DMSO-d6) 8 2.90 (br s, 2H), 3.36 (br d, 2H), 6.77-7. 51 (m, 15H); MS (ES) 298 (M+H). HPLC shows 99% purity.

Example 87 2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine Following procedures essentially as described in Example 86, 5- (2-bromo-benzylidene)- 10, 11-dihydro-5H-dibenzo [a, d] cycloheptene gives the title compound in 85% yield as a yellow foam, mp 145. 2°C after purification using silica gel chromatography (75: 24: 1 hexanes: CH2C12 : 2M NH3/MeOH). IH NMR (CDC13) 8 3.25 (br s, 4H), 3.80 (s, 2H), 6.45-7. 51 (m, 13H); MS (ES) 298 (M+H). HPLC shows 95% purity.

Example 88 4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine

Following procedures essentially as described in Example 86, 5- (4-bromo-benzylidene)- 10, 11-dihydro-5H-dibenzo [a, d] cycloheptene gives the title compound in 54% yield as an orange solid, mp >250°C after purification by triturating with hot CH2C12.'H NMR (DMSO-d6) 5 2.86 (br s, 2H), 3.32 (br d, 2H), 6.74 (s, 1H), 6.89-7. 48 (m, 14H); MS (ES) 298 (M+H). HPLC shows 98% purity.

Example 89 5- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-2-methoxy-phenylamine Following procedures essentially as described in Example 86, 5- (3-bromo-4-methoxy- benzylidene) -10, 11-dihydro-5H-dibenzo [a, d] cycloheptene gives the title compound in 36% yield as a yellow foam, mp 62. 7°C after purification via silica gel chromatography (1: 9 ethyl acetate: hexanes). 1H NMR (CDC13) 5 2.69-3. 73 (br m, 6H), 3.80 (s, 3H), 6.36 (s, 1H), 6.48 (dd, 1H), 6.60 (d, 1H), 6.66 (s, 1H), 7.00-7. 50 (m, 8H); MS (ES) 328 (M+H). HPLC shows 98% purity.

Example 90 N- [3- (10, 1 I-Dihydro-dibenzo [ad] cyclohepten-5-ylidenemethyl) -phenyl]- methanesulfonamide

Dissolve 3- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine (400mg, 1. 34mmol) in anhydrous pyridine (lOmL) and add methanesulfonyl chloride (616mg, 4160L, 5. 38mmol). Stir overnight at room temperature, then concentrate. Take residue up in ethyl acetate and 1N HCl and separate the layers. Extract aqueous layer with ethyl acetate, combine organics, and dry (MgS04). Concentrate to a brown oil.

Purify via silica gel chromatography (2: 3 ethyl acetate: hexanes) to yield 350mg (70%) of yellow foam, mp 66. 3°C. IH NMR (CDC13) 8 2.71 (s, 3H), 2.75-3. 56 (br m, 4H), 6.09 (s, 1H), 6.64-7. 43 (m, 13H); MS (ES) 398 (M+23), 374 (M-H). HPLC shows 96% purity.

Example 91 Ethanesulfonic acid [3- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenyl]-amide Following procedures essentially as described in Example 90, 3- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenylamine and ethanesulfonyl chloride gives the title compound in 74% yield as a brown solid, mp 1 80. 2°C. IH NMR (CDC13) 6 1.25 (t, 3H), 2.80-3. 60 (br m, 6H), 6.06 (br s, 1H), 6.71-7. 51 (m, 13H); MS (ES) 412 (M+Na), 388 (M-H). HPLC shows 99% purity.

Example 92 Propane-2-sulfonic acid [3- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenyl]-amide

Following procedures essentially as described in Example 90, 3- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine and isopropylsulfonyl chloride gives the title compound in 22% yield as a white solid, mp 187.7°C. 1H NMR (CDC13) # 1.28 (d, 6H), 2.80-3. 60 (br m, 5H), 6.47 (s, 1H), 6.75-7. 50 (m, 13H); MS (ES) 426 (M+Na), 402 (M-H). HPLC shows 94% purity.

Example 93 N- [3- (10, 1 1-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- benzenesulfonamide Following procedures essentially as described in Example 90, 2- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenylamine and benzenesulfonyl chloride gives the title compound in 82% yield as a white solid, mp 121. 9°C. tH HMR (CDC13) 8 2.76-3. 56 (br m, 4H), 6.64-7. 77 (m, 19H) ; MS (ES) 460 (M+Na), 436 (M-H). HPLC shows 98% purity.

Example 94 3, 5-Dimethyl-isoxazole-4-sulfonic acid [3- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidenemethyl)-phenyl]-amide

Following procedures essentially as described in Example 90, 2- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine and 3, 5-dimethyl-isoxazole-4- sulfonyl chloride gives the title compound in 80% yield as a white solid, mp 149. 3°C. IH NMR (CDC13) 8 2.21 (s, 3H), 2.40 (s, 3H), 2.77-3. 54 (br m, 4H), 6.57 (s, 1H), 6.69 (d, 2H), 6.86-7. 48 (m, 11H) ; MS (ES) 479 (M+Na) 455 (M-H). HPLC shows 95% purity.

Example 95 1-Methyl-1H-imidazole-4-sulfonic acid [3- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidenemethyl)-phenyl]-amide Following procedures essentially as described in Example 90, 2- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine and 1-methyl-lH-imidazole-4- sulfonyl chloride gives the title compound in 40% yield as a white solid, mp 257. 0°C. IH NMR (DMSO-d6) 8 2.90 (br s, 2H), 3.35 (br s, 2H), 3.64 (s, 3H), 6.46 (d, 1H), 6.67 (s, 1H), 6.80-7. 46 (m, 11H), 7.79 (d, 2H), 6.11 (s, 1H); MS (ES) 464 (M+Na). HPLC shows 100% purity.

Example 96 1, 2-Dimethyl-lH-imidazole-4-sulfonic acid [3- (10, 11-dihydro-dibenzo [a, d] cyclohepten- 5-ylidenemethyl)-phenyl]-amide

Following procedures essentially as described in Example 90, 2- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine and 1, 2-dimethyl-1H-imidazole- 4-sulfonyl chloride gives the title compound in 1% yield as a white solid. MS (ES) 456 (M+H). HPLC shows 100% purity.

Example 97 N- [5- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-2-methoxy-phenyl]- methanesulfonamide Following procedures essentially as described in Example 90-, 5- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-2-methoxy-phenylamine and methanesulfonyl chloride gives the title compound in 77% yield as a tan foam, mp 192. 1°C.'H NMR (CDC13) 8 2.74 (s, 3H), 2.80-4. 61 (brm, 4H), 4.81 (s, 3H), 6.67-7. 50 (m, 13H); MS (ES) 423 (M+NH4), 404 (M-H). HPLC shows 100% purity.

Example 99 N- [4- (l 0, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide

Following procedures essentially as described in Example 90, 4- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenylamine and methanesulfonyl chloride gives the title compound in 48% yield as a tan solid, mp 210. 7°C. IH NMR (CDC13) 8 2.72-3. 58 (br m, 7H), 6.49 (s, 1H), 6.74 (s, 1H), 6.96-7. 49 (m, 12H); MS (ES) 398 (M+Na), 374 (M-H). HPLC shows 98% purity.

Example 104 Propane-1-sulfonic acid [3- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenyl]-amide

Following procedures essentially as described in Example 90, 3- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine (50mg, 0. 168mmol) and 1- propanesulfonyl chloride (144mg, l. Olmmol) affords 34mg (50%) of the title compound as a white foam. MS (ES) 426 (M+Na), 402 (M-H) ; HPLC shows 99% purity.

Example 105 Butane-1-sulfonic acid [3- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) - phenyl]-amide

Following procedures essentially as described in Example 90, 3- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine (50mg, 0. 168mniol) and 1- butanesulfonyl chloride (158mg, l. Olmmol) affords 41mg (58%) of the title compound as a colorless oil. MS (ES) 440 (M+Na); HPLC shows 99% purity.

Example 106 Ethanesulfonic acid [4- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenyl]-amide

Following procedures essentially as described in Example 90, 4- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine (100mg, 0. 336mmol) and ethanesulfonyl chloride (129mg, l. Olmmol) affords 74mg (57%) of the title compound as a colorless oil. MS (ES) 412 (M+Na), 388 (M-H); HPLC shows 97% purity.

Example 107 Propane-2-sulfonic acid [4- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenyl]-amide

Following procedures essentially as described in Example 90, 4- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine (100mg, 0.336mmol) and 2- propanesulfonyl chloride (144mg, l. Olmmol) affords the title compound. MS (ES) 426 (M+Na), 402 (M-H) ; HPLC shows 93% purity.

Example 108 Propane-1-sulfonic acid [4- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) - phenyl]-amide

Following procedures essentially as described in Example 90, 4- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine (100mg, 0. 336mmol) and 1- propanesulfonyl chloride (144mg, l. Olmmol) affords 69mg (51%) of the title compound as a colorless oil. MS (ES) 426 (M+Na), 402 (M-H) ; HPLC shows 99% purity.

Example 109 Butane-1-sulfonic acid [4- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenyl]-amide

Following procedures essentially as described in Example 90, 4- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine (lOOmg, 0. 336mmol) and 1- butanesulfonyl chloride (158mg, l. Olmmol) affords 88mg (63%) of the title compound as a yellow oil. MS (ES) 440 (M+Na), 416 (M-H) ; HPLC shows 98% purity.

Example 110 2-Methyl-propane-l-sulfonic acid [3- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidenemethyl)-phenyl]-amide

Following procedures essentially as described in Example 90, 3- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine (50mg, 0. 168mmol) and 2- methyl-propane-l-sulfonyl chloride (53mg, 0. 336mmol) (prepared as described in Quast, H. , Synthesis (1974), (7), 489-90) affords 15mg (21%) of the title compound as a brown oil. MS (ES) 435 (M+NH4), 416 (M-H) ; HPLC shows 100% purity.

Example 112 Dimethylsulfamic acid [3- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenyl]-amide

Following procedures essentially as described in Example 90, 3- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine (100mg, 0. 336mmol) and dimethylsulfamoyl chloride (144mg, 1. Olmmol) affords 92mg (68%) of the title compound as a yellow oil. MS (ES) 427 (M+Na), 403 (M-H) ; HPLC shows 93% purity.

Example 113 Dimethylsulfamic acid [4- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenyl]-amide Following procedures essentially as described in Example 90, 4- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine (100mg, 0. 336mmol) and dimethylsulfamoyl chloride (144mg, l. Olmmol) affords 83mg (61%) of the title compound as a white solid. MS (ES) 427 (M+Na), 403 (M-H) ; HPLC shows 87% purity.

Example 114 N- [3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenyl]-acetamide Following procedures essentially as described in Example 90, 3- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine and acetyl chloride give the title compound in 25% yield as a white solid. 1H NMR (CDC13) 8 2.12 (s, 3H), 2.76-3. 61 (br m, 4H), 6.71 (d, 1H), 6.75 (s, 1H), 6.96-7. 50 (m, 13H); MS (ES) 340 (M+H). HPLC shows 100% purity.

Example 115 N- [2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenyl]-acetamide

Following procedures essentially as described in Example 90, 2- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine and acetyl chloride give the title compound in 70% yield as a yellow solid, mp 189. 7°C. IH NMR (CDC13) 6 2.16 (s, 3H), 3.26 (br s, 4H), 6.78 (s, 1H), 6.84-7. 50 (m, 11H), 7.82 (d, 1H); MS (ES) 340 (M+H) 338 (M-H). HPLC shows 94% purity.

Example 116 N- [4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-acetamide Following procedures essentially as described in Example 90, 4- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine and acetyl chloride give the title compound in 51% yield as an off-white solid, mp 134. 8°C. IH NMR (CDC13) 8 2.12 (s, 3H), 2.78-3. 61 (br m, 4H), 6.75 (s, 1H), 6.95-7. 52 (m, 13H); MS (ES) 340 (M+H). HPLC shows 95% purity.

Example 117 N- [4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-isonicotinamide

Following procedures essentially as described in Example 90, 4- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine and isonicotinoyl chloride give the title compound in 17% yield as a yellow solid, mp 252. 1°C. 1H NMR (DMSO-d6) 8 2.94 (br s, 2H), 3.87 (br s, 2H), 6.82 (s, 1H), 6.90-7. 62 (m, 12H), 7.83 (d, 2H), 8.79 (d, 2H), 10.47 (s, 1H); MS (ES) 403 (M+H), 401 (M-H). HPLC shows 93% purity.

Example 118 [3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-methyl-amine and Example 119 [3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-dimethyl-amine

Using a procedure described in Syn. Comm. 1129-1135 (1991), dissolve 3- (10, 11- dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine (100mg, 0. 336mmol) in toluene (5mL) and add (Bu) 4NBr (2mg, 0.006mmol), K2CO3 (46mg, 0.336), and NaOH

(54mg, 1. 34mmol). Stir for 1 h at 35°C, and then add Me2SO4 (33L, 44mg, 0. 353mmol).

Stir for 2 h, then warm up to 55°C. Stir overnight, then add 200L Me2S04 (26mg, 0. 21 lmmol). Stir at 55°C for 6 h, then cool to room temperature. Dilute reaction with H20 and ethyl acetate. Separate layers and extract aqueous layer with ethyl acetate.

Combine organics, dry (MgS04), and concentrate to an oil containing the two title compounds. Separation and purification of the title compounds is effected via silica gel chromatography (1 : 19 ethyl acetate: hexanes).

[3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-methyl-amine (Example 118) is obtained in 17% yield (18mg) as a colorless oil. 1H NMR (CDC13) 8 2.59 (s, 3H), 2.70-3. 65 (br m, 5H), 6.26 (s, 1H), 6.40 (d, 1H), 6.46 (d, 1H), 6.74 (s, 1H), 6.97-7. 53 (m, 9H); MS (ES) 312 (M+H). HPLC shows 99% purity.

[3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-dimethyl-amine (Example 119) is obtained in 14% yield (15mg) as a colorless oil. 1H NMR (CDC13) b 2.62 (s, 6H), 2.68-3. 58 (br m, 4H), 6.33 (s, 1H), 6.44 (m, 2H), 6.67 (s, 1H), 6.95-7. 44 (m, 9H); MS (ES) 326 (M+H). HPLC shows 98% purity.

Example 120 [2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenyl]-methyl-amine and Example 121 [2-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidenemethyl)-p henyl]-dimethyl-amine

Following procedures essentially as described in Examples 118 and 119, 2- (10, 11- dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenylamine gives the title compounds.

[2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-methyl-amine (Example 85) is obtained in 21% yield as a yellow oil.'H NMR (CDC13) 8 2.91 (s, 3H), 3.26 (br s, 4H), 3.94 (br s, 1H), 6.47 (t, 1H), 6.62 (d, 1H), 6.70 (s, 1H), 6.71 (d, 1H), 6.86- 7.51 (m, 9H); MS (ES) 312 (M+H). HPLC shows 98% purity.

[2- (10, ll-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-dimethyl-amine (Example 86) is obtained in 16% yield as a colorless oil.'H NMR (CDC13) 6 2.96 (s, 6H), 3.24 (br s, 4H), 6.66 (m, 2H), 6.94-7. 28 (m, 10H), 7.57 (d, 1H); MS (ES) 326 (M+H).

HPLC shows 96% purity.

Example 122 [4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenyl]-methyl-amine Example 123 [4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-dimethyl-amine

Following procedures essentially as described in Examples 118 and 119, 4- (10, 11- dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenylamine gives the title compounds.

[4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenyl]-methyl-amine (Example 122) is obtained in 47% yield as a yellow solid. 1H NMR (CDC13) 8 2.66-3. 55 (br m, 4H), 2.72 (s, 3H), 4.60 (s, 1H), 6.33 (d, 2H), 6.61 (s, 1H), 6.80 (d, 2H), 6.96-7. 43 (m, 8H); MS (ES) 312 (M+H). HPLC shows 98% purity.

[4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenyl]-dimethyl- amine (Example 123) is obtained in 2% yield as a white solid. 1H NMR (CDC13) 8 2.71- 3.65 (br m, 4H), 2.90 (s, 6H), 6.51 (d, 2H), 6.69 (s, 1H), 6.92 (d, 2H), 7.04-7. 50 (m, 8H); MS (ES) 326 (M+H). HPLC shows 99% purity.

Example 124 N- [3- ( 10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-N-methyl- methanesulfonamide

Dissolve N- [3- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide (lOOmg, 0. 265mmol) in DMF (4mL) and add NaH (13mg of a 60% suspension in mineral oil, 0. 318mmol). Stir at room temperature for 50min, then add MeI (33 CL, 75mg, 0.530mmol). Stir at room temp for 1h. Dilute reaction mixture with H20 and ethyl acetate. Separate layers, and wash organics with H20. Dry organics (MgS04) and concentrate to lOlmg (100%) of a pale yellow solid, mp 124. 2°C. IH NMR (CDC13) 8 2.53 (s, 3H), 2.72-3. 54 (br m, 4H), 6.74 (s, 1H), 6.78 (s, 1H), 6.91-7. 43 (m, 11H) ; MS (ES) 412 (M+Na). HPLC shows 97% purity.

Example 125 N- [3- (10, 1 1-Dihydro-5H-dibenzo [a, d] cyclohepten-5-ylmethyl)-phenyl]- methanesulfonamide Dissolve N- [3- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide (100mg, 0.265) in ethanol (25mL) and add 10% Pd/C (56mg).

Pressurize to 60psi with H2 and shake overnight at room temperature. Filter reaction through a pad of Celite and concentrate filtrate to 54mg (54%) of white foam, mp 149. 0°C. 1H NMR (CDC13) 8 2.70 (s, 3H), 2.98 (br q, 2H), 3.28 (d, 2H), 3.40 (br q, 2H), 4.11 (br s, 1H), 6.16 (s, 1H), 6.58 (s, 1H), 6.82-7. 20 (m, 11H) ; MS (ES) 395 (M+Na), 376 (M-H). HPLC shows 94% purity.

Example 126 3-(10,11-Dihydro-5H-dibenzo [a, d] cyclohepten-5-yhnethyl)-phenol

Following procedures similar to those as described in Example 125, 3- (10, 11-Dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenol and a H2 balloon gave the title compound in 64% yield as a white solid, mp 76. 6°C. IH NMR (CDC13) 8 3.06 (br q, 2H), 3.33 (d, 2H), 3.47 (br q, 2H), 4.2 (br s, 1H), 4.74 (s, 1H), 6.40 (s, 1H), 6.39 (m, 2H), 6.96- 7.17 (m, 9H); MS (ES) 299 (M-H). HPLC shows 93% purity.

Example 127 [2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-urea According to the procedure of F. Kurzer, Org. Syn. Coll. Vol (IV) 49 (1963), mix 2- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine ( (133mg, 0. 54mmol) with HOAc (4mL) and water (2mL). Dissolve sodium cyanate (80mg, 1. 2mmol) in water (lmL) and add this solution to the amine derivative. Stir the reaction at room temperature for 2 h. and then pour into water (lOOmL). Extract the title compound into EtOAc, dry (MgS04) and concentrate to give 240mg crude product.

Purify on silica gel using EtOAc/hexane to give 150mg (48%) product as a colorless oil.

MS (ES) 341 (M+1), 339 (M-1). HPLC shows 96.6% purity.

Example 128 [3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-urea

Following procedures essentially as described in Example 127 and using 3- (10, 11- dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenylamine (200mg, 0. 67mmol) provides the title compound in 66% yield as a colorless oil. MS (ES) 341 (M+1), 339 (M- 1). HPLC shows 100% purity.

Example 129 [4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-urea

Following procedures essentially as described in Example 127 and using 4- (10, 11- dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenylamine (143mg, 0. 58mmol) provides the title compound in 41% yield as a colorless oil. MS (ES) 341 (M+1), 339 (M- 1). HPLC shows 100% purity.

Example 130 5-(2-Methyl-benzylidene)-10,11-dihydro-5H-dibenzo [a, d] cycloheptene

Combine 5-bromomethylene-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (0.5 g, 1.75 mmol) and o-tolylboronic acid (0. 238 g, 1.75 mmol) using procedures essentially as described in Example 219, below. Pass through a plug of silica gel equilibrated with hexanes. Concentrate the filtrate to give the title product: MS (m/e) 296 (M+); Analysis for C23H20 : Calcd: C, 93.19 H, 6. 80. Found: C, 93.42 H, 6.79.

Example 131 5- (2-Methyl-benzyl)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene Add the 5- (2-methyl-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (0.19 g, 0.64 mmol) to a mixture of 10% Pd/C (0. 075 g) suspended in absolute ethanol (4.0 mL) and ethyl acetate (2.0 mL) and hydrogenate under a balloon of hydrogen at room temperature and pressure. Stir for 17 h, remove the catalyst via filtration through a pad of Celite, evaporate the filtrate and pass through a plug of silica gel equilibrated with hexanes. Concentrate the filtrate to give the title product: MS (m/e) 298 (M+). Analysis for C23H22 : Calcd: C, 91.99 H, 7.39. Found: C, 91.95 H, 7.39.

Example 132 5- (3-Methyl-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene Combine 5-bromomethylene-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (0.5 g, 1.75 mmol) and m-tolylboronic acid (0.238 g, 1.75 mmol) using procedures essentially as described in Example 219, below. Pass through a plug of silica gel equilibrated with

hexanes. Concentrate the filtrate to give the title product: MS (m/e): 296 (M+) ; HPLC (IS080-10M)) t=17.78min (95%).

Example 133 5- (3-Methyl-benzyl)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene

Add 5- (3-methyl-benzylidene)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene (0.18 g, 0.61 mmol), to a mixture of 10% Pd/C (0.045 g) suspended in absolute ethanol (4.0 mL) and ethyl acetate (2.0 mL) and hydrogenate under a balloon of hydrogen at room temperature and pressure. Stir for 17 h, remove the catalyst via filtration through a pad of Celite.

Evaporate the filtrate and pass through a plug of silica gel equilibrated with hexanes.

Concentrated the filtrate to give the title product. MS (m/e): 298 (M+). HPLC (IS080- lOM) t=l 1. 00 (98%).

Example 134 5-(2-Trifluoromethyl-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene

Combine 5-bromomethylene-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (0.5 g, 1.75 mmol) and 2- (trifluoromethyl) phenyl boronic acid (0.33 g, 1.75 mmol) using procedures essentially as described in Example 219, below. Pass through a plug of silica gel equilibrated with hexanes. Concentrate the filtrate to give the title product. Analysis for C23Hl7F3 : Calcd: C, 78.84 H, 4.89 ; Found: C, 78.65 H, 4.96. HPLC (IS080-10M)) t=16. 67min (99%).

Example 135 5- (2-Trifluoromethyl-benzyl)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene

Add 5- (2-trifluoromethyl-benzylidene)-10, 11-dihydro-5H-dibenzo [a, dJcycloheptene (0.16 g, 0.45 mmol) to a mixture of 10% Pd/C (0.075 g) suspended in absolute ethanol (4.0 mL) and ethyl acetate (2.0 mL) and hydrogenate under a balloon of hydrogen at room temperature and pressure. Stir for 17 h, remove the catalyst via filtration through a pad of Celite. Evaporate the filtrate and pass through a plug of silica gel equilibrated with hexanes. Concentrated the filtrate to give the title product. MS (m/e): 352 (M+).

Analysis for C23HigF3 : Calcd: C, 78.39 H, 5.43. Found: C, 78.84 H, 5.11.

Example 136 5- (3-Trifluoromethyl-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene Combine 5-bromomethylene-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (0.5 g, 1.75 mmol) and 3- (trifluoromethyl) phenyl boronic acid (0.33 g, 1.75 mmol) using procedures essentially as described in Example 219, below. Pass through a plug of silica gel equilibrated with hexanes. Concentrate the filtrate to give the title product. Analysis for C23Hs7F3 : Calcd: C, 78. 84 H, 4.89 ; Found: C, 79.03 H, 5.03. HPLC (IS080-lOM)) t=16. 30min (98%).

Example 137 5- (3-Trifluoromethyl-benzyl)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene

Add 5- (3-trifluoromethyl-benzylidene)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene (0.145 g, 0.41 mmol), to a mixture of 10% Pd/C (0.04 g) suspended in absolute ethanol (4.0 mL) and ethyl acetate (4.0 mL) and hydrogenate under a balloon of hydrogen at room temperature and pressure. Stir for 17 h, remove the catalyst via filtration through a pad of Celite. Evaporate the filtrate and pass through a plug of silica gel equilibrated with hexanes. Concentrated the filtrate to give the title product. MS (m/e) : 352 (M+); GC retention time=7. 11 min.

Example 138 5- (4-Trifluoromethyl-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene Combine 5-bromomethylene-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (0.5 g, 1.75 mmol) and 4- (trifluoromethyl) phenyl boronic acid (0.33 g, 1.75 mmol using procedures essentially as described in Example 219, below. Pass through a plug of silica gel equilibrated with hexanes. Concentrate the filtrate to give the title product: MS (m/e): 350 (M+). HPLC (IS080-lOM)) t=17. 32 min.

Example 139 5- (4-Trifluoromethyl-benzyl)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene

Add the 5- (4-trifluoromethyl-benzylidene)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene (0.14 g, 0.45 mmol), to a mixture of 10% Pd/C (0.05 g) suspended in absolute ethanol (4.0 mL) and ethyl acetate (4.0 mL) and hydrogenate under a balloon of hydrogen at room temperature and pressure. Stir for 17 h, remove the catalyst via filtration through a pad of Celite. Evaporate the filtrate and pass through a plug of silica gel equilibrated with hexanes. Concentrate the filtrate to gives the title product. MS (m/e): 352 (M+); Analysis for C23Hl9F3 : Calcd: C, 78. 39 H, 5.43. Found: C, 78. 70 H, 5.16.

Example 140 5- (3, 5-Bis-trifluoromethyl-benzylidene) -10, 11-dihydro-SH-dibenzo [a, d] cycloheptene Combine 5-bromomethylene-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (0.5 g, 1.75 mmol) and 3,5-bis (trifluoromethyl) phenyl boronic acid (0.449 g, 1.75 mmol) using procedures essentially as described in Example 219, below. Pass through a plug of silica gel equilibrated with hexanes. Concentrate the filtrate to give the title product. Analysis for C24Hi6F6 : Calcd: C, 68.90 H, 3.85. Found: C, 68.64 H, 3.80. HPLC (IS080-10M)) t=5. 64min (98%).

Example 141 5- (3, 5-Bis-Trifluoromethyl-benzyl) -10, 11-dihydro-SH-dibenzo [a, d] cycloheptene

Add 5-(3, 5-bis-trifluoromethyl-benzylidene)-10, 1 1-dihydro-5H-dibenzo [a, d] cycloheptene (0.28 g, 0.67 mmol) to a mixture of 10% Pd/C (0.08 g) suspended in absolute ethanol (4.0 mL) and ethyl acetate (4.0 mL) and hydrogenate under a balloon of hydrogen at room temperature and pressure. Stir for 17 h, remove the catalyst via filtration through a pad of Celite. Evaporate the filtrate and pass through a plug of silica gel equilibrated with hexanes. Concentrate the filtrate to give the title product. MS (m/e) : 420 (M+); Analysis for C24Hs8F6 : Calcd: C, 68.56 H, 4.31. Found: C, 68.55 H, 4.01.

Example 142 5-Pyridin-2-yl-thiophene-2-sulfonic acid [4- (10, 1 1-dihydro-dibenzo [a, d] cyclohepten-5- ylidenemethyl)-phenyl]-amide Prepared according to procedures essentially as described in Example 90, using 4- (10, 11)- dihydro-dibenzo (a, d) cyclohepten-5-ylidene methyl phenylamine (297mg, l. Ommol) and 5-pyridin-2-yl-thiophene-2-sulfonyl chloride (260mg, l. Ommol) to give the title compound (HOW MUCH). Purify using column chromatography ethyl acetate/hexane to give 48mg (10%) product. MS (ES) 521 (M+1), 519 (M-1). HPLC shows 97% purity.

Example 143 1-Methyl-lH-imidazole-4-sulfonic acid [4- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidenemethyl)-phenyl]-amide

Prepared according to procedures essentially as described in Example 90, using 4- (10, 11)- dihydro-dibenzo (a, d) cyclohepten-5-ylidene methyl phenylamine (297mg, l. Ommol) and l-methyl-lH-imidazole-4-sulfonyl chloride (180mg, l. Ommol) to give the title compound 44mg (10%) after being purified by mass guided reverse-phase HPLC. MS (ES) 442 (M+1). HPLC shows 97% purity.

Example 144 3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzylamine Dissolve 1. Og (3. 25mmol) of the corresponding nitrile (prepared as described in Example 81) in diethyl ether (70mL). Add lithium aluminum hydride (250mg, 6.6mmol) and stir at room temperature for 3 h. Quench the reaction by adding 8 drops water, 8 drops 5N NaOH and 16 drops water. Filter the inorganic solids and wash with ether. After drying (MgS04) and concentration, the title compound was obtained in 98% yield as a colorless oil, MS (ES) 312 (M+1). HPLC shows 98% purity.

Example 145 N- [3- (10, ll-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzyl]- methanesulfonamide

Following procedures essentially as described in Example 90, reaction of the benzylamine (70mg, 0. 225mmol) prepared in Example 144 and methanesulfonyl chloride (520L, 0. 68mmol) affords 40mg of the title compound in 46% yield as a colorless oil after purification using column chromatography (30% ethyl acetate/hexane). MS (ES) 388 (M-1). HPLC shows 97% purity.

Example 1. 46 2- [3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-4- trifluoromethyl-1 H-imidazole According to Matthews et al, J. Med. Chem. 33 317 (1990), mix 1, 1-dibromo-l', l', l'- trifluoroacetone (216mg, 0. 8mmol), NaOAc (112mg, 1. 4mmol) and water (2mL). Warm the solution at 60°C for 0. 5h. Cool the solution in an ice bath and add 3- (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl) -benzaldehyde (145mg, 0. 47mmol) in methanol (2mL) and concentrated NH40H (2mL) and stir overnight at room temperature.

Concentrate and collect the solid. Purify by column chromatography (30% ethyl acetate/hexane) to give 19% title compound. MS (ES) 417 (M+1), 415 (M-1). HPLC shows 86% purity.

Example 147 2- [4- ( 10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-4- trifluoromethyl-lH-imidazole

Prepare using procedures as described in Example 146 to give the title compound as a pale yellow powder, MS (ES) 417 (M+1), 415 (M-1). HPLC shows 95% purity.

Example 148 5- (4-Fluoro-3-methoxy-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene

Following procedures essentially as described in Example 28 and using 4-fluoro-3- methoxybenzaldehyde (1.59g, 10. 3mmol), dibenzosuberane (1.94g, lOmmol, provides 1.66g of title compound in 49% yield as a light tan oil that slowly crystallized.

HPLC shows 93% purity.

Example 149 5- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-2-fluoro-phenol

Demethylation of the corresponding methoxy derivative of Example 148 using the procedures as described in Example 57, provides 1.28g (90%) of title compound as a pale tan oil. MS (ES) 315 (M-1). HPLC shows 95% purity.

Example 150 5- (2-Fluoro-5-methoxy-benzylidene)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene

Following procedures essentially as described in Example 28 and using 2-fluoro-5- methoxybenzaldehyde (1.59g, 10.3 mmol) and dibenzosuberane (1.94g, 10 mmol), provides 210mg of title compound as white crystals. mp 110. 7°C (hexane). HPLC shows 99% purity.

Example 151 3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-4-fluoro-phenol

Demethylation of the corresponding methoxy derivative of Example 150 using the procedures as described in Example 57, provides 110mg of title compound in 46% yield as a colorless oil. MS (ES) 315 (M-1). HPLC shows 94% purity.

Example 152 5- (2-Fluoro-3-methoxy-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene Following procedures essentially as described in Example 28 and using 2-fluoro-3- methoxybenzaldehyde (2.4g, 15. 4mmol) and dibenzosuberane (3. 0g, 15. 4mmol), provides 1.5g of title compound as white crystals. mp 148. 9°C. HPLC shows 96% purity.

Example 153 3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -2-fluoro-phenol Demethylation of the corresponding methoxy derivative of Example 152 using the procedures as described in Example 57, provides 410mg (47%) of title as light tan crystals, mp 143. 2°C. MS (ES) 315 (M-1). HPLC shows 94% purity.

Example 154 5- (3-Fluoro-5-methoxy-benzylidene)-10, 11-dihydro-SH-dib enzo [a, d] cycloheptene

Following procedures essentially as described in Example 219, below, and using 3-fluoro- 5-methoxyphenylboronic acid (300mg, 1. 76mmol) and 5-bromomethylene-10, 11-dihydro- 5H-dibenzo [a, d] cycloheptene (450mg, 1. 6mmol) provides 275mg of title compound in 52% yield as a pale yellow oil. HPLC shows 97% purity.

Example 155 3- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-5-fluoro-phenol

Demethylation of the corresponding methoxy derivative of Example 154 using BBr3 provides the title compound in 62% yield as a colorless, viscous oil. MS (ES) 315 (M-1).

HPLC shows 94% purity.

Example 156 5- (4-Chloro-3-methoxy benzylidene)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene Following procedures essentially as described in Example 219, below, and using 4- chloro-5-methoxyphenylboronic acid (160mg, 0. 78mmol) and 5-bromomethylene-10, 11-

dihydro-5H-dibenzo [a, d] cycloheptene (222mg, 0. 85mmol) provides 80mg of title compound in 23% yield as a colorless oil. HPLC shows 92% purity.

Example 157 2-Chloro-5-(10, 1 1-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol

Demethylation of the corresponding methoxy derivative of Example 154 using BBr3 provides the title compound in 42% yield as a colorless, oil. MS (ES) 333 (M+1), 331 (M-1).

Preparation 23 5-Methylene-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene

Add methylmagnesium bromide (3M solution in Et20, 48. OmL, 144mmol) dropwise to a cooled (0°C) solution of dibenzosuberone (20. 0g, 96.03mmol) in THF (140mL) under N2 (exothermic). Let solution warm up to room temperature and continue stirring for 2h.

Cool solution to 0°C and quench with saturated aqueous NH4C1 (exothermic, emits gas).

Extract into ethyl acetate, dry organics (MgS04) and concentrate in-vacuo. Dissolve residue in 4N HCl/dioxane (40mL) and stir at room temperature overnight. Concentrate and dilute with H20. Extract into ethyl acetate, dry organics (MgS04) and concentrate to a yellow oil. Purify crude product by loading onto a 30g plug of silica gel and eluting with hexanes until eluent shows no W activity. Combine and concentrate hexane washes to afford 16.72g (84%) of the title compound as a white solid, mp 65. 1°C. HPLC shows 98% purity.

Preparation 24 5-Bromomethylene-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene

Dissolve 5-methylene-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (10. 00g, 48. 48mmol) in CHC13 (125mL) and add 4- (dimethylamino) pyridinium tribromide (19.35g, 53. 32mmol). Stir at room temperature for 2. 5h and quench with saturated aqueous Na2S03. Separate layers, wash organics with saturated aqueous NaHCO3, then H20. The dried organics (MgS04) and concentrated to a yellow oil. Purify crude product by loading onto a 20g plug of silica gel and eluting with hexanes until eluent shows no UV activity.

Combine and concentrate hexane washes to afford 13. 01g (94%) of the title compound as a white solid, mp 73. 6°C. HPLC shows 99% purity.

Preparation 25 (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidene) -boronic acid Add t-BuLi (1.7M in pentane, 36.3mL, 61.71mmol) portionwise (exotherm) to a solution of 5-bromomethylene-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (8. 00g, 20. 05mmol) in dry THF (150mL) at-78°C under N2. Stir at-78°C for 45min and add trimethyl borate (8.75g, 84. 15mmol). Warm to room temperature and stir for 30min. Concentrate reaction mixture to a pale yellow gritty oil, add ethylene glycol (30mL) and toluene (lOOmL), and reflux overnight. Cool to room temperature, separate layers and extract ethylene glycol layer with toluene. Combine and concentrate toluene layers to a yellow oil. Purify by silica gel chromatography (40g) eluting with 3: 1: 0.02 ethyl acetate: hexanes : triethylamine to afford 2.68g (35%) of the title compound as a white foam. MS (ES) 249 (M-H) ; HPLC shows 91% purity.

Example 158 5- (3-Nitro-benzylidene)-5H-dibenzo [a, d] cycloheptene

Dissolve the phosphonate [generate from heating 3-nitobenzyl bromide (786mg, 3.6 mmol) in triethyl phosphite (0. 62ml, 3.6 mmol) at 80°C for 12h. ] in DMF (10ml) at RT under nitrogen atmosphere. To this mixture, add sodium hydride (87.3mg, 3. 6mmol) and stir for lh. Add dibenzosuberenone (250mg, 1.2mmol) in 2ml of DMF and stir for 18h.

Partition the residue between 1N HCl/EtOAc. Dry (MgS04) and concentrate to give 121.6mg of a pale yellow oil. IH NMR (CDC13) 67. 84 (dt, 1H), 7.72 (t, 1H), 7.45 (d, 1H), 7.4-7. 3 (m, 2H), 7.3-7. 2 (m, 2H), 7.2-7. 0 (m, 4H), 7.0-6. 85 (m, 3H), 6.42 (s, 1H).

Example 159 3-Dibenzo [a, d] cyclohepten-5-ylidenemethyl-phenylamine Dissolve 5- (3-nitro-benzylidene)-5H-dibenzo [a, d] cycloheptene (120mg, 0.4 mmol) in absolute ethanol. Add (lOml tin chloride (416mg, 2.0 mmol) and heat to reflux. After 18 h, cool and partition between IN NaOH/EtOAc. Dry the organic layers (MgS04) and concentrate to give 92.3mg of a white solid. MS [EI+] 296 (M+H).

Example 160 N- (3-Dibenzo [a, d] cyclohepten-5-ylidenemethyl-phenyl)-methanesulfonamide Dissolve 3- dibenzo [a, d] cyclohepten-5-ylidenemethyl-phenylamine (90mg, 0.3 mmol) in 5mL of

methylene chloride under a nitrogen atmosphere. Add pyridine (0. 05mL, 0.6 mmol) then methanesulfonyl chloride (0. 03mL, 0. 3mmol). Stir at room temperature for 12h, then partition between water/methylene chloride and dry with MgS04. Concentrate to give 65.9mg of a white solid. 1H NMR (CDC13) 67. 84 (d, 1H), 7.72 (s, 1H), 7.45 (d, 1H), 7.4- 7.3 (m, 2H), 7.3-7. 2 (m, 2H), 7.2-7. 0 (m, 4H), 7.0-6. 85 (m, 2H), 6.61 (m, 1H), 6.50 (s, 1H), 2.85 (s, 3H). MS [EI+] 374 (1\4+H) +, 391 (M+18).

Section 2 (derivatives of Formula I having substitution on both the"C"ring and furtheron the"A"and/or"B"rings.) Example 161 N- [3- (2-Methoxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide (E-isomer and Z-isomer) E-isomer Z-isomer Following the procedures essentially as described in Example 219, below, and using 5- bromomethylene-2-methoxy-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (E/Z mixture, 700mg, 2. 22mmol) (Prepared from 2-methoxydibenzosuberone as described in Preparations 23 and 24) with 3-methanesulfonylaminophenylboronic acid (522mg, 2. 4mmol) to give 485mg (54%) of an E/Z mixture of isomers. Use UV guided reverse-

phase HPLC with 1/1 acetonitrile/0.1% aqueous trifluoroacetic acid to separate the isomers. The E isomer comes off the column first. MS (ES) 406 (M+1), 404 (M-1).

HPLC purity is 99.6%. The second isomer off the column is the Z-isomer, MS (ES) 406 (M+1), 404 (M-1). HPLC purity is 98%.

Example 162 N- [3- (2-Hydroxy-10, 1l-dihydro-dibenzo [a, d] cyclohepten-S-ylidenemethyl)-phenyl]- methanesulfonamide (E/Z mixture)

Demethylate the corresponding methoxy mixture of Example 161 using BBr3 to give the title compound in 69% yield. MS (ES) 392 (M+1), 390 (M-1). HPLC shows 48% of the faster eluting isomer and 45% of the slower isomer.

Example 163 Ethanesulfonic acid [3-(2-methoxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidenemethyl) -phenyl] -amide (E/Z mixture) 4 Following the procedures essentially as described in Example 219, below, and using 5- bromomethylene-2-methoxy-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (E/Z mixture,

97mg, 0. 31mmol) with 3-ethanesulfonylaminophenylboronic acid (78mg, 0. 34mmol) to give 57mg (44%) of an E/Z mixture of the title compound. MS (ES) 420 (M+1) weak, 418 (M-1). HPLC shows 45% of the E isomer and 53% of the Z isomer.

Example 165 N-[2-(2-Methoxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide (E/Z mixture) Following the procedures essentially as described in Example 219, below, and using 5- bromomethylene-2-methoxy-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (E/Z mixture, 100mg, 0. 32mmol) with 4-methanesulfonylaminophenylboronic acid (75mg, 0. 35mmol) to give 35mg (27%) of an E/Z mixture of the title compound. MS (ES) 406 (M+1), 404 (M-1). HPLC shows 53% of the E isomer and 44% of the Z isomer.

Example 166 4- (2-Methoxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine (E/Z mixture) Isolate the title compound, which is derived from an impurity in the starting 4- methanesulfonylaminophenylboronic acid in the above reaction. MS (ES) 328 (M+1).

HPLC shows 41% of the faster eluting isomer and 58% of the slower isomer.

Example 167 3- (2-Methoxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol

Following the procedures essentially as described in Example 219, below, and using 5- bromomethylene-2-methoxy-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (E/Z mixture, 100mg, 0. 32mmol) with 3-hydroxyphenylboronic acid (48mg, 0. 35mmol) to give 43mg (41%) of an E/Z mixture of the title compound as a tan foam. MS (ES) 327 (M-1).

HPLC shows 42% of the E isomer and 55% of the Z isomer.

Example 168 4- (2-Methoxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenol (E/Z mixture) Following the procedures essentially as described in Example 219, below, and using 5- bromomethylene-2-methoxy-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (E/Z mixture, 220mg, 0. 7mmol) with 4-hydroxyphenylboronic acid (llOmg, 0. 8mmol) to give 117mg (51%) of an E/Z mixture of the title compound as a tan foam. MS (ES) 327 (M- 1). HPLC shows 40% of the E isomer and 54% of the Z isomer.

Example 169 5- (4-Hydroxy-benzylidene)-10, 11-dihydro-SH-dibenzo [a, d] cyclohepten-2-ol (E/Z mixture)

Demethylate the corresponding methoxy derivative mixture from Example 168 using BBr3 to give the title compound in 80% yield. MS (ES) 315 (M+1), 313 (M-1). HPLC shows 44% of the faster eluting isomer and 52% of the slower isomer.

Example 170 (a) and (b) N- [3- (2, 3-Dimethoxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide (E-isomer) and N- [3- (2, 3-Dimethoxy-10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-methanesulfonamide (Z-isomer) E-isomer Z-isomer Following procedures essentially as described in Example 239, below, the title compounds are prepared from the corresponding dimethoxydibenzosuberone and m- bromobenzylmagnesium bromide. These bromo derivatives are converted to the amino derivatives using procedures described in Example 86. The intermediate E and Z amines are reacted with methanesulfonyl chloride as described in Procedure M. The title compounds are purified on silica gel using 33% ethyl acetate/hexane to give 170mg E/Z mixture. Use column chromatography (20% ethyl acetate/hexane) to give 50mg of the E isomer (Example 170 (a) ) ; MS (ES) 434 (M-1), HPLC 92% and 35mg of the Z isomer (Example 170 (b) ) ; MS (ES) 434 (M-1), HPLC 95%.

Example 171 N- [3- (2, 3-Dihydroxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide (E/Z mixture)

Demethylate N-[3-(2, 3-dimethoxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidenemethyl)-phenyl]-methanesulfonamide (60mg, 0. 14mmol) form Example 170 using BBr3 to give 53mg (93%) the title compound as a tan semi-solid. MS (ES) 408 M+1), 406 (M-1). HPLC shows 47% faster eluting isomer and 53% slower isomer.

Example 172 1-Chloro-5- (4-chloro-3-methoxy-benzylidene)-10, 11-dihydro-5H- dibenzo [a, d] cycloheptene (mixture of E/Z isomers)

Following procedures essentially as described in Example 219, below, and using 4- chloro-3-methoxyphenylboronic acid (160mg, 0. 85mmol) with 5-bromomethylene-1- chloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (249mg, 0. 78mmol) to give 440mg crude product. Purify by chromatography to give 210mg (71%) colorless oil. HPLC (IS090-10M) shows 51% at t=7.62min and 45% at t=9. 86min.

Example 173 2-Chloro-5- (1-chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol (Z-isomer, LY2054560, ERO-A01846-65B) and 2-Chloro-5- (1-chloro-10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenol (E-isomer) Z isomer E isomer Demethylate 1-chloro-5- (4-chloro-3-methoxy-benzylidene)-10, 11-dihydro-5H- dibenzo [a, d] cycloheptene (mixture of E/Z isomers) (215mg, 0.56mmol) from Example 172 using BBr3. Separate the isomers using a chromatatron (2% EtOAc/hexane) to give 47mg Z isomer. MS (ES) 365 (M-1). HPLC shows 98% purity. The lower spot is the E isomer, 33mg. MS (ES) 365 (M-1). HPLC shows 96% purity.

Example 174 2-Chloro-5- (2-trifluoromethyl-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene Following procedures essentially as described in Example 219, below, and using 2- (trifluoromethyl) phenylboronic acid (59mg, 0. 3 lmmol) and 5-bromomethylene-2-chloro- 10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (9lmg, 0.28mmol) provides 97mg (90%) title compound. GC/MS data: retention times in minutes (MS data for M+ ion) : 18.19 (384), 18.38 (384) Mass Spec (EI+) 384 Example 175 2-Chloro-5- (2-methyl-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene

Following procedures essentially as described in Example 219, below, and using o- tolylboronic acid (9lmg, 0. 67mmol) and 5-bromomethylene-2-chloro-10, 11-dihydro-5H- dibenzo [a, d] cycloheptene (178mg, 0. 56mmol) provides the title compound. GC/MS data: retention times in minutes (MS data for M+ ion) : 19.62 (330), 19. 83 (330) Mass Spec (EI+) 330.

Example 177 2-Chloro-5- (3-methyl-benzylidene)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene Following procedures essentially as described in Example 219, below, and using m- tolylboronic acid (61mg, 0. 45mmol) and 5-bromomethylene-2-chloro-10, 11-dihydro-5H- dibenzo [a, d] cycloheptene (119mg, 0. 37mmol) provides the title compound.

GC/MS data: retention times in minutes (MS data for M+ ion) : 19.60 (330), 19.95 (330) Mass Spec (EI+) 330.

Example 178 3- (2-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol

Following procedures essentially as described in Example 219, below, and using (3- hydroxyphenyl) boronic acid (108mg, 0. 78mmol) and 5-bromomethylene-2-chloro-10, 11- dihydro-5H-dibenzo [a, d] cycloheptene (209mg, 0. 65mmol) provides the title compound.

Mass Spec (EI+) 332.

Example 179 2-Chloro-5- (4-trifluoromethyl-benzylidene)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene

Following procedures essentially as described in Example 219, below, and using 4- (trifluoromethyl) phenylboronic acid (114mg, 0. 60mmol) and 5-bromomethylene-2- chloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (156mg, 0. 48mmol) provides the title compound. GC/MS data: retention times in minutes (MS data for M+ ion) : 18.52 (384), 18.78 (384) Mass Spec (EI+) 384.

Example 180 4- (2-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol

Following procedures essentially as described in Example 219, below, and using (4- hydroxyphenyl) boronic acid (55mg, 0.40mmol) and 5-bromomethylene-2-chloro-10, 11- dihydro-5H-dibenzo [a, d] cycloheptene (103mg, 0. 32mmol) provides the title compound.

Mass Spec (EI+) 332.

Example 181 3- (2-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenol (Z-isomer) and 3- (2-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenol (E- isomer) \ I \ I I if I o 0 0 Z isomer E isomer Following procedures essentially as described in Example 219, below, and using 3- hydroxyphenylboronic acid (99mg, 0. 72mmol) and 5-bromomethylene-10, 11-dihydro-5H- 2-chlorodibenzo [a, d] cycloheptene (209mg, 0. 65mmol) (prepared from 2- chlorodibenzosuberone using procedures as described in Preparations 23 and 24) provides 90mg Z isomer, MS (ES) 332,334 (M+1), 331,333 (M-1). HPLC shows 95% purity.

The E isomer (51mg) was isolated as a colorless oil, MS (ES) 332,334 (M+1), 331,333 (M-1). HPLC shows 99% purity.

Example 182 N- [3- (2, 8-Dichloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide

Following procedures essentially as described in Example 219, below, and using 3- methanesulfonamidophenylboronic acid (154mg, 0.71mmol) and 5-bromomethylene- 10, 11-dihydro-5H-2, 8-dichlorodibenzo [a, d] cycloheptene (230mg, 0. 65mmol) (prepared from 2,8-dichlorodibenzosuberone (M. R. Pavia et al, J. Med. Chem. (35) 4238-4248 (1992)) using procedures as described in Preparations 23 and 24) provides 164mg (57%) title compound as a white solid, mp 182. 4°C. MS (ES) 444 (M+1), 442 (M-1. HPLC shows 97% purity.

Example 183 3- (2, 8-Dichloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenol Following procedures essentially as described in Example 219, below, and using 3- hydroxyphenylboronic acid (98mg, 0. 71mmol) and 5-bromomethylene-10, 11-dihydro-5H- 2,8-dichlorodibenzo [a, d] cycloheptene (230mg, 0. 65mmol) (prepared from 2,8- dichlorodibenzosuberone (M. R. Pavia et al, J. Med. Chem. (35) 4238-4248 (1992) ) using procedures as described in Preparations 23 and 24) provides 178mg title compound in 75% yield as a pale yellow oil. MS (ES) 365 (M-1). HPLC shows 93% purity.

Example 184 N- [3- (1-Fluoro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide (Z-isomer) and N- [3- (l-Fluoro-10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-methanesulfonamide (E-isomer) F F I u . N . N if p 0 o o Z isomer E isomer Following procedures essentially as described in Example 219, below, and using 3- methanesulfonamidophenylboronic acid (388mg, 1. 8mmol) and 5-bromomethylene-1- fluoro-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene (E/Z mixture, 500mg, 1. 65mmol) (Prepared from 1-fluorodibenzosuberone (Chem. Abstr. 70 106272a (1969) using procedures as described in Preparations 23 and 24) provides the title compound. Separate the isomers using column chromatography (gradient of 10% EtOAc/hexane to 25% EtOAc/hexane) to give 66mg Z isomer as a white powder, mp 153. 5°C, MS (ES) 392 (M- 1). HPLC shows 100% purity. Isolate 18mg E isomer as the slower moving spot, MS (ES) 392 (M-1). HPLC shows 97% purity.

Example 185 3- (1-Fluoro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenol (E-isomer) and 3- (1-Fluoro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenol (Z- isomer) F F I I In in 0 0 E-isomer Z-isomer

Following procedures essentially as described in Example 219, below, and using 3-hydroxyphenylboronic acid (250mg, 1. 8mmol) and 5-bromomethylene-1-fluoro-10, 11- dihydro-5H-dibenzo [a, d] cycloheptene (E/Z mixture, 500mg, 1. 65mmol) (Prepared from 1- fluorodibenzosuberone (Chem. Abstr. 70 106272a (1969) using procedures as described in Preparations 23 and 24) provides 750mg crude product of the title compound. Separate the isomers using radial chromatography (hexane+3% EtOAc/hexane) to give 115mg Z- isomer as a pale yellow foam, mp 119. 9°C MS (ES) 315 (M-1). HPLC shows >95% purity. The E-isomer is the slower moving material, 69mg yellow foam, mp 158. 1°C.

MS (ES) 315 (M-1). HPLC shows 99% purity.

Example 186 3- (1-Fluoro-10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-5-ylmethyl)-phenol Dissolve 3- (1-fluoro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol (170mg, 0. 54mmol) in EtOH (5mL) and add 10% Pd/C (50mg). Stir for 18h under an atmosphere of hydrogen. Filter and concentrate. Purify the crude product using column chromatography (10% EtOAc/hexane @ 25% EtOAc/hexane) to give 98mg (57%) product as a colorless oil. MS (ES) 317 (M-1). HPLC shows 99% purity.

Example 187 N- [3- (l-Fluoro-10, 1 1-dihydro-5H-dibenzo [a, d] cyclohepten-5-ylmethyl)-phenyl]- methanesulfonamide

Dissolve 150mg (0. 38mmol) N- [3- (1-fluoro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidenemethyl)-phenyl]-methanesulfonamide in EtOH (5mL) and add 10% Pd/C (50mg).

Stir for 18h under an atmosphere of hydrogen. Filter and concentrate. Purify the crude product using column chromatography (10% EtOAc/hexane o 25% EtOAc/hexane) to give 6mg product as a colorless oil. MS (ES) 394 (M-1). HPLC shows 99% purity.

Example 188 N- [3- (3-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide (Z-isomer) andN- [3- (3-Chloro-10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-methanesulfonamide (E-isomer) E-isomer Z-ismoer Following procedures essentially as described in Example 219, below, and using 3- methanesulfonamidophenyl boronic acid (473mg, 2. 2mmol) with 5-bromomethylene-3- chloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (640mg, 2mmol) provides 1.17 crude product as a brown oil. Purify the crude product using column chromatography eluting with 5% EtOAc/hexane to 25%, EtOAc/hexane to give 315mg of the Z-isomer, mp

177. 1°C, (MS (ES) 408 (M-1), HPLC 99% purity) and 115mg E-isomer, mp 130. 5°C, (MS (ES) 408 (M-1), HPLC 90% purity).

Example 189 N- [3- (3-Chloro-10, 1 1-dihydro-5H-dibenzo [a, d] cyclohepten-5-ylmethyl)-phenyl]- methanesulfonamide Dissolve N- [3- (3-chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenyl]-methanesulfonamide (200mg, 0. 49mmol) in EtOAc (30mL) and add 5% Pt/C (150mg). Stir for 18h under an atmosphere of hydrogen. Add 5% Pt/C (200mg). Stir for 24h under an atmosphere of hydrogen. Filter and concentrate to give 140mg crude product. Purify using reverse-phase UV guided HPLC to give 28mg viscous tan oil, MS (ES) 410 (M-1). HPLC shows 99% purity.

Example 190 3- (3-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenol (Z-isomer) and 3- (3-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenol (E- isomer) E-isomer Z-isomer Following procedures essentially as described in Example 219, below, and using 3- hydroxyphenyl boronic acid (300mg, 2.2mmol) with 5-bromomethylene-3-chloro-10, 11-

dihydro-5H-dibenzo [a, d] cycloheptene (640mg, 2mmol) to give 880mg crude product.

Purify using reverse-phase UV guided HPLC (1/1 CH3CN/0. 1% TFA) to give 163mg Z- isomer as a pink foam (HPLC shows 99% purity at t=4.96min) and 43mg E-isomer (MS (ES) 331 (M-1), HPLC shows 95% purity at t=5. 22min).

Example 191 N- [3- (2, 8-Dimethoxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide Following procedures essentially as described in Example 219, below, and using 3- methanesulfonamidophenyl boronic acid (473mg, 2. 2mmol) with 5-bromomethylene-2,8- dimethoxy-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (690mg, 2mmol) to give 1.3g crude product. Purify the crude product using column chromatography eluting with 10% EtOAc/hexane to 30% EtOAc/hexane to give 340mg (39%) product as a pale yellow solid, mp 109. 6°C. MS (ES) 436 (M+1), 434 (M-1). HPLC shows 91% purity at t=3. 11min.

Example 192 N- [3- (2, 8-Dihydroxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide

Demethylate N-[3-(2, 8-dihydroxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidenemethyl)-phenyl]-methanesulfonamide (112mg, 0. 26mmol) with BBr3. Purify on silica gel eluting with 25% EtOAc/hexane to 35% EtOAc/hexane to give 72mg (68%) title compound as a colorless oil, MS (ES) 408 (M+1), 406 (M-1). HPLC shows 98% purity.

Example 193 3- (2, 8-Dimethoxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol

Following procedures essentially as described in Example 219, below, and using 3- hydroxyphenyl boronic acid (304mg, 2. 2mmol) with 5-bromomethylene-2,8-dimethoxy- 10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (690mg, 2mmol) to give 990mg crude product. Purify the crude product using column chromatography eluting with 8% EtOAc/hexane to 25% EtOAc/hexane to give 240mg (33%) product as a colorless oil.

MS (ES) 357 (M-1). HPLC shows 99% purity at t=3. 33min.

Example 194 5-(3-Hydroxy-benzylidene)-10, 1 1-dihydro-5H-dibenzo [a, d] cycloheptene-2,8-diol

Demethylate 3- (2, 8-dimethoxy-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenol (9lmg, 0. 25mmol) with BBr3 to give crude title compound. Purify on silica gel eluting with 25% EtOAc/hexane to 35% EtOAc/hexane to give 80mg (96%) as a light pink solid, MS (ES) 331 (m+1), 329 (M-1). HPLC shows 96% purity.

Example 195 3- [2- (2-Morpholin-4-yl-ethoxy)-10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidenemethyl] -phenol (E-isomer) and 3- [2- (2-Morpholin-4-yl-ethoxy)-10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl] -phenol (Z-isomer) Z-isomer E-isomer Following procedures essentially as described in Example 219, below, and using 4- [2- (5- bromomethylene-10, 1 1-dihydro-5H-dibenzo [a, d] cyclohepten-2-yloxy)-ethyl]-morpholine (220mg, 0. 53mmol) and 3-hydroxyphenylboronic acid (80mg, (0. 58mmol). Attempted purification on silica gel eluting with 70% EtOAc/hexane to 100% EtOAc/hexane gave 136mg of an E/Z mixture. Separate the isomers using UV guided reverse-phase using 34% CH3CN/66% 0. 1% aq. TFA. Pool the pure fractions and neutralize with aq.

NaHC03. Concentrate to remove the organic solvent and extract the product into EtOAc.

After drying (MgS04) and concentration, 40mg of the E-isomer was obtained as a tan foam, MS (ES) 428 (M+1). HPLC 95% purity at t=1. 88min. Similarly, 7.2mg of the Z- isomer was obtained as a viscous oil, MS (ES) 428 (M+1). HPLC 96% purity at t=2.27min.

Example 196 N- {3-[2-(2-Morpholin-4-yl-ethoxy)-10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidenemethyl]-phenyl}-methanesulfonamide Following procedures essentially as described in Example 219, below, and using 4- [2- (5- bromomethylene-10, 1 1-dihydro-5H-dibenzo [a, d] cyclohepten-2-yloxy)-ethyl]-morpholine (220mg, 0. 53mmol) and 3-methanesulfonamidophenylboronic acid (125mg, 0. 58mmol). Purification on silica gel eluting with EtOAc then EtOAc/1% MeOH/NH3, gave 57mg of pure E-isomer. MS (ES) 505 (M+1), 503 (M-1). HPLC shows 92% purity at t=1.79min.

Example 197 N- [3- (1, 2-Dichloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide (Z-isomer) and N- [3- (1, 2-Dichloro-10, 1l-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-methanesulfonamide (E-isomer)

Z-isomer E-isomer Following procedures essentially as described in Example 219, below, and using 3- methanesulfonamidophenyl boronic acid (473mg, 2. 2mmol) with 5-bromomethylene-1, 2- dichloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (700mg, 2mmol) to give 1.29g crude product. Purify the crude product using column chromatography eluting with 10% EtOAc/hexane to 20% EtOAc/hexane, to give the Z-isomer, 330mg yellow foam, mp 190. 1°C, MS (ES) 442 (M-1). HPLC shows 98% purity at t=3. 55min. Continue to elute and obtain 126mg E-isomer, mp 168. 6°C, MS (ES) 442 (M-1). HPLC shows 97% purity at t=3. 84min.

Example 198 3- (1, 2-Dichloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenol (Z- isomer) and 3- (1, 2-Dichloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenol (E-isomer) ci ci ci CI cl 1 \ \ cl I I I 0 0 Z-isomer E-isomer

Following procedures essentially as described in Example 219, below, and using 3- hydroxyphenyl boronic acid (310mg, 2. 2mmol) with 5-bromomethylene-1, 2-dichloro- 10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (700mg, 2mmol) to give 1.39g crude product. Purify the crude product using column chromatography eluting with 5% EtOAc/hexane to 15% EtOAc/hexane to give the Z-isomer, 330mg yellow foam, mp 67. 6°C, MS (ES) 365 (M-1). HPLC shows 94% purity at t=4. 05min. Continue to elute and obtain 190mg E-isomer, MS (ES) 365 (M-1). HPLC shows 94% purity at t=4.34min Example 199 N- [3- (2-Fluoro-10, ll-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide (Z-isomer) and N- [3- (2-Fluoro-10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-methanesulfonamide (E-isomer) F X, F ( u RIZ I i i N . N /\ os, ° Z-isomer ° E-isomer Following procedures essentially as described in Example 219, below, and using 3- methanesulfonamidophenyl boronic acid (596mg, 2. 77mmol) with 5-bromomethylene-2- fluoro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (765mg, 2.52mmol) to give 1.49g crude product. Purify the crude product using column chromatography (15% EtOAclhexane + 25% EtOAc/hexane) to give 212mg Z-isomer as a colorless foam, mp 150. 6°C. MS (ES) 392 (M-1). HPLC (IS060-15M) shows 94% purity at t=12. 34min.

Continue to elute and obtain 203mg E-isomer as a white foam, mp 145. 7°C. MS (ES) 392 (M-1). HPLC (IS060-15M) shows 94% purity at t=l 1. 86min.

Example 200 3- (2-Fluoro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol (Z-isomer) and 3-(2-Fluoro-10,11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenol (E- isomer) F 1 I \ 1 F I\ I\ i i OH OH Z-isomer E-isomer

Following procedures essentially as described in Example 219, below, and using 3- hydroxyphenyl boronic acid (415mg, 3. 0mmol) with 5-bromomethylene-2-fluoro-10, 11- dihydro-5H-dibenzo [a, d] cycloheptene (825mg, 2. 72mmol) to give 1.07g crude product.

Purify the crude product using column chromatography eluting with 5% EtOAc/hexane to 15% EtOAc/hexane to give 120mg pure Z-isomer as a tan viscous oil, MS (ES) 315 (M-1). HPLC (IOS80-10M) shows 94% purity at t=4. 02min. Continue to elute and obtain 120mg E-isomer as tan oil, MS (ES) 315 (M-1). HPLC (IOS80-lOM) shows 94% purity at t=3. 86min.

Example 201 N- [3- (1, 9-Difluoro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide

Following procedures essentially as described in Example 219, below, and using 3- methanesulfonamidophenyl boronic acid (592mg, 2. 75mmol) and 5-bromomethylene-1, 9- difluoro-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene (803mg, 2.75mmol), provides 1.52g of the title compound crude product. The crude product is purified using column chromatography (15% EtOAc/hexane to 30% EtOAc/hexane) to give 690 mg (67%) white solid. MS (ES) 410 (M-1). HPLC (IS090-10M) shows 92% purity at t=2.64min.

Example 202 3- (1, 9-Difluoro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol Following procedures essentially as described in Example 219, below, and using 3- hydroxyphenyl boronic acid (380mg, 2. 75mmol) and 5-bromomethylene-1, 9-difluoro- 10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (803mg, 2. 75mmol), provides to 1.04 g of the title compound as crude product. The crude product is purified using column chromatography eluting with 15% EtOAc/hexane to 30% EtOAc/hexane to give 500mg (60%) product as a light yellow foam, mp 129. 5°C. MS (ES) 333 (M-1). HPLC (IS090- 1 OM) shows 98% at t=2.90min.

Example 203 3- (1-Chloro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine

Heat a suspension of NaH (60% suspension in mineral oil, 49mg, 1. 2mmol) in DMSO (6mL) to 80°C under N2 until evolution of H2 stops. Dissolve (3-nitro-benzyl)- phosphonic acid diethyl ester (prepared according to procedures as described in Okamoto et. al. , Bull. Chem. Soc. Jpn. (1987), 60 (1), 277-82) (338mg, 1. 2mmol) in DMSO (lmL) and add to reaction mixture. Add l-chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-one (prepared according to procedures as described in Humber et al. , J. Med. Chem. (1978), 21 (12), 1225-31) (200mg, 0. 824mmol) at once and heat to 100°C for 48h. Cool to room temperature. Dilute reaction mixture with ethyl acetate (50mL) and wash twice with H20.

Dry (MgS04) and concentrate organics to a brown oil. Chromatograph on silica gel (lOg), eluting with 2% to 4% ethyl acetate/hexanes to afford a mixture of compounds.

Dissolve this mixture in ethanol (lOmL) and add SnCl2 (dihydrate, 508mg, 2. 25mmol).

Heat to reflux for 3h and cool to room temperature. Concentrate reaction mixture, then dissolve residue in diethyl ether. Wash organics with H20, 1. OON aqueous NaOH, then twice with H20. Dry (MgS04) and concentrate organics to a yellow oil. Chromatograph on silica gel (lOg), eluting with 5% to 10% ethyl acetate/hexanes to afford 28mg (10%) of the title compound as a colorless oil. MS (ES) 330 (M+H) ; HPLC reveals 36: 64 mixture of geometric isomers-36% at 4. 977min, 64% at 5. 218min-overall 100% purity.

Example 204 N- [3- (l-Chloro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-methanesulfonamide Following procedures essentially as described in Example 90, and using 3- (l-chloro- dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine (63mg, 0. 190mmol), affords 26mg (33%) of the title compound as a white foam. MS (ES) 425 (M+NH4), 406 (M-H); HPLC reveals a mixture of geometric isomers-41% at 2. 879min, 59% at 2. 985min- overall 100% purity.

Example 205Ca). (b\ and (c) N- [3- (I-Chloro-10, 1 1-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide

CI CI CI cCo c ("C Cl Cl Cl 0 w w 0-0 0 I'S . N N . N 0 : S\ 0 ; S : S mixture Z-isomer E-isomer Following procedures essentially as described in Example 219, below, and using 5- bromomethylene-l-chloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (100mg, 0. 313mmol) and 3-methanesulfonylamino-phenylboronic acid (74mg, 0. 344mmol), affords 102mg (79%) of the title compound (Example 205 (a) ) as a mixture of geometric isomers. MS (ES) 408 (M-H); HPLC reveals a 57: 43 mixture of geometric isomers- 54% at 3. 061min, 40% at 3. 197min-overall 94% purity. Separate geometric isomers on a 1000 micron silica gel chromatatron rotor, (10% to 13% ethyl acetate/hexanes) to afford 22mg (17%) of the Z-isomer of the title compound (Example 205 (b), (MS (ES) 410 (M+H). HPLC shows 98% purity. Continue to elute to give 1 lmg (9%) of the E-isomer of the title compound (Example 205 (c)) (MS (ES) 410 (M+H), 408 (M-H); HPLC shows 94% purity).

Example 206 (a) and N- [3- (2-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide (Z isomer and E isomer)

Z-isomer E-isomer Following procedures essentially as described in Example 219, below, and using 5- bromomethylene-2-chloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (100mg, 0. 313mmol) and 3-methanesulfonylaminophenylboronic acid (74mg, 0. 344mmol), affords 37mg (29%) of the Z-isomer (Example 206 (a) ) of the title compound as a colorless oil (MS (ES) 408 (M-H). HPLC shows 99% purity. Continue to elute and obtain 23mg (18%) of the E-isomer (Example (b)) of the title compound as a colorless oil (MS (ES) 408 (M-H) ; HPLC shows 92% purity).

Example 207 N- [3- (2-Chloro-10, 11-dihydro-SH-dibenzo [a, d] cycloheptenylmethyl)-phenyl]-<BR> methanesulfonamide Dissolve N- [3- (2-chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenyl]-methanesulfonamide (mixture of geometric isomers, 100mg, 0. 243mmol) in ethanol (15mL) and add 5% Pt/C (20mg).-Stir at room temperature under aH2 balloon for 72h. Filter reaction mixture through a pad of Celite, and concentrate filtrate to a colorless oil. Chromatograph on silica gel (lOg), eluting with 15% to 25% ethyl acetate/hexanes.

Re-purify by UV-guided semi-preparatory reverse-phase HPLC to afford 44mg (44%) of

the title compound as a colorless oil. MS (ES) 429 (M+NH4), 410 (M-H) ; HPLC shows 98% purity.

Example 208 (a), lob), and (c) Ethanesulfonic acid [3- (l-chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidenemethyl)-phenyl]-amide ci ci cl 1 I _ 1 I _ 1 I \ I I I I O\\s, N O, N O8, N , V, vv I I I r o r o o mixture Z-isomer E-isomer Following procedures essentially as described in Example 219, below, and using 5- bromomethylene-l-chloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (100mg, 0. 313mmol) and 3-ethanesulfonylaminophenylboronic acid (79mg, 0. 344mmol), affords 112mg (84%) of a mixture of geometric isomers of the title compound (Example 208 (a)) as a yellow solid (MS (ES) 424 (M+H); HPLC shows 94% purity). Separate geometric isomers using a chromatatron rotor (10% ethyl acetate/hexanes) to afford 13mg (10%) of the Z-isomer (Example 208 (b) ) of the title compound as a white solid, (MS (ES) 424 (M+H), 422 (M-H). HPLC shows 96% purity). Continue to elute and isolate 6mg (5%) of the E-isomer (Example 208 (c)) of the title compound as a white solid (MS (ES) 424 (M+H), 422 (M-H) ; HPLC shows 97% purity).

Example 210 N- [4- (l-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5ylidenemethyl)-phenyl]- methanesulfonamide

Following procedures essentially as described in Example 219, below, and using 5- bromomethylene-1-chloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (100mg, 0. 313mmol) and 4-methanesulfonylaminophenylboronic acid (74mg, 0.344mmol), affords 55mg (43%) of a mixture of geometric isomers of the title compound as a brown oil. MS (ES) 408 (M-H) ; HPLC shows 96% purity.

Example 211 (a) and (b) 3- (1-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol Z-isomer E-isomer Following procedures essentially as described in Example 219, below, and using 5- bromomethylene-1-chloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (100mg, 0. 313mmol) and 3-hydroxyphenylboronic acid (47mg, 0. 344mmol) affords 8mg (8%) of the Z-isomer of the title compound (MS (ES) 331 (M-H). HPLC shows 95% purity.

Continue to elute and isolate 27mg (26%) of the E-isomer of the title compound, MS (ES) 331 (M-H). HPLC shows 97% purity.

Example 212 4- (1-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol

Following procedures essentially as described in Example 219, below, and using 5- bromomethylene-l-chloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (100mg, 0. 313mmol) and 4-hydroxyphenylboronic acid (47mg, 0. 344mmol), affords 84mg (81%) of a mixture of geometric isomers of the title compound as a brown oil. MS (ES) 331 (M- H); HPLC shows 97% purity.

Example 213 5-Bromomethylene-3-fluoro-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene A. Following the procedures essentially as described in Preparation 23, using 3.84g (16.97m) of 3-fluoro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-one (prepared according to procedures as described in published PCT Int. Appl. WO 9856752 Al 19981217 (1998) ) to obtain 2.88g (75%) of 3-fluoro-5-methylene-10, 1 1-dihydro-5H- dibenzo [a, d] cycloheptene as a white solid.

B. Following the procedures essentially as described in Preparations 24 and 25, 2.62g (11. 70mmol) of the material from Step A, above, affords 3. 152g (89%) of a mixture of geometric isomers of the title compound as a yellow oil. MS [EI] 302, 304 ; HPLC shows 99% purity.

Example 214 N- [3- (3-Fluoro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide

Following the procedures essentially as described in Example 219, below, and using 5- bromomethylene-3-fluoro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (200mg, 0.660mmol) and 3-methanesulfonylaminophenylboronic acid (156mg, 0.726mmol), affords 212mg (82%) of a mixture of geometric isomers of the title compound as a yellow solid. MS (ES) 411 (M+NH4), 392 (M-H) ; HPLC shows 98% purity.

Example 215 3- (3-Fluoro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol

Following the procedures essentially as described in Example 219, below, and using 5- bromomethylene-3-fluoro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (200mg, 0. 660mmol) and 3-hydroxyphenylboronic acid (100mg, 0. 726mmol), affords 192mg (92%) of a mixture of geometric isomers of the title compound as a yellow oil. MS (ES) 339 (M+Na), 315 (M-H) ; HPLC shows 95% purity.

Section 3 (derivatives of Formula I wherein the"C"ring further represents a heterocyclic or benzofused heterocyclic ring.) Example 216 5- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-3H-benzooxazol-2-one

Add phenyl chloroformate (24pL, 0. 195mmol) to a suspension of 2-amino-4-(10,11- dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol (61mg, 0.195mmol) (see Example 63) and NaHCO3 (16mg, 0. 195mmol) in water (5mL) and methanol (lOmL).

Stir for 30min at room temperature and add aqueous NaOH (1. OON, 1950L). Stir overnight and add aqueous HCl (1. OON, 195 nL). Extract with CH2Ck, dry organics (MgS04), and concentrate to a brown oil containing the title compound. Purify on silica gel (lOg) eluting with 10% TO 35% ethyl acetate/hexanes, and then triturate with 50% CH2Cl2/hexanes to afford 8mg (13%) of a white solid. MS (ES) 357 (M+NH4), 338 (M- H); HPLC shows 94% purity.

Example 217 5- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-benzooxazole Dissolve 2-amino-4- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol (see Example 63) (60mg, 0. 191mmol) in triethylorthoformate (3mL) and heat to reflux for 4. 5h. Cool to room temperature and concentrate in-vacuo to a brown oil. Chromatograph on lOg silica gel eluting with 5% to 25% ethyl acetate/hexanes to afford 52mg (84%) of the title compound as a colorless oil. MS (ES) 324 (M+H), 322 (M-H), HPLC shows 94% purity.

Example 218 5- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -2-methyl-benzooxazole

Dissolve 2-amino-4- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenol (60mg, 0. 191mmol) in triethylorthoacetate (5mL) and heat to reflux for 4h. Cool to room temperature and concentrate in-vacuo to a brown oil. Chromatograph on lOg silica gel eluting with 5% to 25% ethyl acetate/hexanes to afford 51mg (79%) of the title compound as a colorless oil. MS (ES) 338 (M+H); HPLC shows 98% purity.

Example 219 6-(10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-lH-indole In a 1-dram vial, mix (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidene) -boronic acid (100mg, 0. 400mmol) and 6-bromoindole (86mg, 0. 440mmol) in dioxane (2. 5mL) and 2. 0M aqueous Na2C03 (4000L, 1. OOmmol). Sparge with N2 for 5min, add Pd (PPh3) 4 (23mg, 0.02mmol), and immediately seal vial. Heat to 85°C overnight, then concentrate under N2. Add Ha0 (1mL) and CH2C12 (ImL) and load onto a Varian ChemElut CE1005 solid-phase extraction cartridge. Elute, collect, and concentrate 15mL CH2C12 to obtain crude product. Chromatograph on silica gel (lOg), eluting with 0% to 25% ethyl acetate/hexanes to obtain 24mg (19%) of the title compound as a colorless oil. 1H-NMR (CDC13) 8 2.75-3. 60 (br m, 4H), 6.81 (s, 1H), 7.00-7. 30 (m, 12H), 7.50 (m, 1H); HPLC shows 99% purity.

Example 220 4-(10, 1 1-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-lH-indole

Following the procedures essentially as described in Example 219,4-bromoindole (86mg, 0. 440mmol) and (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidene) -boronic acid (100mg, 0. 400mmol) afford 6mg (5%) of the title compound as a colorless oil. IH-NMR (CDC13) 8 2.77-3. 63 (br m, 4H), 6.79 (s, 1H), 6.97-7. 29 (m, 12H), 7.49 (m, 1H). HPLC shows 96% purity.

Preparation 26 2-Oxo-2, 3-dihydro-benzooxazole-5-boronic acid Add n-BuLi (1.6M in hexanes, 8.76mL, 14. 02mmol) portionwise (exotherm) to a solution of 5-bromo-3H-benzooxazol-2-one (l. OOg, 4. 67mmol) in dry THF (28mL) at-78°C under N2. Stir at 40°C for lh and add trimethylborate (1.94g, 18. 68mmol) at once. Warm up to room temperature overnight. Add 1N aqueous HC1 (50mL) and stir for 3h at room temperature. Extract into ethyl acetate, dry (MgS04) and concentrate organics to a brown solid. Triturate with hexanes/toluene and collect 766mg (92%) of the title compound as a brown powder. MS (ES) 179 (M+H), 177 (M-H) ; HPLC shows 80% purity.

Example 221 (a) and (b) 5- (1-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-3H-benzooxazol- 2-one (Z isomer and E isomer)

Z-isomer E-isomer Following procedures essentially as described in Example 219 and using 5- bromomethylene-l-chloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (200mg, 0. 630mmol) and 2-oxo-2,3-dihydro-benzooxazole-5-boronic acid (134mg, 0.750mmol) provides 29mg (12%) of the Z-isomer (Example 221 (a)) of title compound as a tan solid (MS (ES) 372 (M-H); HPLC shows 99% purity) and 0 23mg (10%) of the E-isomer (Example 221 (b) ) of the title compound as a tan solid. MS (ES) 372 (M-H); HPLC shows 97% purity.

Example 222 (a) and (b) 5- (2-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-3H-benzooxazol- 2-one (Z isomer and E isomer) Z-isomer E-isomer Following procedures essentially as described in Example 219 and using 5- bromomethylene-2-chloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (200mg, 0. 630mmol) and 2-oxo-2,3-dihydro-benzooxazole-5-boronic acid (134mg, 0. 750mmol), provides the title compound. Purify by UV-guided semi-prep reverse-phase HPLC to obtain 14mg (6%) of the Z-isomer (Example 222 (a) ) of title compound as a white solid (MS (ES) 391 (M+NH4), 372 (M-H); HPLC shows 94% purity) and 5mg (2%) of the E-

isomer (Example 222 (b) ) of the title compound as a white solid. MS (ES) 391 (M+NH4), 372 (M-H) ; HPLC shows 96% purity.

Preparation 27 5-Bromo-1,3-dihydro-benzoimidazol-2-one

Add phenyl chloroformate (922mg, 5. 89mmol) to a suspension of 4-bromo-benzene-1, 2- diamine (l. OOg, 5. 35mmol) and NaHC03 (483mg, 5. 89mmol) in methanol (20mL) and H20 (lOmL). Stir at room temperature for 3. 5h and add 1. OON aqueous NaOH (6mL, 6. 00mmol). Stir overnight at room temperature and filter. Wash the filter cake with Ha0 and dry in-vacuo overnight to obtain 386mg (34%) of the title compound as a brown powder. MS (ES) 213,215 (M+H), 211,213 (M-H) ; HPLC shows 95% purity.

Example 223 5- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-1, 3-dihydro-benzoimidazol- 2-one Following procedures essentially as described in Example 230, below, and using (10,11- dihydro-dibenzo [a, d] cyclohepten-5-ylidene) -boronic acid (0.0825M in toluene, lOmL, 0. 825mmol) and 5-bromo-1, 3-dihydro-benzoimidazol-2-one (117mg, 0. 550mmol), provides the title compound. Purify by triturating with CH2C12 to obtain 85mg (45%) of the title compound as a white powder. MS (ES) 339 (M+H), 337 (M-H) ; HPLC shows 93% purity.

Preparation 28 4-Bromo-1, 3-dihydro-indol-2-one

Add a solution of 12 (2.62g, 10. 30mmol) in DMF (lOmL) dropwise to a solution of 4- bromoindole (2. 00g, 10. 20mmol) and KOH (1.43g, 25. 5mmol) in DMF (40mL). Stir for 30min at room temperature and add saturated aqueous Na2S03. Stir at room temperature for 15min, then dilute reaction mixture with ethyl acetate (lOOmL). Wash organics three times with H20, dry organics (MgS04) and concentrate to a brown oil. Dissolve oil in 2- methoxyethanol (40mL) and heat to 100°C. Add H3PO4 (9mL) and heat to reflux for 48h.

Cool to room temperature and dilute with H20 (75mL). Extract into ethyl acetate, dry (MgS04) and concentrate organics to a dark brown oil. Chromatograph on silica gel (90g), eluting with 20% to 40% ethyl acetate/hexanes to afford 121mg (6%) of the title compound as a tan solid. MS (ES) 212,214 (M+H), 210, 212 (M-H) ; HPLC shows 76% purity.

Example 224 4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-1, 3-dihydro-indol-2-one Following procedures essentially as described in Example 229 and using (10, 11-dihydro- dibenzo [a, d] cyclohepten-5-ylidene) -boronic acid (0.0825M in toluene, 7. 4M1, 0. 61mmol) (concentrated to dryness before use in reaction). Add 4-bromo-1, 3-dihydro-indol-2-one (108mg, 0. 510mmol) to provide 37mg (22%) of the title compound as a tan solid. MS (ES) 338 (M+H); HPLC shows 96% purity.

Preparation 29 2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylboronic acid

Add n-BuLi (1.6M in hexanes, 12. 98M1, 20.76mmol) portionwise (exothermic) to a solution of 5-(2-bromo-benzylidene)-10,11-dihydro-5H-dibenzo [a, d] cycloheptene (5. 00g, 13. 84mmol) in dry THF (50M1) at-78°C under N2. Let stir at-78°C for 30min, then add triisopropyl borate (5.21g, 27. 68mmol) and warm up to room temperature overnight. Add 50MI l. OON HCl and stir for 15min. Extract into ethyl acetate, dry (MgS04) and concentrate organics to a brown foam. Recrystallize from boiling hexanes, then chromatograph on silica gel (40g), eluting with 20% to 50% ethyl acetate/hexanes to afford the title compound as a white foam, mp 134. 1°C. MS (ES) 325 (M-H); HPLC shows 82% purity.

Example 225 2- [2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-pyrazine In a 1-dram vial, mix 2- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenylboronic acid (100mg, 0. 307mmol), chloropyrazine (69mg, 0. 460mmol), cesium fluoride (94mg, 0. 614mmol), and [1, 1'-bis (diphenylphosphino) - ferrocene] dichloropalladium (II) (1: 1 complex with CH2Cl2, 25mg, 0. 031mmol) in dioxane (2mL). Heat to 85°C for 72h, then remove solvent under nitrogen. Take up the resulting residue in H20 (1mL) and CH2C12 (1mL) and load onto a Varian ChemElut CE1005 solid-phase extraction cartridge. Elute, collect, and concentrate 15mL CH2Clz to

obtain crude product. Purify by mass-guided reverse-phase HPLC to obtain 2.3mg (2%) of the title compound. MS (ES) 361 (M+H) ; HPLC shows 93% purity.

Example 226 4- [2- (10, 1 1-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-3, 5-dimethyl- isoxazole Following procedures essentially as described in Example 225 and using 2- (10, 11- dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylboronic acid (100mg, 0. 307mmol) and 4-bromo-3,5-dimethylisoxazole (81mg, 0.460mmol), provides the title compound in 2% yield. MS (ES) 378 (M+H); HPLC shows 94% purity.

Example 227 2- [2- (10, 1l-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-pyridine Following procedures essentially as described in Example 225 and using 2- (10, 11- dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenylboronic acid (100mg, 0. 307mmol) and 2-chloropyridine (52mg, 0. 460mmol), provides the title compound.

Purify further via silica gel chromatography to obtain 14.7mg (13%) of material that is 84% pure by HPLC. MS (ES) 360 (M+H).

Example 228 3- [2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-pyridine

Following procedures essentially as described in Example 225 and using 2- (10, 11- dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenylboronic acid (100mg, 0. 307mmol) and 3-bromopyridine (73mg, 0. 460mmol) provides the title compound.

Purify further via silica gel chromatography to obtain 14.9mg (14%) of material that is 98% pure by HPLC. MS (ES) 360 (M+H).

Example 229 5- [3- (10, 1l-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]-lH-pyrazole In a 6-dram vial mix (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidene) -boronic acid (0.0825M in toluene, lOmL, 0. 825mmol), 5- (3-bromo-phenyl)-lH-pyrazole (153mg, 0. 688mmol), K2CO3 (570mg, 4.125mmol) and ethanol (5mL). Sparge reaction mixture with N2 for lOmin and add Pd (PPh3) 4 (56mg, 0. 048mmol). Seal vial immediately and heat to 85°C for 72h. Concentrate under N2, then add Ha0 (lmL) and ethyl acetate (lmL). Load onto a Varian ChemElut CE1005 solid-phase extraction cartridge. Elute, collect, and concentrate 30mL ethyl acetate. Chromatograph on 35g silica gel, eluting with 25% to 35% ethyl acetate/hexanes. Re-purify by UV-guided semi-preparatory reverse-phase HPLC to afford 35mg (15%) of the title compound as a milky white oil.

MS (ES) 349 (M+H), 347 (M-H); HPLC shows 99% purity.

Example 230 6- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-pyridin-2-ylamine

Following procedures essentially as described in Example 219 and using 2-amino-6- bromopyridine (95mg, O. 550mmol) and (10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidene) -boronic acid (0.197M in dioxane, 3.35mL, 0. 660mmol), provides 98mg (60%) of the title compound as a yellow oil. MS (ES) 299 (M+H) ; HPLC shows 97% purity.

Example 231 N-[6-(10, 1 1-Dihydro-dibenzo [and] cyclohepten-S-ylidenemethyl)-pyridin-2-yl]-<BR> methanesulfonamide Mix 6-(10,11-dihydro-dibenzo[a,d]cyclohepten-5-ylidenemethyl)-py ridin-2-ylamine (70mg, 0. 235mmol), triethylamine (68p. L, 0.470mmol), N, N-dimethylaminopyridine (3mg, 0. 024mmol), and methanesulfonyl chloride (19µL, 0. 247mmol) in CH2C12 (2mL).

Stir at room temperature overnight and add 150#L triethylamine and 40gel methanesulfonyl chloride. Stir at room temperature for 6h and add 1. OON aqueous HCl (1mL). Load mixture onto a Varian ChemElut CE1005 solid-phase extraction cartridge, then elute, collect, and concentrate 45mL CH2C12. Dissolve crude product in THF (5mL), add l. OM tetrabutylammonium fluoride (0.25mL), and heat to reflux for 1h. Cool to room temperature and dilute with H20 and brine. Extract into ethyl acetate, dry (MgS04)

and concentrate organics. Chromatograph on silica gel (lOg), eluting with 20% to 35% ethyl acetate/hexanes to afford 61mg (69%) of the title compound as a yellow oil. MS (ES) 377 (M+H), 375 (M-H); HPLC shows 96% purity.

Example 232 6- (10, 11-Dihydro-dibenzo[a,d] cyclohepten-5-ylidenemethyl) -pyrazin-2-ylamine Following procedures essentially as described in Example 219 and using 2-amino-6- chloropyrazine (71mg, 0. 550mmol) and (10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidene) -boronic acid (0.197M in dioxane, 3.35mL, 0. 660mmol), provides the title compound. Purify by recrystallization (ethyl acetate/hexanes) to obtain 48mg (29%) of the title compound as a yellow solid. MS (ES) 300 (M+H) ; HPLC shows 96% purity.

Example 233 N- [6- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-pyrazin-2-yl]- methanesulfonamide Mix 6- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -pyrazin-2-ylamine (35mg, 0. 117mmol), triethylamine (34p. L, 0. 234mmol), N, N-dimethylaminopyridine (2mg, 0. 018mmol), and methanesulfonyl chloride (lOjL, 0. 123mmol) in CH2C12 (2mL).

Stir at room temperature overnight and add 150pL triethylamine and 40µL

methanesulfonyl chloride. Stir at room temperature for 6h and add 1. OON aqueous HC1 (lmL). Load mixture onto a Varian ChemElut CE1005 solid-phase extraction cartridge, then elute, collect, and concentrate 45mL CH2Cl2. Dissolve crude product in THF (5mL), add l. OM tetrabutylammonium fluoride (0. 30mL), and heat to reflux for lh. Cool to room temperature and dilute with H20 and brine. Extract into ethyl acetate, dry (MgS04) and concentrate organics. Chromatograph on silica gel (4g), eluting with 20% + 35% ethyl acetate/hexanes to afford 19mg (43%) of the title compound as a white solid. MS (ES) 378 (M+H), 376 (M-H) ; HPLC shows 100% purity.

Example 234 2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-pyridin-4-ylamine Following procedures essentially as described in Example 225 and using 4-amino-2- chloropyridine (216mg, 1. 68mmol) and (10, 11-dihydro-dibenzo [a, d] cyclohepten-5- ylidene) -boronic acid (0.197M in dioxane, 10.2mL, 2. 01mmol), provides the title compound. Chromatograph on silica gel (35g), eluting with 40% to 60% ethyl acetate/hexanes to afford 250mg (42%) of the title compound as a brown oil. MS (ES) 299 (M+H). HPLC shows 98% purity.

Example 235 N- [2- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-pyridin-4-yl]- methanesulfonamide

Mix 2- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-pyridin-4-ylamine (176mg, 0. 590mmol), triethylamine (600pL, 4. 13mmol), N, N-dimethylaminopyridine (7mg, 0.059mmol), and methanesulfonyl chloride (137µL, 1. 769mmol) in CH2C12 (lOmL). Stir at room temperature for 3h and dilute with H20 (15mL). Extract into CH2C12, dry (MgS04) and concentrate organics. Dissolve crude product in THF (lOmL), add 1. OM tetrabutylammonium fluoride (0.89mL), and heat to reflux for 4h. Cool to room temperature and dilute with H2O. Extract into ethyl acetate, dry (MgS04) and concentrate organics. Chromatograph on silica gel (lOg), eluting with 80% o 90% ethyl acetate/hexanes to afford 150mg (68%) of the title compound as a yellow foam. MS (ES) 377 (M+H), 375 (M-H); HPLC shows 96% purity.

Example 236 5- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-pyridin-3-ol Following procedures essentially as described in Example 225 and using 5-chloro-2- pyridinol (77mg, 0. 591mmol) and (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidene)- boronic acid (0. 197M in dioxane, 3. 58mL, 0.709mmol), provides the title compound.

Chromatograph on silica gel (lOg), eluting with 60% to 75% ethyl acetate/hexanes to give 40mg of brown oil. Re-chromatograph on silica gel (5g) eluting with 60% ethyl

acetate/hexanes to afford 15mg (8%) of the title compound as a brown oil. MS (ES) 300 (M+H), 298 (M-H) ; HPLC shows 95% purity.

Example 237 4- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-1H-pyrazole

Following procedures essentially as described in Example 229 and using 4-iodopyrazole (107mg, 0. 55mmol) and (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidene) -boronic acid (0.198M in dioxane, 4.2mL, 0. 825mmol), provides 27mg (18%) of the title compound as a colorless oil. MS (ES) 273 (M+H), 271 (M-H). HPLC shows 98% purity.

Example 238 4-Benzylidene-9, 10-dihydro-4H-1-thia-benzo [f] azulene (E and Z isomer)

A. Add a 1.0 M solution of benzyl magnesium bromide (0. 5mL, 0. 5mmol) in THF to a solution of 9, 10-dihydro-1-thia-benzo [f] azulene-4-one (20. 8mg, 0. 97mmol) (prepared according to procedures of Bollinger, P.; Cooper, P.; Gubler, H. U.; Leutwiler, A.; Payne, T. Helv. Chien. Acta 1990,73, 1197) in 1.0 mL of THF under Ar. Stir the resulting solution for 2h at 25 °C before quenching with ca. 100 p. L of saturated, aqueous ammonium chloride. Filter the mixture and wash the magnesium salts with copious amounts of diethyl ether. Wash the filtrate with 1-mL portions of water and brine, dry (Na2S04) and concentrate under reduced pressure. The tertiary alcohol can be purified by column chromatography (9: 1 hexanes: ethyl acetate).

B. Dissolve the crude oil in 1.5 mL of CHC13, add ca. 40 RL (2 drops) of concentrated hydrochloric acid, and then stir the resulting dark solution for 2 h at 25 °C.

Add 1 mL of water and 1 mL of CHC13, separate the layers, and wash the organic layer successively with 0.5-mL portions of saturated, aqueous sodium bicarbonate and brine.

Dry (MgS04) and concentrate via rotary evaporation. Purify by flash chromatography (hexanes) to afford 6.7 mg (24%, 2 steps) of a white solid as a 2: 1 mixture of E-and Z- isomers. MS (CI) : 289 (M+1). 1H NMR (CDC13,400 MHz) 8 2.90-3. 60 (m, 4 H), 6.53 (d, J = 5.4 Hz, 1/3 H), 6.66 (s, 1/3 H), 6.86 (d, J = 5.4 Hz, 1/3 H), 6.94 (s, 2/3 H), 7.01- 7.34 (m, 10 H), 7. 39-7. 41 (m, 2/3 H); HPLC shows >95 % purity: tR = 5.854 min (E + Z; 80: 20 MeOH: H20 to MeOH).

Section 4 (derivatives of Formula I wherein the"A"and/or"B"ring represents a heterocyclic ring.) Example 239 4- (2, 4-Dichloro-benzylidene) -9, 10-dihydro-4H-1-thia-benzo [f] azulene (mixture of E and Z isomers) Following the procedures essentially as described in Example 238 and using 9,10- dihydro-l-thia-benzo [/] azulene-4-one (40.8mg, 0. 19mmol) and 2,4-dichlorobenzyl magnesium chloride (0.575 mmol) in THF: diethyl provides, after dehydration, 30.0 mg (44%) of the title compound as a 3: 1 mixture of E-and Z-isomers. 1H NMR (CDC13) 8 2.88-3. 40 (m, 4 H), 6.26 (d, J = 4.8 Hz, 1/4 H), 6.50 (d, J = 8.2 Hz, 3/4 H); 6.63 (s, 1/4 H, Z), 6.74 (s, 3/4 H), 6.76 (td, J = 8.6 Hz, 2.0 Hz, 3/4 H), 6.88 (td, J = 8.2 Hz, 1.2 Hz, 3/4 H), 6.96 (s, 3/4 H), 6.95-6. 98 (m, 1/4 H), 7.06 (d, J = 4. 8 Hz, 3/4 H), 7.08-7. 20 (m, 14/4 H), 7.28 (d, J = 2.0 Hz, 3/4 H), 7.34 (d, J = 2.4 Hz, 1/4 H), 7.35-7. 38 (m, 1/4 H); TLC shows. 95 % purity: Rf= 0.20 (hexanes).

Example 240 4- (3, 5-Dimethyl-benzylidene) -9, 10-dihydro-4H-1-thia-benzo [flazulene (mixture of E-and Z-isomers)

Following the procedures essentially as described in Example 238 and using 9,10- dihydro-l-thia-benzo [f] azulene-4-one (47. 0mg (0. 22mmol) and solution of 3,5- dimethylbenzyl magnesium bromide (0. 650 mmol) in THF, provides, after dehydration, 39.6 mg (57%) of the title compound as a 1.6 : 1 mixture of E-and Z-isomers. MS (El) : 316 (M+); 1H NMR (CDC13) 8 2. 13 (s, 18/5 H), 2.24 (s, 12/5 H), 2.40-3. 80 (m, 4 H), 6.54 (d, J = 5.6 Hz, 2/5 H), 6.53-6. 55 (m, 7/5 H), 6.74 (s, 3/5 H), 6.83-6. 84 (m, 2/5 H), 6.86 (s, 3/5 H), 6.93 (s, 3/5 H), 7.01-7. 02 (m, 1 H), 7.08 (app d, J = 5.6 Hz, 2/5 H), 7.14 (app d, J = 5.6 Hz, 2/5 H), 7.19-7. 25 (m, 4 H), 7.30 (d, J = 8.0 Hz, 3/5 H), 7.37-7. 39 (m, 2/5 H).

Example 241 E-and Z-4-Benzylidene-9, 10-dihydro-4H-3-thia-benzo[f]azulene (mixture of E-and Z- isomers) Following the procedures essentially as described in Example 238 and using 9,10- dihydro-3-thia-benzo [f] azulene-4-one (32.9mg, 0. 153mmol) (prepared according to Hallberg, A.; Pedaja, P. Tetrahedron 1983, 39, 819) and solution of benzyl magnesium bromide (0.470 mmol) in THF, provides 15.1 mg (34%) of the title compound as a 4: 1 mixture of E-and Z-isomers: MS (CI) : 289 (M+1) ; 1H NMR (CDC13) b 2.98-3. 12 (m, 4 H), 6.61 (d, J = 5.2 Hz, 1/5 H), 6.65 (s, 1/5 H); 6.66 (d, J = 5.6 Hz, 4/5 H), 6.96 (s, 4/5 H),

6.97 (d, J = 3.2 Hz, 4/5 H), 6.97 (d, J = 3.2 Hz, 4/5 H), 6.96 (s, 38/5 H), 7.28-7. 31 (m, 4/5 H).

Example 242 4- (2, 4-Dichloro-benzylidene) -9, 10-dihydro-4H-3-thia-benzo [f] azulene (E-and Z- isomers) Following the procedures essentially as described in Example 238 and using 9,10- dihydro-3-thia-benzo [f] azulene-4-one (23.3mg, 0. 108mmol) and solution of 2,4- dichlorobenzyl magnesium chloride (0.325 mmol) in THF provides, after dehydration, 12.5 mg (32%) of the title compound as a 3: 1 mixture of E-and Z-isomers: 1H NMR (CDC13) S 2.88-3. 40 (m, 4 H), 6.26 (d, J = 4.8 Hz, 1/4 H), 6.50 (d, J = 8.2 Hz, 3/4 H); 6.63 (s, 1/4 H, Z), 6.74 (s, 3/4 H), 6.76 (td, J = 8.6 Hz, 2.0 Hz, 3/4 H), 6.88 (td, J = 8.2 Hz, 1.2 Hz, 3/4 H), 6.96 (s, 3/4 H), 6.95-6. 98 (m, 15/4 H), 7.28 (d, J = 2.0 Hz, 3/4 H), 7.34 (d, J = 2.4 Hz, 1/4 H), 7.35-7. 38 (m, 1/4 H); TLC shows > 95 % purity: Rf= 0.20 (hexanes).

Example 243 (a) and <BR> <BR> <BR> E-N [3- (9, 10-Dihydro-l-thia-benzoazulen-4-ylidenemethyl)-phenyl]-metha nesulfonamide (E-isomer) and Z-N [3- (9, 10-Dihydro-1-thia-benzoazulen-4-ylidenemethyl)-phenyl]- methanesulfonamide (Z-isomer)

Following the procedures essentially as described in Example 219 and using 4- bromomethylene-9, 10-dihydro-4H-1-thia-benzo [f] azulene (54. 1mg, 0.186 mmol) and 3- methylsulfonaminophenyl boronic acid (43.4mg, 0. 202mmol), (prepared according to M.

L. Quan, J. Wityak, C. Dominguez, J. V. Duncia, C. A. Kettner, C. D. Ellis, A. Y. Liauw, J. M. Park, J. B. Santella, R. M. Knabb, M. J. Thoolen, P. C. Weber and R. R. Wexler Bioorg. Med. Chem. Lett. 1997, 13, 1595), provides the title compound. Purify the crude residue by column chromatography (hexanes to 7: 3 hexanes: ethyl acetate) to give 49.7mg (ca. 70 %) of the title compound as a 1: 1 mixture of E-and Z-isomers. The isomers were separated via HPLC on a Waters Symmetry C18 5-1lu 19-mm x 300-mm semi- preparatory column using a 7: 3 MeCN: H20 (0.1 % TFA) eluent and were identified on the basis of the following spectroscopic properties. E-N [3- (9, 10-Dihydro-l-thia- benzoazulen-4-ylidenemethyl)-phenyl]-methanesulfonamide (Example 243) a) ) : MS (CJ) : 382 (M+1) ; 1H NMR (CDC13, 400 MHz) 8 2.78 (s, 3 H), 2.90-3. 45 (m, 4 H), 6.12 (s, 1 H), 6.72 (app s, 1 H), 6.91 (s, NH, 1 H), 6.93-7. 03 (m, 3 H), 7.10-7. 23 (m, 4 H), 7.32 (d, J = 7.8 Hz, 1 H); HPLC shows >95 % purity : tR = 3.194 min (80: 20 MeOH : H20 to MeOH). Z-N-[3-(9, 10-Dihydro-l-thia-benzoazulen-4-ylidenemethyl)-phenyl]- methanesulfonamide (Example 243 (b) ) : MS (CI) : 382 (M+1) ; 1H NMR (CDC13, 400 MHz) 8 2.94 (s, 3 H), 3.24 (br s, 4 H), 6.50 (d, J = 5.0 Hz, 1 H), 6.64 (s, 1 H), 6.88 (d, J = 5.0 Hz, 1 H), 7.08-7. 18 (m, 3 H), 7.26-7. 30 (m, 4 H), 7.38-7. 40 (m, 1 H); HPLC shows >95 % purity: tR = 3.194 min (80: 20 MeOH : H20 to MeOH).

Example 244 3- (8-Chloro-5, 6-dihydro-benzo [5,6] cyclohepta [1, 2-b] pyridin-1 l-ylidenemethyl)-phenol, (Z-isomer) A. Prepare 11- (3-bromo-benzylidene)-8-chloro-6, 11-dihydro-5H- benzo [5,6] cyclohepta [1, 2-b] pyridine according to procedures essentially as described in

Example 28 using m-bromobenzylmagnesium bromide (7. 5mmol) and 8-chloro-5, 6- dihydro-benzo [5,6] cyclohepta [1, 2-b] pyridin-1 l-one (600mg, 2. 5mmol) in ether (25mL).

Separate the E and Z isomers by column chromatography (15% ethyl acetate/hexane).

B. Separately, convert each isomer to the hydroxyl derivative by using the following procedure : Mix 11- (3-bromo-benzylidene)-8-chloro-6, 11-dihydro-SH- benzo [5,6] cyclohepta [1, 2-b] pyridine (500mg, (1. 26mmol), pinacol diborane (416mg, 1. 64mmol), KOAc (375mg, 3. 8mmol) in DMSO (lOmL). Sparge with nitrogen for 10 minutes and then add Pd (dppf) Cl2 (160mg, 0.2mmol) and heat at 80°C for 4h. Shake with water and ethyl acetate. Dry the organic layer (MgS04) and concentrate to give 650mg crude product. Purify by column chromatography (15% ethyl acetate/hexane) to give 310mg (56%) 8-chloro-11-[3-(4, 4,5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-yl) - benzylidene] -6, 11-dihydro-5H-benzo [5,6] cyclohepta [1, 2-b] pyridine. MS (ES) 444 (M+1). Purify by HPLC is 89%.

C. Mix 8-chloro-ll- [3- (4, 4,5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-yl) -benzylidene]- 6, 11-dihydro-5H-benzo [5,6] cyclohepta [1, 2-b] pyridine (300mg, 0.68mmol), HOAc (lmL), water (1mL), THF (5mL) and 30% H202 (mL). Stir the reaction at RT for 4h. Quench with aqueous Na2S203 and extract the product into EtOAc. Dry (MgS04) and concentrate to give 250mg crude product. Purify by column chromatography (15% ethyl acetate/hexane) to give 66mg 3- (8-chloro-5, 6-dihydro-benzo [5,6] cyclohepta [1, 2- b] pyridin-11-ylidenemethyl)-phenol, Z-isomer as a white solid, mp 221. 2°C. MS (ES) 334 (M+1), 332 (M-1). HPLC shows 99% purity.

Example 245 3- (8-Chloro-5, 6-dihydro-benzo [5,6] cyclohepta [1, 2-b] pyridin-1l-ylidenemethyl)-phenol, (E-isomer)

Prepared as described in Example 244, above, to provide 90mg (57%) product as a white solid, mp >250°C. MS (ES) 334 (M+1), 332 (M-1). HPLC shows 94% purity.

Example 246 N- [3- (8-Chloro-5, 6-dihydro-benzo [5,6] cyclohepta [1, 2-b] pyridin-1l-ylidenemethyl)- phenyl]-methanesulfonamide (E isomer,)

Following procedures as described in Example 219 and using 11-bromomethylene-8- chloro-6, 11-dihydro-5H-benzo [5,6] cyclohepta [1, 2-b] pyridine (E- isomer) (820mg, 2. 56mmol) and 3-methanesulfonylaminophenylboronic acid (605mg, 2. 8mmol), provides the title compound in 53% yield as a white foam after purification on silica gel using 50% EtOAc/hexane. MS (ES) 411 (M+1), 409 9M-1).

HPLC shows 97% purity.

Example 247 N- [3-(2-Methyl-9,10-dihydro-1-oxa-3-awza-benzo[f]azulen-4-ylid enmethyl)-phenyl]- methanesulfonamide

Prepare the corresponding ketone (2-methyl-9, 10-dihydro-1-oxa-3-aza-benzo [flazulen-4- one) as described by E. E. Galantay, et al, J. Med. Chem. (17) 1316-1327 (1974) and convert to the corresponding Z-isomer of the vinyl bromide using procedures essentially as described in Preparations 23 and 24. Then, following procedures essentially as described in Example 219, combine the ketone with 3-methanesulfonamidophenyl boronic acid (325mg, 1. 5mmmol). Purify the crude product using column chromatography (30% EtOAc/hexane to 50% EtOAc/hexane) to provide 180mg (38%) Z-isomer as a light tan solid, mp 184. 6°C, MS (ES) 381 (M+1), 379 (M-1). HPLC shows 94% purity at t=1.99min.

Example 248 3- (2-Methyl-9, 10-dihydro-1-oxa-3-aza-benzo [f] azulen-4-ylidenemethyl)-phenol Prepare the corresponding ketone (2-methyl-9, 10-dihydro-1-oxa-3-aza-benzo [flazulen-4- one) as described by E. E. Galantay, et al, J. Med. Chem. (17) 1316-1327 (1974) and convert to the corresponding Z-isomer of the vinyl bromide using procedures essentially as described in Preparations 23 and 24. Then, following procedures essentially as described in Example 219, combine the ketone with 3-hydroxyphenyl boronic acid (207mg, 1. 5mmmol). Purify the crude product using column chromatography (15% EtOAc/hexane to 30% EtOAc/hexane) to give 26mg title compound, MS (ES) 304 (M+1). HPLC shows 93% purity at t=2. 48min.

Example 249 (E)-N-[3-(5, 6-Dihydro-benzo [5,6] cyclohepta [1, 2-b] pyridin-11-ylidenemethyl)-phenyl]- methanesulfonamide (LY2076945, JN9-A01943-65)

Following procedures essentially as described in Example 219, combine 11- bromomethylene-6, 11-dihydro-5H-benzo [5, 6] cyclohepta [1, 2-b] pyridine (250mg, 0. 87mmol) and 3-methanesulfonamide-phenyl boronic acid (244mg, l. lmmol). Purify the product via flash chromatography, eluting the product with solutions of increasing concentrations of ethyl acetate in hexanes (10% to 50%). Combine product fractions, concentrate and dry to yield 190mg (58%) of product as a white solid. LC/MS (APCI- pos): 377.1 (M+H). 1H NMR (CDCl3, 400 MHz) : 88. 49 (dd, lH), 7.42 (d, lH), 7.32 (s, lH), 7.29 (d, lH), 7.23-7. 11 (m, 3H), 7.01 (bd, 3H), 6.94 (d, lH), 6.86 (s, 2H), 3.6-2. 9 (bm, 4H), 2.78 (s, 3H).

Example 250 (F)-3- (5, 6-Dihydro-benzo [5,6] cyclohepta [1, 2-b] pyridin-1l-ylidenemethyl)-phenol Following procedures essentially as described in Example 219, combine 11- bromomethylene-6, 1 1-dihydro-5H-benzo [5, 6] cyclohepta [1, 2-b] pyridine (250mg, 0.87mmol) and (3-hydroxyphenyl) boronic acid (133mg, 0. 96mmol). Purify to provide product 166mg (63%) as an off-white solid. LC/MS : 300.1 (1\4+H).'H NYR (DMSO, 400 MHz): 59. 22 (s, lH), 8.40 (d, lH), 7.49 (d, lH), 7.34 (d, lH), 7.24 (d, lH), 7.21 (d, 3H), 7.15 (s, lH), 7.04 (t, 1H), 6.92 (d, lH), 6.90 (d, lH), 6.52 (d, lH), 6.40-6. 42 (m, 2H), 3.4-2. 8 (m, 4H).

Example 251 (@-N-[3-(10, 11-Dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridin-5-ylidenemethyl)-phenyl]- methanesulfonamide

Following procedures essentially as described in Example 219, combine (Z)-5- bromomethylene-10, 11-dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridine (153mg, 0. 53mmol) with 3-methanesulfonamide-phenyl boronic acid (150mg, 0. 7mmol). After work-up, purify the crude product by flash chromatography (10% ethyl acetate/hexanes to 25% ethyl acetate/hexanes to 50% ethyl acetate/hexanes) to provide 1 80mg (90%) of purified product. LC/MS : 377.1 (M+H) 375 (M-H). Purity by LC/MS 95%.

Example 252 (Z)-3-(10, 1 1-Dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridin-5-ylidenemethyl) -phenol Following procedures essentially as described in Example 219, combine (Z)-5- bromomethylene-10, 11-dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridine (153 mg, 0.53 mmol) 3-hydroxyphenyl boronic acid (85mg, 0. 59mmol). After work-up, purify the crude product by flash chromatography (10% ethyl acetate/hexanes to 25% ethyl acetate/hexanes to 50% ethyl acetate/hexanes) to provide 68mg (43%) of purified product.

LC/MS : (300.1 (M+H). Purity by HPLC is 95%.

Example 253 (E)-N-[3-(10,11-Dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridin-5-ylidenemethyl)-phenyl]- methanesulfonamide

Following procedures essentially as described in Example 219, combine (E)-5- bromomethylene-10, 11-dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridine (105mg, 0. 37mmol) 3-methanesulfonamide-phenyl boronic acid (103mg, 0. 18mmol). After work-up, purify the crude product by flash chromatography (10% ethyl acetate/hexanes to 25% ethyl acetate/hexanes to 50% ethyl acetate/hexanes) to provide 105mg (76%) of purified product. LC/MS : 377.1 (M+H), 375 (M-H). Purity by LC/MS is 95%. 1H NMR (CDC13, 400 MHz) : 88. 44 (dd, lH), 7.82 (dd, lH), 7.31 (d, 2H), 7.26-7. 14 (m, 3H), 7.03 (dq, 2H), 6.95 (dd, lH), 6.87 (d, lH), 6.80-6. 77 (m, 3H), 3.6-2. 9 (bm, 4H), 2.80 (s, 3H).

Example 254 (E)-3-(10, 1 1-Dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridin-5-ylidenemethyl) -phenol Following procedures essentially as described in Example 219, combine (E)-5- bromomethylene-10, 11-dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridine (105mg, 0. 37mmol) 3-hydroxyphenyl boronic acid (58mg, 0. 4mmol). After work-up, purify the crude product

by flash chromatography (10% ethyl acetate/hexanes to 25% ethyl acetate/hexanes to 50% ethyl acetate/hexanes) to provide 45mg (41%) of purified product. LC/MS : 300.1 (M+H).

IH NM : R (CDC13, 400 MHz) : 88. 25 (d, lH), 7.79 (d, lH), 7.18-7. 12 (m, lH), 7.01-6. 90 (m, 5H), 6.68 (s, lH), 6.58 (dd, lH), 6.54 (d, lH), 6.37 (s, lH), 3.5-2. 6 (m, 4H).

Section 5 (derivatives of Formula I wherein the bridge depicted by-X-Y-represents a fused cyclopropyl structure. ) Example 255 N- [3- (8, 8-Difluoro-4-ylidine methyl-2, 3,5, 6-dibenzobicyclo [5.1. 0] octane)-phenyl]- methanesulfonamide Following procedures essentially as described in Example 219 and using 8,8-difluoro-4- bromomethylene-2,3, 5,6-dibenzobicyclo [5.1. 0] octane (163mg, 0.4 mmol) and 3- (methylsulfonamido) phenylboronic acid (116mg, 0. 54mmol) to provide the title compound. Evaporate and purify on silica gel (methanol/dichloromethane) to obtain 99mg (48%) of the title compound. Add ethyl acetate to obtain a crystalline material. MS (ES) 423 (M-1).

Example 256 N- [3- (8, 8-Difluoro-4-ylidine methyl-2, 3,5, 6-dibenzobicyclo [5.1. 0] octane)-phenol

Following procedures essentially as described in Example 219 and using 8,8-difluoro-4- bromomethylene-2,3, 5,6-dibenzobicyclo [5. 1. 0] octane (166mg., 0. 5mmol) and (3- hydroxypheny) boronic acid (76mg., 0. 55mmol). Purify with silica gel (ethyl acetate/hexanes) chromatography to obtain 103 mg (60%) foam. MS (ES) 346 (M-1).

Example 257 N- [3- (4-Ylidine methyl-2, 3,5, 6-dibenzobicyclo [5.1. 0] octane)-phenyl]- methanesulfonamide

Following procedures essentially as described in Example 219 and using 4- bromomethylene-2,3, 5,6-dibenzobicyclo [5.1. 0] octane (208 mg, 0.7 mmol) and 3- (methylsulfonamido) phenylboronic acid (166 mg, 0.77 mmol) to provide the title compound. Purify on silica gel using methanol/dichloromethane and ethyl acetate/hexanes by radial chromatography. Obtain 83. 5mg (31%). MS (ES) 387 (M-1).

Example 258 N- [3- (4-Ylidine methyl-2,3, 5,6-dibenzobicyclo [5.1. 0] octane)-phenol

Following procedures essentially as described in Example 219 and using 4- bromomethylene-2,3, 5,6-dibenzobicyclo [5.1. 0] octane (208mg. , 0. 7mmol) and (3- hydroxypheny) boronic acid (106mg, 0.77 mmol) to provide the title compound. Evaporate the reaction and add to a Celite cartridge using dichloromethane. Elute with dichloromethane. Evaporate the eluent and purify on silica gel ethyl acetate/hexanes chromatography to obtain 60mg (28%) of the title compound as a foam. GC/MS t=21. 49min MW=310.

Example 259 N [3- (8, 8-Dichloro-4-ylidene methyl-2, 3,5, 6-dibenzobicyclo [5.1. 0] octane)-phenyl]- methanesulfonamide Following procedures essentially as described in Example 219, combine 8,8-Dichloro-4- bromomethylene-2,3, 5,6-dibenzobicyclo [5. 1. 0] octane (160 mg, 0. 44 mmol) and 3-methanesulfonamide-phenyl boronic acid (103 mg, 0.48 mmol to provide the title compound. Purify the product using radial chromatography eluting the product with solutions of increasing concentrations of ethyl acetate in hexanes (5,10, 15,20, and 25%).

Combine product fractions, concentrate and dry to yield 120 mg (60%) of product as a white solid, mp 199-201°C. LC/MS (ES): 474 (M+NH4t, 456 w).

Example 260 N- [3- (8, 8-Dichloro-4-ylidene methyl-2, 3,5, 6-dibenzobicyclo [5.1. 0] octane)-phenol

Following procedures essentially as described in Example 219, combine 8,8-dichloro-4- bromomethylene-2,3, 5,6-dibenzobicyclo [5.1. 0] octane (160mg, 0. 44mmol) and (3-hydroxyphenyl) -boronic acid (70mg, 0.4 mmol) to provide the title compound. Purify the product radial chromatography eluting the product with solutions of increasing concentrations of ethyl acetate in hexanes (5,10, 15, and 20%). Combine product fractions, concentrate and dry to yield 59mg (36%) of product as a white solid. LC/MS (ES+) : 397 (M+NH4+), 379 (M). IH NMR (CDC13, 400 MHz): 87. 50 (d, 1H), 7.42 (d, 1H), 7.36 (dd, 1H), 7.35-7. 26 (m, 3H), 7.12-7. 02 (m, 3H), 6.72-6. 62 (m, 3H), 6.55 (dd, 1H), 4.89 (s, 1H), 3.46 (d, 1H), 3.35 (d, 1H).

Section 6 (derivatives of Formula I wherein the bridge depicted by-X-Y-contains a heteroatom or heteroatom containing group at either the X or Y position.) Example 261 N- [3- (6-Oxo-5, 6-dihydro-dibenzo [b, e] azepin-1 l-ylidenemethyl)-phenyl]- methanesulfonamide

Following procedures essentially as described in Example 158 and using 5H- dibenzo [b, e] azepine-6, 11-dione (97mg, 0. 31mmol) and methanesulfonyl chloride (26 CL, 0. 34mmol), followed by procedures essentially as described in Example 90,83g of the title compound is provided in 68% yield as a white solid. 1H NMR (DMSO) 610. 54 (s, 1H), 9.67 (s, 1H), 7.82 (d, 1H), 7.63 (t, 1H), 7.52 (d, 1H), 7.46 (m, 1H), 7.25 (m, 2H), 7.15 (m, 1H), 7.02 (s, 1H), 6.99 (d, 1H), 6.98 (m, 2H), 6.80 (m, 2H), 2.81 (s, 3H). MS [EI+] 391 (M+H).

Example 262 N- [3- (llH-10-Thia-dibenzo [a, d] cyclohepten-5-ylidenemethyl) -phenyl]- methanesulfonamide ( Dissolve 3-(llH-10-thia-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine (20mg, 0.06 mmol) in 5mL of methylene chloride under a nitrogen atmosphere. Then, following procedures essentially as described in Example 90 22.3mg of the title compound is provided as a white solid. 1H NMR (CDC13) 67. 49 (m, 1H), 7.48 (d, 1H), 7.35 (td, 1H), 7.25-7. 15 (m, 2H), 7.15-7. 10 (m, 2H), 7.10-6. 95 (m, 3H), 6.87 (d, 1H), 6.79 (s, 1H), 6.24 (m, 1H), 6.10 (s, 1H), 5.00 (d, 1H), 3.55 (d, 1H), 2.80 (s, 3H). MS [EI+] 394 (M+H), 392 (M-H).

Example 263 N- [3- (10-0xo-10, ll-dihydro-10-thia-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenyl]-methanesulfonamide

In 5mL of acetonitrile add Fe (N03) 3 9H20 (5. lmg, 0. 013mmol) and FeBr3 (1. 9mg, . 006mmol). Add N- [3- (l lH-10-thia-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenyl]- methanesulfonamide (50mg, 0. 13mmol) and stir for 2h at ambient temperature. Extract with methylene chloride, dry (MgS04) and concentrate. Purify by recrystallization from carbon tetrachloride to yield 13.6mg of a yellow solid. 1H NMR (CDC13) 67. 85 (m, 1H), 7.57 (m, 1H), 7. 55 (m, 1H), 7. 35 (td, 1H), 7.25-7. 15 (m, 2H), 7.10 (d, 1H), 7.02 (dd, 1H), 7.00-6. 95 (m, 3H), 6.22 (s, 1H), 4.60 (b, 2H), 3.55 (d, 1H), 2.80 (s, 3H). MS [EI+] 410 (M+H) +, 408 (M-H)-.

Example 264 N- [3- (10, 10-Dioxo-10, ll-dihydro-10-thia-dibenzo [a, d] cyclohepten-5-ylidenemethyl)- phenyl]-Methanesulfonamide

Dissolve N- [3- (10-oxo-10, 11-dihydro-I k-thia-dibenzo [a, d] cyclohepten-5- ylidenemethyl)-phenyl]-methanesulfonamide (35mg, 0. 085mmol) in 5mL of methylene chloride at ambient temperature. Add 300mg of silica gel followed by t-butylperoxide (0. 012mL, 0. 085mmol). Stir overnight, filter and evaporate. Recrystallize from 1: 1 ether: pentane to obtain 10.6mg of the product as a yellow solid. 1H NMR (CDC13) 8 8.91

(b, 1H), 7.85 (m, 1H), 7.57 (m, 1H), 7.55 (m, 1H), 7.35 (m, 1H), 7.25-7. 15 (m, 2H), 7.10 (m, 1H), 7.02 (m, 1H), 7.00-6. 95 (m, 1H), 6.30 (d, 2H), 6.15 (d, 1H), 5.25 (t, 1H), 4.40 (t, 1H), 2.80 (s, 3H). MS [EI+] 424 (M-H).

Example 265 1l- (3-Nitro-benzylidene-6, 1l-dihydro-dibenzo [b, e] oxepine Following procedures as described in Example 229 combine 11-bromomethylene-6, 11- dihydydro-dibenzo [b, e] oxepine (500mg) with m-nitrophenyl boronic acid (290mg). Flash chromatography'eluting with 1: 1 toluene: hexanes gave 310gofa3 : 1 mix of both isomers (54.4% yield). 1H NMR (400 MHz, CDC13) 8 7.96-7. 94 (d, 1H), 7.87 (s, 1H), 7.52-7. 47 (m, 2H), 7.37-7. 16 (m, 5H), 7.00-6. 95 (t, 3H), 6.85-6. 83 (d, 1H).

Example 266 3- (6H-Dibenzo [b, e] oxepin-l l-. ylidenemethyl)-phenylamine Dissolve 11- (3-Nitro-benzylidene-6, 11-dihydro-dibenzo [b, e] oxepine (200mg) in ethanol (lOmL) add tin chloride dihydrate (680mg) and reflux for 5h. Concentrate the reaction in vacuo, re-dissolve in ethyl acetate and wash with 1N sodium hydroxide solution.

Separate the layers wash with brine and dry over sodium sulfate. Purity using filter

chromatography eluting with 10% ethyl acetate : toluene to give 60mg of product (56% yield).

MS m/z : 300 (M+ +1).

Example 267 N- [3- (6H-Dibenzo [b, e] oxepine-l l-ylidenemethyl)-phenyl]-methanesulfonamide Following the procedures essentially as described in Example 90, the aniline of Example 266 (180mg) is reacted with methanesulfonyl chloride (50L) to provide the title compound. Elute with 1-3-6% ethyl acetate : toluene (silica gel) over a step gradient to give 40mg title product (17.6% yield) 1H NMR (400 MHz, CDC13) 8 7.5-7. 46 (t, 2H), 7.34- 7.30 (t, 1H), 7.21-7. 15 (m, 3H), 7.06-6. 9 (m, 5H), 6.83-6. 80 (d, 1H), 6.76 (s, 1H), 6.16 (s, 1H), 2.8 (s, 3H).

MS m/z: 376. 1 (M-1).

Example 268 N- [3- (6H-Dibenzo [b, e] oxepin-l l-ylidenemethyl)-phenyl]-methanesulfonamide Following the procedures essentially as described in Example 90, the aniline of Example 266 (1 80mg) is reacted with methanesulfonyl chloride (50L) to provide 5mg (2.2% yield) of the title compound. 1H NMR (400 MHz, CDC13) 6 7. 48-7. 45 (d, 1H), 7.41-7. 37 (m,

1H), 7.34-7. 32 (m, 2H), 7.20-7. 17 (d, 1H), 7.15-6. 99 (m, 5H), 6.90-6. 88 (d, 1H), 6.67- 6.61 (m, 2H), 6.26 (s, 1H), 5.33 (broad s, 2H), 2.87 (s, 3H).

MS m/z: 376. 1 (M-1).

Example 269 E-4-Methoxy-11- (3-nitro-benzylidene)-6, 1l-dihydro-dibenzo [b, e] oxepine

Following procedures essentially as described in Example 230, 11-bromomethylene-4- methoxy-6, 1 l-dihydro-dibenzo [b, e] oxepine is combined with m-nitrophenyl boronic acid.

The pure E isomer is isolated by recrystallization with hexanes and diethyl ether to give 311 mg of product (33% yield). 1H NMR (400 MHz, CDC13) 8 7.979-7. 949 (d, 1H), 7.874 (s, 1H), 7.509-7. 491 (d, 1H), 7.365-7. 324 (t, 1H), 7.305-7. 237 (m, 2H), 7.204-7. 162 (t, 1H), 7.123-7. 100 (d, 1H), 6.992-6. 912 (m, 3H), 6.864-6. 840 (d, 1H), 5.75 (broad s, 1H), 5.19 (broad s, 1H), 3.84 (s, 3H).

Example 270 3- (4-Methoxy-6H-dibenzo [b, e] oxepin-11-ylidenemethyl)-phenylamine

Prepare the title compound by Snack reduction of 4-methoxy-11-(3-nitro-benzylidene)- 6, 11-dihydro-dibenzo [b, e] oxepine (from Example 270) to provide 267mg of product (93.7% yield). This material is used without further characterization.

Example 271 N- [3- (4-Methoxy-6H-dibenzo [b, e] oxepin-1l-ylidenemethyl)-phenyl]- methanesulfonamide

Following procedures essentially as described in Example 90, the title compound is prepared from 3- (4-Methoxy-6H-dibenzo [b, e] oxepin-11-ylidenemethyl)-phenylamine and methanesulfonyl chloride. Flash chromatography eluting with 5 to 10 to 20% ethyl acetate : toluene provides 198mg product (60% yield) of the title final product.

H NMR (400 MHz, CDC13) 8 7.482-7. 463 (d, 1H), 7.321-7. 237 (m, 2H), 7.193-7. 149 (t, 1H), 7.110-7. 086 (d, 1H), 7.035-6. 973 (m, 2H), 6.936-6. 881 (m, 3H), 6.840-6. 815 (d, 1H), 6.763 (s, 1H), 6.127 (s, 1H), 3.83 (s, 3H), 2.80 (s, 3H).

MS m/z : 406.1 (M--l).

Example 272 7-Chloro-11- (3-nitro-benzylidene)-6, 11-dihydro-dibenzo [b, e] oxepine Following procedures essentially as described in Example 230, 11-bromomethylene-7- chloro-6, 1 l-dihydro-dibenzo [b, e] oxepine is combined with m-nitrophenyl boronic acid to provide the title compound. The pure Z isomer is isolated by crystallization (diethyl

ether) to give 1.4g (31.7% yield) product. 1H NMR (400 MHz, CDC13) 8 8.038-8. 017 (d, 1H), 7.976 (s, 1H), 7.511-7. 491 (d, 1H), 7.431-7. 410 (d, 1H), 7.369-7. 253 (m, 3H), 7.160- 7.121 (t, 1H), 7.041-7. 005 (m, 2H), 6.928-6. 919 (d, 1H), 6.908-6. 898 (d, 1H), 5.60 (s, 2H).

Example 273 3- (7-Chloro-6H-dibenzo [b, e] oxepin-11-ylidenemethyl)-phenylamine Prepare the title compound by SnCl2 reduction of 7-chloro-1 1-(3-nitro-benzylidene)-6, 11- dihydro-dibenzo [b, e] oxepine (from Example 272) to provide 900mg (98%) of product.

MS m/z : 334.1 (m+ +1)., Example 274 N- [3- (7-Chloro-6H-dibenzo [b, e] oxepin-l l-ylidenemethyl)-phenyl]-methanesulfonamide Following procedures essentially as described in Example 90, the title compound is prepared from 3- (7-chloro-6H-dibenzo [b, e] oxepin-11-ylidenemethyl)-phenylamine and methanesulfonyl chloride. Elute on silica gel with 15% ethyl acetate : toluene gave 530mg product (86%). 1H NMR (400 MHz, CDC13) # 7.463-7. 443 (d, 1H), 7. 358-7. 337 (d, 1H),

7.230-7. 155 (m, 2H), 7.116-7. 077 (t, 1H), 7.016-6. 840 (m, 7H), 6.264 (s, 1H), 5.563 (s, 2H), 2.88 (s, 3H) MS m/z: 410. 1 (M-1).

Section 2 Preparation 30 1- {2- [4- (2, 8-Dimethoxy-10, 1 1-dihydro-dibenzo [a, dlcyclohepten-5-ylidenemethyl)- phenoxy]-ethyl}-piperidine Mix 5-bromomethylene-2, 8-dimethoxy-10, 11-dihydro-5H-dibenzo [ad] cycloheptene (270mg, 0. 78mmol) and 1- [2- (phenoxy-4-boronic acid) -ethyl] -piperidine (580mg, 2.35 mmol) in 1,4-dioxane (8mL) and aqueous sodium carbonate (2.0 M, 2mL). Sparge solution with N2 for 15 min, then add Pd (Ph3P) 4 (140mg, 0. 12mmol) and heat to 85°C for 2 h. Cool reaction mixture to room temperature, dilute with dichloromethane (lOOmL), and wash organic once with saturated aqueous ammonium chloride. Dry (MgS04) and concentrate organics to a brown oil. Chromatography on silica gel (40g), eluting with 5 : 1 dichloromethane: methanol affords 180mg (50%) of the title compound as a light brown oil. MS (ES) 470 (M+H); TLC Rf= 0.40 (5: 1 dichloromethane: methanol).

Example 275 5- [4- (2-Piperidin-1-yl-ethoxy)-benzylidene]-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene- 2,8-diol hydrochloride

Mix 1-12- [4- (2, 8-dimethoxy-10, 11-dihydro-dibenzo [ad] cyclohepten-5-ylidenemethyl)- phenoxy] -ethyl} -piperidine (180mg, 0. 38mmol) and ethereal hydrogen chloride (1. 0 M, 1 mL) in dichloromethane (5mL). Concentrate under reduced pressure. Dilute residue with dichloromethane (5mL) and cool to 0°C. Add boron tribromide (lOOuL, 1.14mmol) and allow to warm to ambient temperature. Dilute with dichloromethane (50mL) and saturated aqueous sodium bicarbonate (lOmL). Separate organics, dry over (MgS04), and concentrate to a brown oil. Chromatography on silica gel (40g), eluting with 5: 1 dichloromethane: methanol yields the product as a light brown oil. React with ethereal hydrogen chloride (1.0 M, 1mL) in dichloromethane (5mL). Concentrate under reduced pressure. Isolate the hydrochloride salt which weighs 70mg (50%) MS (ES) 442 (M+H); TLC Rf= 0.35 (5: 1 dichloromethane: methanol) ; 1H-NMR (DMSO) 8 1.29-1. 40 (br m, 2H), 1.83-1. 60 (br m, 4H), 2.59-3. 26 (br m, 8H), 3.36-3. 48 (br m, 2H), 4.30 (br s, 2H); 6.42 (dd, J=8.3, 5.9Hz, 1H), 6.47 (d, J=2.3Hz, 1H), 6.57 (dd, J=8.4, 2.7Hz, 1 H), 6.59 (s, 1H), 6.63 (d, J=8.3Hz, 1H), 6.70 (d, J=2.3Hz, 1H), 6.77 (d, J=9. OHz, 2H), 6.94 (d, J=8.9Hz, 2H), 7.22 (d, J=8.4Hz, 1H), 9.27 (s, 1H), 9.34 (s, 1H), 10.08 (br s, 1H).

Example 276 5- [4- (2-Piperidin-1-yl-ethoxy)-benzyl]-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene-2, 8- diol hydrochloride

Mix 5- [4- (2-piperidin-1-yl-ethoxy)-benzylidene]-10, 11-dihydro-5H- dibenzo [a, d] cycloheptene-2, 8-diol (25mg, 0. 06mmol) and 10% palladium on carbon (lOmg) in ethanol (5mL). Place under ambient hydrogen atmosphere. Stir overnight.

Filter through Celite and concentrate under reduced pressure. Chromatography on silica gel (40g), eluting with 5: 1 dichloromethane: methanol yields the product as a light brown oil. React with ethereal hydrogen chloride (1.0 M, 1 mL) in dichloromethane (5 mL). Concentrate under reduced pressure. Isolate the hydrochloride salt which weighs 25mg (95%) MS (ES) 444 (M+H); TLC Rf= 0.35 (5: 1 dichloromethane: methanol).

Section 7 (derivatives of Formula I wherein R8 is not hydrogen and the bridge depicted by - X-Y-contains either a heteroatom or heteroatom containing group at either the X or Y position or both X and Y are CH2.) Preparation 31 1- [2- (5-Methylene-10, 11-dihydro-SH-dibenzo [a, d] cyclohepten-2-yloxy)-ethyl]-piperidine

Dissolve 5-methylene-10, 11-dihydro-5H-dibenzo [ad] cyclohepten-2-ol (200mg, 0. 90mmol) in dimethylformamide (5mL). Add sodium hydride (90mg, 2.25mmol) followed by 2-chloro-ethyl-1-piperidine hydrochloride (190mg, 1. 03mmol). Stir at room temperature overnight. Dilute with dichloromethane (50mL) and saturated aqueous ammonium chloride (15mL). Separate organic, dry over magnesium sulfate, filter and concentrate under reduced pressure. Chromatograph the residue on silica gel (40g), eluting with 5: 1 dichloromethane: methanol. Isolate the product as a light brown oil which weighs 300mg (100%) MS (ES) 334 (M+H); TLC Rf= 0.45 (5: 1 dichloromethane : methanol).

Preparation 32 1- [2- (5-Bromomethylene-10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-2-yloxy)-ethyl]- piperidine Dissolve 1- [2- (5-methylene-10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-2-yloxy)-ethyl]- piperidine (360mg, 1. 08mmol) in dichloromethane (15mL). Add dimethylaminopyridinium tribromide (390mg, 1. 08mmol). Stir at room temperature for 30min. Dilute with dichloromethane (50mL) and 10% aqueous sodium thiosulfite (15mL). Separate organic, dry over magnesium sulfate, filter and concentrate under reduced pressure. Chromatograph the residue on silica gel (40g), eluting with 5: 1 dichloromethane : methanol. Isolate the product as a light brown oil which weighs 210mg (47%) MS (ES) 414 (M+H) ; TLC Rf= 0.48 (5: 1 dichloromethane: methanol).

Example 277 4-[2-(2-Piperidin-l-yl-ethoxy)-10, 1 1-dihydro-dibenzo [a, ducyclohepten-5-ylidenemethyl]- phenol hydrochloride Ci

Mix 1- [2- (5-bromomethylene-10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-2-yloxy)- ethyl] -piperidine (210mg, 0. 51mmol) and 4-hydroxyphenylboronic acid (110mg, 0. 76mmol) in 1,4-dioxane (7mL) and aqueous sodium carbonate (2.0 M, 4mL). Sparge solution with N2 for 15 min, then add Pd (Ph3P) 4 (60mg, 0. 05mmol) and heat to 85°C for 2 h. Cool reaction mixture to room temperature, dilute with dichloromethane (lOOmL), and wash organic once with saturated aqueous ammonium chloride. Dry (MgS04) and concentrate organics to a brown oil. Chromatograph the residue on silica gel (40g), eluting with 5: 1 dichloromethane: methanol. Isolate the product as a light brown oil..

React with ethereal hydrogen chloride (1.0 M, 1 mL) in dichloromethane (5 mL).

Concentrate under reduced pressure. Isolate the hydrochloride salt which weighs 1 lOmg (47%) MS (ES) 426 (M+H); TLC Rf= 0.40 (5: 1 dichloromethane: methanol). NMR data is reported for the free base of the major olefin isomer :'H-NMR (CDC13) 8 1.42- 1.48 (br m, 2H), 1.58-1. 65 (br m, 4H), 2.49-2. 58 (br m, 4H), 2.70-3. 50 (br m, 4H), 2.77 (t, J=6.2Hz, 2H), 4.70 (t, J=6.3Hz, 2H); 6.49-6. 58 (m, 4H), 6.64 (s, 1H), 6.76 (d, J=9. OHz, 2H), 6.98-7. 04 (m, 2H), 7.18 (dt, J=7.4, 1. 8Hz, 1H), 7.25 (d, J=7. 5Hz, 1H), 7.32 (d, J=8.7Hz, 1H).

Additional Examples The following additional preparations and examples further illustrate the invention and represent typical synthesis for the compounds of Formula I, including any novel compounds, as described generally above.

Additional preparations for, and examples of compounds of Formula I having substitution on the"C"ring but not on the"A"or"B"rings. (Section 1 as represented by original Examples 1-160) Example 278 5- (3-Methylsulfanyl-benzylidene)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene Following procedures as described in Example 219, mix 5-bromomethylene-10, 11- dihydro-5H-dibenzo [a, d] cycloheptene (1 equivalent), 4,4, 5, 5-tetramethyl-2- (3- methylsulfanyl-phenyl)- [1, 3,2] dioxaborolane (1.25 equivalents), 2N Na2C03 (2 equivalents) and tetrakistriphenylphosphine palladium (0.05 equivalents) in a suitable solvent. Purify the product by silica gel chromatography to obtain a 79% yield of the title compound. MS (ES) = 329 (+) Example 279 5-(3-Methanesulfonyl-benzylidene)-10, 1 1-dihydro-5H-dibenzo [a, d] cycloheptene Mix 5- (3-methylsulfanyl-benzylidene)-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (1 equivalent) and sodium perborate hydrate (2.2 equivalents) in 50: 50

dichloromethane/glacial acetic acid and stir at room temperature for 18 hours. Then warm to 45°C for four hours. Partition between dichloromethane and 0. 1N NaOH. Dry and evaporate the organic layer. Purify the product by silica gel chromatography to obtain a 72% yield of the title compound. MS (ES) = 361 (+) Examples 280-288 contained in Table II, herein, provide yet additional examples of compounds of Formula I having substitution on the"C"ring, but not on the"A"or"B" rings. These examples, which further illustrate the present invention are prepared according to the procedures as described generally in the Schemes and literature references described above.

Additional preparations for, and examples of compounds of Formula I having having substitution on both the"C"ring and the"A"and/or"B"rings. (Section 2 as represented by original Examples 161-215) Preparation 33 E-and Z-5-Bromomethylene-2-chloro-10, 11-dihydro-5H-dibenzo [and] cycloheptene Cool a mixture of 2.8 equiv of bromomethyltriphenylphosphonium bromide (prepared asdescribed in G. Vassilikogiannakis, M. Hatzimarinaki, M. Orfanapoulos J Org. Chem., 65,8180) in THF (0.5 M) to-78 °C and add 2.8 equiv of LiHMDS-THF dropwise to give a bright yellow mixture. Stir for 1 h at-78 °C and then 10 min at 0 °C. Recool the mixture to-78 °C and add 2-chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-one.

Allow the dark mixture to warm to room temperature and stir for 3.5 h before adding saturated, aqueous saturated ammonium chloride and diluting with pentane. Filter through celite, concentrate filtrate and concentrate under reduced pressure. Purify by column chromatography (1% to 2% to 3% to 5% EtOAc: hexanes) to give title compound (30 %) as a 1: 1 mixture of geometric isomers: GC-MS (GRAD60-280°C) t = 7.23 (90 %).

MS (En : 320 (M+).

Example 289 3- (2-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-phenylamine

Following procedures essentially as described in Example 219, and using 5- bromomethylene-2-chloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene and 3- aminophenylboronic acid, a mixture of the E and Z isomers of the title compound is prepared.

Preparation 34 5-Methylene-10, 1 1-dihydro-5H-dibenzo [a, d] cyclohepten-2-ol Prepared from commercially available 2-hydroxy-10, 11-dihydro- dibenzo [a, d] cyclohepten-5-one following procedures essentially as described in Preparation 23. MS (ES-) 221.

Preparation 35 5-Bromomethylene-10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-2-ol

Prepared from 5-methylene-10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-2-ol using procedures essentially as described in Preparation 24. MS (ES-) 301.

Examples 290-435 contained in Table II, herein, provide yet additional examples of compounds of Formula I having substitution on both the"C"ring and the"A"and/or "B"rings. These examples, which further illustrate the present invention are prepared according to the procedures as described generally in the Schemes and literature references described above.

Additional preparations for, and examples of compounds of Formula I wherein the"C"ring represents a heterocyclic or benzofused heterocyclic ring. (Section 3 as represented by original Examples 216-237) Preparation 36 1- (2-morpholin-4-yl-ethyl)-5- (4, 4,5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-yl)-1, 3-dihydro- benzoimidazol-2-one.

Following procedures as described in Scheme IX.

Step A: Preparation of (4-bromo-2-nitro-phenyl)- (2-morpholin-4-yl-ethyl)-amine.

Mix 5-bromo-2-fluoro-nitrobenzene (lOg, 45mmol) and 4-(2-aminoethyl) morpholine (11. 8mL, 90mmol) in THF (lOOmL). Stir at room temperature for 18h. Remove the THF under reduced pressure and partition the residue between water (200mL) and ethyl acetate (200mL). Dry the organic layer (MgS04) and concentrate to give 15.3g (100%) title compound. HPLC (IS080-lOM) t=1. 83min (94%), MS (ES) 331 (M+1).

Step B: Preparation of 4-bromo-Nl-(2-morpholin-4-yl-ethyl)-benzene-1, 2-diamine

Dissolve (4-bromo-2-nitro-phenyl)- (2-morpholin-4-yl-ethyl)-amine (15.3g, 46. 4mmol) in ethyl acetate (1L) and add 5% Pt/C (sulfide) (382mg). Place the slurry under 60psi hydrogen gas at room temperature of 8h. Filter and concentrate to give 23g crude product as a dark red oil. Purify using a short plug of silica gel and 10% 2N NH3 in MeOH/dichloromethane to give 13. 5g of a brown oil. HPLC (IS060-lOM) t=1. 46 (94%), MS (ES) 301 (M+1).

Step C: Preparation of 5-bromo-1- (2-morpholin-4-yl-ethyl)-1, 3-dihydro-benzoimidazol-2- one.

In a 500-mL round-bottomed flask, mix 4-bromo-Nl- (2-morpholin-4-yl-ethyl)-benzene- 1,2-diamine 13.25g, 44. 1mmol), NaHC03 (5.4g, 66. 2mmol), water (50mL) and methanol (250mL). Slowly add phenyl chloroformate (8. 3mL, 66. 2mmol). Stirr the reaction for lh at room temperature and then add 5N NaOH (20mL) and stir overnight at room temperature.

Collect the solid by vacuum filtration and wash with methanol. HPLC (IS060-l OM) t=1.42 (97%), MS (ES) 326 (M+1).

Step D: Preparation of 1- (2-morpholin-4-yl-ethyl)-5- (4, 4,5, 5-tetramethyl- [1,3, 2] dioxaborolan-2-yl)-1, 3-dihydro-benzoimidazol-2-one.

Under a blanket of nitrogen, cool a THF (150mL) solution of 5-bromo-1-(2-morpholin-4- yl-ethyl)-1, 3-dihydro-benzoimidazol-2-one (7. 5g, 20mmol) to 5°C and add 3N ethylmagnesium bromide (8mL, 24mmol). After ! 4h, cool the reaction to-72°C and slowly add 1.7M t-BuLi (170mL, lOOmmol). Allow the reaction to warm to-55°C, add trimethyl borate (80mmol) and allow the reaction to stir at room temperature overnight.

Add 5N HC1 (50mL) and stir for 4h. Adjust the pH to 6-7 and extract the crude boronic acid into ethyl acetate. Dry (MgS04) and concentrate to give 10.4g crude product. Slurry with toluene (500mL) and add pinacol (64mmol). Heat briefly and then stir overnight.

Add ethyl acetate and aqueous NaHC03. Wash the organic extract with water and evaporate the dried (MgSO4) organic layer to give 5. 0g (67%) title boronic ester as a white solid. LC/MS (IS070-lOM) 374 (M+1). Recrystallize from ethyl acetate/hexane.

'H NMR (CDC13) d 1.34 (s, 12H), 2.55 (br s, 4H), 2.70 (br s, 2H), 3.68 (br s, 4H), 4.02 (br s, 2H), 7.03 (s, lH), 7.52 (s, 1H), 7.56 (d, 1H), 8.78 (br s, 1).

Preparation 37 5- (4, 4,5, 5-Tetramethyl- [ 1, 3,2] dioxaborolan-2-yl)-1, 3-dihydro-benzoimidazol-2-one 5-Bromo-1, 3-dihydro-benzoimidazol-2-one (20.0 g, 93.9 mmol) is dissolved in argon purged anhydrous DMF (150 mL). To this solution is added bis (pinacolato) diboron (28.6 g, 113 mmol), KOAc (27.6 g, 282 mmol), and PdCl2 (dppf), 1: 1 complex with CH2C12 (7.67 g, 9.40 mmol). The reaction is heated to 95 °C overnight with mechanical stirring then cooled to room temperature and diluted with brine (500 mL) and EtOAc (750 mL). The mixture is filtered to remove a dark brown solid, which is washed thoroughly with EtOAc. The layers are separated and the organics washed with water (3 x 500 mL), then dried (MgS04), filtered and evaporated under reduced pressure.

Trituration with 1: 1 CH2Cl2/hexanes affords the product (10.9 g, 44%).

Rf 0. 52 (silica gel, 85: 15 CH2C4lMeOH) ; mp 313-315 °C (dec) ;'H NMR (300 MHz, DMSO-d6) 21. 27 (s, 12 H), 6.92 (d, J= 7.7 Hz, 1H), 7.17 (s, 1H), 7.28 (d, J= 7.7 Hz, 1H), 10.62 (s, 1H), 10.74 (s, 1H) ; APCI MS m/z 261 [Cl3Hl7BN203 + H] + ; HPLC = 98.3%, tR= 18. 3 min; Analysis for C13Hl7BN203 : C, 57.07 ; H, 6.82 ; N, 10.24. Found: C, 56.69 ; H, 6.44 ; N, 10.21.

HPLC conditions: Waters Symmetry C18 column (4.6 mm x 250 mm); 95: 5 to 0: 100 water/MeCN ; 1.0 mL/min (25 min), D = 254 nm Example 436 5- (2, 8-difluoro-10, 11-dihydro-dibenzo[a,d]cyclohepten-5-ylidenemethyl)-1-(2-mor pholin- 4-yl-ethyl) -1,3-dihydro-benzoimidazol-2-one

Following procedures essentially as described in Example 219, mix 1- (2-morpholin-4-yl- ethyl)-5- (4, 4,5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-yl)-1, 3-dihydro-benzoimidazol-2-one (520mg, 1. 4mmol), 5-bromomethylene-2, 8-difluoro-10, 11-dihydro-5H- dibenzo [a, d] cycloheptene (51Omg, 1. 6mmol) (prepared using a procedure essentially as described for the 2,8-dichloro derivative in Example 182), 2N NaH03 (1mL), dioxane (lOmL) and (Ph3P) 4Pd (67mg, 0.06mmol). Purify the crude product by column chromatography using MeOH/ethyl acetate to give 310mg colorless oil that solidified upon drying, HPLC (IS080-10M) t=2. 03 (97%). MS (ES) 488 (M+1), 486 (M-1). H NMR 10.69 (s, 1H), 7.49 (dd, 1H, J=8. 4,6. 2 Hz), 7.22 (dd, 1H, J=9. 7,2. 2 Hz), 7.02 (td, 1H, J=12. 0,4. 2 Hz), 6.97-6. 83 (m, 4H), 6.81 (s, 1H), 6.72 (d, 1H,. J=7. 9 Hz), 6.56 (s, 1H), 3.80 (t, 2H, J=6. 2 Hz), 3.47 (t, 4H, J=4. 2 Hz), 3.31 (s, 2H), 2.90 (s, 2H), 2.48 (m, 2H), 2.38 (s, 4H).

Example 437 5- (2, 8-difluoro-10,11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-1, 3-dihydro- benzoimidazol-2-one Following procedures essentially as described in Example 219, mix 5- (4, 4,5, 5- tetramethyl- [1, 3,2] dioxaborolan-2-yl)-1, 3-dihydro-benzoimidazol-2-one (535mg, 2. 06mmol) (prepared from 5-bromo-1, 3-dihydro-benzoimidazol-2-one (Preparation 27) according to the procedure reported by M Murata, T Takashi, S Watanabe and Y Yusuru, J. Org. Chem.; 65 (1) 164-168 (2000) ), 5-bromomethylene-2, 8-difluoro-10, 11-dihydro- 5H-dibenzo [a, d] cycloheptene (550mg,-1. 71mmol), 2N Na2CO3 (2mL), dioxane (14mL) and (Ph3P) 4Pd (200mg, 0. 17mmol). Purify the crude product by column chromatography using dichloromethane/ethyl acetate to give 285mg white solid, mp 257°C. HPLC (IS080-10M) t=2.62 (97%), MS (ES) 373 (M-1). H NMR 10.55 (s, 1H), 10.45 (s, 1H), 7.48 (dd, 1H, J=8. 4,6. 2 Hz), 7.21 (dd, 1H, J=9. 7,2. 2 Hz), 7.01 (td, 1H, J=12. 2,4. 2 Hz),

6.94 (dd, 1H, J=10. 1,2. 2 Hz), 6.90 (d, 2H, J=6. 2 Hz), 6.85 (dd, 1H, J=8. 6,2. 4 Hz), 6.78 (s, 1H), 6.72 (d, 1H, J=8. 4 Hz), 6.67 (d, 1H, J=7. 9 Hz), 6.51 (s, 1H), 3.30 (s, 2H), 2.89 (s, 2H), 6.90 (d, 1H, J=6. 2 Hz).

Example 438 5- (2, 8-difluoro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-1- (3-morpholin- 4-yl-propyl)-1, 3-dihydro-benzoimidazol-2-one Following procedures essentially as described in Example 219, mix 1- (2-morpholin-4-yl- propyl)-5- (4, 4,5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-yl)-1, 3-dihydro-benzoimidazol-2- one (458mg, 1. 18mmol), 5-bromomethylene-2,8-difluoro-10, 11-dihydro-5H- dibenzo [a, d] cycloheptene (400mg, 1.25mmol), 2N Na2C03 (1. 3mL), dioxane (8mL) and (Ph3P) 4Pd (45mg, 0.04mmol). Purify the crude product by column chromatography using 2% 2N NH3 in MeOH/dichloromethane to give 170mg title compound as a white foam.

HPLC (IS080-lOM) t=1.86 (98%), MS (ES) 502 (M+1), 500 (M-1). H NMR 8.38 (s, 1H), 7.42 (dd, 1H, J=8. 4,5. 7 Hz), 7.01 (dd, 1H, J=9. 2,2. 6 Hz), 6.95 (dd, 1H, J=8. 4,5. 7 Hz), 6.91 (dd, 1H, J=8. 4,2. 6 Hz), 6.85 (d, 1H, J=8. 4 Hz), 6.80 (dd, 1H, J=9. 7,2. 2 Hz), 6.71 (dd, 1H, J=8. 6,2. 4 Hz), 6.64 (s, 1H), 3.89 (t, 2H, J=6. 8 Hz), 3.68 (s, 4H), 3.59-2. 71 (m, 4H), 1.60 (s, 2H), 1.94 (s, 2H), 2.40 (s, 4H), 6.76 (m, 2H).

Examples 439-474 contained in Table II, herein, provide yet additional examples of compounds of Formula I wherein the"C"ring represents a heterocyclic or benzofused heterocyclic ring. These examples, which further illustrate the present invention are prepared according to the procedures as described generally in the Schemes and literature references described above.

Additional preparations for, and examples of compounds of Formula I wherein the"A"and/or"B"ring represents a heterocyclic ring. (Section 4 as represented by original Examples 238-254) Preparation 38 4-Methylene-9, 10-dihydro-4H-1-thia-benzo [/] azulene Following procedures as described in Scheme X: Add 3 equiv of a 0.5 M solution of Tebbe reagent in toluene to a solution (-40 °C) 9,10- dihydro-l-thia-benzo [flazulene-4-one (prepared as described in P. Bollinger, P. Cooper.; H. U. Gubler, A. Leutwiler, T. Payne Helv. Chim. Acta (1990), 73, 1197) and 3 equiv of pyridine in THF (0.1 M) under Ar. Stir the resulting dark red mixture for 2 h then allow to warm to 0 °C over ca. 30 min period before diluting with diethyl ether. Carefully add 5 N sodium hydroxide until bubbling ceases, add solid Na2S04, and then stir for 1 h. Filter the mixture through Celite (8 :), and concentrate the filtrate by rotary evaporation. Purify the crude residue by column chromatography (hexanes) to give the title compound as white crystals (56 %): HPLC (IS080-20M) t =1. 903 (98 %). MS (APCI) : 213 (M+1). 1H NMR (CDC13) 8 3.07-3. 12 (m, 2 H), 3.14-3. 17 (m, 2 H), 5.32 (s, 1 H), 5.63 (s, 1 H), 7.05 (app d, J = 5. 4 Hz, 1 H), 7.08 (d, J = 5. 4 Hz, 1 H), 7.19-7. 26 (m, 3 H), 7.35 (dd, J = 7. 6 Hz, 1.6 Hz, 1 H).

Example 475 and Example 476

Following procedures essentially as described in Preparation 24 followed by procedures essentially as described in Example 219, and using 4-methylene-9, 10-dihydro-4H-l-thia- benzo [f] azulene, the title compounds are made.

Example 477 3- (9, 10-Dihydro-1-thia-benzo [f] azulen-4-ylidenemethyl)-phenylamine

4-Methylene-9, 10-dihydro-4H-1-thia-benzo [f] azulene is converted to the vinyl bromide as in Preparation 24 and the vinyl bromide coupled with 3-aminophenylboronic acid using the procedures essentially as described in Example 219.

Example 478 3-(7-Chloro-9, 1 O-dihydro-1-thia-benzo [n azulen-4-ylidenemethyl)-phenylamine

7-chloro-9, 10-dihydro-benzo [4,5] cyclohepta [1, 2-b] thiophen-4-one (prepared as described in Bastian et al, Helv. Chim. Acta; 49 214-234 (1966) ) is converted to the title compound following procedures as described in Scheme VII.

Example 479 3-(2-Chloro-9, 10-dihydro-1-thia-benzo [pazulen-4-ylidenemethyl)- phenylamine

Add 2.2 equiv of n-BuLi-hexanes dropwise to a solution of 3- (9, 10-dihydro-1-thia- benzo [fazulen-4-ylidenemethyl)-phenylamine in THF (0.1 M) at 0 °C under Ar. Stir the resultant dark solution for 1 h before adding 2.5 equiv of hexachloroethane in THF. Stir for 2 h, quench with excess water, and acidify to neutral pH. Extract the aqueous layer with diethyl ether (3 X) and then dry (MgS04) and concentrate the combined organic layers under reduced pressure. Purify the crude residue by column chromatography (0% to 2% to 20% EtOAc: hexanes) to give title compound as an oil (22 %) along with recovered starting material: HPLC (IS080-20A) t = 1. 903 (90 %). MS (APCI) : 338 (M+1).

Example 480 3- (2, 7-Dichloro-9, 1 O-dihydro-l-thia-benzo [fazulen-4-ylidenemethyl)-phenylamine As in Example 553 (above), using 3- (7-chloro-9, 10-dihydro-1-thia-benzo [fJazulen-4- ylidenemethyl)-phenylamine, n-BuLi in hexanes, THF, and hexachloroethane. Purify the crude residue by column chromatography (5% to 20% to 30% EtOAc: hexanes) to give title compound as an oil (21 %) along with recovered starting material: 1H NMR (CDC13,400 MHz) 8 2.06-3. 02 (m, 4 H), 3.53 (br s, 2 H), 6.32 (s, 1 H), 6.38 (d, J = 7.2 Hz, 1 H), 6.48 (dd, J = 7. 2 Hz, 1. 6 Hz, 1 H), 6.79 (s, 1 H), 6.93-6. 96 (m, 3 H), 7.02 (dd, J = 8.2 Hz, 2.2 Hz, 1 H), 7.27 (d, J = 8.2 Hz, 1 H). TLC Rf= 0.55 (30 % EtOAc: hexanes).

Example 481 N- [3- (2-Chloro-9, 10-dihydro-l-thia-benzo [f] azulen-4-ylidenemethyl)-phenyl]- methanesulfonamide

Following procedures essentially as described in Example 90 and using 3- (2-chloro-9, 10- dihydro-l-thia-benzo [fjazulen-4-ylidenemethyl)-phenylamine, the title compound is prepared.

Example 482 N- [3- (2, 7-Dichloro-9, 10-dihydro-1-thia-benzo [fazulen-4-ylidenemethyl)-phenyl]- methanesulfonamide

Following procedures essentially as described in Example 90 and using 3- (2, 7-dichloro- 9, 10-dihydro-1-thia-benzo [fazulen-4-ylidenemethyl)-phenylamine, the title compound is prepared.

Preparation 39 2-Methyl-4-methylene-9, 10-dihydro-4H-3-thia-1-aza-benzo [f) azulene

Add 1.2 equiv of n-BuLi-hexanes dropwise to a solution of 4-methylene-9, 10-dihydro- 4H-3-thia-1-aza-benzo [flazulene (prepared from 9, 10-dihydro-3-thia-l-aza-

benzo [flazulen-4-one (see Scheme Xin (b) as in Preparation 23) in THF (0.08 M) at-78 °C under Ar. Stir the resultant dark green solution for 5 min before adding 1.2 equiv of iodomethane in THF. Allow to warm and stir at room temperature for 18 h before quenching with excess water. Separate layers and extract the aqueous layer with diethyl ether (3 X) and then dry (MgS04) and concentrate the combined organic layers under reduced pressure. Use in the next step without further purification: 1H NMR (CDC13, 400 MHz) b 2.60 (s, 3 H), 3.03-3. 13 (m, 4 H), 5.34 (s, 1 H), 5.53 (s, 1 H), 7.20-7. 28 (m, 3 H), 7.33 (m, J = 7.2 Hz, 1 H). TLC Rf= 0.30 (10 % EtOAc: hexanes). <BR> <BR> <P> Example 483 (a)<BR> N- [3- (2-Methyl-9, 10-dihydro-3-thia-l-aza-benzo [f) azulen-4-ylidenemethyl)-phenyl]- methanesulfonamide (E-isomer) ; and <BR> <BR> Example 483 (b)<BR> N- [3- (2-Methyl-9, 10-dihydro-3-thia-l-aza-benzo [f] azulen-4-ylidenemethyl)-phenyl]- methanesulfonamide (Z-isomer) E Isomer Z Isomer Following procedures essentially as described in Preparation 24 followed by procedures essentially as described in Example 219, and using 2-methyl-4-methylene-9,10-dihydro- 4H-3-thia-1-aza-benzo [fJazulene and 3-methanesulfonylaminophenylboronic acid, the title compounds are made.

Preparation 40 3-Chloro-2-oxo-5-phenyl-pentanoic acid methyl ester

Charge a flask with equimolar methyl dichloroacetate and 3-phenyl-prionaldehyde in diethyl ether (3.0 M). Cool the solution to 0 °C and add 1.1 equiv of sodium methoxide in methanol (2.8 M) over a 1 h period. Vigorously stir the mixture for 2 h at 0 C and then allow to warm to room temperature before adding brine. Separate layers and dry (MgS04) and concentrate organic layer to give the crude residue in 92 % yield. GC-MS (GRAD60-280°C) t = 13. 01 (90 %). MS (En : 240 (M-).

Preparation 41 2-Amino-5-phenethyl-thiazole-4-carboxylic acid methyl ester Reflux equimolar 3-chloro-2-oxo-5-phenyl-pentanoic acid methyl ester and thiourea in MeOH (1.0 M) for 4 h. Basify with ammonia-MeOH and add brine. Extract with ethyl acetate (4 X). Wash combined organic layers with brine, dry (MgS04), and concentrate under reduced pressure to give (91 %) of title compound. HPLC (GRAD80-100M) t = 2.193 (95 %). MS (APCI) : 263 (M+1).

Preparation 42 5-Phenethyl-thiazole-4-carboxylic acid methyl ester Reflux one equiv of 2-amino-5-phenethyl-thiazole-4-carboxylic acid methyl ester and 3 equiv of isoamyl nitrite in THF (0.13M) for 3 h. Evaporate volatile components to give 55 % yield of title compound. HPLC (GRAD80-100M) t = 2.410 (99 %). MS (APCI) : 248 (M+1).

Preparation 43 9, 10-Dihydro-l-thia-3-aza-benzo [f] azulen-4-one

Rapidly stir and heat a thick slurry of 5-phenethyl-thiazole-4-carboxylic acid methyl ester and polyphosphoric acid (PPA) at 140 °C for 24 h and then 150 °C for 5 h. Carefully add hot mixture to ice-cold aqueous sodium hydroxide. Extract well with EtOAc (4 X).

Wash combined organic layers with brine, dry (MgS04), and concentrate under reduced pressure. Purify the crude residue by column chromatography (10% to 50% EtOAc: hexanes) to give title compound as a brown solid (37 %). HPLC (GRAD80- 100M) t = 2.088 (99 %). MS (APCI) : 216 (M+1).

Preparation 44 9, 1 0-Dihydro-3-thia-1-aza-benzo [f] azulen-4-one To a room temperature solution of 2-amino-9, 10-dihydro-3-thia-1-aza- benzo [f] azulen-4-one (5.31 g, 23.1 mmol) in DMF (50 mL) is added isoamyl nitrite (5.95 g, 50.8 mmol) and the reaction stirred for 30 min. The reaction mixture is heated to 80 °C for 2 h, and then cooled to room temperature. The solvent is removed under reduced pressure and ice-cold Ha0 (100 mL) is added. The aqueous layer is extracted with EtOAc (2 x 150 mL) and the combined organic layers are dried (MgS04), filtered and the solvent removed under reduced pressure. The dark red oil is subjected to flash chromatography (silica gel, 75: 25 Hex/EtOAc) to afford the slightly impure product as an orange-red solid.

The product is further purified by trituration using Hex/EtOAc (90: 10) to afford the title compound (2.59 g, 52%) as an orange solid: Rf0. 33 (1: 1 EtOAc/Hex) ; mp 83-86 °C ; 1H NMR (300 MHz, CDC13) 8. 89 (s, 1H), 7.96 (dd, J= 1. 2,7. 7 Hz, 1H), 7.50 (dt, J= 1. 4, 7.4 Hz, 1H), 7.37 (m, 1H), 7.30 (d, J= 7.5 Hz, 1H), 3.36 (m, 2H), 3.24 (m, 2H); ESI MS m/z 216 [Cl2H9NOS + H] +. Anal. Calcd for Cl2HgNOS : C, 6-6. 95 ; H, 4. 21 ; N, 6.51.

Found: C, 66.81 ; H, 3.99 ; N, 6.48.

Preparation 45 7-Fluoro-9, 10-dihydro-3-thia-1-aza-benzo [f] azulen-4-one; and

5-Fluoro-9, 10-dihydro-3-thia-1-aza-benzo[f] azulen-4-one To a room temperature solution of a 85: 15 mixture of 2-amino-7-fluoro-9, 10- dihydro-3-thia-1-aza-benzo [f] azulen-4-oneand2-amino-5-fluoro-9, 10-dihydro-3-thia-l- aza-benzo [f] azulen-4-one (6.00 g, 24.2 mmol) in DMF (80 mL) is added t-butyl nitrite (5.48 g, 53.2 mmol). The reaction mixture is then heated to 60 °C for 2 h (gas evolution may be observed after 5-10 min of heating), then cooled to room temperature. The solvent is removed under reduced pressure and ice-cold Ha0 (100 mL) and EtOAc (700 mL) are added. The organic layer is washed with saturated aqueous NaHC03 (100 mL) and saturated aqueous NaCl (100 mL). The organic layer is dried (MgS04), filtered and concentrated under reduced pressure. The resulting red oil is subjected to flash chromatography (silica gel, 80: 20 to 70: 30 Hex/EtOAc) to afford the products (3.16 g, 56%) as a partially separable mixture of 5-and 7-fluoro regioisomers. The fractions obtained as a mixture (1.19 g) contain some of the minor isomer (-3 : 7 5-fluoro/7-fluoro): 'H NMR of 5-fluoro isomer, subtracted from the mixture (300 MHz, CDC13) D 8. 88. (s, 1H), 7.41 (m, 1H), 7,12-6. 98 (m, 2H), 3.32 (m, 2H), 3.39-3. 19 (m, 2H).

The fractions obtained pure (1.97 g) contain only the major isomer (7-fluoro) which is isolated as an orange solid: Rf0. 52 (1: 1 EtOAc/Hex); mp 122-125'C ;'H NMR (300 MHz, CDC13) D 8.89 (s, 1H), 8.02 (dd, J= 8.7, 6.0 Hz, 1H), 7.06 (m, 1H), 7.00 (dd, J= 9.1, 2.5 Hz, 1H), 3.37 (m, 2H), 3.22 (m, 2H); APCI MS m/z 232 [Cl2H8FNOS-H]-.

Anal. Calcd for CuHgFNOS : C, 61.79 ; H, 3.46 ; N, 6.00. Found: C, 61.70 ; H, 3.43 ; N, 6.04.

Preparation 46 4-Methylene-9, 10-dihydro-4H-1-thia-3-aza-benzo [f] azulene Following procedures essentially as described in Preparation 23, and using 9,10-dihydro- l-thia-3-aza-benzo [flazulen-4-one, the title compound is made. <BR> <BR> <P> Example 484 (a)<BR> N- [3- (9, 10-Dihydro-l-thia-3-aza-benzo [f] azulen-4-ylidenemethyl)-phenyl]- methanesulfonamide (E isomer) and Example 484 (b) N- [3- (9, 10-Dihydro-l-thia-3-aza-benzo [fJazulen-4-ylidenemethyl)-phenyl]-

s s I wN N I u N j methanesulfonamide (Z isomer) E Isomer Z Isomer Following procedures essentially as described in Preparation 24 followed by procedures essentially as described in Example 219, and using the product of Preparation 46 and 3- methanesulfonylaminophenylboronic acid, the title compounds are made.

Preparation 47 E-11- (4, 4,5, 5-Tetramethyl-[1, 3,2] dioxaborolan-2-yhnethylene)-6, 11-dihydro-5H- benzo [d] pyrrolo [1, 2-a] azepine and Z-11- (4, 4,5, 5-Tetramethyl- [1, 3,2] dioxaborolan-2-ylmethylene)-6, 11-dihydro-5H- benzo [d] pyrrolo [1, 2-a] azepine E Isomer Z Isomer Add one equiv of 5, 6-dihydro-benzo [d] pyrrolo [1, 2-a] azepin-1l-one (prepared as described in Y. Girard, J. G. Atkinson, P. C. Belanger, J. J. Fuentes, J. Rokach, C. S. Rooney, D. C. Remy, C. A. Hunt J Org. Chem. 1983, 48, 3220) in THF to a solution of 2.5 equiv of pinicol lithio (trimethylsilyl) methaneboronate (as described in D. S. Matteson,

D. Majumder Organometallicsl983, 2,230), 1 equiv TMEDA, 2.5 equiv of tetramethylpiperidine (TMP), and THF at-78 °C. Allow the solution to warm to room temperature and stir for 3.5 h before quenching with excess water. Extract well with Et2O (4 X). Dry (MgS04) and concentrate under reduced pressure. Purify the crude residue by column chromatography (5% to 10% EtOAc: hexanes) to give pure E-isomer (45 %) and Z-isomer (24 %). E-isomer: HPLC (GRAD80-100M) t = 4.340 (99 %). MS (APCI) : 322 (M+1).

Z-isomer (24 %) HPLC (GRAD80-100M) t = 4.423 (99 %). MS (APCI) : 322 (M+1).

Example 485 (a) N- [3- (5, 6-Dihydro-benzo [d] pyrrolo [1,2-a] azepin-11-ylidenemethyl)-phenyl]- methanesulfonamide (E-isomer) and Example 485fob) N- [3- (5, 6-Dihydro-benzo [d] pyrrolo [1,2-a] azepin-11-ylidenemethyl)-phenyl]- methanesulfonamide (Z-isomer) E Isomer Z Isomer Following procedures essentially as described in Example 219, and using E-and Z-11- (4,4, 5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-ylmethylene)-6, 1 1-dihydro-5H- benzo [d] pyrrolo [1, 2-a] azepine and N- (3-iodo-phenyl)-methanesulfonamide, the E and Z isomers of the title compound are prepared.

Preparation 48 2- [2- (3-Fluoro-phenyl)-ethyl]-nicotinic acid

Dissolve diisopropylamine (3.8 mL, 27.3 mmol) in dry tetrahydrofuran (75 mL). Chill the resulting mixture to-78 °C and add butyl lithium (1.6M solution in hexanes, 17.1 mL, 27.3 mmol). Warm the reaction mixture to 0 °C and add a fine slurry of 2-methyl- nicotinic acid (1.5 g, 10.9 mmol) in THF (25 mL) portionwise during 10 min. Stir the resulting slurry for lh, then add 3-fluorobenzyl bromide (2.0 mL, 16.4 mmol) and stir 5 min. Quench the reaction with water (100 mL). Extract the reaction mixture with diethyl ether (100 mL). Adjust the pH of the aqueous layer to 3.1 with concentrated aqueous hydrochloric acid solution. Treat the resulting slurry with ethyl acetate and stir to dissolve all solids. Separate the layers and extract the aqueous layer with ethyl acetate.

Concentrate the combined extracts to dryness. LCMS (APCI-pos): 244.1 (M+H).

Preparation 49 8-Fluoro-10, 1 1-dihydro-benzo [4,5] cyclohepta [1, 2-b} pyridin-5-one Combine crude 2- [2- (3-fluoro-phenyl)-ethyl]-nicotinic acid (2.06 g, 15.0 mmol) and polyphosphoric acid (100 g) and heat the mixture to 160 °C for 6 h. Allow slow cooling of the reaction mixture over 12h, then reheat the mixture to 160 °C and pour it into ice (200 g). Complete the transfer using water and adjust the pH of the aqueous mixture to -8. 0 with 50% aqueous sodium hydroxide solution. Extract the product with methylene chloride. Dry the combined organic extracts with magnesium sulfate, filter and concentrate. Purify the crude product via flash chromatography (25% ethyl acetate/hexanes to 50% ethyl acetate/hexanes) to provide 1.54 mg (81%) of purified product. LCMS (APCI-pos): 228.1 (M+H). l R (CDCI3, 400 MHz): 88. 63 (dd, 1H), 8.39 (dd, 1H), 8.01 (dd, 1H), 7.31 (dd, 1H), 7.02 (dt, 1H), 6.95 (dd, 1H), 3.46-3. 43 (m, 2H), 3.23-3. 21 (m, 2H).

(Literature reference : Journal ofHeterocyclic Chemistry 1971,73).

Preparation 50 8-Fluoro-5-methylene-10, 11-dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridine

Chill a mixture of 8-fluoro-10, 11-dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridin-5-one (1.3 g, 5.7 mmol) and dry tetrahydrofuran (50 mL) to 0 °C. Treat this mixture with methyl magnesium bromide (3. 0M solution in diethyl ether, 5.7 mL, 17.2 mmol). Remove cooling and stir the admixture at room temperature for 15 min. Quench the reaction, while cooling with an ice-water bath, by adding saturated aqueous ammonium chloride solution (50 mL). Separate the layers and extract the aqueous layer with methylene chloride (2x50 mL). Dry the combined organic layers with magnesium sulfate, filter and concentrate to provide the intermediate product as a thick. crude oil.

Without further purification, dissolve this residue in a solution of solfuric acid in acetic acid (3% by volume, 50 mL) and stir the resulting mixture at room temperature for 12-18 h. Concentrate the reaction mixture to remove excess solvent and dissolve the resulting orange residue in IN aqueous sodium hydroxide solution (25 mL) and ethyl acetate (50 mL). Adjust the pH of the resulting mixture to-8 with 5N aqueous sodium hydroxide solution. Separate the layers and extract the aqueous layer with ethyl acetate.

(2x50 mL). Dry the combined organic layers with magnesium sulfate, filter and concentrate to 1.3g (91%) of the title product as an orange-brown oil. LCMS: 226.1 (M+H).

Preparation 51 (E+Z)-5-Bromomethylene-8-fluoro-10, 11-dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridine

Make the title compounds according to Preparation 24, beginning with 8-fluoro-5- methylene-10, 11-dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridine (1.1 g, 5.1 mmol). After workup and purification and separation by flash chromatography (25% ethyl acetate/hexanes to 50% ethyl acetate/hexanes) isolate 700 mg (44%) of (E)-5- bromomethylene-10, 11-dihydro-8-fluoro-benzo [4,5] cyclohepta [1, 2-b] pyridine and 550 mg (34%) of (Z)-5-bromomethylene-10, 11-dihydro-8-fluoro-benzo [4,5] cyclohepta [1, 2- b] pyridine. For (Z)-5-bromomethylene-10, 11-dihydro-8-fluoro-benzo [4,5] cyclohepta [1, 2- b] pyridine, LCMS (APCI-pos): 304,305, 306, 307. HNMR (CDC13, 400 MHz) : 88. 45 (dd, 1H), 7.69 (dd, 1H), 7.18 (dd, 1H), 7.13 (dd, 1H), 6.87-6. 83 (m, 2H), 6.61 (s, 1H), 3.6- 2.4 (m, 4H). For (E)-5-bromomethylene-10, 11-dihydro-benzo [4,5] cyclohepta [1, 2- b] pyridine, LCMS (APCI-pos): 304,305, 306, 307. tHNMR (CDC13, 400 MHz) : 88. 45 (dd, 1H), 7.56 (dd, 1H), 7.25 (dd, 1H), 7.09 (dd, 1H), 6.99 (dd, 1H), 6.92 (dt, 1H), 6.69 (s, 1H), 3.6-2. 8 (m, 4H).

Example 486 (E)-N-[3-(3-fluoro-10,11-dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridin-5-ylidenemethyl) - phenyl]-methanesulfonamide Following procedures essentially as described in Example 219, beginning with (E)-5- bromomethylene-8-fluoro-10, 11-dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridine (200 mg, 0.66 mmol). After work-up, purify the crude product by flash chromatography (50% ethyl acetate/hexanes to 75% ethyl acetate/hexanes) to provide 197 mg (76%) of purified product. LCMS (APCI-pos): 395.1 (M+H). LCMS (APCI-neg): 393.0 (M-H). Purity by LCMS (UV Area percent) 99%. IHNMR (d6-DMSO, 400 MHz): 89. 62 (s, 1H), 8.41 (dd, 1H), 7.90 (dd, 1H), 7.28-7. 24 (m, 2H), 7.14 (t, 1H), 6.96-6. 87 (m, 5H), 6.75 (d, 1H), 3.6-2. 9 (m, 4H), 2.79 (s, 3H).

Example 487 (E)-5-(8-Fluoro-10, 1 1-dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridin-5-ylidenemethyl)-1, 3- dihydro-benzoimidazol-2-one

Following procedures essentially as described in Example 219, beginning with (E)-5- bromomethylene-8-fluoro-10, 11-dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridine (100 mg, 0.33 mmol) and 5- (4, 4,5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-yl)-1, 3-dihydro- benzoimidazol-2-one (111 mg, 0.43 mmol). After work-up, purify the crude product by flash chromatography (100% ethyl acetate to 10% ethanol/ethyl acetate) to provide 70 mg (60%) of purified product. LCMS (APCI-pos): 358.0 (M+H). LCMS (APCI-neg): 356.0 (M-H). Purity by LCMS (UV Area percent): 99%. IHNMR (d6-DMSO, 400 MHz) : 810. 56 (s, 1H), 10/46 (s, 1H), 8.38 (dd, 1H), 7.88 (dd, 1H), 7.28 (dd, 1H), 7.23 (dd, 1H), 6.96-6. 90 (m, 2H), 6.89 (s, 1H), 6.73 (d, 1H), 6.68 (d, 1H), 6.52 (s, 1H), 3.5-3. 3 (m, 2H), 3.1-2. 9 (m, 2H).

Preparation 52 2- (3-Fluoro-5-nitro-phenyl)-4, 4,5, 5-tetramethyl-[1, 3,2] dioxaborolane Make according to literature precedent (Journal of Organic Chemistry 1995, 60, 7508) beginning with l-fluoro-3-iodo-5-nitrobenzene (1.0 g, 3.7 mmol). Purify the crude product by flash chromatography (1: 3- 4% acetic acid in tetrahydrofuran/hexanes) and combine product fractions. Strip to dryness and add 50 mL ethanol and strip to dryness to

provide 945 mg (94%) of purified product. Purity by GCMS: 80%, mass 267. 0. IHNMR (CDC13,400 MHz) : 88. 43 (bs, 1H), 7.98 (dt, 1H), 7.80 (dd, 1H), 1.36 (s, 12H) Preparation 53 3-Fluoro-5- (4, 4,5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-yl)-phenylamine Combine 1-fluoro-3-iodo-5-nitrobenzene 2-(3-Fluoro-5-nitro-phenyl)-4, 4,5, 5-tetramethyl- [1, 3,2] dioxaborolane (940 mg, 3.5 mmol), 5% palladium on carbon (-60% H2O, 200 mg), and anhydrous ethanol (25 mL). Purge and fill the reaction vessel with hydrogen three times. Stir the reaction mixture under 1 atm of hydrogen. When the reaction is complete by LCMS, filter the reaction mixture through celite to remove the catalyst and wash the filter cake with ethanol. Strip to dryness and purify the crude product by flash chromatography (25% ethyl acetate/hexanes) and combine product fractions. Strip to dryness to provide the crude product. LCMS (APCI-pos): mass 238.2 (M+1), Purity by LCMS (UV area percent): 85%. IHNMR (CDC13, 400 MHz) : 86. 88-6.83 (m, 2H), 6.47- 6.43 (m, 1H), 3.55-3. 9 (bs, 2H), 1.32 (s, 12H) Preparation 54 N- [3-Fluoro-5- (4, 4,5, 5-tetramethyl-[1, 3,2] dioxaborolan-2-yl) -phenyl]- methanesulfonamide

Combine 3-fluoro-5- (4, 4,5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-yl)-phenylamine (610 mg, 2.6 mmol), methanesulfonyl chloride (240 iL, 3.09 mmol) in pyridine (25 mL). Stir the reaction mixture under nitrogen for 18-24h. Strip to dryness and partition the crude product between methylene chloride (100 mL) and brine (100 mL). Separate the layers and dry the organic layer with magnesium sulfate. Purify the crude product by crystallization (methylene chloridelhexanes) to provide 625 mg of purified product.

LCMS (APCI-pos): mass 333.1 (M+H20), Purity by LCMS (UV area percent) : 99%.

1HNMR (CDC13,400 MHz) : 57. 31-7.20 (m, 3H), 6.44 (s, 1H), 3.03 (s, 3H), 1.34 (s, 12H).

Example 488 (E)-N- [3-Fluoro-5- (8-fluoro-10, 11-dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridin-5- ylidenemethyl)-phenyl]-methanesulfonamide Following procedures essentially as described in Example 219, beginning with (E)-5- bromomethylene-8-fluoro-10, 11-dihydro-benzo [4,5] cyclohepta [1, 2-b] pyridine (50 mg, 0.16 mmol) and N- [3-fluoro-5- (4, 4,5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-yl) -phenyl]- methanesulfonamide (62 mg, 0.20 mmol). After work-up, purify the crude product by flash chromatography (50% ethyl acetate/hexanes to 75% ethyl acetate/hexanes) to provide 44 mg (65%) of purified product. LCMS (APCI-pos): 413.0 (M+H). LCMS (APCI-neg): 411.0 (M-H). Purity by LCMS (UV Area percent) 98%. IHNMR (d6- DMSO, 400 MHz): 89. 91 (s, 1H), 8.42 (dd, 1H), 7.91 (dd, 1H), 7.29-7. 25 (m, 2H), 6.92 (s, 2H), 6.90 (d, 1H), 6. 77-6.74 (m, 2H), 6.52-6. 49 (m, 1H), 3.4-2. 8 (m, 4H), 2.87 (s, 3H).

Examples 489-601 contained in Table II, herein, provide yet additional examples of compounds of Formula I wherein the"A"and/or"B"ring represents a heterocyclic ring.

These examples, which further illustrate the present invention are prepared according to the procedures as described generally in the Schemes and literature references described above.

Examples 602-606 contained in Table II, herein, provide yet additional examples of compounds of Formula I wherein the bridge depicted by-X-Y-represents a fused cyclopropyl structure. (Section 5 as represented by original Examples 255-260). These examples, which further illustrate the present invention are prepared according to the procedures as described generally in the Schemes and literature references described above.

Additional preparations for, and examples of compounds of Formula I wherein the bridge depicted by-X-Y-contains a heteroatom or heteroatom containing group at either the X or Y position. (Section 6 as represented by original Examples 261-274) Preparation 55 3, 8-difluoro-6H-dibenzo [b, e] oxepin-ll-one Prepare starting ketones for oxepine derivatives as described by M Kurokawa, F Sato, Y Masuda, T Yoshida and Y Ochi, Chem. Pharm. Bull. , 39; 10; (1991) 2564-5273.

Example 607 5- (3-Fluoro-6H-dibenzo [b, e] oxepin-11-ylidenemethyl)-1- (2-morpholin-4-yl-ethyl)-1, 3- dihydro-benzoimidazol-2-one

Following procedures essentially as described in Example 219, mix 1- (2-morpholin-4-yl- ethyl)-5- (4, 4,5, 5-tetramethyl-[1, 3,2] dioxaborolan-2-yl)-1, 3-dihydro-benzoimidazol-2-one (330mg, l. lmmol), 11-bromomethylene-3-fluoro-6, 1 l-dihydro-dibenzo [b, e] oxepine (E- isomer, 300mg, 1. 03mmol) (prepared following procedures essentially as described in Preparations 55,23, and 24), 2N Na2C03 (1. 4mL), dioxane (lOmL) and (Ph3P) 4Pd (44mg, 0. 04mmol). Recrystallize the crude product from toluene and then further purify by using an SCX column by eluting with 1/1 MeOH/dichloromethane then 1/1 2N NH3 MeOH/dichloromethane. Obtain 51mg of title compound as a white solid, HPLC (IS080- 10M) t=1. 82 (99%). MS (ES) 472 (M+1), 470 (M-1). HNMR (DMSO-d6) 610. 72 (s, 1H), 7.57 (m, 2H), 7.35 (t, 1H, J=7.5 Hz), 7.23 (t, 1H, J=7.5 Hz), 7.00 (d, 1H, J=7.4 Hz), 6.97 (s, 1H), 6.93 (d, 1H, J=8.4 Hz), 6.79 (td, 1H, J=11. 9,4. 3 Hz), 6.73 (d, 1H, J=8.4 Hz), 6.60 (m, 2H), 5.31 (d, 2H, J=225.4 Hz), 3.80 (t, 2H, J=6.4 Hz), 3.46 (t, 4H, J=4.4 Hz), 2.48 (t, 3H, J=6.2 Hz), 2.38 (s, 4H), 2.48 (t, 2H, J=6.2 Hz).

Example 608 5- (3-fluoro-6H-dibenzo [b, e] oxepin-11-ylidenemethyl)-1- (3-morpholin-4-yl-propyl)-1, 3- dihydro-benzoimidazol-2-one Following procedures essentially as described in Example 219, mix 1- (2-morpholin-4-yl- propyl)-5- (4, 4,5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-yl)-1, 3-dihydro-benzoimidazol-2- one (205mg, 0. 53mmol) (prepared following procedures essentially asdescribedin Preparation 36), 11-bromomethylene-3-fluoro-6, 11-dihydro-dibenzo [b, e] oxepine (E- isomer, 150mg, 0. 5mmol), 2N Na2C03 (0. 5mL), dioxane (5mL) and (Ph3P) 4Pd (53mg, 0. 046mmol). Purify the crude product by column chromatography using 2N NH3 in MeOH/dichloromethane. Triturate the product obtained (192mg) with hexane to give 170mg pure title compound, HPLC (IS080-lOM) t=1. 72 (100%). MS (ES) 486 (M+1),

484 (M-1). H NMR (DMSO-d6) 10.68 (s, 1H), 7.57 (m, 2H), 7.35 (t, 1H, J=7. 5 Hz), 7.22 (t, 1H, J=7. 7 Hz), 6.96 (m, 3H), 6.78 (td, 1H,. J=12. 0,4. 2 Hz), 6.71 (d, 1H, J=7. 5 Hz), 6.60 (m, 2H), 5.31 (br d, 2H), 3.72 (t, 2H, J=6. 6 Hz), 3.46 (t, 4H, J=4. 2 Hz), 2.48 (m, 4H), 1.71 (m, 2H), 2.20 (m, 6H).

Example 609 1-cyclopropyl-5- (3-fluoro-6H-dibenzo [b, e] oxepin-11-ylidenemethyl)-1, 3-dihydro- benzoimidazol-2-one Following procedures essentially as described in Example 219, mix 1-cyclopropyl-2-oxo- 2, 3-dihydro-1H-benzoimidazole-5-boronic acid (120mg, 0. 55mmol) (prepared essentially as described in Preparation 36), 11-bromomethylene-3-fluoro-6, 1 l-dihydro- dibenzo [b, e] oxepine (E and Z mixture, 177mg, 0. 58mmol), 2N Na2Co3 (0.7mL), dioxane (8mL) and (Ph3P) 4Pd (38mg, 0.033mmol). Purify the crude product by column chromatography using THF/hexane to give 65mg title compound as a gray powder.

HPLC (ISO80-10M) t=3. 53 (93%), MS (ES) 399 (M+1), 397 (M-1). H NMR 10.58 (s, 1H), 7.58 (m, 3H), 7.35 (t, 1H, J=7. 5 Hz), 7.23 (t, 1H, J=7. 5 Hz), 6.96 (m, 3H), 7.58 (m, 2H), 6.80 (dd, 1H, J=7. 9,2. 6 Hz), 6.75 (d, 1H, J=7. 5 Hz), 6.60 (dd, 1H, J=10. 6,2. 2 Hz), 6.57 (s, 1H), 5.84-4. 79 (m, 2H), 2.75 (m, 1H), 0.93 (m, 2H), 0.77 (m, 2H).

Example 610 5- (3-fluoro-6H-dibenzo [b, e] oxepin-1l-ylidenemethyl)-l- (2-morpholin-4-yl-ethyl)-1, 3- dihydro-benzoimidazol-2-one

Following procedures essentially as described in Example 219, mix 1- (2-morpholin-4-yl- ethyl)-5- (4, 4,5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-yl)-1, 3-dihydro-benzoimidazol-2-one (300mg, 1. 03mmol), 11-bromomethylene-3-fluoro-6,11-dihydro-dibenzo [b, e] oxepine (E isomer, 330mg, 1. 08mmol), 2NNa2C03 (1. 4mL), dioxane (lOmL) and (Ph3P) 4Pd (44mg, 0.038mmol). Purify the crude product by column chromatography using 40% THF/hexane to yield 80mg title compound as a pale yellow powder. HPLC (IS080-10M) t=1.84 (96%), MS (ES) 472 (M+1), 470 (M-1). H NMR (DMSO-d6) 10.72 (s, 1H), 7.57 (m, 2H), 7.35 (t, 1H, J=7. 5 Hz), 7.23 (t, 1H, J=7. 5 Hz), 7.00 (d, 1H, J=7. 5 Hz), 6.97 (s, 1H), 6.93 (d, 1H, J=8. 4 Hz), 6.79 (td, 1H, J=11. 9,4. 3 Hz), 6.73 (d, 1H, J=8. 4 Hz), 6.60 (m, 2H), 5.82-4. 79 (m, 2H), 3.80 (t, 2H, J=6. 4 Hz), 3.46 (t, 4H, J=4. 4 Hz), 2.48 (m, 2H), 2.38 (s, 4H).

Example 611 5- (3-Fluoro-6H-dibenzo [b, e] oxepin-11-ylidenemethyl)-1, 3-dihydro-benzoimidazol-2-one Following procedures essentially as described in Example 219, using 11- bromomethylene-3-fluoro-6, 1 l-dihydro-dibenzo [b, e] oxepine (E-isomer, 1. 05 eq. ) and 5- (4,4, 5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-yl)-1, 3-dihydro-benzoimidazol-2-one (1 eq. ).

Purify crude product on silica gel, eluting with 60% to 100% ethyl acetate/CHC13 to afford a light yellow solid. Triturate with acetone to afford the title compound as a white solid. HPLC (IS060-10) t=4. 09min, 100%; MS [ES] 357 (M-H), 359 (M+H) ; IN-NOR

(DMSO-d6) 8 10.56 (s, 1H), 10.46 (s, 1H), 7.56 (m, 2H), 7.35 (t, 1H, J=7. 5 Hz), 7.23 (t, 1H, J=7. 5 Hz), 6.99 (d, 1H, J=7. 5 Hz), 6.94 (s, 1H), 6.78 (td, 1H, J=12. 0,4. 2 Hz), 6.71 (d, 1H, J=8. 4 Hz), 6.66 (d, 1H, J=8. 4 Hz), 6.59 (dd, 1H, J=10. 6,2. 6 Hz), 6.57 (s, 1H), 5.83-4. 71 (br d, 2H).

Example 612 5- (3-Fluoro-6H-dibenzo [b, e] oxepin-11-ylidenemethyl)-1-isopropyl-1, 3-dihydro- benzoimidazol-2-one Following procedures essentially as described in Example 219, mix 11-bromomethylene- 3-fluoro-6, 11-dihydro-dibenzo [b, e] oxepine (150mg, 0.493mmol), 1-isopropyl-2-oxo-2, 3- dihydro-lH-benzoimidazole-5-boronic acid (103mg, 0. 468mmol) (prepared according to Scheme IX by using isopropylamine in Step A), Na2C03 (2M in water, 620 gel, 1. 23mmol), dioxane (4mL), and Pd (PPh3) 4 (29mg, 0. 025mmol). Purify the crude product on silica gel (24g), eluting with 25% to 50% THF/hexanes to afford 130mg (69%) of the title compound as a yellow foam. HPLC (IS080-10) t=3. 86min, 98%; MS [ES] 399 (M- H) ; 1H-NMR (CDCl3) # 9.10 (s, 1H), 7.44 (m, 2H), 7.32 (t, 1H, J=7. 5 Hz), 7.22 (t, 1H, J=7. 5 Hz), 7.11 (d, 1H, J=7. 5 Hz), 6.93 (d, 1H, J=8. 4 Hz), 6.86 (s, 1H), 6.75 (d, 1H, J=8. 4 Hz), 6.69 (s, 1H), 6.66 (td, 1H, J=l 1. 7,4. 1 Hz), 6.52 (dd, 1H, J=10. 3,2. 4 Hz), 5.92-4. 73 (m, 2H), 4.66 (m, 1H), 1.51 (d, 6H, J=7. 0 Hz).

Example 613 5- (3, 8-Difluoro-6H-dibenzo [b, e] oxepin-11-ylidenemethyl)-1, 3-dihydro-benzoimidazol-2- one

Following procedures essentially as described in Example 219, mix 11-bromomethylene- 3,8-difluoro-6, 11-dihydro-dibenzo [b, e] oxepine (E-isomer, 326mg, l. Olmmol), 5- (4, 4,5, 5- tetramethyl- [1, 3,2] dioxaborolan-2-yl)-1, 3-dihydro-benzoimidazol-2-one (250mg, 0. 961mmol), Na2CO3 (2M in water, 1. 20mL, 2. 40mmol), dioxane (7mL), and Pd (PPh3) 4 (58mg, 0. 051mmol). Purify the crude product on silica gel (12g) eluting with 50% to 70% THF/hexanes to afford two lots of yellow solid weighing 180mg and 151mg.

Dissolve the 180mg lot in boiling MeOH (20mL), concentrate to lOmL and cool to-26°C to precipitate 165mg (46%) of the title compound as a white solid. Repeat the recrystallization on the 151mg lot to afford 98mg (27%) of the title compound as a white solid. HPLC (IS080-10) t=2.38min, 97% ; MS [ES] 375 (M-H), 377 (M+H) ; 1H-NMR (DMSO-d6) 8 10.57 (s, 1H), 10.46 (s, 1H), 7.57 (dd, 1H, J=8. 4,7. 0 Hz), 7.49 (dd, 1H, J=9. 2,2. 6 Hz), 7.08 (td, 1H, J=12. 5,4. 3 Hz), 7.01 (d, 1H, J=5. 7 Hz), 6.97 (s, 1H), 6.79 (td, 1H, J=12. 0,4. 2 Hz), 6.73 (d, 1H, J=8. 4 Hz), 6.67 (d, 1H, J=8. 4 Hz), 6.61 (dd, 1H, J=10. 6,2. 6 Hz), 6.52 (s, 1H), 5.78-4. 78 (br d, 2H).

Example 614 5- (3-Chloro-6H-dibenzo [b, e] oxepin-11-ylidenemethyl)-1, 3-dihydro-benzoimidazol-2-one Following procedures essentially as described in Example 219, mix 11-bromomethylene- 3-chloro-6, 11-dihydro-dibenzo [b, e] oxepine (E-isomer, 40mg, 0. 124mmol) (prepared essentially as described in Preparation 55), 5- (4, 4,5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-

yl)-1, 3-dihydro-benzoimidazol-2-one (31mg, 0. 118mmol), Na2CO3 (2M in water, 1480L, 0. 295mmol), dioxane (lmL), and Pd (PPh3) 4 (7mg, 0. 006mmol). Purify the crude product on silica gel (12g) eluting with 2% to 5% (2M NH3/MeOH)/CH2Cl2 to afford 3 lmg (69%) of the title compound as a white solid. HPLC (IS080-10) t=2. 85min, 99%; MS [ES] 373 (M-H) ; 1H-NMR (DMSO-d6) #10. 57 (s, 1H), 10.47 (s, 1H), 7.56 (dd, 2H, J=7. 8,6. 1 Hz), 7.35 (t, 1H, J=7. 5 Hz), 7.24 (t, 1H, J=7. 7 Hz), 6.98 (m, 3H), 6.82 (d, 1H, J=2. 2 Hz), 6.69 (m, 2H), 6.57 (s, 1H), 5.89-4. 79 (br d, 2H).

Example 615 5- (3, 7-Difluoro-6H-dibenzo [b, e] oxepin-11-ylidenemethyl)-1- (2-morpholin-4-yl-ethyl)- 1,3-dihydro-benzoimidazol-2-one Following procedures essentially as described in Example 219, mix 11-bromomethylene- 3,7-difluoro-6, 11-dihydro-dibenzo [b, e] oxepine (E-isomer, 200mg, 0. 619mmol) (prepared essentially as described in Preparation 55), 1- (2-morpholin-4-yl-ethyl)-5- (4, 4,5, 5- tetramethyl- [1, 3,2] dioxaborolan-2-yl)-1, 3-dihydro-benzoimidazol-2-one (220mg, 0. 589mmol), Na2C03 (2M in water, 736UL, 1.47mmol), dioxane (4mL), and Pd (PPh3) 4 (36mg, 0. 031mmol). Purify the crude product on silica gel (64g) eluting with 2% (2M NH3/MeOH)/CH2CI2 to afford 191mg (66%) of the title compound as a white foam.

HPLC (IS080-10) t=1. 95min, 98%; MS [ES] 488 (M-H), 490 (M+H) ;'H-NMR (DMSO- d6) 8 10. 69 (s, 1H), 7.58 (dd, 1H, J=8. 8,7. 0 Hz), 7.24 (m, 2H), 7.02 (s, 1H), 6.96 (d, 1H, J=8. 4 Hz), 6.80 (m, 3H), 6.64 (m, 2H), 5.56-5. 20 (br d, 2H), 3.81 (t, 2H, J=6. 4 Hz), 3.46 (t, 4H,J=4. 4 Hz), 2.48 (m, 2H), 2.37 (s, 4H).

Example 616 5- (3, 7-Difluoro-6H-dibenzo [b, e] oxepin-11-ylidenemethyl)-1, 3-dihydro-benzoimidazol-2- one

Following procedures essentially as described in Example 219, mix 11-bromomethylene- 3,7-difluoro-6, 11-dihydro-dibenzo [b, e] oxepine (E-isomer, 68mg, 0. 21mmol), 5- (4, 4,5, 5- tetramethyl- [1, 3,2] dioxaborolan-2-yl)-1, 3-dihydro-benzoimidazol-2-one (52mg, 0. 20mmol), Na2C03 (2M in water, 251pL, 0. 503mmol), dioxane (2mL), and Pd (PPh3) 4 (12mg, O. OlOmmol). Purify on silica gel (12g) eluting with THF to afford a brown solid.

Triturate with acetone to afford 56mg (74%) of the title compound as a white solid.

HPLC (IS080-10) t=2.42min, 96%; MS [ES] 375 (M-H) ;'H-NMR (DMSO-d6) 8 10. 58 (s, 1H), 10.46 (s, 1H), 7.57 (dd, 1H, J=8. 8,7. 0 Hz), 7.24 (m, 2H), 7.00 (s, 1H), 6.81 (m, 2H), 6.72 (m, 2H), 6.64 (dd, 1H, J=10. 6,2. 6 Hz), 6.59 (s, 1H), 5.55-5. 19 (br d, 2H).

Example 617 5- (3, 8-Difluoro-6H-dibenzo [b, e] oxepin-11-ylidenemethyl)-1- (2-morpholin-4-yl-ethyl)- 1,3-dihydro-benzoimidazol-2-one Following procedures essentially as described in Example 219, mix 11-bromomethylene- 3,8-difluoro-6, 11-dihydro-dibenzo [b, e] oxepine (E-isomer, 40mg, 0. 12mmol), 1- (2- morpholin-4-yl-ethyl)-5- (4, 4,5, 5-tetramethyl-[1,3, 2] dioxaborolan-2-yl) -1, 3-dihydro- benzoimidazol-2-one (44mg, 0. 12mmol), Na2C03 (2M in water, 155pL, 0.310mmol), dioxane (lmL), and Pd (PPh3) 4 (7mg, 0. 006mmol). Purify on silica gel (12g), eluting with 2% to 5% (2M NH3/MeOH)/CH2Cl2 to afford 45mg (78%) of the title compound as a

white foam. HPLC (IS080-10) t=1. 86min, 99%; MS [ES] 488 (M-H), 490 (M+H) ; in- NMR (DMSO-d6) 8 10.70 (s, 1H), 7.59 (dd, 1H, J=8. 5,7. 1 Hz), 7.51 (dd, 1H, J=8. 8,2. 6 Hz), 7.08 (td, 1H, J=12. 5,4. 3 Hz), 7.01 (m, 2H), 6.96 (d, 1H, J=7. 9 Hz), 6.80 (td, 1H, J=12. 0,4. 2 Hz), 6.73 (d, 1H, J=7. 9 Hz), 6.62 (dd, 1H, J=10. 3,2. 4 Hz), 6.58 (s, 1H), 5.72- 4.85 (br d, 2H), 3.81 (t, 2H, J=6. 4 Hz), 3.47 (t, 4H, J=4. 4 Hz), 2.48 (m, 2H), 2.38 (s, 4H).

Preparation 56 8-Fluoro-11 H-10-oxa-1-aza-dibenzo [a, d] cyclohepten-5-one

Prepare according to literature precedent: Journal of Medicinal Chemistry 1990,33, 3095.

Preparation 57 8-Fluoro-5-methylene-5, 11-dihydro-10-oxa-1-aza-dibenzo [a, d] cycloheptene

Combine 8-fluoro-1lH-10-oxa-1-aza-dibenzo [a, d] cyclohepten-5-one (567 mg, 2.47 mmol) and anhydrous tetrahydrofuran (25 mL). Chill the solution to 0 °C and add Tebbe reagent (0. 5M/L solution in toluene, 5.4 mL, 2.72 mmol). Remove cooling and stir the admixture for 10 min. Quench the reaction by adding saturated aqueous Rochelle's salt solution (75 mL). Stir the biphasic mixture rapidly for 10 min, then separate the layers and extract the aqueous layer with ethyl acetate. Dry the combined organic layers with magnesium sulfate, filter and strip. Purify the crude product by flash chromatography (25% ethyl acetate/hexanes) to provide 416 mg (74%) of purified product. LCMS (APCI- pos): 228.1 (M+H). LCMS (APCI-neg): 226.9 (M-H).

Preparation 58 <BR> <BR> <BR> (E++)-5-Bromomethylene-8-fluoro-5, 11-dihydro-10-oxa-1-aza-dibenzo [a, d] cycloheptene

Make the title compounds according to proceduresessentially as described in Preparation 24, beginning with 8-fluoro-5-methylene-5, 11-dihydro-10-oxa-1-aza- dibenzo [a, d] cycloheptene (416 mg, 1.83 mmol). After workup and purification and separation by flash chromatography (25% ethyl acetate/hexanes) isolate 383 mg (68%) of (E)-5-bromomethylene-8-fluoro-5, 11-dihydro-l O-oxa-l-aza-dibenzo [a, d] cycloheptene and 125 mg (23%) of (Z)-5-bromomethylene-8-fluoro-5, 1l-dihydro-10-oxa-1-aza- dibenzo [a, d] cycloheptene. For (E)-5-bromomethylene-8-fluoro-5, 11-dihydro-10-oxa-1- aza-dibenzo [a, d] cycloheptene, LCMS (APCI-pos): 306, 308. 1HNMR (d6-DMSO, 400 MHz) : 88. 55 (d, 1H), 7.86 (d, 1H), 7.49 (dd, 1H), 7.40 (dd, 1H), 7.25 (s, 1H), 6.84 (dt, 1H), 6.73 (dd, 1H), 5.23 (bs, 2H). For (Z)-5-bromomethylene-8-fluoro-5, 11-dihydro-10- oxa-l-aza-dibenzo [a, d] cycloheptene, LCMS (APCI-pos): 306, 308. 1HNMR (d6-DMSO, 400 MHz) : 58. 50 (dd, 1H), 7.81 (d, 1H), 7.50 (dd, 1H), 7.40 (dd, 1H), 7.09 (s, 1H), 6.99- 6.93 (m, 2H), 5.22 (bs, 2H).

Example 618 (E)-5- (8-Fluoro-11H-10-oxa-1-aza-dibenzo [a, d] cyclohepten-5-ylidenemethyl)-1- (2- morpholin-4-yl-ethyl)-1, 3-dihydro-benzoimidazol-2-one Following procedures essentially as described in Example 219, beginning with (E)-5- bromomethylene-8-fluoro-5, 11-dihydro-10-oxa-l-aza-dibenzo [a, d] cycloheptene (192 mg, 0. 63 mmol)and 1-(2-morpholin-4-yl-ethyl)-5-(dihyroxyborolan-2-yl)-1, 3-dihydro- benzoimidazol-2-one (219 mg, 0.75 mmol). Partition the reaction mixture between ethyl acetate (50 mL) and 1N aqueous hydrochloric acid solution (50 mL). Separate the layers

and extract the aqueous layer with methylene chloride (2x50 mL). Combine the organic layers and extract with 1N aqueous hydrochloric acid solution (50 mL). Adjust the pH of the combined aqueous layers to 8.0 with 5N aqueous sodium hydroxide solution, and extract the product with ethyl acetate (3x 50 mL). Purify the crude product by flash chromatography (25% ethanol/ethyl acetate) to provide 115 mg (39%) of purified product.

LCMS (APCI-pos): 473.1 (M+H). PuritybyLCMS (UVAreapercent) 98%.'HNMR (d6-DMSO, 400 MHz) : 810. 70 (s, 1H), 8.51 (d, 1H), 7.64 (t, 1H), 7.39 (d, 1H), 7.27 (dd, 1H), 7.09 (s, 1H), 6.97 (d, 1H), 6.85 (dt, 1H), 6.73 (d, 1H), 6.69 (dd, 1H), 6.61 (s, 1H), 5.5-5. 3 (bs, 2H), 3.81 (t, 2H), 3.30 (s, 4H), 2.48 (s, 4H), 2.34 (bs, 2H).

Example 630 A. Preparation of 2- [2- (3-nitrophenylethynyl)] benzyl alcohol: 2-ethynylbenzyl alcohol (1.65 g, 12.5 mmol), PdCl2 (PPh3) 2 (437 mg, 0.623 mmol), CuI (237 mg, 1.25 mmol) are successively added to a solution of 3-iodonikobenzene (3., 1 g, 12.5 mmol) in 62 mL of Et3N at rt. The reaction mixture is stirred at rt for lh. Water (100 mL) is added followed by EtOAc (100 mL). The layers are separated and the aqueous layer extracted with additional 100 mL of EtOAc. The combined organic layer is dried and concentrated to give a dark yellow residue. The residue is purified by column

chromatography to give 2 as a yellow solid (2.59 g, 10.25 mmol, 82 % yield). 1H NMR (300 MHz, CDCl3) 8 8. 37 (m, 1 H), 8.21 (m, 1 H), 7.82 (m, 1 H), 7.60-7. 32 (m, 5 H), 4.94 (d, J = 5.9 Hz, 2 H), 1.97 (t, J= 2.3 Hz, 1 H). Yu, H. RG6-R6H-070.

B. Preparation of: To a mixture of 2-bromo-5-fluorophenol (3.77 g, 19.8 mmol) and the alkyne from Step A, above (5.0 g, 19.8 mmol) in 125 mL of anhydrous THF is added triphenylphosphine (7.8 g, 29.6 mmol) at rt. The reaction mixture is cooled to 0 °C and diisopropylazodicarboxylate (5.99 g, 29.6 mmol) is added dropwise under N2. The reaction mixture is warmed up to rt and stirred at rt for 2h. 200 mL of water isadded followed by 200 mL of EtOAc. The layers are separated and the aqueous layer further extracted with 200 mL of EtOAc. The combined organic layer is dried and concentrated to give a brown residue. The residue is purified by column chromatography (5% EtOAc/hexane) to give the product (6.70 g, 15.7 mmol, 79 % yield) as an off-white solid.

IH NMR (300 MHz, CDC13) b 8.30 (m, 1 H), 8.20 (m, 1 H), 7.78 (m, 1 H), 7.69-7. 35 (m, 6 H), 6.78 (m, 1 H), 6.61 (m, 1 H), 5.18 (s, 2H). Yu, H, RG6-R6H-087.

C. Preparation of:

A mixture of the product of Step B, above (56 mg, 0.131 mmol), Pd (OAc) 2 (3 mg, 0.013 mmol) and tri-O-tolylphosphine (8.0 mg, 0.026 mmol) in 0.7 mL of acetonitrile is stirred under N2 at rt. Formic acid (96 %, 18.2 mmol, 0.394 mmol) is added dropwise followed by piperidine (45 mg, 0.526 mmol). The reaction mixture is heated at 70 °C overnight.

TLC shows starting material still remains. Additional Pd (OAc) 2 (3 mg, 0.013 mmol), tri- O-tolylphosphine (8.0 mg, 0.026 mmol), formic acid (96 %, 18.2 mmol, 0.394 mmol) and piperidine (45 mg, 0.526 mmol) are added in this sequence. The reaction mixture is heated at 70 °C for additional 4 h with until no starting observed by TLC. The reaction mixture is concentrated to a black residue and purified through 5 g of silica gel to give the aniline product (17 mg, 0.054 mmol, 41% yield) as a beige solid.'H NMR (300 MHz, CDC13) 8 7.42 (m, 2 H), 7.31 (dt, J= 9.6 Hz, J= 1. 3 Hz, 1 H), 7.21 (dt, J = 9.6 Hz, J= 1.3 Hz, 1 H), 7.11 (m, 1 H), 6.93 (t, J= 9.6 Hz, 1 H), 6.78 (s, 1 H), 6.65 (m, 1 H), 6.53- 6.29 (m, 4 H), 3.46 (bs, 2 H). Yu, H. RG6-R6H-074.

D. Preparation of Final Title Compound: To a mixture of the aniline of Step C (1.0 mg, 0. 0132 mmol) in 0.1 mL of methylene chloride is added pyridine (0.3 mg, 0.0038 mmol) followed by methanesulfonylchloride (0.4 mg, 0.0035 mmol) at rt under N2. The reaction mixture is stirred at rt for 2h. The reaction mixture is concentrated to dry and the residue is purified by column chromatogrphy to give Title Compound as a solid.'H NMR (300 MHz, CDC13) 8 7.44 (m, 2 H), 7.32 (t, J= 7.5 Hz, 1 H), 7.17 (m, 2 H), 7.00 (m, 2 H), 6.87 (m, 2 H), 6.78 (m, 1 H), 6.67 (dt, J= 11. 7 Hz, J= 4.1 Hz, 1 H), 6.53 (dd, J= 10. 6 Hz, J= 2.5 Hz, 1 H), 6.07 (s, 1H), 2.81 (s, 3 H).

Examples 619-751 contained in Table II, herein, provide yet additional examples of compounds of Formula I wherein the bridge depicted by-X-Y-contains a heteroatom or heteroatom containing group at either the X or Y position.. These examples, which further illustrate the present invention are prepared according to the procedures as described generally in the Schemes and literature references described above.

Additional preparations for, and examples of compounds of Formula I wherein R8 is other than hydrogen and the bridge depicted by-X-Y-contains either a

heteroatom or heteroatom containing group at either the X or Y position or both X and Y are CH2. (Section 7) Example 752 N-{3-[1-(8-Methoxy-6,11-dihydro-dibenzo [b, e] oxepin-11-yl)-ethyl]-phenyl}- methanesulfonamide

Mix N- {3- [l- (8-methoxy-6H-dibenzo [b, e] oxepin-11-ylidene)-ethyl]-phenyl}- methanesulfonamide (prepared essentially a sdescribed in Example 271) (1.0 eq) with 10% Pd/C (65.2 weight %) in EtOH and heat at 60°C overnight under 500 psi hydrogen. Remove the solvent and purify by chromatography (ISCO Combi Flash, 3/1 hexane/ethyl acetate) to give 29% of the title compound as a racemic mixture. HPLC (Xterra C 18 2. 1x50µm 3. 5yM, 5-100% acetonitrile with 0.2% formic acid. ) t= 4.55 (100%). MS (ES) 424 (M+1), 422 (M-1).

Preparation 59 (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidine)-acetic acid ethyl ester

Prepared as described in Bergmann, E. D. , Solomonovici, A., Synthesis, 1970,183-189.

Preparation 60 Bromo- (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidine)-acetic acid ethyl ester

Dissolve (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidine)-acetic acid ethyl ester (1 equivalent) in a suitable dry solvent and chill to 0° C under a dry atmosphere. Add bromine (1. 05 equivalents) dropwise and stir at 0° C for 20 minutes. Remove the ice bath and stir at room temperature for three hours. Return to the ice bath and add potassium tert-butoxide (1. l. equivalents) and stir for one hour. Quench the mixture with aqueous Na2S03 and partition between dichloromethane and water and dry the organic layer over anhydrous sodium sulfate. Purify the residue obtained after evaporation by silica gel chromatography to yield 71% of the title compound.

Example 753 (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidene)- (3-methanesulfonylamino-phenyl)- acetic acid ethy lester Following procedures essentially as described in Example 219, mix bromo- (10, 11- dihydro-dibenzo [a, d] cyclohepten-5-ylidine)-acetic acid ethyl ester (1 equivalent), N- [3-

(4,4, 5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-yl)-phenyl]-methanesulfonamide (1.25 equivalents), 2N Na2C03 (2 equivalents) and tetrakistriphenylphosphine palladium (0.05 equivalents) in a suitable solvent. Purify the product by silica gel chromatography to obtain a 78% yield of the title compound. MS (ES) = 446 (+) Example 754 (10, 11-Dihydro-dib enzo [a, d] cyclohepten-5-ylidene)- (3-methanesulfonylamino-phenyl)- acetic acid

Treat (10,11-dihydro-dibenzo [a, d] cyclohepten-5-ylidene)- (3-methanesulfonylamino- phenyl) -acetic acid ethyl ester with a 50: 50 mixture of IN NaOH and ethanol and heat under reflux conditions for 14 hours. Acidify with IN HCl and collect the solid by filtration and dry. Purify by reverse phase HPLC to obtain a 20% yield of the title compound. MS (ES) = 437 (+NH3) Example 755 N- {3- [1- (10, 11-Dihydro-dibenzo [a, d] cyclohepten-5-ylidene)-2-hydroxy-ethyl]-phenyl}-<BR> methanesulfonamide

Treat (10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidene)- (3-methanesulfonylamino- phenyl) -acetic acid ethyl ester (1 equivalent) with lithium aluminum hydride (2 equivalents) in a suitable dry solvent and stir at room temperature for four hours. Quench by the dropwise addition of water and partition between dichloromethane and water. Dry the organic layer over anhydrous sodium sulfate and evaporate. Purify the crude residue by silica gel chromatography to obtain a 33% yield on the title compound.

MS (ES) =404 (+) Preparation 61 (2-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidene) -acetic acid methyl ester Title compound is prepared from 2-chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-one as described in Bergmann, E. D. , Solomonovici, A., Synthesis, 1970, 183-189.

Preparation 62 2- (2-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidene)-ethanol Dissolve (2-chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidene) -acetic acid methyl ester (1 equivalent) in a suitable dry solvent and cool to 0°C under a dry atmosphere. Add

1M diisobutylaluminun hydride solution in toluene (3 equivalents) dropwise and stir the mixture for one hour. Quench with aqueous citric acid solution and partition between water and ethyl acetate. Dry and evaporate the organic layer to obtain the title compound in 87% yield.

Preparation 63 2-Chloro-5- (2-methoxy-ethylidene)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene

Treat 2-(2-chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidene) -ethanol (1 equivalent) with sodium hydride (2 equivalents) in a suitable dry solvent at 0°C and stir for 15 minutes. Add dimethyl sulfate dropwise (2 equivalents) and stir at 0°C for one hour. Quench with aqueous citric acid solution and partition between water and ethyl acetate. Dry and evaporate the organic layer. Purify the residue by silica gel chromatography to give the title compound in 82% yield Preparation 64 5- (1-Bromo-2-methoxy-ethylidene)-2-chloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene

Treat 2-chloro-5- (2-methoxy-ethylidene)-10, 11-dihydro-SH-dibenzo [a, d] cycloheptene essentially as described in Preparation 24 to give the title compound in 43% yield.

Example 756 N- 3- [1- (2-Chloro-10, 11-dihydro-dibenzo [a, d] cyclohepten-5-ylidene)-2-methoxy-ethyl]- phenyl}-methanesulfonamide

Following procedures essentially as described in Example 219, mix 5- (l-bromo-2- methoxy-ethylidene)-2-chloro-10, 11-dihydro-5H-dibenzo [a, d] cycloheptene (1 equivalent), N- [3- (4, 4,5, 5-tetramethyl- [1, 3,2] dioxaborolan-2-yl) -phenyl]- methanesulfonamide (1.25 equivalents), 2N Na2C03 (2 equivalents) and tetrakistriphenylphosphine palladium (0.05 equivalents) in a suitable solvent. Purify the product by silica gel chromatography to obtain a 62% yield of the title compound.

MS (ES) =452 (-) Preparation 65 11-Fluoromethylene-6, 1l-dihydro-dibenzo [b, e] oxepine Dissolve 11-Bromomethylene-6, 11-dihydro-dibenzo [b, e] oxepine (1 eq. ) in dry THF (0.1 M). Cool the solution to-78C in a dry ice/acetone bath. Slowly add s-butyl lithium (1.2 eq. , 1.3 M in cyclohexane) to the above solution. Stir the dark brown solution at-78 C for two hours. Add a solution of N-fluorobenzene sulfonimide (1.2 eq. ) in dry THF (0.4 M) over 2 minutes. Remove the cold bath and allow the reaction mixture to warm to ambient temperature. Stir the reaction mixture at room temperature for 1 hour. Quench the reaction with water. Wash the resulting mixture with saturated aqueous NaHCO3.

Separate the organic phase and dry over sodium sulfate. Filter the mixture and concentrate under reduced pressure to afford a crude product. Purify the crude product by chromatography on silica gel, eluting with 30% CH2C12 in hexanes. MS (En = 226 (M).

Preparation 66 11-Bromo-fluoro-methylene-6, 1l-dihydro-dibenzo [b, e] oxepine Dissolve ll-Fluoromethylene-6, 11-dihydro-dibenzo [b, e] oxepine in methylene chloride (0.2 M). Add (4-Dimethylamino) pyridinium tribromide (1.05 eq. ). Stir the mixture at ambient temperature for 2 hours. Wash the resulting solution with aqueous sodium disulfite, dry with sodium sulfate and concentrate the filtrate. Purify the crude product by silica gel chromatography using 30% methylene chloride in hexanes. MS (EI) = 304/306 (M).

Examples 757-843 contained in Table II, herein, provide yet additional examples of compounds of Formula I wherein R8 is other than hydrogen and the bridge depicted by -X-Y-contains either a heteroatom or heteroatom containing group at either the X or Y position or both X and Y are CH2. These examples, which further illustrate the present invention are prepared according to the procedures as described generally in the Schemes and literature references described above.

As stated, Table II, below provides formulae and physical data for additional compounds of Formula I. In the table, the heading"Example No. "refers to the example number of the compound,"Structure"refers to the chemical formula of the particular compound, "MS Data"refers to the mass spectroscopy data generated for the particular compound, and"HPLC"refers to the-high pressure liquid-chromatography data generated for the particular compound. Some of the entries in the Table do not contain either MS Data or HPLC values, instead the designation"NMR"appears in the MS Data column.

For these Examples, nuclear magnetic resonance data are provided below.

Example 621 1H NMR (400 MHz, CDC13) 8.02 (d, 1H, J= 5), 7.97 (s, 1H), 7.50 (dd, 1H, J= 5,1), 7.42 (d, 1H, J= 5. 2), 7.35 (t, 1H, J= 9. 7,5), 7.28 (m, 2H), 7.14 (t, 1H, J= 9.7, 5), 7.02 (m, 2H), 6.91 (m, 2H), 5.6 (s, 2H).

Example 658 1H NMR (CDC13, 400MHz) 8 8.03 (d, J=8.56Hz, 1H), 7.50-6. 97 (m, 12H), 6.79 <BR> <BR> <BR> (bs, 1H), 5.70 (d, -J=12. 80Hz, 1H), 4.84 (d, -J=12. 80Hz, 1H), 3.48 (bs, 3H), 2.73 (bs, 3H) Example 659 1H NMR (d6-DMSO, 400MHz) 8 9.58 (bs, 1H), 8.09 (d, J=2.20Hz, 1H), 7.75 (dd, J=8.35Hz, 2. 20Hz, 1H), 7.58 (d, J=6.59Hz, 1H), 7.34 (dt. J=7.47Hz, 1.32Hz, 1H), 7.23 (dt. J=7.47Hz, 1.32Hz, 1H), 7.05 (s, 1H), 7.00-6. 94 (m, 3H), 6.87 (d, J=8. 79Hz, 1H), 6.78 (d, J=7. 91Hz, 1H), 5.65 (vbs, 1H), 5.13 (vbs, 1H), 3.30 (bs, 3H), 2.78 (s, 3H) Example 660 1H NMR (CDC13, 400MHz) 8 7.76-7. 72 (m, 2H), 7.44-7. 41 (m, 2H), 7.35-7. 34 (m, 2H), 7.26-7. 17 (m, 2H), 7.06-7. 04 (m, 1H), 6.88 (d, J=8.79Hz, 1H), 6.28 (bs, 1H), 5.58 (vbs, 2H), 3.72 (s, 3H), 2.83 (s, 3H) Example 670 1H NMR (CDC13, 400MHz) 8 7.45-7. 09 (m, 9H), 6.75-6. 72 (m, 1H), 6.65-6. 61 (m, 2H), 6.38 (bs, 1H), 5.43 (vbs, 2H), 3.87 (s, 3H), 2.88 (s, 3H) Example 671 1H NMR (CDC13, 400MHz) 6 7.48-7. 46 (m, 1H), 7. 34-6. 63 (m, 12H), 5.75 (vbs, 1H), 5.10 (m, 1H), 2.83 (s, 3H) Example 672

1H NMR (CDC13, 300MHz) 8 7.47-7. 06 (m, 8H), 6.86-6. 82 (m, 2H), 6.73-6. 67 (m, 2H), 6.54-6. 52 (m, 1H), 5.31 (vbs, 2H), 2.89 (s, 3H) Example 673 1H NMR (CDC13, 300MHz) 8 7.45 (d, J=7.58Hz, 1H), 7.32 (dt, J=7.42, 1.32, 1H), 7.22-7. 14 (m, 3H), 7.04-6. 98 (m, 2H), 6.92-6. 86, (m, 3H), 6.80-6. 73 (m, 2H), 6.47 (bs, 1H), 5.25 (vbs, 2H), 2.81 (s, 3H) Example 675 1H NMR (CDC13, 300MHz) 8 7.47-6. 81 (m, 1H), 5.63 (vbs, 1H), 5.05 (vbs, 1H), 2.82 (s, 3H), 2.18 (s, 1.5H) 2.14 (s, 1. 5H) Example 676 1H NMR (CDC13, 400MHz) 8 7.41-7. 15 (m, lOH), 6.76 (s, 1H), 6.61 (s, 1H), 6.48 (bs, 1H), 5.30 (vbs, 2H), 2.90 (s, 3H), 2.06 (s, 3H) Example 677 1H NMR (CDC13, 400MHz) 8 7.63-6. 84 (m, 13H), 5.60 (vbs, 1H), 4.95 (vbs, 1H), 2. 81 (s, 3H), 2.32 (s, 3H).

Example 679 1H NMR (CDC13, 400MHz) 8 7.64 (s, 1H), 7.44 (d, J=7.47Hz, 1H), 7.39-7. 28 (m, 2H), 7.19-7. 12 (m, 2H), 7.01-6. 98 (m, 2H), 6.91-6. 83 (m, 4H), 6.70 (s, 1H), 5.57 (vbs, 1H), 5.00 (vbs, 1H), 2.82 (s, 3H), 2.30 (s, 3H).

Example 681 1H NMR (CDC13, 400MHz) 8 7.45-7. 26 (m, 5H), 7.21-7. 17 (m, 2H), 7.09 (dd, J=7. 91Hz, 1. 32Hz, 1H), 7. 05 (dd, J=8.79Hz, 2.63Hz, 1H), 6.98 (d, J=2.64Hz, 1H), 6.83 (d, J=8.79Hz, 1H), 6.65 (s, 1H), 6.41 (bs, 1H), 5.33 (vbs, 2H), 2.90 (s, 3H).

Example 682 1H NMR (CDC13, 400MHz) 8 7.46-7. 44 (m, 2H), 7.32 (dt, J=7.47Hz, 1.32Hz, 2H), 7.21-7. 10 (m, 3H), 7.03-6. 98 (m, 2H), 6.91-6. 88 (m, 2H), 6.80 (s, 1H), 6.75 (d, J=8.79Hz, 1H), 6.40 (bs, 1H), 5.63 (vbs, 1H), 4.93 (vbs, 1H), 2.82 (s, 3H).

Example No. Structure MS Data HPLC Section v \/\ I 278 ES 329 NA 1 s v\ I\ I 279 ES 361 NA 1 X CHEZ u 280 ES 321 (-)/323 (+) (GRAD) t=3. 392 (95%) 1 N N u 281 0428 (-) (iS080-10) t= 5. 59 (100%) 1 ZON if FXF F EA ; C23H22 282 ~ th ; C, 91. 45 H, 7. 41 t = 2. 96 (97. 4%) 1 fd ; C, 91. 99 H, 7. 39 EA ; C23H19F3 283 CX TOFMSEt+=352 th ; C, 78. 39 H, 5. 43 1 fd ; C, 78. 84 H, 5. 11 i 284 TOF MS El+ 298 NA 285 TOF MS El+ 352 NA F F 286 H. ES 391 (+) t= 5. 05 min (100%) 1 c'90 a tN 11 0 , 287 m/a = 300 (M+1) IS060-10. M, ret time = 14. 15 1 min. ; 100% I NHZ I 288 m ES 347 (-)/349 (+) (iS090-10) t= 3. 15 (99%) 1 Q 289 NA NA 2 N cri u APCI GRAD 80-100M 290 Ns/P 506 (+) t = 6. 048 (100 %) Ói wN °Y 'a APCI GRAD 80-IOOM 291 i 490 (+) t=5. 638 (100%) zozo os (\ F cl 2g2 1 APCI GRAD 80-lOOM 2 292 486 (+)/484 (-)) I Uai ce i APCI GRAD 80-100M 2 293 502 (+)/500 (-) t = 5. 464 (100 %) q a 1 w 294 APCI GRAD 80-100M 2 542 (+)/540 (-) zero s I a 0 a C4 u j (+)/540 (-) t= 6. 221 (100%) s O ci a s 1 I 296 N/i° t = 3. 876 (100 %) N,'to N90 O a 0 u 0 -c GRAD 80-100M v APCI tl=4. 316 (50%) 2 297 r ° 550 (+) t2=4. 553 (50%) a cC ISOMER ML N HC O a 1 GRAD 80-100M APCI tl=5. 210 (500/o) 2 298 374 APCI t2=5. 340 (50%) 2 374 (+) ISOMER MIX on OH APCI GRAD 80-IOOM 299 OzN 404 (+) t = 5. 343 (100 %) OON zip °00 APCI GRAD 80-100M 300 OyN 392 (+) t = 5. 282 (95 %) Own HO /1/\ u H, c 301 ES 388 390 (+) (GRAD) t=3. 477 (99%) 2 1\ N H'ci U 302 ES 388 390 (+) (GRAD) t=3. 488 (97 %) 2 ZAIN b H 303 ES 388 390 (+) (GRAD) t= 3. 435 (97%) 2 N zozo u S 304 ES 388 390 (+) (GRAD) t=3. 424 (100%) 2 N "<o e 1 I \ H, c 305 ES 388 390 (+) (GRAD) t=3. 531 (100%) 2 cl, ci% cH, 1 _1 I 306 ES 450 452 (GRAD) t=3. 712 (96%) 2 \SON Fi'° O u 307 ES 388 390 (GRAD) t=3. 467 (99%) 2 i O=T=O CH, a_1 1 I I 308 N ES 450 452 (GRAD) t=3. 744 (100%) 2 itc w 309 oS ES 388 (-)/390 (+) (GRAD) t=3. 531 (94%) 2 O=T=O o=S=o OH, H, c \ 310 N ES388 (-)/390 (+) (GRAD) t=3. 445 (100%) 2 O=T=o ca, I 311 ES 388 (7) 390 (GRAD) t=8. 790 (100%) 2 O\ ZON 0 /\/\ 0 312 ES 388 390 (GRAD) t=11. 057 (100%) 2 N "0 1 'i Y 313 X ES 388 (-)/390 (+) (GRAD) t=8. 128 (100%) 2 N,//0 H, O u 314 ES 388 390 (GRAD) t=9. 738 (100%) 2 SO " u ES 388 390 (GRAD) t=7. 626 (97%) 2 o=s=o CH, I 316 ES 388 390 (GRAD) t=6. 508 (99%) 2 o=s=o O=T=O Foc 317 i ES 388 (-)/390 (+) (GRAD) t=4. 790 (99%) 2 i o=s=o cl, s 1 I ° I 318 0=1 ES 388 390 (GRAD) t=4. 932 (100%) 2 Tao CF S 319 ES 420 (-) 422 (GRAD) t=3. 424 (100%) 2 N po O S i\ 320 ES 420 422 (GRAD) t=3. 424 (100%) 2 o5°\e 0 CF //\ cr-7 321 ES 452 (-)/454 (+) (GRAD) t=2. 779 (100%) 2 N coti 322 ES 420 422 (GRAD) t=6. 50 (100%) 2 oslo os, oS o /U 323 ES 452 454 (GRAD) t=13. 40 (100%) 2 N,--0 zu =0 I \J 324 ES 452 454 (GRAD) t=17. 90 (100%) 2 , 0 O Ci-6 Hic I//\ cH, N, ES 402 404 NA 2 H, C3 5, H30 326 y ES 388 (-)/390 (+) (GRAD) t=3. 381 (97%) 2 N Hic CSO F1C H, C I -J 327 ES 388 (-)/390 (+) (GRAD) t=3. 413 (97%) 2 C),-s 0 n, c 328 ES-390. 3, ES+ = 392. 2 NA 2 ow1 i 329 ES-= 390. 3, ES+ = 392. 2 NA 2 + I 330 °,, ° ES-= 494 (Mixture) NA 2 _ 1 I °v-as to-cA 331 ES-= 418 NA 2 to-cC 332 ES-432 NA 2 o-VTY°x 333 ES 470 (+) t=1. 40 2 0 F F 334 W ES 347 (-) (IS080-10) t= 3. 41 (96%) 2 OH 335 C ES 347 (-) (IS080-10) t= 3. 74 (99%) 2 , H OH 336 El 343 (IS080-10) t= 7. 08 (47%), 2 N 7. 31 (52%) F 0 H, 0. co Hz 337 OH ES 390 (-)/392 (+) (IS080-10) t= 2. 40 (93%) 2 OH o. o0 i 338 OH ES390 (-) (IS080-10) t=2. 01 (92%) 2 t_N o I I 339 iT ES467 (-) () S080-10) t=1. 90 (82%) 2 Cit 340 OH ES 322 (-) (IS080-10) t= 3. 43 (98%) 2 OH a 1 I w ; N I 341 ES 322 (-) (IS080-10) t= 3. 09 (96%) 2 OH 342 ES 399 401 (IS080-10) t= 3. 12 (98%) 2 0 0 CL, CI1, CF I \ N H non 348 \\5N ES 442 (-)/444 (+) (IS080-10) t= 1. 88 (98%) 2 F A 1/ F_ F 344 ES 410 (-)/412 (+) (IS070-10) t= 5. 73 (75%), 2 | as¢4 OZON o'N a chez 345 ES 422 424 (GRAD 5-100) t=5. 52 2 O=T=O CH, O=S=O HSc I\ ) / ru 346 ES422 (-)/424 (+) (GRAD 5-100) t=5. 71 2 0=SUD cet a. o \ I 347 sS ES 406 (+) NA 2 SN ".'"S O o-cet 348 ES 406 NA 2 NC 11 H Fi, CO H 349 ES 407 t 4. 89 min 2 0 0 HOX 0 ES 392 t 4. 46 min (100%) 2 0 °"C03 0 FiCO/ H H 351 s ES 407 (+) t = 4. 80 min (100%) 2 OH I OH 352 ES 392 t = 4. 24 nin (100%) 2 C) X 11 /\ \ Y ES 405 t 5. 85 min (100%) 2 0 s5 0 354 i ES 392 (-) (IS060-15M) t=11. 22 (100%) 2 " - 355 ES 392 (-) (IS060-15M) t=10. 90 (96%) 2 ruz - 356 F_ ES 315 (-) (IS080-10M) t=4. 02 (94%) 2 0 F 357 _F ES 315 (-) (IS080-10M) t=3. 86 (95%) 2 o F i 358 i ES 410 (-) (IS090-10M) t=2. 64 (92%) 2 ? 359 e ES 333 (-) (IS090-10M) t=2. 90 (98%) 2 F- ( If 360 ES 410 (IS080-10M) t=3. 56 (99%) 2 -- "CDC O F \ F 361 ES 333 (IS090-10M) t=2. 63 (99%) 2 \ 2 362 i ES 311 (-) (IS090-10M) t=2. 94 (92%) 2 AN 1 B l \ 363 ES 322 (IS080-10M) t=3. 40 (96%) 2 OH oH iN f I X) ES 322 (-) (15060-1 (+ OH ciel cl 365 ES 408 (IS080-10M) t=4. 15 (90%) 2 zoo ICI 0 ci a B I 366 e ES 408 (-)/410 (+) (IS080-1 OM) t=3. 81 (100%) 2 N, I,' cul ci B I 367 OH ES 331 (-)/333 (+) (IS080-10M) t=4. 10 (99%) 2 OH OH 368 ES 327 329 (IS080-1 OM) t=3. 66 (100%) 2 ° o 369 ES 327 (-)/329 (+) (IS080-10M) t=4. 15 (99%) 2 H, o c o I 370 X ES 332 (-)/334 (+) (IS080-1 OM) t=4. 53 (99%) 2 OH B o I 371 ES 377 (-) (IS080-10M) t=5. 93 (96%) 2 OH ex Br f I 372 W ES 377 (-) (IS080-10M) t=6. 28 (95%) 2 OH Br 0 373 X ES 467 (-) (IS080-10M) t=5. 26 (95%) 2 OH OU F F 1 s/\ I J 374 (J ES424 (-) ( ! S080-10M) t=3. 45 (92%) 2 Is° ; si /\ F 375 I ES 424 (-) (IS080-10M) t=3. 06 (94%) 2 NU ; ils OH 376 ES 313 315 (IS080-10M) t=2. 15 (99%) 2 OH H I 377 ES 313 (-) l 315 (+) (IS080-10M) t=2. 50 (98%) 2 OH H 0 J I 378 I \ ES 325 (-) (IS080-10M) t=3. 00 (93%) 2 OH ou O H 1/I . 379 X ES 325 (-) (IS080-10M) t=3. 22 (94%) 2 OH OH F F 380 X ES 347 (-) (IS080-10M) t=3. 48 (89%) 2 on OU F F 381 t ES 424 (-) (IS080-10M) t=3. 44 (92%) 2 N, WF ou F F 382 ES 424 (IS080-10M) t=3. 16 (93%) 2 zozo ; Is- cl3 F \ f H X ES 394 (-) (15060-1'< OZON Zu F I I \ F 384 ES 334 (+) (IS080-10M) t=4. 14 (98%) 2 F_X_F F I I \ F I u 305 INF ES 357 (-) (IS080-10M) t=3. 93 (89%) 2 I (N N P u S° 386 ES 432 (IS080-1 OM) t=3. 21 (91 %) 2 H, O oX I v 387 Ho_//_N ES 432 (-) (IS080-10M) t=3. 49 (94%) 2 \ o I 388 NA (IS080-10M) t=3. 20 (95%) 2 so 5 389 HC, _e NA (IS080-10M) t=4. 08 (93%) 2 N 5// "CH, F F F 1 A \ u 390 ES 442 (-) (IS080-10M) t=4. 39 (99%) 2 Nô /1'IF I/I \ FF vu 391 ES 442 (-) (IS080-10M) t=4. 39 (93%) 2 t\S aS 0'" 0 I 392 N, ES 452 (-) (IS080-10M) t=2. 07 (93%) 2 0 00 a 1 I \ o/I I 393 ES 452 (-) (IS080-10M) t=2. 43 (99%) 2 Nos 0'cl, 394 332 (ES+) NA 2 330 (ES-) N 395/spin 408 (ES-) NA 2 o vN/ 396 390 (ES-) 388 (ES+) T" O C 397 fy 402 (El+) NA 2 Ny N'N n0 C MS (ES+) = 424. NA 2 IN- 0 399 470/472 (ES-) NA 2 400 400 8 V 426 (ES-) NA 2 I'F NTTIttIffF O L géx 369 (ES-) NA 2 N O Nazi O U 402 419 (ES+) NA 2 N J 403 N-"0 Isomers separated NA 2 nua 0 404 419 (ES+) NA 2 s c O 405 433 (ES+) NA 2 0 0 0 406 433 (ES+) NA 2 tNi. c0o" O U 407 391 (ES+) NA 2 H, N_ 9 han HxN/1i I \ I U 408 nu 391 (ES+) NA 2 ZOO zu 1 I \ I 409 fi 391 (ES+) NA 2 so Fixe H, N 410 391 (ES+) NA 2 z o cH, r1 I\ 411 450 (ES-) NA 2 " 5 O r 450 (ES-) NA 2 ci I 426/428 (ES-) 100% 2 F N lf F 0 ci u 414 S 42d/425 (ES-) F N l f F 0 HiN r 1 I _\ 415 X 419 (ES+) 93% 2 zoo nez I 416 g,, 419 (ES+) 97% 2 zoo acne r 1 I oN i 417 g 416 (ES-) NA 2 iso o"crS I v 418 418 (ES-) NA 2 - o s N, c B v r. 0 ES 420 (GRAD) t=3. 30 (97%) 2 0 H, F U 420 a N ES 408 (+) (GRAD) t=3. 49 (100%) 2 " F \ I \ °"' I I 421 0\ NA (GRAD) t=3. 49 (100%) 2 P N N'C O H, c//\ F 422 °\X59 N/A (GRAD) t=3. 46 (98. 4%) 2 \SN cl ? oi I 423 ES 418 420 (GRAD) t=2. 46 (100%) 2 cl, o/ \ cN, I v loch, Cr 424 ° ES 41(-)420 (+) (GRAD) t=2. 46 100%) 2 ". °r O I X 425 q,, N ES 438 (-)/440 (+) (GRAD) t=2. 74 (100%) 2 0 426 H ON N ES 438 (-)/440 (+) NA 2 I v If 426 os,"ES 438 (-)/440 (+) NA 2 SN v ° °,, ° 427 ES-=504, ES+=505.,.- (E Isomer) o 1 I H3C. i 428 °"s°J) ES-=524 (Eisomer) NA 2 629 % ? (E NA 2 cLoS o"o r v 429 ES-= 501, ES+ = 503 (E NA 2 Isomer) (°-Ws Hc Isomer) NA 2 r _ °.. S o \ I ES-= 488, ES+ = 490 (Z Isomer) NA 2 o a_\ I I 432 0.. o I ES-= 444 (E Isomer) NA 2 Hc-s . o _ w Iv 433 Xb ES-= 444 (Z Isomer) NA 2 01... P1 °" o. : o i 434"°'Sb ES-= 432 (E Isomer) NA 2 H, cYo a w v °. : ° I OIS-P 435 N ES-= 432 (Mixture) NA 2 FXF 436 ° ES 488 (+) (IS080-1 OM) t=2. 03 (97%) 3 F, 'F 437 ES 373 (IS080-1 OM) t=2. 62 (97%) 3 oV 439 ES 271 273 (IS090-10) t= 2. 55 (98%) 3 l N 440 i ES 337 (-) l 339 (+) (IS090-10) t= 2. 32 (93%) 3 zu I 441 to ES 338 (+) (IS080-10) t= 3. 61 (96%) 3 N O 442 N ES 353 (-)/355 (+) (IS080-10) t= 4. 03 (98%) 3 N N 443 ES 321 (-)/323 (+) (IS080-10) t= 2. 39 (99%) 3 r 444 ES 336 338 (IS080-10) t= 2. 85 (98%) 3 N 445 ES 336 338 (IS080-1 0) t= 1. 96 (100%) 3 N | ; N N 446 0/3N ES 381 (-) ! 383 (+) (IS080-10) t= 2. 99 (98%) 3 °, " al I I 447 i ES 336 (-)/338 (+) (IS080-10) t= 3. 68 (91 %) 3 Nu 0 F u 448 ES 355 357 (IS080-10) t= 2. 64 (78%) 3 1-N O F 449 J ES355 (-)/357 (+) (iS080-10) t=2. 74 (94%) 3 zon , y-N i0 F A 1/ 450 0 ES 356 (IS080-1 0) t= 3. 93 (92%) 3 F N F u 451 oF ES 356 (-)/358 (+) (IS080-10) t= 3. 81 (92%) 3 zon 'O F u 452"I s ES 387 (-)/389 (+) (IS080-10) t= 2. 58 (96%) 3 O F 453 ES 387 389 (IS080-10) t= 2. 40 (96%) 3 O-N i v ; X ES 351 (-)/353 (+) (15060-10) W zon O 55 ES 362 364 (IS080-1 0) t= 2.. 41 (84%) 3 N '/O I 456 N ES 362 364 (IS080-10) t= 2. 22 (88%) 3 , y-N) O 457 s ES 390 392 (IS080-1 0) t= 4. 71 (96%) 3 zon F F F 1/\ F I J X ES 374 (-) (15060-1 E zon 0 F/1/\ F iq 1, 459 H, ES 387 (-)/389 (+) (iS080-10) t= 3. 72 (95%) 3 foc u 460 ES 372 374 (IS080-1 0) t= 2. 89 (83%) 3 F 461 H. C-N ES 369 (-)/371 (+) (IS080-10) t= 3. 73 (100%) 3 N F F i 462 ES 369 371 (IS080-1 0) t= 3. 64 (99%) 3 F_ ° T For 463 \ 1 ES 373 (-) (IS070-10) t= 3. 54 (78%), 3. 64 (22%) 3 O F e I \ F f / U 464 F F ES 415 (-)/417 (+) (IS080-10) t= 4. 81 (97%) 3 0 ci 465 X ES 371 (-)/373 (+) (IS080-10M) t=2. 95 (93%) 3 zon ci a 466 Ç ES 371 (-)/373 (+) (IS080-1 OM) t=2. 73 (94%) 3 V 0 467 t S ES 354 (-) (IS080-10M) t=4. 87 (100%) 3 zon zon F \ I 468 s ES 372 (-) l 374 (+) (IS080-10M) t=5. 10 (99%) 3 -N zon e I 469 s I e ES 372 (-) ! 374 (+) (IS080-10M) t=4. 97 (99%) 3 O F 470 ES 373 (-)/375 (+) (IS080-10M) t=2. 93 (96%) 3 -N i0 F u 4-71 ES 374 376 (IS080-10M) t=4. 28 (93%) 3 F P ZOZO I d I \ FF u 4iL ES 405 (-) (15060-1 ( zon 473 F F F 1 \ u ES 405 (IS080-10M) t=3. 30 (94%) 3 zon fizz IS080-10. M, ret time = 5. 63, 474 \ m/z = 320 (M+1) 5. 73 min. ; 98. 2% N F 476 lk APCI ISO 80 : 100M 4 N 382 (+) t = 3. 047 (95 %) 476 91 APCI ISO 80 : 100M 4 382 (+) t= 3. 310 (95%) o-g=o 5 i 477 APCI GRAD 80-100M 4 477 304 (+) t=4. 037 (98 %) N EI GRAD60-280 478 337 t=24. 21 (98 %) 4 N ci 481 1t APCI GRAD 80-100M 4 416 (+) t= 1. 852 (100 %) Oz CH, d cri a s a I 482 I i APCI GRAD 80-100M 4 oui 450 (+) t = 5. 466 (100 %) \SON b cC.. S 483 () 1 APCI GRAD 80-lOOM 4 397 (+) t = 2. 799 (95 %) N o=s=o o=s=o CCXNm $ I V S APCI GRAD 80-lOOM 4 " 397 (+) t= 2. 598 (95%)" N 1 ad, XN ' N 484 (a) APCI GRAD 80-IOOM 4 383 (+) t = 2. 128 (100 %) ai, _. O\ N O 8 s ~ APCI GRAD 80-lOOM 4 484 (b) (j GRAD80-100M 383 (k) N =0 @9 APCI GRAD 80-lOOM 4 , 485 (a) 365 (+) t = 2. 823 (99 %) In- H, coo 486 395. 1 (APCI-pos) 98% 4 486 0Y 393. 0 (APCI-neg) °.. N oI N 487 358. 0 (APCI-pos) 98% 4 356. 0 (APCI-neg) F N PN, /1 Fez 488 1 413. 0 (APCI-pos) 98% 4 411. 0 (APCI-neg) Own Cgo 489 APCI GRAD 80-100M 4 289 (+) t=5. 7550 (100 %) 490 NA NA 4 olot GRAD60-280 EI tl 23. 09 (33 %) 4 9 3l6 t2 23. 25 (66 %) ISOMERIC MIX GRAD60-280 492 EI tl 20. 4 (20 %) 4 364 t2 20. 6 (80 %) ISOMERIC MIX i s 493 APCI ISO 70 : 30M 382 (+) t = 4. 351 (95 %) NI o=f-o 494 APCI ISO 80 : 20M 4 494 Y 303 (+) t = 3. 892 (95%) sJ APCI ISO 80 : 20M N-_o-382 (+) t = 3. 413 (95 %) o==a c 496 APCI ISO 80 : 20A 416 (+) t = 3. 527 (95 %) 4 zu s 497 APCI ISO 80 : 100A 4 0. 0 440 (+) t = 6. 922 (95 %) c s 498 EI 303 GRAD60-280 4 21. 15 (98 %) NH, ci APCI IS080-20A 4 °=1=° 416 (+) t=6. 910 (99 %) O=T=O I O=5=O CH 500 APCI IS080-20A 4 440 (+) t=6. 922 (95 %) N Ouzo 501 APCI IS080-20A 4 382 (+) t = 5. 438 (99 %) o=s=o CF s I u 502 1t APCI IS080-20A 4 382 (+) t = 5. 430 (95 %) o=s=o cFt I APCI IS080-20A 4 503 444 (+) t= 6. 682 (95%) N no GRAD 80-100M fT APC ! t=3. 038 (50%) 504 oW 366 (+) t = 3. 336 (so to) 366 (+) ISOMERIC MIX oi ai, v oW 377. 1 (APCI-pos) 95% 4 505 ° 375. 0 (APCI-neg) s S 377. 1 (APCI-pos) 95% 4 506 375. 0 (APCI-neg) N 507 v 300. 1 (APCI-pos) 95% 4 IV N 508 300. 1 (APCI-pos) 95% 4 s 509 377. 1 (APCI-pos) 98% 4 509 375. (APCI-neg) ° ? E" N F 395. 1 (APCI-pos) 99% 4 l 510 0r 393. 0 (APCI-neg) » JF N/f 511 318. 0 (APCI-pos) 95% 4 F F \ N 512 318. 0 (APCI-pos) 95% 4 N 1t 377. 1 (APCI-pos) 96% 4 513 375. (APCI-neg) B 514 C 300. 1 (APCI-pos) 95% 4 377. 1 (APCI-pos) 85% 4 515 375. (APCI-neg) OON O I N 516 300. 1 (APCI-pos) 85% 4 ° N N 517 Cj 379. 0 (APC)-pos) 85% 4 OZON N \ F t) 3, F 358. 0 (APCI-pos) 98% 4 356. 0 (APCI-neg) s F 519 Q) 397. 0 (APO-pos) 98% 4 ozon /ici O v F 520 397. 0 (APCI-pos) 98% 4 F /II F N \ F Iv 463. 0 (APCI-pos) 98% 4 521 461. 0 (APCI-neg) ". 4 llC'' F/'\ F F 463. 0 (APCI-pos) 95% 4 522 461. 0 (APCI-neg) F 5°PO F 413. 0 (APCI-pos) g5% 4 524 F 411. 0 (APCI-neg) cC'il zozo N F / 525 F I 413. 0 (APCI-pos) g8% 411. 0 (APOI-neg) Ils Zozo F N f 1 526 302. 1 (APCI-pos) 98% 4 cCo 527 302. 1 (APCI-pos) 98% 4 F 1 l Fi 528 318. 0 (APO-pos) HO 316. 0 (APCI-neg) 4 F NU I 318. 0 (APCI-pos) 98% 4 529 HO 316 0 (APCI-neg) pX I 530 317. 1 (APCI-pos) 95% 4 M N F u 631 H2 317. 1 (APCI-pos) 98% 4 NH, F N u zizi 317. 1 (APCI-pos) 95% 4 N F N F u 533 J 317. 1 (APC !-pos) 90% 4 NH- F _1/ I 534 317. 1 (APCI-pos) 95% 4 XF 535 sus 317. 1 (APCI-pos) 95% 4 F N 536 375. 0 (APCI-pos) 95% 4 536 373. 0 (APCI-neg) -N /O N F s t X 395. 0 (APCI-pos) 95% 4 538 377. 1 (APCI-pos) 95% 4 0-1 N F N v 1/\ u Bs | S 352 0 (APCI-pos) 98% 4 F , 1/\ F 540 F 352. 0 (APCI-pos) 99% 4 F F N 541 ¢W 352. 0 (APCI-pos) 98% 4 F r N F : u 542 352. 0 (APCI-pos) 98% 4 FF F N I 543 F 352. 0 (APCI-pos) 98% 4 F F u F 544 Fs 352. 0 (APCI-pos) 95% 4 F F N u 545 HCmf N 359. 1 (APCI-pos) 98% 4 H. OYN 0 F 420. 0 (APCI-pos) ° 4 546 °, N 417. 9 (APCI-neg) 99/° N F 547 °Q8 420. 0 (APCI-pos) 98% 4 Foc ° zon 548 ES 427 429 (+) (IS080-10) t= 2. 66 (99%) 4 s F 0 u s 0 ES 396-)/399 (+) (IS080-10) t= 2. 49 (96%) 4 F s cl 550 ES 433 435 (+) (IS080-10) t= 3. 75 (92%) 4 off CH, F cils 551 ES433 (-)/435 (+) ( ! S080-10) t=3. 48 (92%) 4 oint 0-7 CI, ci 552 APCI 417 (+) (GRAD 80-100) t=1. 31 (96%) 4 N zozo CI-1 y a/v S I 553 ES417 (+) (GRAD 70-100) t=2. 10 (95%) 4 s ci S, CI 554 ES 417 NA 4 N /% CFa O _ /sJ 555 ES 382 384 (IS060-10M) t=4. 31 (98%) 4 ° ° I J 556 ES 382 384 NA 4 X S O I V 557 Vi ES 393 (-)/395 (+) (IS050-10) 1=2. 09 (98%) 4 v/ b C//N I 558 ES 438 440 (IS060-10M) t=3. 40 (98%) 4 N_NH, zu H, C razz 559 ES 396 (-)/398 (+) (IS040-10M) t=2. 45 (92%) 4 N po Ho HC r , S 560 ES 319 321 NA 4 OH C) I-s 561 oF ES 344 (-)/346 (+) (IS060-10M) t=2. 46 (94%) 4 zon 562 oX ES 345 (-)/347 (+) (IS060-1 OM) t=4. 23 (88%) 4 zon O R Ls v 563 ES 399 401 (IS080-1 OM) t=2. 42 (100%) 4 F N F 6i64 0 ES 399 401 (IS080-1 OM) t=2. 42 (91 %) 4 ZON s 0 F 565 ES 362 (-) l 364 (+) (ISO80-10M) t=1. 98 (94%) 4 N 0 I s I u 566 ES 362 364 (IS060-10M) t=2. 55 (97%) 4 zon N kN I N 567 APCI 411, 413 (+) LCMS (IS08020M) t=2. 60 4 en 568 I ? D- APCI 334, 336 (+) LCMS (IS08020M) t=3. 28 4 CCCr 569 APCI 411, 413 (+)/409, 411 (-) LCMS (IS08020M) t=2. 56 4 o=s N 570 ES 411, 413 (+)/409, 411 LCMS (IS08020M) t=1. 94 4 o ci 571 ES 334, 336 (+)/332, 334 (-) LCMS (IS08020M) t=2. 40 4 N, 572 ES 334, 336 (+)/332, 334 (-) LCMS (IS08020M) t=2. 91 4 0 i 573 19 ES 411, 413 (+)/409, 411 (-) LCMS (ISO X v 574 APCI 396 (+) LCMS (IS07030M) t=6. 44 4 N O=S=O N 575 C APCI 318 (+) LCMS (IS07030M) t=8. 96 4 N N 576 APCI 395 (+) LCMS (IS07030M) t=4. 51 4 IDE 1 OcS=O N 577 ACE 318 (+) LCMS (IS07030M) t=6. 54 4 00 578 APCI 320 (+) LCMS (GRA80100M} t=4. 48 4 N Vin 579 APCI 320 (+) LCMS (GRA80100M) t=4. 05 4 F F 1/N 580 APCI 320 (+) LCMS (GRA80100M) t=4. 33 4 F Ne 581 APCI 320 (+) LCMS (GRA80100) t=4. 32 4 N 0 1/\ F 582 APCI 320 (+) LCMS (GRA80100) t=4. 58 4 /\ F I 583 ACE 320 (+) LCMS (GRA80100M) t=4. 24 4 F F A N 584 oX APCI 360 (+) LCMS (GRA80100M) t=3. 76 4 1. coo C F N I 585 APCI 360 (+) LCMS (GRA80100) t=3. 54 4 p o /\ F I 586 APCI 360 (+) LCMS (GRA80100M) t=3. 82 4 0 0 api, I I 667 gX APCI 360 (+) LCMS (GRA80100M) t=3. 77 4 Fuzz I | cU t APCI 360 (+) LCMS (GRA80100M) t=4. 26 4 0 i 1/v F (N) 589 X APCI 360 (+) LCMS (GRA80100M) t=3. 95 4 0 F N I u 590 APCI 370 (+) LCMS (GRA80100M) t=4. 70 4 F F FEZ F S \/\ i 591 APCI 383 (+)/381 (-) LCMS (GRA80100M) t=1. 98 4 0 \ F I N 592 APCI 400 (+)/398 ( 0 "03 F N 593 APCI 398 (+)/396 (-) LCMS (GRA80100M) t=2. 97 4 Nr //O F N F F 594 APCI 461 (-) LCMS (IS07030M) t=6. 52 4 olr CH, O a F N \/_\ F F F 595 APCI 463 (+)/461 (-) LCMS (ISO A 0f° C6 i N I V 596 N APCI 471 (+)/469 (-) LCMS (IS08020M) t=2. 41 4 F N I F F 597 ACE 445 (+)/443 (-) LCMS (IS07030M) t=5. 49 4 N O O ' (chez F F 598 F APCI 445 (+)/443 (-) LCMS (IS07030M) t=7. 35 4 for con , GRAD60-280 599 5 EI 286 17. 84 (95 %) 4 _\/_ 600 11 APCI 90% 4 T ° /psi 0 601 ACE 90% 4 v Hn, 602 ES 386 (-)/388 (+) LCMS (IS08020M) t=3. 04 5 ° 603 ES 311 (+) LCMS (IS08020M) t=3. 79 5 vs ° i 604 APCI 310 (+) LCMS (GRA80100M) t=3. 60 5 H,, H i / APCI 366 (+) LCMS (GRA80100M) t=4. 96 5 N Su H,. H U 606 APCI 352 (+) LCMS (GRA80100M) t=4. 28 5 0 F 607 ES 471 (-)/473 (+) (IS080-1 OM) t=1. 79 (98%) 6 a _ 608 ES 484 (-)/486 (+) (IS080-1 OM) t=1. 72 (100%) 6 u i 609 oF ES 397 (-) l 399 (+) (IS080-10M) t=3. 68 (93%) 6 0 f"CYv /\ F I 611"'i ES 357 (-) (IS060-10) t= 3. 94 (93%) 6 zon 0 ° __ \ F 612 oLS ES 399 (-)/401 (+) (IS080-10) t= 3. 74 (96%) 6 0 F 1/\ F 613 oF ES 375 (-) (IS080-10) t= 2. 38 (98%) 6 ),-N fizz cul u 614 oFt ES 373 (-) (IS080-10) t= 2. 85 (99%) 6 zon b F o 617 ES 488 (-)/490 (+) (IS080-10) t= 1. 86 (99%) 6 dv yvF Fiv 618 473. 1 (APCI-pos) 95% 6 0 I_ 619 ES 340 342 (IS080-1 0) t= 2. 98 (95%) 6 Na-" ° 0 I 620 ES 340 342 (IS080-1 0) t= 2. 96 (92%) 6 a--sX r 621 NMR NA 6 y 622 ES 410 NA 6 oX zu a \ I I 623 430. 0 (APCI-pos) 95% 6 427. 9, 428. 9, 429. 9 (APCI-neg) 0', lN I-LC'' 0 cri 624"Q 430. 0 (APO-pos) 624 430. 0 (APCI-pos) 95% 427. 9, 428. 9, 429. 9 (APCI-neg) 6 if a O 0 0 F 625 N 360. 0 (APCI-pos) 99% 6 kN i0 626 ES 339 (IS080-1 0) t= 2. 21 (96%) 6 zon O u 627 i ES 317 (-)/319 (+) (IS080-10) t= 3. 33 (96%) 6 OH 0 F 628 VH ES 317 (-)/319 (+) (IS080-10) t= 3. 21 (96%) 6 OH F/ 629 ES 394 396 (IS060-10) t= 8. 44 (90%) 6 N OUI CHIEZ 00" u 630 ES 394 396 (IS060-10) t= 8. 06 (97%) 6 o CL, CN F 631 N i ES 357 (-) (IS060-10) t= 4. 30 (95%) 6 -N '/O F u LX ES355 (-)/360 (+) (15060-10) < zon i0 0 \ 633 e ES 358 (-) (IS080-10) t= 3. 04 (92%) 6 zon zon 'O F : 634 H. cMY- ES371 (-)/373 (+) () S080-10) 1=3. 11 (92%) 6 zon i0 ° \ I e 635 °'N ES 371 (-)/373 (+) (IS080-10) t= 3. 00 (92%) 6 4 t m 636 ES 374 (IS080-1 0) t= 3. 91 (97%) 6 0 zon O u -X 374 (15060-1) l =3. E3 (93%) 6 zon r0 \ I u 638 ES 399 401 (IS080-1 0) t= 3. 91 (94%) 6 Nu O, CF 0 / 05 I 639 f ES369n () S070-10) t=2. 15 (75%), N 2. 25 (15%) cCo"' 640 El 352 (IS080-1 0) t= 5. 64 (100%) 6 F F 0 ci 641 ES 373 (-) (IS080-10) t= 2. 68 (99%) 6 zon fizz O u 642 oF ES 357 (-) (IS080-10) t= 2. 15 (99%) 6 nez ,)-N vil0 F /\ F \ I u 643 ; 43 ES 407 (IS080-1 0) t= 2. 82 (99%) 6 a-N F F U 644 N ES 375 (IS080-10) t= 2. 36 (96%) 6 0 a0 O u 645 oF ES 359 (-) (IS060-10) t= 3. 71 (100%) 6 0 N '-nu- fr - 646 ES 454 (-)/456 (+) (IS080-10) t= 1. 75 (98%) 6 fCY° / 647 ES 486 488 (IS080-10) t= 2. 07 (95%) 6 0 v IN 648 ES 470 (+) (IS080-10) t= 1. 80 (96%) 6 C') N e 649 ES 313. 9 (+) NA 6 o C% ; 650 y ES 314. 0 (+) NA 6 -N' ° i N 651 ES 327. 0 (+) NA 6 N O 652 ES 405. 0 (+) NA 6 \son O O N v v 653 ES 391. 0 (+) NA 6 su N 654 ES 361. 0 (+) NA 6 c ° 656 ci ES 347. 9 (+) NA 6 zu ° i N 656 ES 375. 9 (+) NA 6 po N ci 657 ES 389. 9 NA 6 0 CHEZ ° I 658 N NMR NA 6 0 0 I/i o 659 0 NMR NA 6 O L. N our en, O u 660 ES 406. 1 (+) NA 6 CF Of CH, 0 _\ S °\N r cl, ES 406. 1 (+) NA 6 O1 CI O u 662 ES 410. 0 NA 6 % Ole CI, Cul /1/\ u 663 ES 410. 0 (+) NA 6 OON 0 ? CL, cl. C3 664 ES 410. 0 (+) NA 6 0 IN os CH, 0 665 lu NA >95% (254nM) 6 N oui CI 0 u 666 NA >99% (254nM) 6 C H'oS : . o5 ouzo cri I 667 ES 424 NA 6 cor5 0 s CF _ _ er W 668 ES 486 NA 6 g, N () 6 CM, "0 I 669 fry NMR NA 6 1 o to-- 0 1 I\ I 670 fi NMR NA 6 ZAIN Off CF 0 'u F 671 lu NMR NA 6 °, J oui CH, O F 672 NMR NA 6 N CF6 OU, FIC O u 673 ES 390. 1 (-) NA 6 e $ 0 CH, u 674 ° c, NMR NA 6 zon CF CI1 "'""coo I 675 i NMR NA 6 N CF CH, O XcC 676 NMR NA 6 N CF CH2 Hic u H, c I 677 ES 390. 1 (-) NA 6 N It CF cH, 678 lu NMR NA 6 0\\ N 0 CH, O o- o c 679 ES 406. 5 (-) NA 6 N CHEZ Cri, 0 cl ci \ 680 NMR NA 6 N ORS cri ci 681 NMR NA 6 N CHU CH, F 0 F 682 ES 444. 1 (-) NA 6 N O I CL3 _1/_ F 683 ES 444. 1 (-) NA 6 N\ N Hz o\ 684 Cl 453. 93 t =3. 24 min (100%) 6 gaz o 0 I 685 Cl 454 t 3. 18 min (100%) 6 N-0 O s 686 Cl 424 t= 2. 24 min (64 %) 6 t= 2. 29 min (34 %) zu N O 1 S I 687 CI = 454 t = 3. 18 min (100%) 6 zip O N S 688 ES 332 t 2. 66 min (99 %) 6 S 689 APCI = 401 t = 3. 88 min (92%) 6 my Nx'N '10 1 690 \N ? I, N ES 522 (+) t = 3. 93 min (98%) 6 s 691 ES 356 t 3. 3 min (100) 6 nez 'IO O 5 I 692 APCI 424 t 3. 29 min (100%) 6 t N9- O S C APCI = 410 t= 2. 97 min (100 %) 6 t 0 s I 694, APCI = 4 min (100%) 6 " !" O t = 5. 64 min (24 %) p t=5. 87min (76%) NII- 5 I 696 APCI = 424 t= 3. 12 min (100 %) 6 s-"i s cri 697 t° APCI = 462 t = 4. 3 min 6 nez ' o'*o 698 ES 418 t 3. 36 min (100 %) 6 L ou s 699 ACE 313 t = 3. 66 min (100%) 6 OH S 700 i r ES 522 (-) t = 3. 75 min (97 %) 6 " ! N 11 s F 0 F /\ F 701 APCI 301 t = 4. 43 min 6 S a f \ a cri N_ i-a-S 11 I r70 ES407 (+) tI-4. 4anint100o/. 1 6 zu 0 0 I J o 704 ES 407 (+) t = 4. 39 min (100%) 6 0 0 O O 705 0 ES 407 (+) t = 4. 47 min (100 %) 6 NS-CH, g- °"cC I J if 706 ES 407 t 4. 53 min (100%) 6 N"CH, c 0 o_S I 707 ES 407 t 4. 61 min (100%) 6 s N_ll_CH, 0 FI, CL 0 708 ES 407 t 4. 61 min (100%) 6 0 M 0 11 \ I 709 ES 397 399 (IS080-10M) t=3. 53 (93%) 6 0 O F e 1 v Iv S w L1 X ES 413 t ;/41 _ () (15090-t 0 3 F e_1 I I w I 711 FX ES 413 (-)/415 (+) (IS080-10M) t=4. 82 (95%) 6 e_ 1 I Iv I 712 ES 471 473 (IS080-10M) t=1. 82 (97%) 6 F 0 713. I ES 357 (-) (IS080-10M) t=2. 39 (97%) 6 zon '/O 0 /1/\ u 714 oX ES 357 (-) (IS080-10M) t=2. 26 (100%) 6 zon 0 0 u 715 N ES 374 (IS080-10M) t=2. 57 (97%) 6 zon zon O a X ES 374 (15060-t C | < 0 O -0 \1 F iq 1, 717 X ES 367 (+) (IS060-t ON < Ct F F 718 ES 477 479 (IS060-10M) t=1. 64 (94%) 6 OY" IV into F Y'S 719 °"ES 477 (-) l 479 (+) (IS060-10M) t=1. 51 (88%) 6 I H o 720 Nò"SzU APCI 428 t = 3. 41 min (93%) 6 s w u 721 X59F 530 96% (220 nm) 6 NC) F 5 S u 722 0 406 (ES-) NA 6 \\ CH2 Neo 0 F /_\ I u L 1 394 (ES-) 100% 6 cet 0 F I 724 394 (ES-) 94. 80% 6 asz cri 0 I 725 =t 9 410 (ES-) NA 6 z ci I 726 410 (ES-) NA 6 Zoo 0 Cil a 727 lu 410/412 (ES-) NA 6 N- CH, 0 a 728 Lj 410/412 (ES-) NA 6 zozo zu \ Iw F I 729 ! lu 394 (ES-) NA 6 N, 11' zea CL. /\/\ u F I 730 (j 394 (ES-) NA 6 zozo . 0 0 \/\ 73i 394 (ES-) NA 6 - zoo I 732 394 (ES-) NA 6 N,//0 CH, I-1'C'O O w 733 1 ES 408 (-) 410 t=4. 58 (100%) 6 H, C'X 0 NgCFl3 O O O 734 0 ES 408 (-) 409 t 4. 39 (100%) 6 NCM, 11 ° F I 735 N, 1/0 ES 424 1426 t 4. 58 (100%) 6 CF ° ° 1 v 0 736 ES 424 1426 t 4. 62 (100%) 6 0 1 l \ o 737 ES 408 410 t 4. 49 (67%) 6 1\-/i 0' H'1 s A/1 \ 738 ES 514 516 (GRAD) t=3. 49 (100%) 6 0 \ SO 5 cOo I u 739... ES 454 (-)/456 (+) (GRAD) t=3. 44 (100%) 6 cl. (V S 740 ES 406 408 (GRAD) t=3. 29 (97%) 6 N NaH50 aXd9 u 741 ES 426 428 (GRAD) t=2. 49 (85%) 6 0".-. N 0 Fi, C O S 742 ES 426 (GRAD) t=2. 49 (100%) 6 0 N "0 H, C D S XraS 743 % S ES 406 (-)/408 (+) (GRAD) t=2. 43 (100%) 6 ° 9S H, C N S //\ 744 ES 406 408 (GRAD) t=2. 41 (100%) 6 0,., N S0 N, C o 5 F I 745 ES 410 412 (GRAD) t=2. 36 (100%) 6 zain zu F6c U 746 ES 410 412 (GRAD) t=2. 36 (91%) 6 0\ CH. s I_\ I 747 N ES 422 424 (GRAD) t=2. 34 (100%) 6 H, 9 s I 748 H, C9so ES 406 (-)/408 (+) (GRAD) t=2. 59 (95%) 6 0 SiN S 749. T ES406 (-)/408 (+) (GRAD) t=2. 61 (100%) 6 oSN SCH, ", cl I \ c er i 750 ES 406 (-)/4os (+) (GRAD) t=2. 77 (100%) 6 F6 CF "°'°o ber H t = 4. 55 (100° ! °) 7 752 W ES 424 (-)/422 (+) t 4. 55 (100%) 7 zozo v 753 0 ES 446 NA 7 nu nus // 0 ? H f oH 754 S) ES 437 (+NH3) NA 7 -CF 0 ou OU v I OH 755 ES 404 (+) NA 7 DMSO 0 C, 6 756 ES 452 NA 7 N, 10 O su 0'CF u 758 APC'95% 7 °. N zain 759 ES 364 (+) NA 7 r N 760 ES 326 (+) NA 7 N I /\ I 761 ES 312 NA 7 N 762 ES 450 NA 7 763 ES 402 NA 7 o"f° 764 ES 402 NA 7 765 ES 388 NA 7 I 766 ES 450 NA 7 NU I \T< 767 ES 526 NA 7 1 if 768 g -/\ ES 480 (-) NA 7 o 769 ES 388 NA 7 N 770 ES 464 NA 7 N o/\ cS u cH, ES 416 418 (GRAD) t=3. 648 (98%) 7 ''goo "m, I i/\ c I 772 N '° ES 430 (-)/432 (+) (GRAD) t=3. 733 (98%) 7 , ° ou cil Hic u | ES 402 (-)/404 (+) (GRAD) t=3. 445 (100%) 7 °'' ; r o r HC 774 H ES416 (-)/418 (+) (GRAD) t=3. 541 (100%) 7 0- H, C O_S° HC F I \ cH, 775 ES 424 443 (+NH4) (GRAD) t=3. 349 (100%) 7 H, C H, c F 776 O r ES 438 (-)/440 (+) (GRAD) t=3. 456 (100%) 7 H, C H, c e/\ a 1 J 777 ES 456 (-)/475 (+NH4) (GRAD) t=3. 733 (99%) 7 "SO c a I 778 ES 470 489 (+NH4) (GRAD) t=3. 819 (95%) 7 HIC HC I J 779 ES 416 435 (+NH4) (GRAD) t=3. 552 (100%) 7 N po H, C HC LJ 780 ES416 (-)/435 (+NH4) (GRAD) t=3. 595 (97%) 7 nu c H, C 781/ 'ES 402 (-)/412 (+NH4) (GRAD) t=3. 477 (100%) 7 po HC I V 782/ES402 (-)/412 (+NH4) (GRAD) t=3. 509 (100%) 7 etc CF i 783 V1, ° ES 430 (-) NA 7 c, zon H 784 CH. ES 404. 1 NA 7 s° Hz : ru 784 \ ES 404. 1 (-) NA 7 NS O IO CH, e I i ai, 785 s ES 492. 0 (-) NA 7 I'O cOo" 0 /1 \ , I w S 786 ES 404. 1 (-) NA 7 N CF F F 787 I "'ES 408. 0 (-) NA 7 Fic N Asz ouzo 0 chez 788 ES 408. 0 (-) NA 7 0 N en, 0 f I \ \ aia X ; ES 406 0 (-) NA 7 00g°N Of Cit 0 IF 790 ovE ES 408. 0 (-) NA 7 O N. 0 c ; i tic 791 LJ""'ES424. 0 (-) NA 7 --- OF'I cool a I u 792 CF ES 424. 0 (-) NA 7 oxo N 0-1. CH, cCo ftr 793 CF 422/424 (ES-) 100% 7 Wa N,/10 a \ a u 794 N 5//° 422/424 (ES-) 99. 60% 7 ; psi CHEZ u 795 CH 390 (ES-) 99. 80% 7 zozo "CH, O 0 u | 7 C 390 (ES-) 100% 7 Iso 0 0 fir w crt, | X 424/425 (ES-) NA 7 iso cCo C, ci I 798 fez 424/426 (ES-) NA 7 o 0" 0--\ nCn so o a-t, 1 I\ I 800 404 (ES-) 97. 40% 7 cT 1 I\ I 416 (ES-) Iso N, 0 I 802 418 (ES-) NA 7 os. 0 a 1/\ F 803 I 442/444 (ES-) NA 7 N/° , s F cri 11 F /\ a 804 442/444 (ES-) NA 7 DMSO pi a'a O e u F 805 MS (ES+) = 424. NA 7 CHEZ 1/w I 806 394 (ES-) NA 7 s° ; ils chez F 807 N 5/° 408 (ES-) NA 7 o' ; Is- CL3 F I \ CHO 808 N 5/° 408 (ES-) NA 7 s° CH, ouf6 0 I U 809 N 5A° 426 (ES-) NA 7 ; Is- fowl Erz 810 426 (ES-) NA 7 N° 5 "coo u 811 N 5/° 422 (ES-) NA 7 N, 0 F 812 N 5/° 422 (ES-) NA 7 //0 cob fff I 813 CN MS (ES-) = 460. NA 7 , ° 0' 0 814 CN 460 (ES-) NA 7 Nso o cN, 0 fuzz COB crs 815 C 434 (ES-) NA 7 s° 0'" 0 Cl o I 816 tc 462 (ES-) NA 7 r p ---- d 0 u l ES 420 (-)/422 (+) t=4 5 < N, Cl 0 Fclo I 818 W ES 420 (-)/422 (+) t = 4. 57 (100%) 7 JO Ost F O i 819 o ES438 (-)/440 (+) t= 4. 63 (100%) 7 ;"-Ct ° o 1 Cil 820 N 5A/° ES 438 (-)/440 (+) t = 4. 69 (100%) 7 o 0 its, I 821 t ES 434 (-)/436 (+) t = 4. 77 (100%) 7 So o' 'Cit /1/v o, o 0 822 ES 434 436 t 4. 68 (100%) 7 oeF o 0 n, c I 823 N 5z° ES 452 (-)/454 (+) t = 4. 84 (100%) 7 CH, F r_ 1 I °'° \ I 8DI s ES 452 (-)/454 (+) t = 4 X L5-° o r 1/v I v I i 825 ES ES458 (-)460 (+t = 5. 30 (100%) 7 N. S () () () f"°'- Iw I i E326 ES 458 460 t 5. 27 (100%) 7 () () (> 0 827 NA (GRAD) t=3. 40 (86%) 7 r W °-S I w I 828 to~F ES 432 (-) (GRAD) t=3. 35 (98. 8%) 7 N, Cos C I v 829 ES 432 (-) (GRAD) t=3. 48 (97%) 7 F C% vs I 830 NA (GRAD) t=3. 53 (100%) 7 I\ N 11C c F CH2 I u I \ cr r NA (GRAD) t=3. 52 (100%) 7 N H, C CHEZ Fla \/\ F I \ I cr, a 832 tY NA (GRAD) t=3. 48 (100%) 7 ZAIN H, v f 833 CF ES 434 (GRAD) t=2. 54 (96%) 7 OON F tS /\ F 834 ES 434 (GRAD) t=2. 54 (96%) 7 N F toWS_ F/yCH, 835 0 ES 434 NA 7 zu N fez -UN 636 WCH, APCI 427 (+)/425 (-) LCMS (IS07030M) t=4. 88 7 N zozo CON CFia N 837 APCI 427 (+)/425 (-) LCMS (IS07030M) t=6. 89 7 z lSSO ° CH, 0 e \ I 838 CF 373. 0 (APCI-pos) 95% 7 N F colt 839 JL 373. 0 (APCI-pos) 95% 7 N ils S PF o °N, 840 ° ES 436 (-)/438 (+) (GRAD) t=2. 35 (100%) 7 ZAIN '0 5 o a5 N ES 436 438 (GRAD) t=2. 54 (100%) 7 ". cl cet I 842 Y ES436 (-)/438 (+) (GRAD) t=2. 54 (100%) 7 OON 0 0 O I 643 W MS (ES-) 434 NA 7 zu O